0001437749-24-03397910-Q Avinger Inc 20241107202411071705381705381705381

gaap:AdditionalPaidInCapitalMember2022-12-31 0001506928us-gaap:CommonStockMember2022-12-31 0001506928us-gaap:PreferredStockMember2022-12-31 0001506928us-gaap:RetainedEarningsMember2024-07-012024-09-30 0001506928us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0001506928us-gaap:CommonStockMember2024-07-012024-09-30 0001506928us-gaap:PreferredStockMember2024-07-012024-09-30 0001506928us-gaap:RetainedEarningsMember2024-06-30 0001506928us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001506928us-gaap:CommonStockMember2024-06-30 0001506928us-gaap:PreferredStockMember2024-06-30 0001506928us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001506928us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001506928us-gaap:CommonStockMember2023-07-012023-09-30 0001506928us-gaap:PreferredStockMember2023-07-012023-09-30 0001506928us-gaap:RetainedEarningsMember2023-06-30 0001506928us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001506928us-gaap:CommonStockMember2023-06-30 0001506928us-gaap:PreferredStockMember2023-06-30 00015069282024-11-04 Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549Â Â Â FORMÂ 10-Q Â Â (Mark One) Â Â â˜’ QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OFÂ 1934 Â For the quarterly period ended September 30, 2024 or Â â˜ TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OFÂ 1934 Â Commission File Number: 001-36817 Â Â AVINGER, INC. (Exact name of registrant as specified in its charter) Â Â Delaware Â 20-8873453 (State or other jurisdiction of Â (I.R.S. Employer incorporation or organization) Â Identification Number) Â 400 Chesapeake Drive Redwood City, California 94063 (Address of principal executive offices and zip code) Â (650)Â 241-7900 (Telephone number, including area code) Â Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class: Â Trading Symbol(s): Â Name of each exchange on which registered: Common Stock, par value $0.001 per share Â AVGR Â The Nasdaq Capital Market Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Â Accelerated filer â˜ Â Â Non-accelerated filer â˜’ Â Smaller reporting company â˜’ Â Â Â Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes â˜ No â˜’ Â As of November 4, 2024, the number of outstanding shares of the registrantâ€™s common stock, par value $0.001 per share, was 3,196,791. Â Â Â Â Â SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Â This Quarterly Report on FormÂ 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as â€œanticipate,â€ â€œassume,â€ â€œbelieve,â€ â€œcontemplate,â€ â€œcontinue,â€ â€œcould,â€ â€œdue,â€ â€œestimate,â€ â€œexpect,â€ â€œgoal,â€ â€œintend,â€ â€œmay,â€ â€œobjective,â€ â€œplan,â€ â€œpredict,â€ â€œpotential,â€ â€œpositioned,â€ â€œseek,â€ â€œshould,â€ â€œtarget,â€ â€œwill,â€ â€œwouldâ€ and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: Â Â â— our ability to continue as a going concern; Â Â â— our ability to regain and remain in compliance with the listing requirements of the Nasdaq Capital Market; Â Â â— the outcome of and expectations regarding our current clinical studies and any additional clinical studies we initiate; Â Â â— our plans to modify our current products, or develop new products, to address additional indications; Â Â â— our ability to obtain additional financing through future equity or debt financings; Â Â â— the expected timing of 510(k)Â clearances by the U.S. Food and Drug Administration (â€œFDAâ€) which may include but are not limited to additional versions of Pantheris, Ocelot, Tigereye and Lightbox; Â Â â— the expected timing of 510(k)Â submission to the FDA, and associated marketing clearances by the FDA, which may include but are not limited to additional versions of Pantheris, Ocelot, Tigereye and Lightbox; Â Â â— our ability to realize benefits from our license and collaboration agreements with Zylox-Tonbridge; Â Â â— the expected growth in our business and our organization; Â Â â— our expectations regarding government and third-party payor coverage and reimbursement, including the ability of Pantheris to qualify for reimbursement codes used by other atherectomy products; Â Â â— our ability to retain and recruit key personnel, including the continued development of our sales and marketing infrastructure; Â Â â— our ability to obtain and maintain intellectual property protection for our products; Â Â â— our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing; Â Â â— our expectations regarding revenue, cost of revenue, gross margins, and expenses, including research and development and selling, general and administrative expenses; Â Â â— our ability to identify and develop new and planned products and acquire new products, including those for the coronary market; Â Â â— our financial performance; Â Â â— our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business, both in the United States and internationally; and Â Â â— developments and projections relating to our competitors or our industry. Â Â Â Â We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on managementâ€™s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and managementâ€™s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on FormÂ 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the â€œRisk Factorsâ€ section and elsewhere in this Quarterly Report on FormÂ 10-Q and our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2024. We urge you to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on FormÂ 10-Q. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. Â You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on FormÂ 10-Q to conform these statements to actual results or to changes in our expectations. Â You should read this Quarterly Report on FormÂ 10-Q and the documents that we reference in this Quarterly Report on FormÂ 10-Q and have filed with the United States Securities and Exchange Commission (â€œSECâ€) as exhibits to the Quarterly Report on FormÂ 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. Â Â Â Â AVINGER,Â INC. AS OF AND FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 Â TABLE OF CONTENTS Â Â Â Page PartÂ I Financial Information Â ItemÂ 1. Unaudited Financial Statements 1 Â Condensed Balance Sheets 1 Â Condensed Statements of Operations and Comprehensive Loss 2 Â Condensed Statements of Stockholdersâ€™Â Equity 3 Â Condensed Statements of Cash Flows 5 Â Notes to Condensed Financial Statements 6 ItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 23 ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk 38 ItemÂ 4. Controls and Procedures 38 Â Â Â PartÂ II Other Information Â ItemÂ 1. Legal Proceedings 38 ItemÂ 1A. Risk Factors 39 ItemÂ 2. Unregistered Sales of Equity Securities and Use of Proceeds 43 ItemÂ 3. Defaults Upon Senior Securities 43 ItemÂ 4. Mine Safety Disclosures 43 ItemÂ 5. Other Information 43 ItemÂ 6. Exhibits 44 Â Â Â Signatures 45 Â â€œAvinger,â€ â€œPantheris,â€ â€œLumivascular,â€ and â€œTigereyeâ€ are trademarks of our company. Our logo and our other trade names, trademarks and service marks appearing in this Quarterly Report on FormÂ 10-Q are our property. Other trade names, trademarks and service marks appearing in this Quarterly Report on FormÂ 10-Q are the property of their respective owners. Solely for convenience, our trademarks and trade names referred to in this Quarterly Report on FormÂ 10-Q appear without the â„¢ symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and trade names. Â Â Â Â Â PARTÂ I. FINANCIAL INFORMATION Â ITEM 1.Â Â Â Â UNAUDITED FINANCIAL STATEMENTS Â AVINGER,Â INC. CONDENSED BALANCE SHEETS (unaudited) (In thousands, except share and per share data) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Assets Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 5,901 Â Â $ 5,275 Â Accounts receivable, net of allowance for doubtful accounts of $56 and $41 at September 30, 2024 and December 31, 2023, respectively Â Â 877 Â Â Â 1,014 Â Inventories, net Â Â 3,759 Â Â Â 5,298 Â Prepaid expenses and other current assets Â Â 947 Â Â Â 575 Â Total current assets Â Â 11,484 Â Â Â 12,162 Â Â Â Â Â Â Â Â Â Right of use asset Â Â 1,427 Â Â Â 1,102 Â Property and equipment, net Â Â 466 Â Â 487 Â Other assets Â Â 224 Â Â Â 19 Â Total assets Â $ 13,601 Â Â $ 13,770 Â Â Â Â Â Â Â Â Â Liabilities and stockholdersâ€™ equity (deficit) Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $ 921 Â Â $ 777 Â Accrued compensation Â Â 1,962 Â Â Â 2,311 Â Preferred stock dividends payable Â Â 653 Â Â Â â€” Â Accrued expenses and other current liabilities Â Â 589 Â Â Â 817 Â Leasehold liability, current portion Â Â 1,210 Â Â Â 1,102 Â Borrowings Â Â 4,168 Â Â Â 14,293 Â Total current liabilities Â Â 9,503 Â Â Â 19,300 Â Â Â Â Â Â Â Â Â Leasehold liability, long-term portion Â Â 217 Â Â Â â€” Â Other long-term liabilities Â Â 6 Â Â Â 672 Â Total liabilities Â Â 9,726 Â Â Â 19,972 Â Â Â Â Â Â Â Â Â Commitments and contingencies (Note 6) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholdersâ€™ equity (deficit): Â Â Â Â Â Â Â Preferred stock issuable in series, par value of $0.001; Â Â Â Â Â Â Â Shares authorized: 5,000,000 at September 30, 2024 and December 31, 2023; Â Â Â Â Â Â Â Shares issued and outstanding: 30,229 and 62,881 at September 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $18,338 and $62,796 at September 30, 2024 and December 31, 2023, respectively Â Â â€” Â Â Â â€” Â Common stock, par value of $0.001; Â Â Â Â Â Â Â Shares authorized: 100,000,000 at September 30, 2024 and December 31, 2023; Â Â Â Â Â Â Â Shares issued and outstanding: 2,783,891 and 1,279,928 at September 30, 2024 and December 31, 2023, respectively Â Â 3 Â Â 1 Â Additional paid-in capital Â Â 438,153 Â Â Â 414,493 Â Accumulated deficit Â Â (434,281) Â Â (420,696) Total stockholdersâ€™ equity (deficit) Â Â 3,875 Â Â Â (6,202) Total liabilities and stockholdersâ€™ equity (deficit) Â $ 13,601 Â Â $ 13,770 Â Â Â 1 Â Â Â AVINGER,Â INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (In thousands, except per share data) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues Â $ 1,650 Â Â $ 1,817 Â Â $ 5,356 Â Â $ 5,746 Â Cost of revenues Â Â 1,224 Â Â Â 1,429 Â Â Â 4,209 Â Â Â 4,117 Â Gross profit Â Â 426 Â Â Â 388 Â Â Â 1,147 Â Â Â 1,629 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 1,086 Â Â Â 1,044 Â Â Â 3,052 Â Â Â 3,388 Â Selling, general and administrative Â Â 3,009 Â Â Â 3,377 Â Â Â 10,980 Â Â Â 10,261 Â Total operating expenses Â Â 4,095 Â Â Â 4,421 Â Â Â 14,032 Â Â Â 13,649 Â Loss from operations Â Â (3,669) Â Â (4,033) Â Â (12,885) Â Â (12,020) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest expense, net Â Â (48) Â Â (455) Â Â (698) Â Â (1,292) Other income (expense), net Â Â 11 Â Â Â 12 Â Â Â (2) Â Â 16 Â Net loss and comprehensive loss Â Â (3,706) Â Â (4,476) Â Â (13,585) Â Â (13,296) Accretion of preferred stock dividends Â Â (349) Â Â 2,436 Â Â Â (652) Â Â â€” Â Gain on exchange of Series A for Series A-1 convertible preferred stock Â Â â€” Â Â Â â€” Â Â Â 1,908 Â Â Â â€” Â Net loss applicable to common stockholders Â $ (4,055) Â $ (2,040) Â $ (12,329) Â $ (13,296) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss per share attributable to common stockholders, basic and diluted Â $ (1.82) Â $ (2.92) Â $ (6.93) Â $ (21.48) Weighted average common shares used to compute net loss per share, basic and diluted Â Â 2,224 Â Â Â 698 Â Â Â 1,780 Â Â Â 619 Â Â 2 Â Â Â AVINGER,Â INC. CONDENSED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (DEFICIT) (unaudited) (In thousands, except share data) Â Â Â Convertible Preferred Stock Â Â Common Stock Â Â Additional Paid-in Â Â Accumulated Â Â Total Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at June 30, 2023 Â Â 60,961 Â Â Â $ â€” Â Â Â 622,578 Â Â Â $ 9 Â Â $ 404,597 Â Â Â $ (411,196) Â $ (6,590) Issuance of common stock in public offerings, net of commissions and issuance costs Â Â â€” Â Â Â â€” Â Â Â 600,454 Â Â Â 1 Â Â Â 5,136 Â Â Â â€” Â Â Â 5,137 Â Conversion of CRG loan principal into Series E convertible preferred stock Â Â 1,920 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,920 Â Â Â â€” Â Â Â 1,920 Â Employee stock-based compensation Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 219 Â Â Â â€” Â Â Â 219 Â Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares Â Â â€” Â Â Â â€” Â Â Â 56,896 Â Â Â (9) Â Â 9 Â Â Â â€” Â Â Â â€” Â Waiver of Series A preferred stock dividends Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 2,436 Â Â Â â€” Â Â Â 2,436 Â Net and comprehensive loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (4,476) Â Â (4,476) Balance at September 30, 2023 Â Â 62,881 Â Â Â $ â€” Â Â Â 1,279,928 Â Â Â $ 1 Â Â $ 414,317 Â Â Â $ (415,672) Â $ (1,354) Â Â Â Â Convertible Preferred Stock Â Â Common Stock Â Â Additional Paid-in Â Â Accumulated Â Â Total Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at June 30, 2024 Â Â 30,229 Â Â Â $ â€” Â Â Â 1,916,434 Â Â Â $ 2 Â Â Â $ 438,326 Â Â Â $ (430,575) Â $ 7,753 Â Issuance of common stock in public offerings, net of commissions and issuance costs Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 45) Â Â Â â€” Â Â Â (45) Â Â Â â€” Â Â Â (45) Â Â Â â€” Â Â Â â€” Â Exercises of pre-funded warrants for common stock Â Â â€” Â Â Â â€” Â Â Â 867,457 Â Â Â 1 Â Â Â â€” Â Â Â â€” Â Â Â 1 Â Employee stock-based compensation Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 222 Â Â Â â€” Â Â Â 222 Â Accretion of preferred stock dividends Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (349) Â Â Â â€” Â Â Â (349) Net and comprehensive loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (3,706) Â Â (3,706) Balance at September 30, 2024 Â Â 30,229 Â Â Â $ â€” Â Â Â 2,783,891 Â Â Â $ 3 Â Â $ 438,153 Â Â Â $ (434,281) Â $ 3,875 Â Â 3 Â Â Â AVINGER,Â INC. CONDENSED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (DEFICIT) (CONTINUED) (unaudited) (In thousands, except share data) Â Â Â Convertible Preferred Stock Â Â Common Stock Â Â Additional Paid-in Â Â Accumulated Â Â Total Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity (Deficit) Â Balance at December 31, 2022 Â Â 60,961 Â Â Â $ â€” Â Â Â 522,177 Â Â Â $ 8 Â Â Â $ 406,514 Â Â Â $ (402,376) Â $ 4,146 Â Issuance of common stock in public offerings, net of commissions and issuance costs Â Â â€” Â Â Â â€” Â Â Â 607,236 Â Â Â 1 Â Â Â 5,173 Â Â Â â€” Â Â Â 5,174 Â Conversion of CRG loan principal into Series E convertible preferred stock Â Â 1,920 Â Â Â â€” Â Â Â â€” Â Â Â 1,920 Â Â Â â€” Â Â Â 1,920 Â Exercise of pre-funded warrants for common stock Â Â â€” Â Â Â â€” Â Â Â 91,425 Â Â Â 1 Â Â Â (2) Â Â Â â€” Â Â Â (1) Issuance of common stock upon vesting of restricted stock units Â Â â€” Â Â Â â€” Â Â Â 2,294 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Employee stock-based compensation Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 703 Â Â Â â€” Â Â Â 703 Â Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares Â Â â€” Â Â Â â€” Â Â Â 56,896 Â Â Â (9) Â Â 9 Â Â Â â€” Â Â Â â€” Â Net and comprehensive loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (13,296) Â Â (13,296) Balance at September 30, 2023 Â Â 62,881 Â Â Â $ â€” Â Â Â 1,279,928 Â Â Â $ 1 Â Â $ 414,317 Â Â Â $ (415,672) Â $ (1,354) Â Â Â Â Convertible Preferred Stock Â Â Common Stock Â Â Additional Paid-in Â Â Accumulated Â Â Total Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity (Deficit) Â Balance at December 31, 2023 Â Â 62,881 Â Â Â $ â€” Â Â Â 1,279,928 Â Â Â $ 1 Â Â $ 414,493 Â Â Â $ (420,696) Â $ (6,202) Issuance of common stock and Series F preferred stock in a Private Placement, net of commissions and issuance costs Â Â 7,224 Â Â Â â€” Â Â Â 75,327 Â Â Â â€” Â Â Â 6,880 Â Â Â â€” Â Â Â 6,880 Â

Issuance of common stock warrants in connection with the Private Placement Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 127 Â Â Â â€” Â Â Â 127 Â Exercises of pre-funded warrants for common stock Â Â â€” Â Â Â â€” Â Â Â 867,457 Â Â Â 1 Â Â Â â€” Â Â Â â€” Â Â Â 1 Â Issuance of common stock in public offerings, net of commissions and issuance costs Â Â â€” Â Â Â â€” Â Â Â 330,000 Â Â Â â€” Â Â Â 5,155 Â Â Â â€” Â Â Â 5,155 Â Conversion of CRG loan principal into Series H convertible preferred stock Â Â 11,000 Â Â Â â€” Â Â Â â€” Â Â Â 11,000 Â Â Â â€” Â Â Â 11,000 Â Cancellation of Series A preferred stock Â Â (60,876) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Issuance of Series A-1 preferred stock, net of commissions and issuance costs Â Â 10,000 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Issuance of common stock upon vesting of restricted stock awards Â Â â€” Â Â Â â€” Â Â Â 368,503 Â Â Â 1 Â Â Â â€” Â Â Â â€” Â Â Â 1 Â Net share settlement of restricted stock awards in satisfaction of tax obligations Â Â â€” Â Â Â â€” Â Â Â (137,324) Â Â â€” Â Â Â (374) Â Â â€” Â Â Â (374) Employee stock-based compensation Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 1,525 Â Â Â â€” Â Â Â 1,525 Â Accretion of preferred stock dividends Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (652) Â Â â€” Â Â Â (652) Net and comprehensive loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (13,585) Â Â (13,585) Balance at September 30, 2024 Â Â 30,229 Â Â $ â€” Â Â Â 2,783,891 Â Â $ 3 Â Â $ 438,153 Â Â $ (434,281) Â $ 3,875 Â Â Â 4 Â Â Â AVINGER,Â INC. CONDENSED STATEMENTS OF CASH FLOWS (unaudited) (In thousands) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities Â Â Â Â Â Â Â Â Net loss Â $ (13,585) Â $ (13,296) Adjustments to reconcile net loss to net cash used in operating activities: Â Â â€” Â Â Â â€” Â Depreciation and amortization Â Â 245 Â Â Â 214 Â Amortization of debt issuance costs and debt discount Â Â 32 Â Â Â 62 Â Stock-based compensation Â Â 1,525 Â Â Â 703 Â Noncash interest expense and other charges Â Â 844 Â Â Â 1,488 Â Change in right of use asset Â Â 16 Â Â Â 42 Â Provision for excess and obsolete inventories Â Â 111 Â Â Â 350 Â Other non-cash charges Â Â 14 Â Â Â (51) Changes in operating assets and liabilities: Â Â â€” Â Â Â â€” Â Accounts receivable Â Â 122 Â Â Â 278 Â Inventories Â Â 1,205 Â Â Â (996) Prepaid expenses and other current assets Â Â (372) Â Â (188) Other assets Â Â (221) Â Â 21 Â Accounts payable Â Â 144 Â Â Â (82) Accrued compensation Â Â (349) Â Â (250) Accrued expenses and other current liabilities Â Â (228) Â Â 240 Â Other long-term liabilities Â Â (666) Â Â 422 Â Net cash used in operating activities Â Â (11,163) Â Â (11,043) Â Â Â Â Â Â Â Â Â Cash flows from investing activities Â Â Â Â Â Â Â Â Purchase of property and equipment Â Â â€” Â Â Â (8) Net cash used in investing activities Â Â â€” Â Â Â (8) Â Â Â Â Â Â Â Â Â Cash flows from financing activities Â Â Â Â Â Â Â Â Proceeds from the issuance of common stock and convertible preferred stock in a private placement, net of commissions and issuance costs Â Â 7,007 Â Â Â â€” Â Proceeds from issuance of common stock upon warrant exercises Â Â 1 Â Â Â â€” Â Proceeds from the issuance of common stock in public offerings, net of commissions and issuance costs Â Â 5,155 Â Â Â 5,173 Â Net share settlement on restricted stock awards in satisfaction of tax obligations Â Â (374) Â Â â€” Â Net cash provided by financing activities Â Â 11,789 Â Â Â 5,173 Â Â Â Â Â Â Â Â Â Net change in cash and cash equivalents Â Â 626 Â Â Â (5,878) Cash and cash equivalents, beginning of period Â Â 5,275 Â Â Â 14,603 Â Cash and cash equivalents, end of period Â $ 5,901 Â Â $ 8,725 Â Â Â Â Â Â Â Â Â Supplemental disclosure of cash flow information Â Â Â Â Â Â Â Noncash investing and financing activities: Â Â Â Â Â Â Â Increase to right of use asset and leasehold liability arising from lease amendment Â $ 1,177 Â Â $ â€” Â Conversion of CRG loan principal and accrued interest into Series H convertible preferred stock Â $ 11,000 Â Â $ 1,920 Â Accretion of preferred stock dividends Â $ 652 Â Â $ â€” Â Reclassification of other long-term liabilities to accrued compensation Â $ â€” Â Â $ 796 Â Transfers between inventory and property and equipment Â $ 223 Â Â $ 32 Â Â See accompanying notes. Â 5 Â Â AVINGER,Â INC. Â Notes to Condensed Financial Statements Â Â 1. Organization Â Organization, Nature of Business Â Avinger, Inc. (the â€œCompanyâ€), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (â€œPADâ€). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (â€œU.S.â€) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (â€œOCTâ€) visualization with interventional catheters and is the industryâ€™s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Companyâ€™s Lumivascular platform consists of a capital component, Lightbox consoles, as well as a variety of disposable catheter products. The Companyâ€™s current catheter products include Ocelot, Tigereye and Tigereye ST, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (â€œCTOâ€). The Company also has image-guided atherectomy products, Pantheris, Pantheris SV and Pantheris LV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California. Â Liquidity Matters Â The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Update (â€œASUâ€) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entityâ€™s ability to continue as a going concern within one year from the date of the issuance of these financial statements. Â In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2024, the Company had an accumulated deficit of $434.3Â million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $5.9 million at September 30, 2024, together with debt and other financing activities and expected revenues from operations will be sufficient to allow the Company to fund its current operations through the end of the fourth quarter of 2024. On March 5, 2024, the Company entered into a financing as part of a broader strategic collaboration with Zylox-Tonbridge Medical Technology Co., Ltd. (â€œZylox-Tonbridgeâ€) in which the Company received an aggregate of $7.5 million before any commissions, legal and accounting fees, and other ancillary expenses as described more fully below. On June 17, 2024, the Company completed a public offering in which it received an aggregate of $6.0 million before any commissions, legal and accounting fees, and other ancillary expenses. The Company had also received net proceeds of approximately $6.5 million from the sale of its common stock under an At The Market Offering Agreement from the time of activation through the quarter ended September 30, 2024. On October 17, 2024, the Company reactivated the ATM Agreement. During October and part of November 2024, the Company sold 107,080 shares of common stock pursuant to the ATM Agreement at an average price ofÂ $0.82 per share for aggregate proceeds of approximately $88,000, of which approximately $2,600Â was paid in the form of commissions to the Agent. The Company may seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives. Â The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for its existing stockholders. Given the volatility in the Companyâ€™s stock price, any financing that the Company may undertake in the next twelve months could cause substantial dilution to its existing stockholders, and there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern. In addition, the macroeconomic environment has in the past resulted in and could continue to result in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company. Â If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development and sale of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Companyâ€™s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding. Â 6 Â Â Additionally, due to the substantial doubt about the Companyâ€™s ability to continue operating as a going concern and the â€œMaterial Adverse Changeâ€ clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively â€œCRGâ€), the entire amount of outstanding borrowings at September 30, 2024 and December 31, 2023 has been classified as current in these financial statements. CRG has not purported that an Event of Default (as defined in the Loan Agreement) has occurred due to a Material Adverse Change. Â Currently substantially all of the Companyâ€™s cash and cash equivalents are held at a single financial institution. The Companyâ€™s previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. The Company has regained access to its accounts with the new institution and is currently reviewing its banking relationships. Potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Companyâ€™s access to cash and cash equivalents. Â If the Company is unable to access its cash and cash equivalents as needed, its financial position and ability to operate its business will be adversely affected. Â Public Offerings Â June 2024 Offering Â On June 13, 2024, the Company entered into a securities purchase agreement with two institutional investors for the issuance and sale of 3,614,457 shares of its common stock in a best efforts public offering (â€œthe Offeringâ€) at a purchase price of $1.66 per share, or pre-funded warrants in lieu thereof. The Company received aggregate net proceeds of approximately $5.2 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Â As a result, the Company issued (i) 330,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 3,284,457 shares of common stock (the â€œPre-Funded Warrantsâ€). During the third quarter ofÂ 2024, a total of 867,457 shares of the Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 867,457 shares of common stock. After giving effect to these aforementioned exercises, as of September 30, 2024,Â 2,417,000 Pre-Funded Warrants remain outstanding. Â In addition, the Company issued to the investors in the Offering (i) Series A-1 warrants (the â€œSeries A-1 Warrantsâ€) to purchase up to an aggregate of 3,614,457 shares of common stock, (ii) Series A-2 warrants (the â€œSeries A-2 Warrantsâ€) to purchase up to an aggregate of 3,614,457 shares of common stock, and (iii) Series A-3 warrants (the â€œSeries A-3 Warrants,â€ and together with the Series A-1 Warrants and Series A-2 Warrants, the â€œWarrantsâ€) to purchase up to an aggregate of 3,614,457 shares of common stock. Each share of common stock or Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. Each Warrant has an exercise price of $1.66 per. Â The Series A-1 Warrants expire on the earlier of August 12, 2029 and 60 days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. The Series A-2 Warrants expire on the earlier of August 12, 2026 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. The Series A-3 Warrants expire on the earlier of May 12, 2025 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO investigational device exemption (â€œIDEâ€) application. Â Pursuant to an engagement letter (the â€œEngagement Letterâ€) with H.C. Wainwright & Co., LLC (the â€œPlacement Agentâ€), the Company, in connection with the Offering, issued warrants to designees of the Placement Agent (the â€œPlacement Agent Warrantsâ€) to purchase up to an aggregate of 216,867 shares of common stock (the â€œPlacement Agent Warrant Sharesâ€). The Placement Agent Warrants have substantially the same terms as the Warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $2.075 per share and expire on June 13, 2029. Â 7 Â Â At The Market Offering Agreement Â On May 20, 2022, the Company entered into an At The Market Offering Agreement (the â€œATM Agreementâ€) with H.C. Wainwright & Co., LLC (the â€œAgentâ€), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.001 per share (the â€œSharesâ€) up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Companyâ€™s shelf registration statement on Form S-3, which was initially filed with the SEC on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on May 20, 2022. On August 3, 2022, the Company suspended sales under the ATM Agreement. On March 17, 2023, the Company reactivated the ATM Agreement. During the year ended December 31, 2023, the Company soldÂ 607,241Â shares of common stock at an average price of $9.01Â per share for aggregate proceeds of approximately $5.5Â million, of which approximately $164,000Â was paid in the form of commissions to the Agent. There were no sales under the ATM Agreement during the three or nine months ended September 30, 2024. On October 17, 2024, the Company reactivated the ATM Agreement. During October and part of November 2024, the Company sold 107,080 shares of common stock pursuant to the ATM Agreement at an average price ofÂ $0.82 per share for aggregate proceeds of approximately $88,000, of which approximately $2,600Â was paid in the form of commissions to the Agent. While the Company may attempt additional sales in the future, there can be no assurance that the Company will be successful in acquiring additional funding through these means. Â Other than the ATM Agreement, the Company currently does not have any commitments to obtain additional funds. Â Strategic Partnership and Private Placement Â On March 4, 2024, the Company entered into a License and Distribution Agreement (the â€œLicense Agreementâ€) with Zylox-Tonbridge effective as of the Initial Closing (defined below), pursuant to which the Company will license and distribute certain of the Companyâ€™s products (including consumables) in the Greater China region, including mainland China, Hong Kong, Macao, and Taiwan (the â€œTerritoryâ€). Zylox-Tonbridge will lead all regulatory activities for the registration of the Avinger products in the Territory. Avinger will also license its intellectual property and know-how related to Avinger products to Zylox-Tonbridge so that Zylox-Tonbridge can manufacture the localized products in the Territory. Avinger will supply Avinger products to Zylox-Tonbridge until Zylox-Tonbridgeâ€™s manufacturing capability has been established and Zylox-Tonbridge has obtained the regulatory approval of the localized products manufactured by Zylox-Tonbridge. All sales of Avinger products locally manufactured by Zylox-Tonbridge with regulatory approval by the regulatory authorities in the Territory and commercialized in the Territory will be royalty bearing to Avinger at a rate from a mid-single to high-single digit percentage depending on the amount of gross revenue as defined in the License Agreement, with certain increases depending on the amount of product gross margin. The License Agreement has an initial term of 20 years, which shall be further automatically extended for additional 20-year terms, subject to certain conditions. The License Agreement may not be terminated by either party, other than for certain uncured material breaches or the other partyâ€™s insolvency. During the three and nine months ended September 30, 2024, the Company received approximately $0.2 million and $0.4Â million respectively from Zylox-Tonbridge related to inventory consumed for regulatory approval which is recorded as a reduction to research and development expenses in the Condensed Statement of Operations and Comprehensive Loss for the three months ended September 30, 2024 which substantially offset the related expenditures associated with the inventory consumption. Â In connection with the License Agreement, on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the â€œCollaboration Agreementâ€ and, together with the License Agreement, the â€œStrategic Collaborationâ€), which provides the opportunity for the Company to access certain Zylox-Tonbridge peripheral vascular products for distribution in the U.S. and Germany. The agreement also provides the option for Avinger to source finished goods inventory from Zylox-Tonbridge following registration of Zylox-Tonbridgeâ€™s manufacturing facility with the FDA. Â Private Placement Â On March 4, 2024, in connection with the Strategic Collaboration, the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the â€œPurchaserâ€), entered into a Securities Purchase Agreement (the â€œPurchase Agreementâ€), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Companyâ€™s common stock, and shares of two new series of the Companyâ€™s preferred stock (the â€œPrivate Placementâ€). On March 5, 2024, (the â€œInitial Closingâ€), the Company issued to the Purchaser 75,327 shares of the common stock at a purchase price per share of $3.664 (the â€œPurchase Priceâ€), and 7,224 shares of a newly authorized Series F convertible preferred stock, par value $0.001 per share (the â€œSeries F

Preferred Stockâ€), at a purchase price per share of $1,000, for an aggregate purchase price ofÂ $7.5 million. Â 8 Â Â Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of common stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock (the â€œSeries F Certificate of Designationâ€). Â Upon completion of the following as mutually agreed upon by the Company and the Purchaser: (i) the successful registration and listing under 21 CFR part 807 with the FDAÂ of the Purchaser and one of its designated affiliates to manufacture Avingerâ€™s products, and (ii) the Company achieving an aggregate of $10 million in gross revenue within any four consecutive fiscal quarters after the Initial Closing, excluding any gross revenue achieved by Avinger under the License Agreement discussed above (together, the â€œMilestonesâ€), the Purchaser will invest an additional $7.5 million (the â€œMilestone Closingâ€) to purchase shares of the Companyâ€™s new Series G convertible preferred stock, par value $0.001 per share (the â€œSeries G Preferred Stockâ€). Each share of Series G Preferred Stock will have a stated value of $1,000 and will be convertible into shares of common stock at a conversion price of equal to the lowest of (x) the Purchase Price, (y) the closing price of the common stock on the date immediately preceding the Milestone Closing, and (z) the average closing price for the last five trading days preceding the Milestone Closing, provided that the conversion price will be no less than $0.20. The Milestone Closing was determined to be a separate freestanding equity-classified instrument issued together with the common stock and Series F preferred stock, all of which are classified within equity. Â On May 22, 2024, the Company held a special meeting of stockholders to vote on the following proposals resulting from the Private Placement (i) accept conversion of the shares of Series F Preferred Stock in excess of 19.9% of the Companyâ€™s outstanding common stock, which may be deemed a â€œchange of controlâ€ under Nasdaq Listing Rule 5635(b) and (ii) issue and sell shares of Series G Preferred Stock upon completion of the Milestones. Both proposals were approved by the Companyâ€™s stockholders. There were no conversions of Series F Preferred Stock during the three months ended September 30, 2024. Â The Company engaged two financial advisors in connection with the Private Placement and agreed to pay them an aggregate cash fee equal to 7% of the gross proceeds to the Company. Additionally, the Company agreed to issue to one financial advisor warrants to purchase an aggregate number of shares of common Stock equal to 2% of the gross proceeds. In connection with the Private Placement, the Company issued the financial advisor warrants (the â€œAdvisor Warrantsâ€) to purchase 40,938 shares of common stock. The cash fee of approximately $0.5 million and warrants with a fair value of approximately $0.1 million are considered financing costs and are recognized as a reduction of the proceeds from the Private Placement. Â Series A Preferred Stock Exchange Â On March 5, 2024, the Company entered into a Securities Purchase Agreement (the â€œA-1 Securities Purchase Agreementâ€) with CRG to exchange all outstanding shares of Series A preferred stock for 10,000 shares of Series A-1 preferred stock (the â€œExchangeâ€). Among other things, the shares of Series A-1 preferred stock: (i) are convertible into an aggregate of approximately 2,729,257 shares of common stock at a conversion price equal to the Purchase Price, (ii) do not accrue or pay dividends payable solely on the Series A-1 preferred stock, (iii) will have no liquidation preference and (iv) will be junior in rank to shares of the Companyâ€™s Series E preferred stock, Series F preferred stock and Series G preferred stock. The Exchange resulted in approximately $1.9 million gain included in the net loss applicable to common holders for the nine months ended September 30, 2024. Â CRG Loan Amendment Â Also on March 5, 2024, the Company entered into Amendment No. 9 to Loan Agreement effective as of the Initial Closing (the â€œAmendmentâ€) with CRG, which amends the Loan Agreement to, among other things: Â Â - extend the interest-only period through December 31, 2026; Â - provide that interest payable through December 31, 2026 may be payable in kind rather than in cash; and Â - permit the payment of dividends on the preserved stock issued or issuable to the Purchaser. Â 9 Â Â Â Â 2. Summary of Significant Accounting Policies Â Basis of Presentation Â The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S.Â GAAPâ€) and pursuant to the rulesÂ and regulations of the SEC. The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Companyâ€™s financial information. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending DecemberÂ 31, 2024, or for any other interim period or for any future year. The DecemberÂ 31, 2023 condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rulesÂ and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Companyâ€™s FormÂ 10-K for the fiscal year ended DecemberÂ 31, 2023, which was filed with the SEC on MarchÂ 20, 2024. The Companyâ€™s significant accounting policies are more fully described in Note 2 of the Notes to Financial Statements included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended DecemberÂ 31, 2023. Â Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Companyâ€™s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Â Concentration of Credit Risk, and Other Risks and Uncertainties Â Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. Â The Companyâ€™s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, First Citizens Bank, which acquired the Companyâ€™s prior banking partner, Silicon Valley Bank, in March 2023. The counterparties to the agreements relating to the Companyâ€™s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Managementâ€™s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and DecemberÂ 31, 2023. The Companyâ€™s previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. Although the Company has regained access to its accounts with this institution, now a division of the acquiring bank, and is currently reviewing its banking relationships, potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Companyâ€™s access to cash and cash equivalents. Â The Companyâ€™s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Managementâ€™s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and December 31, 2023. At September 30, 2024, there was one customer that represented 38% of the Companyâ€™s accounts receivable. At DecemberÂ 31, 2023, there was one customer that represented 24% of the Companyâ€™s accounts receivable. For the nine months ended September 30, 2024 there was one customer that represented 17% of revenues. For the three months ended September 30, 2024, there were two customers that represented 20% and 11% of revenues, respectively. For the three and nine months ended September 30, 2023, there was one customer that represented 22% and 17% of revenues, respectively. Disruption of the Companyâ€™s sales orders or a deterioration of financial condition of its customers would have a negative impact on the Companyâ€™s financial position and results of operations. Â 10 Â Â Product Warranty Costs Â The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Beginning balance Â $ 150 Â Â $ 128 Â Â $ 193 Â Â $ 109 Â Warranty provision Â Â 3 Â Â Â 18 Â Â Â 35 Â Â Â 52 Â Usage/Release Â Â (25) Â Â (7) Â Â (100) Â Â (22) Ending balance Â $ 128 Â Â $ 139 Â Â $ 128 Â Â $ 139 Â Â Net Loss per Share Attributable to Common Stockholders Â Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holdersâ€™ continued service to the Company. As of September 30, 2024 and 2023, there were no shares subject to repurchase. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive. Â Net loss per share applicable to common stockholders was determined as follows (in thousands, except per share data): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss applicable to common stockholders Â $ (4,055) Â $ (2,040) Â $ (12,329) Â $ (13,296) Weighted average common stock outstanding, basic and diluted Â Â 2,224 Â Â Â 698 Â Â Â 1,780 Â Â Â 619 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (1.82) Â $ (2.92) Â $ (6.93) Â $ (21.48) Â The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Common stock warrants equivalents Â Â 14,425,040 Â Â Â 459,019 Â Â Â 5,844,318 Â Â Â 483,947 Â Common stock options Â Â 15 Â Â Â 20 Â Â Â 15 Â Â Â 20 Â Convertible preferred stock Â Â 30,229 Â Â Â 62,151 Â Â Â 35,121 Â Â Â 61,362 Â Unvested restricted stock units Â Â 112,459 Â Â Â 91,630 Â Â Â 114,730 Â Â Â 88,585 Â Â Â Â 14,567,743 Â Â Â 612,820 Â Â Â 5,944,184 Â Â Â 633,914 Â Â 11 Â Â Segment and Geographical Information Â The Company operates and manages its business as one reportable and operating segment. The Companyâ€™s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Companyâ€™s long-lived assets, which are comprised of property and equipment, are based in the United States. For the three months ended September 30, 2024 and 2023, 94% and 91% respectively, of the Companyâ€™s revenues were in the United States. For the nine months ended September 30, 2024 and 2023, 93% and 92%, respectively, of the Companyâ€™s revenues were derived from the United States based on the shipping location of the external customer. The remaining revenues for the three and nine months ended September 30, 2024 and 2023, were primarily derived from Germany. Â Fair Value Measurements Â As of September 30, 2024 and DecemberÂ 31, 2023, cash equivalents were all categorized as LevelÂ 1 and consisted of money market funds. As of September 30, 2024 and DecemberÂ 31, 2023, there were no financial assets and liabilities categorized as Level 2 or 3. There were no transfers between fair value hierarchy levels during the three or nine months ended September 30, 2024 and September 30, 2023. Â Recent Accounting Pronouncements Â Recent accounting standards not yet adopted Â In August 2020, the FASB issued ASU No. 2020-06,Â Debtâ€”Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. Â As a result, after adopting the ASUâ€™s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under Accounting Standards Codification (â€œASCâ€) 815 or (ii) a convertible debt instrument was issued at a substantial premium. The ASU becomes effective for the Company, as a smaller reporting company as defined by the SEC,Â in the first quarter of 2024. The Company has not yet adopted this standard.Â This new standard isÂ not expected to have a material impact on the Companyâ€™s financial statements. Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) â€“ Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has not yet adopted this standard. This new standard is not expected to have a material impact on the Companyâ€™s financial statements. Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU No. 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, if any, with further disaggregation required for significant individual jurisdictions. The ASU is effective for the Company for fiscal years beginning after December 15. ASU No. 2023-09 allows for adoption using either a prospective or retrospective transition method. This new standard is not expected to have a material impact on the Companyâ€™s financial statements. Â Â 3. Inventories Â Inventories consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $ 1,863 Â Â $ 3,203 Â Work-in-process Â Â 154 Â Â Â 25 Â Finished products Â Â 1,742 Â Â Â 2,070 Â Total inventories Â $ 3,759 Â Â $ 5,298 Â Â 12 Â Â Â 4. Borrowings Â CRG Â On September 22, 2015, the Company entered into a Term Loan Agreement, as amended (the â€œLoan Agreementâ€) with CRG under which, subject to certain conditions, the Company had the right to borrow up to $50 million in principal amount from CRG on or before the end of the twenty-fourth (24th) month period commencing on the first Borrowing Date (as defined in the Loan Agreement). The Company borrowed $30 million on September 22, 2015. The Company borrowed an additional $10 million on June 15, 2016 under the Loan Agreement. Â On February 14, 2018, the Company and CRG further amended the Loan Agreement concurrent with the conversion of $38 million of the principal amount of the senior secured term loan (plus $3.8 million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock. Â On August 2, 2023, the Company and CRG entered into a Securities Purchase Agreement (â€œSeries E Purchase Agreementâ€) pursuant to which the Company issued 1,920 shares of a newly authorized Series E convertible preferred stock (â€œSeries E Preferred Stockâ€) in exchange for CRG surrendering for cancellation $1.92 million of outstanding principal and accrued interest of the senior secured term loan under the Loan Agreement. Each share of Series E preferred stock has a stated value of $1,000 per share and is convertible into 93 shares of the Companyâ€™s common stock at a conversion price of $10.725 per share. Â On May 16, 2024, the Company and CRG entered into another Securities Purchase Agreement (â€œSeries H Purchase Agreementâ€) pursuant to which the Company issued 11,000 shares of a newly authorized Series H convertible preferred stock (â€œSeries H Preferred Stockâ€) in exchange for CRG surrendering for cancellation $11.0 million of outstanding principal and accrued interest of the senior secured term loan under the Loan Agreement. Each share of Series H preferred stock has a stated value of $1,000 per share and is convertible into 259 shares of the Companyâ€™s common stock at a conversion price of $3.86 per share. Both the shares of Series E preferred stock and Series H preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess 9.99% of the Companyâ€™s outstanding voting power and in no case will the beneficial ownership

limitation exceed 19.99% of the Companyâ€™s outstanding voting power on a combined basis (as CRG collectively holds all of the issued and outstanding shares of the Companyâ€™s Series A-1 Convertible Preferred Stock, Series E Convertible Preferred Stock and Series H Convertible Preferred Stock), unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). Â The Company has entered into several amendments to the Loan Agreement (the â€œAmendmentsâ€) with CRG since September 2015. The Amendments, among other things: (1)Â extended the interest-only period through DecemberÂ 31, 2026; (2)Â extended the period during which the Company may elect to pay a portion of interest in payment-in-kind (â€œPIKâ€), interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3)Â permitted the Company to make the entire interest payments in PIK interest payments through DecemberÂ 31, 2026 so long as no Default has occurred and is continuing; (4)Â extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2028; (5)Â reduced the minimum liquidity covenant to $3.5 million at all times; (6)Â eliminated the minimum revenue covenants for all years (7) changed the date under the on-going stand-alone representation regarding no â€œMaterial Adverse Changeâ€ to December 31, 2020; (8) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of the Company and its subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; (9) provided CRG with board observer rights and (10) provide that the board observer may be appointed or removed by written notice from the Majority Lenders (as defined in the Loan Agreement). Â On January 26, 2024, the Company entered into Amendment No. 8 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.0 million until April 1, 2024. Thereafter, the Company was subject to the minimum liquidity requirement of $3.5 million. Â On March 5, 2024, the Company entered into Amendment No. 9 to the Loan Agreement with CRG, which (1) extended the interest-only period through December 31, 2026; (2)Â extended the period during which the Company may elect to pay a portion of interest in PIK interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3)Â permitted the Company to make the entire interest payments in PIK interest payments through DecemberÂ 31, 2026 so long as no Default has occurred and is continuing; and (4) permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. The Company assessed Amendment No. 9 to the Loan Agreement and determined that this represented a loan modification. As such, the unamortized portion of previous issuance costs incurred will be amortized over the modified term, and costs incurred with third parties was expensed as incurred. Â 13 Â Â On June 5, 2024, the Company entered into Amendment No. 10 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.5 million for the period commencing June 1, 2024 and ending July 31, 2024. Thereafter, the Company will be subject to the minimum liquidity requirement of $3.5 million. Â Under the amended Loan Agreement, no cash payments for either principal or interest are required until the first quarter of 2027. The interest will be accrued and included in the debt balance based (to the extent not paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of 12.5%. Beginning in the first quarter of 2027, the Company will be required to make quarterly principal payments (in addition to the interest) of $0.5 million with total principal payments of $1.8 million in 2027 and $1.8 million in 2028. Total cash interest payments required to be made are $0.4 million and $0.1 million for 2027 and 2028 respectively. The maturity date of the Loan (as defined in the Loan Agreement) is December 31, 2028. Â The Company may voluntarily prepay the borrowings in full, with a prepayment premium beginning at 5.0% and declining by 1.0% annually thereafter, with no premium being payable if prepayment occurs after seven and half years of the loan. There is currently no prepayment premium payable. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to 1.5% of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to 15.0% of the amounts borrowed plus any PIK is to be payable at the end of the term or when the borrowings are repaid in full. A short-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Companyâ€™s assets. Â The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for a pre-specified liquidity requirement and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents. The minimum liquidity requirement was temporarily reduced to $1.5 million until July 31, 2024. The Loan Agreement also prohibits the payment of cash dividends on the Companyâ€™s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may accelerate the payment terms of the Loan Agreement upon the occurrence of certain â€œEvents of Defaultâ€ set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a â€œMaterial Adverse Changeâ€ thereunder. Â As of September 30, 2024, the Company was in compliance with all applicable covenants under the Loan Agreement. Â As of September 30, 2024, principal, final facility fee and PIK payments under the Loan Agreement, as amended, were as follows (in thousands): Â Year Ending December 31, Â Â Â Â 2024 (remaining three months of the year) Â $ â€” Â 2025 Â Â â€” Â 2026 Â Â â€” Â 2027 Â Â 2,176 Â 2028 Â Â 4,060 Â Total Â Â 6,236 Â Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2024 Â Â (1,934) Less: Amount representing debt issuance costs Â Â (134) Borrowings, current portion, as of September 30, 2024 Â $ 4,168 Â Â In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of September 30, 2024 and DecemberÂ 31, 2023, the balance of the aggregate debt discount was approximately $134,000 and $166,000, respectively. The Companyâ€™s interest expense associated with the amortization of debt discount was approximately $8,000 and $21,000 during the three months ended September 30, 2024 and 2023, respectively. The Companyâ€™s interest expense associated with the amortization of debt discount was approximately $32,000 and $62,000 during the nine months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024 and 2023, the Company incurred interest expense of approximately $116,000 and $512,000, respectively. For the nine months ended September 30, 2024 and 2023, the Company incurred interest expense of approximately $0.8 million and $1.6Â million, respectively. Â 14 Â Â While, as of the date hereof, CRG has not purported that an Event of Default has resulted due to a Material Adverse Change (as those terms defined in the Loan Agreement), due to the substantial doubt about the Companyâ€™s ability to continue operating as a going concern, the entire outstanding amount of borrowings under the Loan Agreement and associated aggregate debt discount at September 30, 2024 and December 31, 2023 were classified as current in these financial statements. Â Â 5. Leases Â The Companyâ€™s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The most recent amendment also provides an optional one-year extension of the lease following the end of the current term on November 30, 2025, which was not included in the assessment of the lease term as it is not reasonably certain the Company will elect to exercise this option. Rent expense is recognized using the straight-line method over the term of the lease. Â The current lease was to expire on November 30, 2024. On March 6, 2024, the Company entered into an amendment to the lease which extended the lease term for a period of one year, subsequent to the original expiration. As amended, the lease will expire on November 30, 2025. Under the terms of the amendment, the Company will be obligated to pay an additional $1.3 million in base rent payments through November 2025, beginning on December 1, 2024. In total, the Company is obligated to pay approximately $7.1 million in base rent payments through NovemberÂ 2025, which began on December 1, 2019. The weighted average remaining lease term as of September 30, 2024 is 1.2 years. Â In connection with the amendment the Company adjusted its right-of-use asset and lease liability to $2.2 million. As of the date of the amendment, the operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit rate. Â The Companyâ€™s operating lease expense, excluding variable maintenance fees and other expenses on a monthly basis, was approximately $105,000. Rent expense for the three months ended September 30, 2024 and 2023 was approximately $316,000 and $314,000, respectively. Rent expense for the nine months ended September 30, 2024 and 2023 was approximately $947,000 and $942,000, respectively. The Companyâ€™s variable expenses for theÂ threeÂ months endedÂ September 30, 2024Â andÂ 2023Â were approximately $90,000Â and $65,000, respectively. The Companyâ€™s variable expenses for theÂ nine months endedÂ September 30, 2024Â andÂ 2023Â were approximately $263,000Â and $233,000, respectively. Operating right-of-use asset amortization for the three months ended September 30, 2024 and 2023 was approximately $290,000 and $288,000, respectively. Operating right-of-use asset amortization for the nine months ended September 30, 2024 and 2023 was approximately $867,000 and $852,000, respectively. Â The following table presents the future operating lease payments and leasehold liability included on the balance sheet related to the Companyâ€™s operating lease as of September 30, 2024 (in thousands): Â Year Ending December 31, Â Â Â 2024 (remaining three months of the year) Â $ 313 Â 2025 Â Â 1,166 Â Total Â Â 1,479 Â Less: Imputed interest Â Â (52) Leasehold liability as of September 30, 2024 Â $ 1,427 Â Â 15 Â Â The following table shows ROU assets and lease liabilities, and the associated financial statement line items, as of September 30, 2024 and December 31, 2023 (in thousands): Â Lease-Related Assets and Liabilities Â Financial Statement Line Items Â Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Right of use assets: Â Â Â Â Â Â Â Â Â Â Â Operating lease Â Right of use asset Â $ 1,427 Â Â $ 1,102 Â Total right of use assets Â $ 1,427 Â Â $ 1,102 Â Lease liabilities: Â Â Â Â Â Â Â Â Â Â Â Operating lease Â Leasehold liability, current portion Â $ 1,210 Â Â $ 1,102 Â Â Â Leasehold liability, long-term portion Â Â 217 Â Â Â â€” Â Total lease liabilities Â $ 1,427 Â Â $ 1,102 Â Â Â 6. Commitments and Contingencies Â Purchase Obligations Â Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $0.7 million as of September 30, 2024. The majority of this amount is related to commitments to purchase inventory components and services related to the manufacturing of inventory. Â Legal Proceedings Â The Company is not currently involved in any pending legal proceedings that it believes could have a material adverse effect on our financial condition, results of operations or cash flows. From time to time, the Company may be involved in legal proceedings or investigations, which could harm our reputation, business and financial condition and divert the attention of our management from the operation of our business. Â Â 7. Stockholdersâ€™ Equity Â Convertible Preferred Stock Â As of September 30, 2024 and December 31, 2023, the Companyâ€™s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of convertible preferred stock with $0.001 par value per share. As of September 30, 2024 and December 31, 2023, 30,229 and 62,881 shares, respectively, were issued and outstanding. Â Series A Preferred Stock Exchange Â On March 5, 2024, the Company entered into the A-1 Securities Purchase Agreement with CRG to exchange all 60,876 outstanding shares of Series A preferred stock for 10,000 shares of Series A-1 preferred stock. Consequently, there are no shares of Series A preferred stock outstanding as of September 30, 2024. Â The exchange was accounted for as a capital transaction constituting an extinguishment of the Series A preferred stock through the issuance of Series A-1 preferred stock with no net impact to stockholdersâ€™ deficit. At the time of the exchange, the Series A preferred stock had approximately $1.9 million excess fair value in comparison to the Series A-1 preferred stock. The difference in fair value is treated as an adjustment to net loss applicable to common stockholders for the purpose of calculating earnings per share, see Note 2 for details. Â 16 Â Â SeriesÂ A-1 Convertible Preferred Stock Â Each share of Series A-1 preferred stock has a stated value of $1,000 per share and is convertible into 273 shares of the Companyâ€™s common stock at $3.664 per share. The Series A-1 preferred stock is convertible into a total of 2,729,257 shares of common stock subject to certain limitations contained in the A-1 Securities Purchase Agreement. Shares of Series A-1 preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Companyâ€™s outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Companyâ€™s outstanding voting power, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b).The Series A-1 preferred stock has no liquidation preference, no voting rights and ranks junior to shares of the Companyâ€™s Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock in terms of repayment and certain other rights. The SeriesÂ A-1 preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. As of September 30, 2024, 10,000 shares of SeriesÂ A-1 preferred stock were outstanding. Â SeriesÂ B Convertible Preferred Stock Â The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no voting rights and is subject to certain ownership limitations. The SeriesÂ B preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. As of September 30, 2024 and December 31, 2023, 85 shares of Series B preferred stock remained outstanding, which are currently convertible into shares of the Companyâ€™s common stock at $1.66 per share. Â SeriesÂ E Convertible Preferred Stock Â Each share of Series E preferred stock has a stated value of $1,000 per share and is convertible into 93 shares of the Companyâ€™s common stock at a conversion price of $10.725 per share. The Series E preferred stock is convertible into a total of 178,560 shares of common stock subject to certain limitations contained in the Series E Purchase Agreement. Shares of Series E preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Companyâ€™s outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Companyâ€™s outstanding voting power, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). The holders of Series E preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series E preferred stock or cash, at the Companyâ€™s option. The shares of Series E preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series E preferred stock rank junior to Series H preferred stock and are senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. The Series E preferred stock accrued additional dividends of less than $0.1 million and $0.1 million during the three and nine months ended September 30, 2024, respectively, which were recognized as a reduction to additional paid-in capital in the statement of stockholdersâ€™ equity (deficit). As of September 30, 2024 and December 31, 2023, 1,920 shares of Series E preferred stock were outstanding. Â Series F Convertible Preferred Stock Â On March 4, 2024, in connection with the Purchase Agreement (see Note 1), the Company issued 7,224 shares of Series F Preferred Stock, at a purchase price per share of $1,000. Each share of Series F preferred stock is convertible into 273 shares of the Companyâ€™s common stock at a conversion price of $3.664 per share. The Series F preferred stock is convertible into a total of 1,972,152 shares of common stock subject to certain limitations contained in the Purchase Agreement. Shares of Series F preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 49.9% of the Companyâ€™s outstanding voting power. The holders of Series F preferred stock are entitled to receive annual accruing dividends at a rate of 5% until the third anniversary of their issuance and 8% thereafter. The dividends are payable in additional shares of Series F preferred stock or cash, at the Companyâ€™s option through the third anniversary of their issuance, and at the holderâ€™s option thereafter. The shares of Series F preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series F preferred stock ranks junior to Series H preferred stock, pari passu with Series E preferred stock and are senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. The Series F preferred stock accrued additional dividends of $0.1 million and $0.2 million during the three and nine months ended September 30, 2024, respectively, which were recognized as a reduction to additional paid-in capital in the statement of stockholdersâ€™ deficit. As of September 30, 2024, 7,224 shares of Series F preferred stock were outstanding. Â 17 Â Â Series H Convertible Preferred Stock Â On May 16, 2024, in connection with the Series H Purchase Agreement (see Note 4), the Company issued 11,000 shares of Series H Preferred Stock, at a purchase price per share of $1,000. Each share of Series H preferred stock is convertible into 259 shares of the Companyâ€™s common stock at a conversion price of $3.86 per share. The Series H preferred stock is convertible into a total of 2,849,000 shares of common stock subject to certain limitations contained in the Purchase Agreement. Shares of Series H preferred stock cannot be converted into common stock to the extent the applicable

holder would beneficially own in excess of 9.99% of the Companyâ€™s outstanding voting power and in no case will such beneficial ownership limitation exceed 19.99%, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). The holders of Series H preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series E preferred stock or cash, at the Companyâ€™s option. The shares of Series H preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series H preferred stock rank senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. The Series H preferred stock accrued additional dividends of $0.2 million and $0.3 million during the three and nine months ended September 30, 2024, which were recognized as a reduction to additional paid-in capital in the statement of stockholdersâ€™ deficit. As of September 30, 2024, 11,000 shares of Series H preferred stock were outstanding. Â Common Stock Â As of September 30, 2024, the Companyâ€™s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 2,783,891 shares were issued and outstanding. Â March 2024 Offering Â On March 5, 2024, in connection with the Purchase Agreement (see Note 1), the Company issued 75,327 shares of common stock at a purchase price per share of $3.664. Â June 2024 Offering Â On June 17, 2024, in connection with the June 2024 Offering (see Note 1), the Company issued 330,000 shares of common stock at a purchase price per share of $1.66. Â 18 Â Common Stock Warrants Â As of September 30, 2024, the Company had outstanding warrants to purchase common stock as follows: Â Â Â Total Outstanding and Exercisable Â Â Underlying Shares of Common Stock Â Â Exercise Price per Share Â Â Expiration Date Â Series 1 Warrants issued in the February 2018 Series B financing Â Â 8,979,000 Â Â Â 2,993 Â Â $ 6,000.00 Â Â February 2025 Â Series 2 Warrants issued in the February 2018 Series B financing Â Â 8,709,500 Â Â Â 2,903 Â Â $ 6,000.00 Â Â February 2025 Â Placement agent warrants issued in the January 2022 financing Â Â 1,330,000 Â Â Â 4,433 Â Â $ 150.00 Â Â January 2027 Â Warrants issued in the January 2022 financing Â Â 16,150,000 Â Â Â 53,833 Â Â $ 144.00 Â Â July 2027 Â Series A Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â Â February 2028 Â Placement agent Preferred Investment Options issued in the August 2022 financing Â Â 171,233 Â Â Â 11,416 Â Â $ 32.85 Â Â August 2027 Â Advisor Warrants issued in the March 2024 financing Â Â 40,938 Â Â Â 40,938 Â Â $ 3.664 Â Â March 2029 Â Pre-Funded Warrants issued in the June 2024 financing Â Â 2,417,000 Â Â Â 2,417,000 Â Â $ 0.001 Â Â Â n/a Â Series A-1 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (1) Â Series A-2 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (2) Â Series A-3 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (3) Â Placement Agent Warrants issued in the June 2024 financing Â Â 216,867 Â Â Â 216,867 Â Â $ 2.075 Â Â June 2029 Â Total as of September 30, 2024 Â Â 51,711,792 Â Â Â 13,784,013 Â Â Â Â Â Â Â Â Â Â (1) The Series A-1 Warrants expire on the earlier of August 12, 2029 andÂ 60 days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. (2) Series A-2 Warrants expire on the earlier of August 12, 2026 andÂ 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. (3) The Series A-3 Warrants expire on the earlier of May 12, 2025 andÂ 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO IDE application. Â During the three months ended September 30, 2024, a total of 867,457Â Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 867,457 shares of common stock. After giving effect to these aforementioned exercises, 2,417,000 Pre-Funded Warrants remained outstanding. On October 3, 2024, holders of Pre-Funded Warrants opted to exercise a total of 306,000 shares of their warrants into common stock leaving 2,111,000 remaining. Â In accordance with their terms, the 2,853,833 Series B Preferred Investment Options, exercisable for 190,259 shares of common stock at an exercise price of $22.53 per share, expired on August 8, 2024. Â 19 Â As of December 31, 2023, the Company had outstanding warrants to purchase common stock as follows: Â Â Â Total Outstanding and Exercisable Â Â Â Underlying Shares of Common Stock Â Â Â Exercise Price per Share Â Expiration Date Series 1 Warrants issued in the February 2018 Series B financing Â Â 8,979,000 Â Â Â 2,993 Â Â $ 6,000.00 Â February 2025 Series 2 Warrants issued in the February 2018 Series B financing Â Â 8,709,500 Â Â Â 2,903 Â Â $ 6,000.00 Â February 2025 Placement agent warrants issued in the January 2022 financing Â Â 1,330,000 Â Â Â 4,433 Â Â $ 150.00 Â January 2027 Warrants issued in the January 2022 financing Â Â 16,150,000 Â Â Â 53,833 Â Â $ 144.00 Â July 2027 Series A Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â February 2028 Series B Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â August 2024 Placement agent Preferred Investment Options issued in the August 2022 financing Â Â 171,233 Â Â Â 11,416 Â Â $ 32.85 Â August 2027 Total as of December 31, 2023 Â Â 41,047,499 Â Â Â 456,096 Â Â Â Â Â Â Â March 2024 Private Placement Â On March 7, 2024, in connection with the closing of the Strategic Partnership and Private Placement, the Company issued Advisor Warrants at an exercise price of $3.664 per share which were immediately exercisable. The Advisor Warrants will expire five years following the time they become exercisable, or March 5, 2029. Â The exercise price and the number of shares of common stock issuable upon exercise of each Advisor Warrant are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Advisor Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Advisor Warrants prior to the fundamental transaction. Â The Advisor Warrants can be exercised at the option of the holders at any time after they become exercisable provided that shares cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% of the Companyâ€™s outstanding common stock immediately after giving effect to the exercise. A holder of the Advisor Warrants may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%. Â June 2024 Offering Â On June 13, 2024, the Company entered into a securities purchase agreement with two institutional investors resulting in the issuance of among other things, Pre-Funded Warrants in lieu of common stock to purchase up to an aggregate of 3,284,457 shares of common stock of which 2,417,000 remain outstanding as of September 2024. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable, and have no expiration date. On October 3, 2024, holders of Pre-Funded Warrants opted to exercise a total of 306,000 of their warrants into common stock leaving 2,111,000 remaining. Â In addition, the Company issued to the investors in the Offering (i) Series A-1 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, (ii) Series A-2 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, and (iii) Series A-3 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock. Each share of common stock or Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. Each Warrant has an exercise price of $1.66 per share. Â 20 Â Â The Series A-1 Warrants expire on the earlier of August 12, 2029Â and 60Â days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. The Series A-2 Warrants expire on the earlier of August 12, 2026 and 60Â days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. The Series A-3 Warrants expire on May 12, 2025 andÂ 60Â days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO IDE application. Â In connection with the Offering, the Company also issued to the placement agent Placement Agent or its designees Placement Agent Warrants to purchase up to an aggregate of 216,867 shares of common stock. The Placement Agent Warrants have substantially the same terms as the warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $2.075 per share and expire on June 13, 2029. Â The exercise price and the number of shares of common stock issuable upon exercise of each Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants immediately prior to the fundamental transaction. Â The Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants can be exercised at the option of the holders at any time after they become exercisable provided that shares of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% (or, upon election by such holder prior to the issuance of any shares of Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants, 9.99%) of the Companyâ€™s outstanding common stock immediately after giving effect to the exercise. A holder of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%. Â In the event of a fundamental transaction in which the holders of our voting securities immediately prior to such fundamental transaction will not, following such fundamental transaction, directly or indirectly own more than 50% of the voting securities of the surviving entity or successor entity, and in which the Company is not the successor entity or does not continue as a reporting issuer under the Exchange Act, then, at the request of the holder, the Company or the successor entity shall purchase the unexercised portion of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants from the holder by paying to the holder an amount, in cash, equal to the fair value of the remaining unexercised portion of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants on the date of such fundamental transaction, subject to certain limitations in the event of a fundamental transaction not within our control. Â Â 8. Stock-Based Compensation Â Stock Plans Â In January 2015, the Board of Directors adopted and the Companyâ€™s stockholders approved the 2015 Equity Incentive Plan (â€œ2015 Planâ€). On December 22, 2023, the Companyâ€™s stockholders approved an additional 300,000 shares of common stock for issuance under the 2015 Plan, which was later registered in an S-8 registration statement filed on January 10, 2024. The 2015 Plan provides for the grant of incentive stock options (â€œISOsâ€) to employees and for the grant of non-statutory stock options (â€œNSOsâ€), restricted stock, restricted stock awards (â€œRSAsâ€), restricted stock units (â€œRSUsâ€), stock appreciation rights, performance units and performance shares to employees, directors and consultants. As of September 30, 2024, 15 share grants were outstanding with 71,442 shares of common stock were available and outstanding for grant under the 2015 Plan. Â 21 Â Â The Companyâ€™s RSUs and RSAs generally vest annually over two years in equal increments. RSAs and RSUs largely contain the same contractual terms except RSAs have the ability to vote along with common holders as an RSA is considered an outstanding security at the time of grant, subject to certain vesting and other restrictions. The Company measures the fair value of RSAs using the closing stock price of a share of the Companyâ€™s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSA activity is presented below: Â Â Â Number of Shares Â Â Weighted Average Grant Date Fair Value Â Â Weighted Average Remaining Contractual Term Â Awards outstanding at December 31, 2023 Â Â 90,190 Â Â $ 18.45 Â Â Â 1.04 Â Awarded Â Â 394,105 Â Â $ 2.75 Â Â Â â€” Â Released Â Â (368,503) Â $ 4.89 Â Â Â â€” Â Forfeited Â Â (3,333) Â $ 18.45 Â Â Â â€” Â Awards outstanding at September 30, 2024 Â Â 112,459 Â Â $ 7.85 Â Â Â 0.30 Â Â As ofÂ September 30, 2024, there wasÂ $0.300 millionÂ of remaining unamortized stock-based compensation expense associated with RSAs, which will be expensed over a weighted average remaining service period of approximately 0.3 years. TheÂ outstanding non-vested and expected to vest RSAs at September 30, 2024 have an aggregate fair value of approximatelyÂ $0.1 million. The Company used the closing market price of $0.95 per share at September 30, 2024, to determine the aggregate fair value for the RSAs outstanding at that date. For the nine months ended September 30, 2024 and 2023, the fair value of RSAs vested was approximately $1.0Â millionÂ andÂ less than $0.1 million, respectively. For the three months ended September 30, 2024 and 2023, stock-based compensation expense recognized associated with the vesting of RSAs was $222,000 and $219,000, respectively. For the nine months ended September 30, 2024 and 2023, stock-based compensation expense recognized associated with the vesting of RSAs was $1.5 million and $0.7 million, respectively. Â Total noncash stock-based compensation expense relating to the Companyâ€™s RSAs recognized, before taxes, during the three and nine months ended September 30, 2024 and 2023, is as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of revenues Â $ 36 Â Â $ 36 Â Â $ 228 Â Â $ 99 Â Research and development expenses Â Â 42 Â Â Â 24 Â Â Â 397 Â Â Â 158 Â Selling, general and administrative expenses Â Â 144 Â Â Â 159 Â Â Â 900 Â Â Â 446 Â Â Â $ 222 Â Â $ 219 Â Â $ 1,525 Â Â $ 703 Â Â Â 9. Restructuring Charges and Expenses Â In June 2024, the Company undertook an organizational realignment and cost reduction plan which included a reduction in force, lowering its total headcount by approximately 24%, or 17 employees, compared to March 31, 2024. Accordingly, the Company recorded a restructuring charge of approximately $66,000, relating to severance related costs at that time. As of September 30, 2024, all 17 employeesâ€™ severance costs related to the June 2024 termination had been incurred and paid. As of September 30, 2024, $4,000 of the total severance costs was included within accrued compensation on the condensed balance sheet. During the three months ending September 30, 2024, the Company recorded $14,000 in severance costs related to R&D and $53,000 to SG&A. For the nine months ending September 30, 2024, an additional $23,000 in severance expenses was recorded to SG&A. Â 22 Â Â Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited financial statements and related notes included elsewhere in this Quarterly Report on FormÂ 10-Q. This discussion and other parts of this Quarterly Report on FormÂ 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections of this Quarterly Report on FormÂ 10-Q and our Annual Report on Form 10-K filed with the SEC on March 20, 2024, titled â€œRisk Factors.â€ Â Overview Â We are a commercial-stage medical device company that designs, manufactures, and sells real-time high-definition image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with PAD. Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. Our mission is to significantly improve the treatment of vascular disease through the introduction of products based on our Lumivascular platform, the only intravascular real-time high-definition image-guided system available in this market. Â We design, manufacture, and sell a suite of products in the United States and select international markets. We are located in Redwood City, California. Our current Lumivascular platform consists of products including our Lightbox imaging console, the Ocelot and Tigereye family of devices, which are image-guided devices designed to allow physicians to penetrate a total blockage in an artery, known as a CTO, and the Pantheris family of catheters, our image-guided atherectomy catheters which are designed to allow physicians to precisely remove arterial plaque in PAD patients. Â We are in the process of developing CTO crossing devices to target the coronary CTO market. However, the market for medical devices in the coronary artery disease (â€œCADâ€) space is highly competitive, dynamic, and marked by rapid and substantial technological development and product innovation and there is no guarantee that we will be successful in developing and commercializing any new CAD product. At this stage, we are working on understanding market requirements, and initiated the development process for the new CAD product, which we anticipate will require additional expenses. Â We obtained CE Marking for our original Ocelot product in September 2011 and received from the U.S. FDA, 510(k) clearance in November 2012. We also received 510(k) clearance from the FDA for commercialization of Pantheris in October 2015. We received an additional 510(k) clearance for an enhanced version of Pantheris in March 2016 and commenced sales of Pantheris in the United States and select European countries promptly thereafter. In May 2018, we received 510(k) clearance from the FDA for our current next-generation version of Pantheris. In April 2019, we received

510(k) clearance from the FDA for our Pantheris Small Vessel (â€œSVâ€), a version of Pantheris targeting smaller vessels, and commenced sales in July 2019. In September 2020, we received 510(k) clearance for Tigereye, a next-generation CTO crossing system utilizing Avingerâ€™s proprietary image-guided technology platform. Tigereye is a product line extension of Avingerâ€™s Ocelot family of image-guided CTO crossing catheters. In January 2022, we received 510(k) clearance from the FDA for our Lightbox 3 imaging console, an advanced version of our Lightbox imaging console that allows for easy portability and offers significant reductions in size, weight, and production cost in comparison to the incumbent version. Â In April 2023, we received 510(k) clearance from the FDA for Tigereye Spinning Tip (â€œSTâ€), a next-generation image-guided CTO crossing system.Â Tigereye ST is a line extension of our Ocelot and Tigereye family of CTO crossing catheters. This new image-guided catheter incorporates design upgrades to the tip configuration and catheter shaft to increase crossing power and procedural success in challenging lesions, as well as design enhancements for ease of image interpretation during the procedure. The low-profile Tigereye ST has a working length of 140 cm and 5 French sheath compatibility. We initiated a limited launch of Tigereye ST in the second quarter of 2023 and subsequently expanded to full commercial availability within the United States during the third quarter of 2023. Â In June 2023, we received 510(k) clearance from the FDA for Pantheris Large Vessel (â€œLVâ€), a next generation image guided atherectomy system for the treatment of larger vessels, such as the superficial femoral artery (â€œSFAâ€) and popliteal arteries. Pantheris LV is a line extension of our Pantheris and Pantheris SV family of atherectomy products. This catheter offers higher speed plaque excision for efficient removal of challenging occlusive tissue and multiple features to streamline and simplify user-operation, including enhanced tissue packing and removal, a radiopaque gauge to measure volume of plaque excised during the procedure, and enhanced guidewire management. We initiated a limited launch of the Pantheris LV during the third quarter of 2023 and expect to expand to full commercial availability within the United States in the second half of 2024. Â 23 Â Â Current treatments for PAD, including bypass surgery, can be costly and may result in complications, high levels of post-surgery pain, and lengthy hospital stays and recovery times. Minimally invasive, or endovascular, treatments for PAD include stenting, angioplasty, and atherectomy, which is the use of a catheter-based device for the removal of plaque. These treatments all have limitations in their safety or efficacy profiles and frequently result in recurrence of the disease, also known as restenosis. We believe one of the main contributing factors to high restenosis rates for PAD patients treated with endovascular technologies is the amount of vascular injury that occurs during an intervention. Specifically, these treatments often disrupt the membrane between the outermost layers of the artery, which is referred to as the external elastic lamina (â€œEELâ€). Â We believe our Lumivascular platform is the only technology that offers radiation free, high-definition real-time visualization of the inside of the artery during PAD treatment through the use of OCT, a high resolution, light-based, radiation-free imaging technology. Our Lumivascular platform provides physicians with high-definition real-time OCT images from the inside of an artery, and we believe Ocelot and Pantheris are the first products to offer intravascular visualization during CTO crossing and atherectomy, respectively. We believe this approach will significantly improve patient outcomes by providing physicians with a clearer picture of the artery using radiation-free image guidance during treatment, enabling them to better differentiate between plaque and healthy arterial structures. Our Lumivascular platform is designed to improve patient safety by enabling physicians to direct treatment towards the plaque, while avoiding damage to healthy portions of the artery. Â During the first quarter of 2015, we completed enrollment of patients in VISION, a clinical trial designed to support our August 2015 510(k) submission to the FDA for our Pantheris atherectomy device. VISION was designed to evaluate the safety and efficacy of Pantheris to perform atherectomy using intravascular imaging and successfully achieved all primary and secondary safety and efficacy endpoints. We believe the data from VISION allows us to demonstrate that avoiding damage to healthy arterial structures, and in particular disruption of the external elastic lamina, which is the membrane between the outermost layers of the artery, reduces the likelihood of restenosis, or re-narrowing, of the diseased artery. Although the original VISION study protocol was not designed to follow patients beyond six months, we worked with 18 of the VISION sites to re-solicit consent from previous clinical trial patients in order for them to evaluate patient outcomes through 12 and 24 months following initial treatment. Data collection for the remaining patients from participating sites was completed in May 2017, and we released the final 12- and 24-month results for a total of 89 patients in July 2017. Â During the fourth quarter of 2017, we began enrolling patients in INSIGHT, a clinical trial designed to support a submission to the FDA to expand the indication for our Pantheris atherectomy device to include the treatment of in-stent restenosis. Patient enrollment began in October 2017 and was completed in July 2021. Patient outcomes were evaluated at thirty days, six months and one year following treatment. In November 2021, we received 510(k) clearance from the FDA for this new clinical indication for treating in-stent restenosis with Pantheris using the data collected and analyzed from INSIGHT. We expect this will expand our addressable market for Pantheris to include a high-incidence disease state for which there are few available indicated or effective treatment options. Â We are pursuing additional clinical data programs including a post-market study, IMAGE-BTK, that is designed to evaluate the safety and efficacy of Pantheris SV in the treatment of PAD lesions below-the-knee. We completed enrollment in 2023. Patient outcomes are being evaluated at thirty days, six months and one year following treatment. We expect this will bolster the application of Pantheris SV as a primary interventional tool to address below-the-knee lesions for which there are few available effective treatment options. Â We focus our direct sales force, marketing efforts and promotional activities on interventional cardiologists, vascular surgeons and interventional radiologists. We also work on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders. Although our sales and marketing efforts are directed at these physicians because they are the primary users of our technology, we consider the hospitals and medical centers where the procedure is performed to be our customers, as they typically are responsible for purchasing our products. We are designing additional future products to be compatible with our Lumivascular platform, which we expect to enhance the value proposition for hospitals to invest in our technology. Pantheris qualifies for existing reimbursement codes currently utilized by other atherectomy products, further facilitating adoption of our products. Â We have assembled a team with extensive medical device development and commercialization experience in both start-up and large, multi-national medical device companies. We assemble all of our catheter products at our manufacturing facility but certain critical processes, such as coating and sterilization, are performed by outside vendors. Our Lightbox 3 imaging console is assembled through a qualified contract manufacturer. We expect our current manufacturing facility in California will be sufficient through at least 2025. Â 24 Â Â We generated revenues of $10.1 million in 2021, $8.3 million in 2022 and $7.7 million in 2023. Revenues during these years were tangentially affected by COVID-19 as hospitals continued to defer elective procedures in certain jurisdictions while increasing volume to accommodate previously deferred procedures in others, which among other things, created unpredictability in case volume. This unpredictability created more volatility in our revenues which continued to affect our business in the aforementioned years. The decline in revenue in 2022 and 2023 was primarily attributable to the adverse effects of staffing shortages, resource constraints on our customers as hospitals deferred elective procedures, and the impact of a very competitive market for talent on the retention of our commercial team. Â Recent Developments Â Nasdaq Delisting Notice Â On April 25, 2023, we received notice (the â€œBid Price Deficiency Letterâ€) from the Listing Qualifications Department (the â€œStaffâ€) of The Nasdaq Stock Market, LLC (â€œNasdaqâ€) notifying us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) (the â€œBid Price Requirementâ€), as the minimum bid price for our listed securities was less than $1.00 for the previous 30 consecutive business days. We had a period of 180 calendar days, or until October 23, 2023, to regain compliance with the rule referred to in this paragraph. As part of our efforts to regain compliance with the aforementioned rule, we effected a 1-for-15 reverse stock split on September 12, 2023. Â On September 27, 2023, we received a letter from Nasdaq notifying us that the Staff had determined that the closing bid price of our common stock had been at $1.00 per share or greater for at least 10 consecutive business days and, accordingly, that we had regained compliance with the Bid Price Requirement. While we have regained compliance with the Bid Price Requirement, there can be no assurance that we will be able to maintain compliance with the Bid Price Requirement, or other continued listing requirements of Nasdaq, in the future. Â As of the date of this quarterly report, the minimum bid price for our common stock has been below $1.00 for the previous 23 consecutive business days. Â On May 18, 2023, we received notice (the â€œStockholdersâ€™ Equity Deficiency Letterâ€) from the Staff that we no longer satisfied the $2.5 million stockholdersâ€™ equity requirement for continued listing on The Nasdaq Capital Market, or the alternatives to that requirements â€“ a $35 million market value of listed securities or $500,000 in net income in the most recent fiscal year or two of the last three fiscal years â€“ as required by Nasdaq Listing Rule 5550(b) (the â€œEquity Requirementâ€). Â As with the Bid Price Deficiency Letter, the Stockholdersâ€™ Equity Deficiency Letter had no immediate effect on our continued listing on The Nasdaq Capital Market. In accordance with the Nasdaq Listing Rules, we were provided 45 calendar days, or until July 3, 2023, to submit a plan to regain compliance with the Equity Requirement (the â€œCompliance Planâ€). We submitted the Compliance Plan to Nasdaq on July 3, 2023. On July 31, 2023, we received a letter from Nasdaq notifying us that the Staff had determined to grant us an extension of 180 calendar days from the date of the Staffâ€™s notice, or November 14, 2023, to regain compliance with the Equity Requirement. Â On November 21, 2023, the Staff formally notified us that the Staff had determined that we were unable to demonstrate compliance with the Equity Requirement and that our securities would be delisted at the open of business on November 30, 2023, unless we timely requested a hearing before the Nasdaq Hearings Panel (the â€œPanelâ€). On November 28, 2023, we requested and were granted a hearing before the Panel which took place on February 20, 2024. At the hearing, we presented a plan to regain and sustain compliance with the Equity Requirement and requested an extension to do so. On March 14, 2024, the results from the hearing were rendered in which we were granted an extension by the Panel. This extension stayed any further action by Nasdaq with respect to our continued listing until May 20, 2024. Â We took definitive steps pursuant to our plan as presented to the Panel to ensure our compliance with the Equity Requirement and all other applicable criteria for continued listing on Nasdaq. We undertook certain actions which included among other things (i) converting $11.0 million of outstanding indebtedness into equity in May 2024, (ii) issuing additional shares of capital stock, (iii) completing a public equity offering in June 2024 in which we received gross proceeds of $6.0 million through the issuance of a combination of common stock and pre-funded warrants and (iv) entring into a securities purchase agreement in March 2024 as part of a larger strategic partnership and collaboration transaction representing entry into a number of financing, licensing and other agreements in which we received gross proceeds of $7.5 million and expect to receive another $7.5 million upon the successful completion of certain milestones, discussed in more detail below. This financing transaction was an integral part of the plan presented to the Panel. Â On May 29, 2024, we were formally notified by Nasdaq that we have regained compliance with the stockholdersâ€™ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and evidenced compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the listing matter, which was reviewed by the Panel has been closed. Â 25 Â Â We will be subject to a â€œMandatory Panel Monitorâ€ as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), through May 29, 2025. If within the monitoring period we fail to evidence compliance with the Equity Requirement, we would not be allowed to provide to the Staff a plan to regain compliance with the Equity Requirement; rather, the Staff would be required to issue a delist determination. We would in that case have the opportunity to request a new hearing before the Panel, which request would stay any further action by the Staff. Â We anticipate we will need to issue additional shares of capital stock through various other financing transactions in order to maintain compliance with the Equity Requirement, the most recent of which occurred in June 2024 in a best efforts public offering resulting in gross proceeds of $6.0 million. However, we may not be successful in executing such future transactions on terms favorable to us, or at all, and may not be able to maintain compliance with Nasdaqâ€™s listing requirements, including the Equity Requirement. Â Global Supply Chain Â We are closely monitoring the general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, we anticipate that our production and operating costs may similarly increase, including costs and availability of materials and labor. In addition, port closures and labor shortages have resulted in manufacturing and shipping constraints. While we have had sufficient inventory on-hand to meet our current production requirements and customer demand, we have experienced some constraints with respect to the availability of certain materials and extended lead times from certain key suppliers. We have also experienced some delays in shipping products to our customers. Any significant delay or interruption in our supply chain could impair our ability to meet the demands of our customers in the future and could harm our business. Â We may need to identify and qualify new suppliers in response to disruptions and difficulties experienced by some of our current suppliers. The process of identifying and qualifying suppliers is lengthy with no guarantee of mitigating the current issues we are experiencing. This process can include but is not limited to delays in qualification, quality issues on components, and higher costs to source these components. All of these issues may impair our ability to meet the demands of our customers in the future. Â Reverse Stock Split Â On September 11, 2023, our board of directors approved an amendment to our amended and restated certificate of incorporation to effect a 1-for-15 reverse stock split of our issued and outstanding common stock. The reverse stock split became effective on September 12, 2023. The par value of the common stock was not adjusted as a result of the reverse stock split. All common stock, stock options, restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Â Strategic Collaboration Â On March 4, 2024, we entered into a License Agreement with Zylox-Tonbridge, pursuant to which we will license and distribute certain of our products (including consumables) in the Greater China region, including mainland China, Hong Kong, Macao, and Taiwan. Zylox-Tonbridge will lead all regulatory activities for the registration of our products in the Territory. We will also license our intellectual property and know-how related to our products to Zylox-Tonbridge so that Zylox-Tonbridge can manufacture the localized products in the Territory.Â All sales of our products locally manufactured by Zylox-Tonbridge with regulatory approval by the regulatory authorities in the Territory and commercialized in the Territory will be royalty bearing to us at varying percentages depending on the amount of gross revenue and product gross margin.Â Â Â Â Â Â Â Â Â Â Â Â Â In connection with the License Agreement, we also entered into a Strategic Cooperation and Framework Agreement with Zylox-Tonbridge, which provides the opportunity for us to access certain Zylox-Tonbridge peripheral vascular products for distribution in the U.S. and Germany. The agreement also provides the option for us to source finished goods inventory from Zylox-Tonbridge following registration of Zylox-Tonbridgeâ€™s manufacturing facility with the FDA. Â 26 Â Â Financing Agreements Â On March 4, 2024, in connection with the Strategic Collaboration, we and the Purchaser, entered into the Purchase Agreement, pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of our common stock, and shares of two new series of our preferred stock. On March 5, 2024, we issued to the Purchaser 75,327 shares of the common stock at a purchase price per share of $3.664 (the â€œPurchase Priceâ€), and 7,224 shares of Series F Preferred Stock at a purchase price per share of $1,000, for an aggregate purchase price ofÂ $7.5 million. Â Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of common stock at a conversion price equal to the Purchase Price, subject to the terms of Series F Certificate of Designation. Â Upon completion of the Milestones, the Purchaser will invest an additional $7.5 million to purchase shares of Series G Preferred Stock. Each share of Series G Preferred Stock will have a stated value of $1,000 and will be convertible into shares of common stock at a conversion price of equal to the lowest of (x) the Purchase Price, (y) the closing price of the common stock on the date immediately preceding the Milestone Closing, and (z) the average closing price for the last five trading days preceding the Milestone Closing, provided that the conversion price will be no less than $0.20. Â On May 22, 2024, we held a special meeting of stockholders to vote on the following proposals resulting from the Private Placement (i) accept conversion of the shares of Series F Preferred Stock in excess of 19.9% of our outstanding common stock, which may be deemed a â€œchange of controlâ€ under Nasdaq Listing Rule 5635(b) and (ii) issue and sell shares of Series G Preferred Stock upon completion of the Milestones. Both proposals were approved by our stockholders. There were no conversions of Series F Preferred Stock during the three or nine months ended September 30, 2024. Â Series A Preferred Stock Exchange Â On March 5, 2024, we entered into the A-1 Securities Purchase Agreement to exchange all outstanding shares of Series A Preferred Stock for 10,000 shares of Series A-1 Preferred Stock. Among other things, the shares of Series A-1 Preferred Stock: (i) are convertible into an aggregate of approximately 2,729,257 shares of common stock at a conversion price equal to the Purchase Price, (ii) do not accrue or pay dividends payable solely on the Series A-1 Preferred Stock, (iii) will have no liquidation preference and (iv) will be junior in rank to shares of our Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock. Â CRG Loan Amendment Â On March 5, 2024, we also entered into Amendment No. 9 to the Loan Agreement effective as of the Initial Closing with CRG, which amends the Loan Agreement to, among other things: (i) extend the interest-only period through December 31, 2026; (ii) provide that interest payable through

December 31, 2026 may be payable in kind rather than in cash; and (iii) permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. Â Lease Extension Â On March 6, 2024, we entered into an amendment to the lease which extended the lease term for a period of one year, subsequent to the original expiration of November 30, 2024. As amended, the lease will expire on November 30, 2025. Under the terms of the amendment, we will be obligated to pay approximately $1.3 million in base rent payments through November 2025, beginning on December 1, 2024. This amendment also provides an optional one year extension of the lease following the end of the current term, as amended. Â 27 Â Â Reduction in Force Â In June 2024, we undertook a cost reduction plan and concurrent organizational realignment which included a company-wide reduction in force lowering our total headcount by 17 employees. This workforce reduction was designed to reduce operating expenses while continuing to support major product development and clinical initiatives related to our coronary product development program. Our sales personnel headcount dedicated to our peripheral business was reduced to 18, down from 27 as of March 31, 2024, a difference of 33%. The organizational realignment within sales was designed, in part, to focus our commercial efforts on driving catheter utilization in our strongest peripheral markets, around our most productive sales professionals. The strategic reduction in the field sales force and one individual in sales leadership was designed to maintain robust engagement with higher volume users of our Lumivascular technology and position us to maintain and support utilization of our catheters within our installed base of accounts leveraging our existing and next generation products, namely Pantheris LV and Tigereye ST. Â Financing Â During the three and nine months ended September 30, 2024, our net loss and comprehensive net loss was $3.7 million and $13.6 million, respectively; during the years ended DecemberÂ 31, 2023 and 2022, our net loss and comprehensive loss was $18.3 million and $17.6 million, respectively. We have not been profitable since inception, and as of September 30, 2024, our accumulated deficit was $434.3 million. Since inception, we have financed our operations primarily through private and public placements of our preferred and common securities and, to a lesser extent, debt financing arrangements. Â In September 2015, we entered into the Loan Agreement with CRG, under which we were able to borrow up to $50.0 million on or before the end of the twenty-four (24) month period commencing on the first Borrowing Date (as defined in the Loan Agreement), subject to certain terms and conditions. Under the Loan Agreement we borrowed $30.0 million on September 22, 2015 and an additional $10.0 million on June 15, 2016. Contemporaneously with the execution of the Loan Agreement, we entered into a Securities Purchase Agreement with CRG (the â€œSecurities Purchase Agreementâ€), pursuant to which CRG purchased 3 shares of our common stock on September 22, 2015 at a price of $1,678,920 per share, which represents the 10-day average of closing prices of our common stock ending on September 21, 2015. Pursuant to the Securities Purchase Agreement, we filed a registration statement covering the resale of the shares sold to CRG and must comply with certain affirmative covenants during the time that such registration statement remains in effect. Â On FebruaryÂ 14, 2018, we entered into a SeriesÂ A preferred stock Purchase Agreement (the â€œSeriesÂ A Purchase Agreementâ€) with CRG, pursuant to which it agreed to convert $38.0 million of the outstanding principal amount of its senior secured term loan (plus the back-end fee and prepayment premium applicable thereto) under the Loan Agreement into newly authorized SeriesÂ A-1 preferred stock. In March 2024, all outstanding shares of Series A preferred stock were cancelled in exchange for the issuance of Series A-1 preferred stock. The Series A-1 preferred stock, which is immediately convertible, carries no liquidation preference or dividend rights. Â We have entered into several amendments to the Loan Agreement with CRG since September 2015. The Amendments, among other things: (1)Â extended the interest-only period through DecemberÂ 31, 2026; (2)Â extended the period during which we may elect to pay a portion of interest in PIK, interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3)Â permitted us to make our entire interest payments in PIK interest payments through DecemberÂ 31, 2026 so long as no Default has occurred and is continuing; (4)Â extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2028; (5)Â reduced the minimum liquidity covenant to $3.5 million at all times; (6)Â eliminated the minimum revenue covenant for all years; (7) changed the date under the on-going stand-alone representation regarding no â€œMaterial Adverse Changeâ€ to December 31, 2020; (8) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement)Â regarding Material Adverse Change such that any adverse change in or effect upon the revenue of us and our subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; (9) provided CRG with board observer rights; and (10) provide that the board observer may be appointed or removed by written notice from the Majority Lenders (as defined in the Loan Agreement). Â 28 Â Â On August 2, 2023, we entered into the Series E Purchase Agreement with CRG, pursuant to which we issued 1,920 shares of newly authorized Series E convertible preferred stock in exchange for CRG surrendering for cancellation $1.92 million of outstanding principal and accrued interest of the senior secured term loan. Each share of Series E preferred stock has a stated value of $1,000 per share and is convertible into 93 shares of our common stock at a conversion price of $10.725 per share. The Series E preferred stock is initially convertible into 178,560 shares of common stock subject to certain limitations contained in the Series E Purchase Agreement. Under the terms of the Series E Purchase Agreement, the holders of Series E preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series E preferred stock or cash, at our option. The shares of Series E preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series E preferred stock rank junior to Series H preferred stock and senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. Â On September 29, 2023, the Company entered into the Waiver Agreement with CRG, who held all of the outstanding shares of the Companyâ€™s Series A and Series E preferred stock. Pursuant to the Waiver Agreement, CRG waived their rights to receive the Series A and Series E preferred dividends for the year ending December 31, 2023. Such waived preferred dividends were not cumulative or accrued. Â On January 26, 2024, we entered into Amendment No. 8 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.0 million until April 1, 2024. Thereafter, we would be subject to the minimum liquidity requirement of $3.5 million. Â On May 16, 2024, we entered into the Series H Purchase Agreement with CRG pursuant to which we issued 11,000 shares of a newly authorized Series H convertible preferred stock in exchange for CRG surrendering for cancellation $11.0 million of outstanding principal and accrued interest of the senior secured term loan under the Loan Agreement. Each share of Series H preferred stock has a stated value of $1,000 per share and is convertible into 259 shares of our common stock at a conversion price of $3.86 per share. The Series H preferred stock is initially convertible into 2,849,000 shares of common stock subject to certain limitations contained in the Series H Purchase Agreement. Under the terms of the Series H Purchase Agreement, the holders of Series H preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series H preferred stock or cash, at our option. The shares of Series H preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series H preferred stock rank senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. Â The shares of Series A-1 preferred stock, Series E preferred stock and Series H preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Companyâ€™s outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Companyâ€™s outstanding voting power on a combined basis (as CRG collectively holds all of the issued and outstanding shares of the Companyâ€™s Series A-1 convertible preferred stock, Series E convertible preferred stock and Series H convertible preferred stock), unless approved by our stockholders in accordance with Nasdaq Listing Rule 5635(b). Â As part of our Strategic Collaboration, we entered into Amendment No. 9 to the Loan Agreement with CRG, which amends the Loan Agreement to, among other things: (i) extend the interest-only period through December 31, 2026; (ii) provide that interest payable through December 31, 2026 may be payable in kind rather than in cash; and (iii) permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. In addition, we completed the Private Placement for gross proceeds, before expenses, of $7.5 million. Â On June 5, 2024, we entered into Amendment No. 10 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.5 million for the period commencing June 1, 2024 and ending July 31, 2024. Thereafter, we will be subject to the minimum liquidity requirement of $3.5 million. Â Critical Accounting Policies and Estimates Â Managementâ€™s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenues, expenses and related disclosures of contingent assets and liabilities. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. There have been no significant and material changes in our critical accounting policies during the three months ended September 30, 2024, as compared to those disclosed in â€œManagementâ€™s Discussion and Analysis of Financial Conditions and Results of Operations - Critical Accounting Policies and Significant Judgments and Estimatesâ€ in our most recent Annual Report on FormÂ 10-K, as filed with the SEC on MarchÂ 20, 2024. Â 29 Â Â Components of Our Results of Operations Â Revenues Â All of our revenues are currently derived from sales of our various PAD catheters in the United States and select international markets, Lightbox consoles, and related services. We expect our revenues to decrease in 2024 due to reductions in sales personnel resulting from reductions in force (â€œRIFâ€), attrition, competitive labor market, and other factors, partially offset by the expansion of market presence of our Tigereye ST and Pantheris LV products. There was one customer that represented 20% and 17% of revenues for each of the three and nine months ended September 30, 2024 respectively. For the three and nine months ended September 30, 2023, there wasÂ oneÂ customer that representedÂ 22% andÂ 17% of revenues, respectively. Â Revenues may fluctuate from quarter to quarter due to a variety of factors including capital equipment purchasing patterns that are typically increased towards the end of the calendar year and decreased in the first quarter and our ability to have product available in light of supply chain challenges. In addition, during the first quarter, our results can be harmed by adverse weather and by resetting of annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures. In the third quarter, the number of elective procedures nationwide is historically lower than other quarters throughout the year, which we believe is primarily attributable to the summer vacations of physicians and their patients. Additionally, we believe hospital capacity and resource staffing issues have had an adverse effect on our ability to generate sales in past periods due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of our products. Â Cost of Revenues and Gross Margin Â Cost of revenues consists primarily of costs related to manufacturing overhead, materials and direct labor. We expense all warranty costs and inventory provisions as cost of revenues. We periodically write-down inventory for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions. A significant portion of our cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. We expect overhead costs as a percentage of revenues to become less significant as our production volume increases. Cost of revenues also includes depreciation expense for production equipment, depreciation and related maintenance expense for placed Lightboxes held by customers and certain direct costs such as those incurred for shipping our products. Â We calculate gross margin as gross profit divided by revenues. Our gross margin has been and will continue to be affected by a variety of factors, primarily production volumes, manufacturing costs, product yields, headcount, charges for excess and obsolete inventories and cost-reduction strategies. We intend to use our design, engineering and manufacturing capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and increase our gross margin. In the future, we may seek to manufacture certain of our products outside the United States to further reduce costs. Our gross margin will likely fluctuate from quarter to quarter as we continue to introduce new products and sales channels, and as we adopt new manufacturing processes and technologies. Â Research and Development Expenses Â Research and development (â€œR&Dâ€), expenses consist primarily of engineering, product development, clinical and regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, quality assurance expenses allocated to R&D programs, consulting, related travel expenses and facilities expenses. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of manufacturing products for clinical trials. We expect R&D expenses to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial and other related activities. Â Selling, General and Administrative Expenses Â Selling, general and administrative (â€œSG&Aâ€), expenses consist primarily of compensation for personnel, including stock-based compensation, selling and marketing functions, physician education programs, business development, finance, information technology and human resource functions. Other SG&A expenses include commissions, training, travel expenses, educational and promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs and general corporate expenses. We expect SG&A expenses to increase as we expand our commercial efforts and additional costs related to corporate matters. Â 30 Â Â Interest Expense, Net Â Interest expense, net consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with our debt agreement. Â Other Income (Expense), Net Â Other income (expense), net primarily consists of gains and losses resulting from the remeasurement of foreign exchange transactions and other miscellaneous income and expenses. Â Results of Operations: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands, except percentages) Â Revenues Â $ 1,650 Â Â $ 1,817 Â Â $ 5,356 Â Â $ 5,746 Â Cost of revenues Â Â 1,224 Â Â Â 1,429 Â Â Â 4,209 Â Â Â 4,117 Â Gross profit Â Â 426 Â Â Â 388 Â Â Â 1,147 Â Â Â 1,629 Â Gross margin Â Â 26 % Â Â 21 % Â Â 21 % Â Â 28 % Operating expenses: Â Â Â

compliance activities. Stock-based compensation expense within SG&A totaled $145,000 and $159,000 for the three months ended SeptemberÂ 30, 2024 and 2023, respectively. We expect SG&A expense to decline based on the impact of the reduced size of our field sales force deployed within the United States, and other cost reduction measures we undertook in the strategic realignment in June 2024, potentially offset by fluctuations in revenues and consequently variable compensation, and other corporate activities that we undertake. Â Interest Expense, Net. Â Interest expense, net is comprised of interest expense net of interest income. Interest Expense, net for the three months ended September 30, 2024 decreased by approximately $0.4 million or 89% compared to the three months ended September 30, 2023, which resulted from lower PIK interest due to a smaller CRG loan balance resulting from the conversion of $11.0 million of principal and accrued interest in May 2024. This was partially offset by a decrease in interest income due to a lower average cash balance. Â Other Income (Expense), Net. Â Other income (expense), net primarily consists of gains and losses resulting from the remeasurement of foreign exchange transactions, which are typically a small percentage of transaction volume, and other miscellaneous income and expenses. Other income (expense), net for the three months ended September 30, 2024 remained relatively flat in comparison to the three months ended September 30, 2023 as both periods consisted primarily of remeasurement gains and losses from foreign exchange transactions resulting in nominal changes between periods.. Â Comparison of Nine Months Ended September 30, 2024 and 2023 Â Revenues. Â For the nine months ended September 30, 2024, revenue decreased by approximately $0.4 million or 7% compared to the nine months ended September 30, 2023. Revenues related to sales of our disposable catheters decreased by 7% to $4.9 million while revenues related to our Lightbox imaging consoles and other revenues decreased by less than 1% to less than $0.1 million. The decreased revenues reflects the impact of the reduced size of our field sales force, as well as a strategic decision we made in June 2024 to realign the focus of our sales force on driving the utilization at our current active user base in our strongest markets rather than on building new active users in other peripheral markets. Â Cost of Revenues and Gross Margin. Â For the nine months ended September 30, 2024, cost of revenues increased by $0.1 million or 2% compared to the nine months ended September 30, 2023. This increase was primarily attributable fluctuations in labor costs and inventory production, increased material costs and other ancillary expenditures. Stock-based compensation expense within cost of revenues totaled $228,000 and $99,000 for the nine months ended September 30, 2024 and 2023, respectively. Â Gross margin for the nine months ended September 30, 2024 decreased to 21%, compared to 28% during the nine months ended September 30, 2023. There are significant amounts of overhead costs, specifically in the form of labor, associated with manufacturing and production of inventory embedded in cost of revenues that will typically fluctuate due to the levels of inventory being produced, production schedule changes, lead times and other factors. The decrease in gross margin was primarily due to the decrease in the production levels of inventory and rising costs of materials. This decrease was compounded by the decrease in revenues which resulted in a decline in economies of scale. Â 32 Â Â Research and Development Expenses. Â R&D expense for the nine months ended September 30, 2024 decreased by approximately $0.3 million or 10% compared to the nine months ended September 30, 2023. The decrease is primarily due to our efforts to complete Â development of Tigereye ST and Pantheris LV occurring during 2023 and reduced headcount, partially offset by ongoing product development of our coronary device program. Stock-based compensation expense within R&D totaled approximately $397,000 and $158,000 for the nine months ended September 30, 2024 and 2023, respectively. We expect R&D expense to fluctuate based on the ongoing product development of our coronary device. Â Selling, General and Administrative Expenses. Â SG&A expense for the nine months ended September 30, 2024 increased by $0.7 million or 7%, compared to the nine months ended September 30, 2023. This increase was primarily attributable to increases in third-party professional services and other ancillary expenses related to the consummation of the Zylox-Tonbridge transaction administration, the special proxy resulting from the closing of the Zylox-Tonbridge transaction, increases in franchise and other taxes, and other corporate activities. There were also increased allocations of quality assurance expenses related to regulatory and compliance activities. Stock-based compensation expense within SG&A totaled $900,000 and $446,000 for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively. We expect SG&A expense to decline based on the impact of the reduced size of our field sales force deployed within the United States, and other cost reduction measures we undertook in the strategic realignment in June 2024, potentially offset by fluctuations in revenues and consequently variable compensation, and other corporate activities that we undertake. Â Interest Expense, Net. Â Interest expense, net is comprised of interest expense net of interest income. Interest Expense, net for the nine months ended September 30, 2024 decreased by approximately $0.6 million or 46% compared to the nine months ended September 30, 2023, which resulted from lower PIK interest due to a smaller CRG loan balance resulting from the conversion of $11.0 million of principal and accrued interest in May 2024. This was partially offset by a decrease in interest income due to a lower average cash balance. Â Other Income (Expense), Net. Â Other income (expense), net primarily consists of gains and losses resulting from the remeasurement of foreign exchange transactions, which are typically a small percentage of transaction volume, and other miscellaneous income and expenses. Other income (expense), net for the nine months ended September 30, 2024 remained relatively flat in comparison to the nine months ended September 30, 2023 as both periods consisted primarily of remeasurement gains and losses from foreign exchange transactions, resulting in nominal changes between periods. Â Liquidity and Capital Resources Â As of September 30, 2024, we had cash and cash equivalents of $5.9 million and an accumulated deficit of $434.3 million, compared to cash and cash equivalents of $5.3 million and an accumulated deficit of $420.7 million as of DecemberÂ 31, 2023. We expect to incur losses for the foreseeable future. We believe that our cash and cash equivalents of $5.9 million at September 30, 2024 and expected revenues, debt and financing activities and funds from operations will be sufficient to allow us to fund our current operations through the end of the fourth quarter of 2024. Â To date, we have financed our operations primarily through net proceeds from the issuance of our preferred stock, common stock and debt financings, our â€œat-the-marketâ€ program, our initial public offering (â€œIPOâ€), our follow-on public offerings and warrant issuances. We do not know when or if our operations will generate sufficient cash to fund our ongoing operations. We will need to raise additional capital through future equity or debt financings in the near future to meet our operational needs and capital requirements for product development, clinical trials and commercialization. Additional debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders and require significant debt service payments, which divert resources from other activities. Additional financing may not be available at all, or if available, may not be in amounts or on terms acceptable to us. If we are unable to obtain additional financing, we may be required to delay the development, commercialization and marketing of our products and we may be required to significantly scale back our business and operations. In the event we determine that additional sources of liquidity will not be available to us or will not allow us to meet our obligations as they become due, we may need to file a voluntary petition for relief under the United States Bankruptcy Code in order to implement a restructuring plan or liquidation. Our financial statements for the three and nine months ended September 30, 2024 do not include any adjustments that might result from the outcome of this uncertainty. Â 33 Â Â Currently substantially all of our cash and cash equivalents are held at a single financial institution, First Citizens Bank, which acquired our prior banking partner, Silicon Valley Bank, in March 2023. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank, now a division of First Citizens Bank, we are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, that could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected. Â Equity Financings Â March 2024 Financing Â In connection with our the Strategic Collaboration, we entered into the Purchase Agreement with the Purchaser, pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of our common stock, and shares of two new series of our preferred stock. On March 5, 2024, we issued to the Purchaser 75,327 shares of the common stock at a purchase price per share of $3.664, and 7,224 shares of a newly authorized Series F convertible preferred stock, par value $0.001 per share, for an aggregate purchase price of $7.5 million. Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of common stock at a conversion price equal to the Purchase Price, subject to the terms of the Series F Certificate of Designation. Â Upon completion of the Milestones, the Purchaser will invest an additional $7.5 million to purchase shares of our new Series G Preferred Stock. Each share of Series G Preferred Stock will have a stated value of $1,000 and will be convertible into shares of common stock at a conversion price of equal to the lowest of (x) the Purchase Price, (y) the closing price of the common stock on the date immediately preceding the Milestone Closing, and (z) the average closing price for the last five trading days preceding the Milestone Closing, provided that the conversion price will be no less than $0.20. There can be no guarantee that such Milestone Closing will occur. Â June 2024 Offering Â On June 13, 2024, we entered into a securities purchase agreement with two institutional investors for the issuance and sale of 3,614,457 shares of its common stock in the Offering at a purchase price of $1.66 per share, or pre-funded warrants in lieu thereof. We received aggregate net proceeds of approximately $5.2 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Â As a result, we issued (i) 330,000 shares of common stock, and (ii) and Pre-Funded Warrants in lieu of common stock to purchase up to an aggregate of 3,284,457 shares of common stock. As of September 30, 2024, 2,417,000 Pre-Funded Warrants remained outstanding. On October 3, 2024, holders of Pre-Funded Warrants opted to exercise a total of 306,000 of their warrants into common stock leaving 2,111,000 remaining. Â In addition, we issued to the investors in the Offering (i) Series A-1 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, (ii) Series A-2 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, and (iii) Series A-3 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock. Each share of common stock or Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. Each Warrant has an exercise price of $1.66 per share. Â 34 Â Â The Series A-1 Warrants expire on the earlier of August 12, 2029 60 days following the public announcement by us of us receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. The Series A-2 Warrants expire on the earlier of August 12, 2026 60 days following the date of the public announcement us of the occurrence of us receiving 510(k) clearance of image-guided Coronary CTO crossing device. The Series A-3 Warrants expire on May 5, 2025 and 60 days following the date of the public announcement by us of the occurrence of us receiving FDA approval of image-guided Coronary CTOIDE application. Â Pursuant to the Engagement Letter with the Placement Agent, we, in connection with the Offering, agreed to issue to the Placement Agent or its designeesPlacement Agent Warrants to purchase up to an aggregate of 216,867 shares of common stock. The Placement Agent Warrants have substantially the same terms as the Warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $2.075 per share and expire on June 13, 2029. Â At The Market Offering Agreement Â On May 20, 2022, we entered into ATM Agreement with the Agent pursuant to which we may offer and sell shares of common stock, par value $0.001 per share up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from us of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to our shelf registration statement on Form S-3, which was initially filed with the SEC on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on May 20, 2022. On August 3, 2022, we suspended sales under the ATM Agreement. On March 17, 2023, we reactivated the ATM Agreement. During the year ended December 31, 2023, we sold 607,241 shares of common stock at an average price of $9.01 per share for aggregate proceeds of approximately $5.5 million, of which approximately $164,000 was paid in the form of commissions to the Agent. There were no sales under the ATM Agreement during the nine months ended September 30, 2024. On October 17, 2024, the Company reactivated the ATM Agreement. During Â October and part of November 2024, the Company soldÂ 107,080Â shares of common stock pursuant to the ATM Agreement at an average price of $0.82Â per share for aggregate proceeds of approximately $88,000, of which approximately $2,600Â was paid in the form of commissions to the Agent While we may attempt additional sales in the future, there can be no assurance that we will be successful in acquiring additional funding through these means. Â Other than the ATM Agreement, we currently do not have any commitment to obtain additional funds. Â Contractual Obligations Â Our principal obligations consist of the operating lease for our facility, our Loan Agreement with CRG and non-cancelable purchase commitments. The following table sets out, as of September 30, 2024, our contractual obligations due by period (in thousands): Â Â Â Payments Due by Period Â Â Â Less Than 1 Year Â Â 2 - 3 Years Â Â 4-5 Years Â Â More Than 5 Years Â Â Total Â Operating lease obligations (1) Â $ 1,267 Â Â $ 212 Â Â $ â€” Â Â $ â€” Â Â $ 1,479 Â CRG Loan (2) Â Â â€” Â Â Â 1,653 Â Â Â 4,584 Â Â Â â€” Â Â Â 6,237 Â Non-cancelable purchase commitments (3) Â Â 686 Â Â Â 11 Â Â Â â€” Â Â Â â€” Â Â Â 697 Â Â Â $ 1,953 Â Â $ 1,876 Â Â $ 4,584 Â Â $ â€” Â Â $ 8,413 Â Â (1) Operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented above, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease will expire on November 30, 2025. (2) The total CRG Loan amount, shown as borrowings on the balance sheet as of September 30, 2024, is $4.2 million. The contractual obligation in the table above of $6.2 million under the CRG Loan includes future interest to be accrued but not paid in cash as well as a $2.1 million back-end fee to be paid in December 2028 upon maturity of the CRG Loan which is being accreted. For more information, see Part I, Item 1 â€œUnaudited Financial Statements, Note 4. Borrowings.â€ (3) Non-cancelable purchase commitments consist of agreements to purchase goods and services entered into in the ordinary course of business. Â 35 Â Â CRG Loan Â We have entered into several amendments to the Loan Agreement with CRG since September 2015. The Amendments, among other things: (1) extended the interest-only period through December 31, 2026; (2) extended the period during which we may elect to pay a portion of interest in payment-in-kind, or PIK, interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted us to make the entire interest payments in PIK interest payments through December 31, 2026 so long as no Default has occurred and is continuing; (4) extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2028; (5) reduced the minimum liquidity covenant to $3.5 million at all times; (6)Â eliminated the minimum revenue covenant for all years; (7) changed the date under the on-going stand-alone representation regarding no â€œMaterial Adverse Changeâ€ to December 31, 2020; (8) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of us and our subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; (9) provided CRG with board observer rights, and (10) provide that the board observer may be appointed or removed by written notice from the Majority Lenders (as defined in the Loan Agreement). The total Loan amount under the Loan Agreement (the â€œCRG Loanâ€), shown as short-term borrowings on the balance sheet as of September 30, 2024, is $4.2 million. However, upon maturity of the obligations under the Loan Agreement in December 2028, we will be obligated to pay $6.2 million under the Loan Agreement, which includes future interest to be accrued but not paid in cash as well as a $2.1 million back-end fee to be paid in December 2028 upon maturity of the CRG Loan which is being accreted to the maturity date. Due to the substantial doubt about our ability to continue operating as a going concern and the â€œMaterial Adverse Changeâ€ clause under the Loan Agreement, the entire amount of outstanding borrowings at September 30, 2024 and December 31, 2023 is classified as current. CRG has not purported that any Event of Default (as defined in the Loan Agreement) has occurred as a result a â€œMaterial Adverse Changeâ€ under the Loan Agreement. Refer to Part 1, Item 1, â€œUnaudited Financial Statements,â€ Note 4 for additional details. Â On January 26, 2024, we entered into Amendment No. 8 to the Loan Agreement with CRG, which reduces the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.0 million until April 1, 2024. Thereafter, we will be subject to the minimum liquidity requirement of $3.5 million. Â As part of our Strategic Collaboration, we entered into Amendment No. 9 to the Loan Agreement with CRG, which amends the Loan Agreement to, among other things: (i) extend the interest-only period through December 31, 2026; (ii) provide that interest payable through December 31, 2026 may be payable in kind rather than in cash; and (iii) permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. Â On June 5, 2024, we entered into Amendment No. 10 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of

the Loan Agreement from $3.5 million to $1.5 million for the period commencing June 1, 2024 and ending July 31, 2024. Thereafter, we will be subject to the minimum liquidity requirement of $3.5 million. Â Lease Agreements Â Our operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented above, the lease requires us to pay property taxes, insurance, maintenance, and repair costs. Rent expense is recognized using the straight-line method over the term of the lease. Â The lease will expire on November 30, 2025. We are obligated to pay a total of approximately $7.1 million in base rent payments through November 2025. The weighted average remaining lease term as of September 30, 2024 is 1.2 years. Â On March 6, 2024, we entered into an amendment to the lease which extended the lease term for a period of one year, subsequent to the original expiration of November 30, 2024. As amended, the lease will expire on November 30, 2025. Under the terms of the amendment, we will be obligated to pay approximately $1.3 million in base rent payments through November 2025, beginning on December 1, 2024. This amendment also provides an optional one year extension of the lease following the end of the current term, as amended. Â 36 Â Â Cash Flows Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net cash (used in) provided by: Â Â Â Â Â Â Â Â Operating activities Â $ (11,163) Â $ (11,043) Investing activities Â Â â€” Â Â Â (8) Financing activities Â Â 11,789 Â Â Â 5,173 Â Net change in cash and cash equivalents Â $ 626 Â Â $ (5,878) Â Net Cash Used in Operating Activities Â Net cash used in operating activities for the nine months ended September 30, 2024 was $11.2 million, consisting primarily of a net loss of $13.6 million and an increase in net operating assets of $0.4 million, partially offset by non-cash charges of $2.8 million. Non-cash charges primarily related to non-cash interest expense of $0.8 million and stock-based compensation of $1.5 million. The increase in net operating assets was primarily due toÂ the increase in prepaid expenses and other current assets due to annual renewals of certain expenses, including insurance coming due; decrease in accrued compensation as certain bonuses relating to retention of key individuals and company-wide bonuses were paid; and a decrease in long-term liabilities relating to certain retention bonuses being reclassified to accrued compensation as they became due within less than one year. These increases were partially offset by a decline in inventory which include components and labor, in an effort to optimize inventory levels in anticipation of forecasted demand in light of extended lead times and shifting product mix primarily related to new product introductions of Tigereye ST and Pantheris LV. Â Net cash used in operating activities for the nine months ended September 30, 2023 was $11.0 million, consisting primarily of a net loss of $13.3 million and an increase in net operating assets of $0.6 million, partially offset by non-cash charges of $2.8 million. Non-cash charges largely related to non-cash interest expense of $1.5 million, excess and obsolete charges related to inventory of $0.4 million, and stock-based compensation of $0.7 million. The increase in net operating assets was primarily due to investments in inventory, which include components and labor, in anticipation of (i) forecasted demand in light of extended lead times and (ii) building inventory in anticipation of the Tigereye ST and Pantheris LV product launches in the second half of 2023 and first half of 2024. These increases were partially offset by the increase in other long-term liabilities as certain variable compensation continues to accrue. Â Net Cash Provided by Financing Activities Â Net cash provided by financing activities for the nine months ended September 30, 2024 of $11.8 million relates to $7.0 million of proceeds, net of commissions and various issuance costs, from the issuance of preferred stock and common stock in the Private Placement in March 2024 and $5.2 million of proceeds, net of commissions and various issuance costs from the issuance of a combination of common stock and pre-funded warrants in June 2024. This was partially offset by the payment of approximately $0.4 million in satisfaction of certain tax obligations related to net share settlement on restricted stock awards vesting during the quarter. Â Net cash provided by financing activities for the nine months ended September 30, 2023 of $5.2 million primarily relates to proceeds of approximately $5.2 million from the sale of common stock pursuant to the ATM Agreement, net of commissions and various issuance costs. Â 37 Â Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â Interest Rate Risk Â The risk associated with fluctuating interest rates is primarily limited to our cash equivalents, which are carried at quoted market prices. Due to the short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our cash equivalents. We do not currently use or plan to use financial derivatives in our investment portfolio. Â Credit Risk Â As of September 30, 2024, our cash and cash equivalents were maintained with one financial institution in the United States, and our current deposits are in excess of insured limits. We have reviewed the financial statements of this institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us. Â Our accounts receivable primarily relate to revenues from the sale of our Lumivascular platform products to hospitals and medical centers in the United States. At September 30, 2024, there was one customer that represented 38% of the Companyâ€™s accounts receivable. At DecemberÂ 31, 2023, there was one customer that represented 24% of the Companyâ€™s accounts receivable. Â Foreign Currency Risk Â Our business is primarily conducted in U.S. dollars. Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our results of operations, financial position or cash flows. Â ITEM 4. CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rulesÂ and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rulesÂ and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Â As required by RuleÂ 13a-15(b)Â under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Exchange Act) as of September 30, 2024. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of September 30, 2024, our disclosure controls and procedures were effective. Â Changes in Internal Control over Financial Reporting Â There were no changes in our internal controls over financial reporting identified in managementâ€™s evaluation pursuant to RulesÂ 13a-15(d)Â and 15d-15(d)Â of the Exchange Act that occurred during the three months ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â PARTÂ II.Â OTHER INFORMATION Â Â ITEM 1.Â LEGAL PROCEEDINGS Â Â None. Â 38 Â Â ITEMÂ 1A. RISK FACTORS Â Except as described below, there have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K filed with the SEC on March 20, 2024.The disclosure of risks identified below does not imply that the risk has not already materialized. Â Nasdaq may delist our securities from its exchange, which could harm our business and limit our stockholdersâ€™Â liquidity. Â Our common stock is currently listed on the Nasdaq Capital Market, which has qualitative and quantitative listing criteria. However, we cannot assure you that our common stock will continue to be listed on Nasdaq in the future. In order to continue listing our common stock on Nasdaq, we must maintain certain financial, distribution and stock price levels. Generally, we must maintain a minimum amount in stockholdersâ€™ equity, a minimum number of holders of our common stock and a minimum bid price. Â On April 25, 2023, we received the Bid Price Deficiency Letter from Staff of The Nasdaq notifying us that we were not in compliance with the Bid Price Requirement, as the minimum bid price for our listed securities was less than $1.00 for the previous 30 consecutive business days. We had a period of 180 calendar days, or until October 23, 2023, to regain compliance with the rule referred to in this paragraph. As part of our efforts to regain compliance with the aforementioned rule, we effected a 1-for-15 reverse stock split on September 12, 2023. Â On September 27, 2023, we received a letter from Nasdaq notifying us that the Staff had determined that the closing bid price of our common stock had been at $1.00 per share or greater for at least 10 consecutive business days and, accordingly, that we had regained compliance with the Bid Price Requirement. While we have regained compliance with the Bid Price Requirement, there can be no assurance that we will be able to maintain compliance with the Bid Price Requirement, or other continued listing requirements of Nasdaq, in the future. Â As of the date of this quarterly report, the minimum bid price for our common stock has been below $1.00 for the previous 23 consecutive business days. Â On May 18, 2023, we received the Stockholdersâ€™ Equity Deficiency Letter from the Staff that we no longer satisfied the Equity Requirement. Â As with the Bid Price Deficiency Letter, the Stockholdersâ€™ Equity Deficiency Letter had no immediate effect on our continued listing on The Nasdaq Capital Market. In accordance with the Nasdaq Listing Rules, we were provided 45 calendar days, or until July 3, 2023, to submit a plan to regain compliance with the Equity Requirement. We submitted the Compliance Plan to Nasdaq on July 3, 2023. On July 31, 2023, we received a letter from Nasdaq notifying us that the Staff had determined to grant us an extension of 180 calendar days from the date of the Staffâ€™s notice, or November 14, 2023, to regain compliance with the Equity Requirement. Â On November 21, 2023, the Staff formally notified us that the Staff had determined that we were unable to demonstrate compliance with the Equity Requirement and that our securities would be delisted at the open of business on November 30, 2023, unless we timely requested a hearing before the Panel. On November 28, 2023, we requested and were granted a hearing before the Panel which took place on February 20, 2024. At the hearing, we presented a plan to regain and sustain compliance with the Equity Requirement and requested an extension to do so. On March 14, 2024, the results from the hearing were rendered in which we were granted an extension by the Panel. This extension stayed any further action by Nasdaq with respect to our continued listing until May 20, 2024. Â On May 29, 2024, we were formally notified by Nasdaq that we have regained compliance with the stockholdersâ€™ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and evidenced compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the listing matter, which was reviewed by the Panel has been closed. Â We will be subject to a â€œMandatory Panel Monitorâ€ as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), through May 29, 2025. If within the monitoring period we fail to evidence compliance with the Equity Requirement, we would not be allowed to provide to the Staff a plan to regain compliance with the Equity Requirement; rather, the Staff would be required to issue a delist determination. We would in that case have the opportunity to request a new hearing before the Panel, which request would stay any further action by the Staff. Â 39 Â Â We anticipate we will need to issue additional shares of capital stock through various other financing transactions in order to maintain compliance with the Equity Requirement, the most recent of which occurred in June 2024 in a best efforts public offering resulting in gross proceeds of $6.0 million. However, we may not be successful in executing such future transactions on terms favorable to us, or at all. In addition, there can be no guarantee that such efforts will succeed in helping us maintain compliance with the Nasdaq Listing Rules. Â If Nasdaq delists our common stock from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including: Â Â â— a limited availability of market quotations for our securities; Â Â â— reduced liquidity for our securities; Â Â â— a determination that our common stock is a â€œpenny stockâ€Â which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; Â Â â— a limited amount of news and analyst coverage; and Â Â â— a decreased ability to issue additional securities or obtain additional financing in the future. Â The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as â€œcovered securities.â€ If our common stock continues to be listed on NASDAQ, our common stock will be a covered security. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Â There is substantial doubt about our ability to continue as a going concern, and we will need additional financing to execute our business plan, to fund our operations and to continue as a going concern, and, if we are unable to obtain additional financing, may be required to pursue a reorganization proceeding under applicable bankruptcy or insolvency laws, including under Chapter 11 of the U.S. Bankruptcy Code. Â Since inception, we have experienced recurring operating losses and negative cash flows and we expect to continue to generate operating losses and consume significant cash resources for the foreseeable future. There is substantial doubt regarding our ability to continue as a going concern. Our independent registered public accounting firm has expressed in its auditorsâ€™ report on our 2023 financial statements, included our Annual Report on Form 10-K filed on March 20, 2024, an emphasis of matter paragraph relating to our ability to continue as a â€œgoing concern,â€ meaning that our recurring losses from operations and negative cash flows from operations raise substantial doubt regarding our ability to continue as a going concern. We have prepared our financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Our financial statements do not include any adjustment to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty, with the exception that all borrowings are classified as current on the balance sheets. Â Under the Loan Agreement with CRG, a â€œMaterial Adverse Changeâ€ or â€œMaterial Adverse Effectâ€ (each as defined in the Loan Agreement) is an â€œEvent of Defaultâ€ thereunder, which gives Majority Lenders (as defined in the Loan Agreement) the right to declare amounts outstanding under the Loan Agreement immediately due and payable. Due to the substantial doubt about our ability to continue operating as a going concern and the Event of Default that could result due to a Material Adverse Change under the Loan Agreement, the entire amount of borrowings at September 30, 2024 and December 31, 2023 are classified as current. In addition, we may not be able to generate sufficient liquidity or revenue to satisfy minimum liquidity and minimum revenue covenants under the Loan Agreement. If we fail to satisfy such requirements, we will be in default under the Loan Agreement and all outstanding amounts under the Loan Agreement will become immediately due. Â Majority Lenders have not purported that an Event of Default has occurred as a result of a Material Adverse Change or breach of other financial covenants. However, there can be no guarantee that Majority Lenders will not invoke such Event of Default in the future, or that we will not experience other Material Adverse Changes or other Material Adverse Effects, or otherwise breach our financial or other covenants under the Loan Agreement, that could give rise to an Event of Default under the Loan Agreement. Â 40 Â Â If we are unable to generate sufficient revenue and liquidity to service our debt, we may be required to pursue a reorganization proceeding under applicable bankruptcy or insolvency laws, including protection (â€œBankruptcy Protectionâ€) under Chapters 7 or 11 of the U.S. Bankruptcy Code. Holders of our common stock will likely not receive any value or payments in a restructuring or similar scenario. Â In the event we pursue Bankruptcy Protection, we will be subject to the risks and uncertainties associated with such proceedings. Â In the event we file for relief under the United States Bankruptcy Code, our operations, our ability to develop and execute our business plan and our continuation as a going concern will be subject to the risks and uncertainties associated with bankruptcy proceedings, including, among others: our ability to execute, confirm and consummate a plan of reorganization; the high costs of bankruptcy proceedings and related fees; our ability to obtain sufficient financing to allow us to emerge from bankruptcy and execute our business plan post-emergence, and our ability to comply with terms and conditions of that financing; our ability to continue our operations in the ordinary course; our ability to maintain our relationships with our customers, business partners, counterparties, employees and other third parties; our ability to obtain, maintain or renew contracts that are critical to our operations on reasonably acceptable terms and conditions; our ability to attract, motivate and retain key employees; the ability of third parties to use certain limited safe harbor provisions of the United States Bankruptcy Code to terminate contracts without first seeking Bankruptcy Court approval; and the actions and decisions of our stakeholders and other third parties who have interests in our bankruptcy proceedings that may be inconsistent with our operational and strategic plans. Any delays in our bankruptcy proceedings would increase the risks of our being unable to reorganize our business and emerge from bankruptcy proceedings and may increase our costs associated with the bankruptcy process or result in prolonged operational disruption for us. Also, we would need the prior approval of the bankruptcy court for transactions outside the ordinary course of business during the course of any bankruptcy proceedings, which may limit our ability to respond timely to certain events or take advantage of certain opportunities. Because of the risks and uncertainties associated with any bankruptcy proceedings, we cannot accurately predict or quantify the ultimate impact of events that could occur during any such proceedings. There can be no guarantees that if we seek Bankruptcy Protection, we will emerge from Bankruptcy Protection as a going concern or that holders of our common stock will receive any recovery from any bankruptcy proceedings. Â In the event we are unable to

pursue Bankruptcy Protection under Chapter 11 of the United States Bankruptcy Code, or, if pursued, successfully emerge from such proceedings, it may be necessary to pursue Bankruptcy Protection under Chapter 7 of the United States Bankruptcy Code for all or a part of our businesses. Â In the event we are unable to pursue Bankruptcy Protection under Chapter 11 of the United States Bankruptcy Code, or, if pursued, successfully emerge from such proceedings, it may be necessary for us to pursue Bankruptcy Protection under Chapter 7 of the United States Bankruptcy Code for all or a part of our businesses. In such event, a Chapter 7 trustee would be appointed or elected to liquidate our assets for distribution in accordance with the priorities established by the United States Bankruptcy Code. We believe that liquidation under Chapter 7 would result in significantly smaller distributions being made to our stakeholders than those we might obtain under Chapter 11 primarily because of the likelihood that the assets would have to be sold or otherwise disposed of in a distressed fashion over a short period of time rather than in a controlled manner and as a going concern. Â We may not be able to secure additional financing on favorable terms, or at all, to meet our future capital needs and our failure to obtain additional financing when needed could force us to delay, reduce or eliminate our product development programs and commercialization efforts or cause us to become insolvent. Â Even though we received net proceeds of approximately $7.0 million from the sale of our common stock and Series F Convertible Preferred Stock in the Private Placement in March 2024 and $5.2 million from the sale of a combination of our common stock and Pre-Funded Warrants in a public offering in June 2024, we believe that our cash and cash equivalents at September 30, 2024, together with the aforementioned financing, debt and other financing activities and expected revenues from operations, will not be sufficient to satisfy our capital requirements and fund our operations beyond the fourth quarter of 2024. We will need to raise additional funds through future equity or debt financings in the near future to meet our operational needs and capital requirements for product development, clinical trials and commercialization. We can provide no assurance that we will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for our existing stockholders. Given the volatility of our stock price, any financing that we undertake could cause substantial dilution to our existing stockholders. Macroeconomic challenges and volatility in capital markets could further limit our ability to raise capital when needed on terms favorable to us, or at all. In addition, while we have been able to raise capital from the sale of shares under our at-the-market program, the limitations under instruction I.B.6 of Form S-3, as well as possible low volume of trading in our securities, will limit our ability to continue raising funds through such program. Â 41 Â Â To date, we have financed our operations primarily through sales of our products and net proceeds from the issuance of our preferred stock and debt financings, our IPO, private offerings, strategic investment, and our follow-on public offerings of our securities. We do not know when or if our operations will generate sufficient cash to fund our ongoing operations. We cannot be certain that additional capital will be available as needed on acceptable terms, or at all. In the future, we may require additional capital in order to (i) continue to conduct research and development activities, (ii) conduct post-market clinical studies, as well as clinical trials to obtain regulatory clearances and approvals necessary to commercialize our Lumivascular platform products, (iii) expand our sales and marketing infrastructure, (iv) acquire complementary businesses technologies or products; or (v) respond to business opportunities, challenges, a decline in sales, increased regulatory obligations or unforeseen circumstances. Our future capital requirements will depend on many factors, including: Â Â â— the degree of success we experience in commercializing our Lumivascular platform products, particularly Pantheris, Ocelot, Tigereye and any future versions of such products; Â Â â— the costs, timing and outcomes of clinical trials and regulatory reviews associated with our future products; Â Â â— the costs and expenses of maintaining or expanding our sales and marketing infrastructure and our manufacturing operations; Â Â â— the costs and timing of developing variations of our Lumivascular platform products and, if necessary, obtaining FDA clearance of such variations; Â Â â— the costs and timing of developing our Coronary products, timing and outcomes of clinical trials and regulatory reviews associated with this product and eventual timing and expenses related to obtaining FDA clearance; Â Â â— the extent to which our Lumivascular platform is adopted by hospitals for use by interventional cardiologists, vascular surgeons and interventional radiologists in the treatment of PAD; Â Â â— the number and types of future products we develop and commercialize; Â Â â— the costs of defending ourselves against future litigation; Â Â â— the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and Â Â â— the extent and scope of our general and administrative expenses. Â We may attempt to raise additional funds in equity or debt financings or enter into credit facilities in order to access funds for our capital needs. Any debt financing obtained by us in the future would cause us to incur additional debt service expenses and could include restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and pursue business opportunities. In addition, due to our current level of debt, future equity investors may require that we convert all or a portion of our debt to equity, and our debtholders may not agree to such terms. If we raise additional funds through further issuances of equity or convertible debt securities, and/or if we convert all or a portion of our existing debt to equity, our existing stockholders could suffer significant dilution in their percentage ownership of our company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. Â If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products, and significantly scale back our operations, or we may become insolvent. In addition, as described above under the risk factor â€œNasdaq may delist our securities from its exchange, which could harm our business and limit our stockholdersâ€™ liquidity,â€ if we are unable to raise capital in a manner accretive to our stockholdersâ€™ equity, our common stock could be delisted from Nasdaq. If this were to occur, our ability to continue to grow and support our business and to respond to business challenges could be significantly limited. Â 42 Â Â ITEM 2.Â Â Â Â Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â None. Â ITEM 3.Â Â Â Â Â DEFAULTS UPON SENIOR SECURITIES Â None. Â ITEM 4.Â Â Â Â Â MINE SAFETY DISCLOSURES Â Not applicable. Â Â ITEM 5.Â Â Â Â Â OTHER INFORMATION Â 10b5-1 Trading Plans Â During the second quarter of 2024, none of our directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangementâ€ (as each term is defined in Item 408(a) of Regulation S-K). Â 43 Â Â Â ITEM 6.Â Â Â Â Â EXHIBITS Â The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q: Â Exhibit Number Â ExhibitÂ Title 31.1* Â Certification of the Principal Executive Officer pursuant to Securities Exchange Act RulesÂ 13a-14(a)Â and 15d-14(a), as adopted pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 31.2* Â Certification of the Principal Financial Officer pursuant to Securities Exchange Act RulesÂ 13a-14(a)Â and 15d-14(a), as adopted pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 32.1*# Â Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101.INS Â Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema Document Â Â Â 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document Â Â Â 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document Â Â Â 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â 104 Â Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. Â # Â The certifications filed as Exhibits 32.1 are not deemed â€œfiledâ€Â for purposes of SectionÂ 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Company under the Securities Exchange Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof irrespective of any general incorporation by reference language contained in any such filing, except to the extent that the registrant specifically incorporates it by reference. Â 44 Â Â Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â Avinger,Â Inc. Â (Registrant) Â Â Â Â Date: November 7, 2024 /s/ JEFFERY M. SOINSKI Â Jeffrey M. Soinski Â Chief Executive Officer Â (Principal Executive Officer) Â Â Date: November 7, 2024 /s/Â NABEEL SUBAINATI Â Nabeel Subainati Â Vice President, Finance Â (Principal Financial and Accounting Officer) Â Â EX-31.1 2 ex_741990.htm EXHIBIT 31.1 ex_741990.htm Â ExhibitÂ 31.1 Â CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER Pursuant to Securities Exchange Act RulesÂ 13a-14(a)Â and 15d-14(a), As Adopted Pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002 Â I, Jeffrey Soinski, hereby certify that: Â 1.Â Â Â I have reviewed this Quarterly Report on FormÂ 10-Q of Avinger,Â Inc.; Â 2.Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.Â Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have: Â a)Â Â Â Â Â Â designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b)Â Â Â Â Â Â designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c)Â Â Â evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d)Â Â Â disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; Â 5.Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a)Â Â Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize, and report financial information; and Â b)Â Â Â Â Â Â any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Dated: November 7, 2024 Â Â /s/ Jeffrey M. Soinski Â Jeffrey M. Soinski Â Chief Executive Officer Â (Principal Executive Officer) Â Â EX-31.2 3 ex_741991.htm EXHIBIT 31.2 ex_741991.htm Â ExhibitÂ 31.2 Â CERTIFICATION OF THE CHIEF FINANCIAL OFFICER Pursuant to Securities Exchange Act RulesÂ 13a-14(a)Â and 15d-14(a), As Adopted Pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002 Â I, Nabeel Subainati, hereby certify that: Â 1.Â Â Â Â Â I have reviewed this Quarterly Report on FormÂ 10-Q of Avinger,Â Inc.; Â 2.Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.Â Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f)Â and 15d-15(f)) for the registrant and have: Â a)Â Â Â Â Â Â designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b)Â Â Â Â Â Â designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c)Â Â Â evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d)Â Â Â disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; Â 5.Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a)Â Â Â Â Â Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize, and report financial information; and Â b)Â Â Â any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Dated: November 7, 2024 Â Â /s/ Nabeel Subainati Â Nabeel Subainati Â Vice President, Finance Â (Principal Financial and Accounting Officer) Â Â EX-32.1 4 ex_741992.htm EXHIBIT 32.1 ex_741992.htm Â ExhibitÂ 32.1 Â CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTIONÂ 1350, AS ADOPTED PURSUANT TO SECTIONÂ 906 OF THE SARBANES-OXLEY ACT OFÂ 2002 Â In connection with the Quarterly Report of Avinger,Â Inc. (the â€œCompanyâ€) on FormÂ 10-Q for the period ended September 30, 2024, as filed with the Securities and Exchange Commission (the â€œReportâ€), Jeffrey Soinski, as Chief Executive Officer of the Company, and Nabeel Subainati, Vice President, Finance of the Company, each hereby certifies, pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. SectionÂ 1350), to his knowledge: Â Â 1. The Report fully complies with the requirements of SectionÂ 13(a)Â or SectionÂ 15(d)Â of the Securities Exchange Act of 1934; and Â Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 7th day of November, 2024. Â /s/ Jeffrey M. Soinski Â /s/ Nabeel Subainati Jeffrey M. Soinski Â Nabeel Subainati Chief Executive Officer Â Vice President, Finance (Principal Executive Officer) Â (Principal Financial and Accounting Officer) Â This certification accompanies the FormÂ 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the FormÂ 10-Q), irrespective of any general incorporation language contained in such filing. Â Â EX-101.SCH 5 avgr-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Organization link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Inventories link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Borrowings link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Leases link:calculationLink

link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Restructuring Charges and Expenses link:calculationLink link:definitionLink link:presentationLink 995460 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995461 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Note 3 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 4 - Borrowings (Tables) link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Note 5 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 7 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 8 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 1 - Organization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 3 - Inventories - Schedule of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 4 - Borrowings (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Borrowings - Schedule of Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 5 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 5 - Leases - Future Operating Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 5 - Leases - ROU Assets and Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 7 - Stockholder's Equity - Outstanding Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 8 - Stock-Based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 9 - Restructuring Charges and Expenses (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 6 avgr-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 avgr-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFour Long Term Debt Maturities, Repayments of Interest in Year Four Amount of interest payments on long-term debt sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Note To Financial Statement Details Textual Advisor Warrants Issued In The March 2024 Financing [Member] Advisor Warrants Issued In The March 2024 Financing Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Customer, Two [Member] Represents Customer Two. Note 3 - Inventories Note 4 - Borrowings Note 5 - Leases Note 7 - Stockholders' Equity June 2024 Offering [Member] Represents June 2024 offering. Note 8 - Stock-based Compensation Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) avgr_ShareOfferingSharesIssuableInBestEfforts Share Offering, Shares Issuable in Best Efforts (in shares) Number of shares issuable in best efforts under share offering. Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Prefunded Warrants Issued in June 2024 [Member] Represents prefunded warrants issued in June 2024. Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) avgr_RestructuringAndRelatedCostNumberOfPositionsEliminatedSeverancePaid Restructuring and Related Cost, Number of Positions Eliminated, Severance Paid Represents the number of eliminated positions for which severance costs have been paid. Note 3 - Inventories - Schedule of Inventory (Details) avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFive Long Term Debt Maturities, Repayments of Interest in Year Five Amount of interest payments on long-term debt sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Note 4 - Borrowings - Schedule of Debt (Details) Public Offering [Member] Represents public offering. Note 5 - Leases - Future Operating Lease Payments (Details) us-gaap_LiabilitiesCurrent Total current liabilities avgr_SeveranceCostsIncludedInAccruedCompensation Severance Costs, Included in Accrued Compensation Amount of expenses included as part of accrued compensation on balance sheet, for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. Note 5 - Leases - ROU Assets and Lease Liabilities (Details) Note 7 - Stockholder's Equity - Outstanding Warrants (Details) Series A-3 Warrants [Member] Represents Series A-3 Warrants. Schedule of Debt [Table Text Block] Loan Agreement Amendment No 8 [Member] Represents loan agreement amendment number 8. Note 8 - Stock-Based Compensation - Stock Option Activity (Details) Loan Agreement Amendment No 10 [Member] Represents loan agreement amendment number 10. Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) avgr_ClassOfWarrantsOrRightsExercisedDuringPeriod Class of Warrant or Right, Exercised (in shares) Number of warrants exercised during period. Notes To Financial Statements avgr_ShareOfferingPurchasePricePerShare Share Offering, Purchase Price Per Share (in dollars per share) Represents purchase price per share for share offering. Notes To Financial Statements [Abstract] Series A-2 Warrants [Member] Represents Series A-2 Warrants. Awards outstanding, Weighted Average Remaining Contractual Term (Year) Series A-1 Warrants [Member] Represents Series A-1 Warrants. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Series A-2 Warrants Issued in June 2024 [Member] Series A-2 Warrants Issued in June 2024. Purchase Commitment, Excluding Long-Term Commitment [Axis] Series A-1 Warrants Issued in June 2024 [Member] Represents Series A-1 Warrants Issued in June 2024. Purchase Commitment, Excluding Long-Term Commitment [Domain] Placement Agent Warrants Issued in June 2024 [Member] Represents Placement Agent Warrants Issued in June 2024. Purchase Commitment [Member] Series A-3 Warrants Issued in June 2024 [Member] Series A-3 Warrants Issued in June 2024. Proceeds from the issuance of common stock and convertible preferred stock in a private placement, net of commissions and issuance costs The cash inflow from issuance of common stocks, and preferred stocks identified as being convertible, into another form of financial instrument, typically the entity's common stock, after deduction of issuance costs. Pre-Funded, Series A-1, Series A-2, Series A-3 and Placement Agent Warrants [Member] Represents Pre-Funded, Series A-1, Series A-2, Series A-3 and Placement Agent Warrants . Awarded, Weighted Average Grant Date Fair Value (in dollars per share) Released, Weighted Average Grant Date Fair Value (in dollars per share) Forfeited, , Weighted Average Grant Date Fair Value (in dollars per share) Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Exercises of pre-funded warrants for common stock Aggregate change in value for shares issued as a result of the exercise of warrants. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Awards outstanding, shares (in shares) Awards outstanding, shares (in shares) Awarded, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Released, shares (in shares) Loan Agreement [Member] Represents information about Term Loan Agreement (Loan Agreement). CRG [Member] Represents information about CRG. avgr_DebtAgreementMaximumBorrowingCapacity Debt Agreement, Maximum Borrowing Capacity Maximum borrowing capacity under a debt agreement on the amount that could be borrowed with a combination of, but not limited to, a line of credit and term loan. Borrowings March 2024 Offering [Member] March 2024 Offering Less: Amount of PIK additions and final facility fee to be incurred subsequent to June 30, 2024 Cumulative paid-in-kind interest treated as additional principal and added to the total carrying amount of the debt. Series F Convertible Preferred Stock [Member] Series F Convertible Preferred Stock avgr_DebtConversionFeesAndPrepaymentPremiumAmount Debt Conversion, Fees and Prepayment Premium Amount The amount of related back-end fees and prepayment premium being converted together with the original debt in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Accrued expenses and other current liabilities Accrued compensation Preferred stock dividends payable Lessee, Operating Leases [Text Block] Accounts payable Credit Facility [Axis] Credit Facility [Domain] us-gaap_PolicyTextBlockAbstract Accounting Policies Common Stock Warrants [Member] Represents information about common stock warrants. Exercises of pre-funded warrants for common stock (in shares) Stock Issued During Period, Shares, Warrants Exercised (in shares) Number of shares issued as a result of the exercise of warrants. Common Stock Options [member] Increase to right of use asset and leasehold liability arising from lease amendment The increase or decrease in value related to the right of use assets and leasehold liability arising from lease amendment. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Cancellation of Series A preferred stock Value of shares of stock being canceled during period. Cancellation of Series A preferred stock (in shares) Number of shares cancelled during the period. avgr_WarrantyPeriod Warranty Period (Year) Represents the typical period of product warranty for parts and labor. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment avgr_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block] Disclosure of accounting policies for credit risk and other risks and uncertainties. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation avgr_ProductWarrantyAccrualPaymentsAndRelease Usage/Release Represents the aggregate decrease in the liability related to payments to satisfy claims for standard and extended product warranties and adjustment to release accrued amounts. Current liabilities: avgr_PreferredStockDividendRatePercentageThereafterThirdAnniversaryOfIssuance Preferred Stock Dividend Rate, Percentage, Thereafter Third Anniversary Of Issuance The percentage rate used to calculate dividend payments on preferred stock after the third anniversary of their issuance. us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Net loss applicable to common stockholders Net loss applicable to common stockholders us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition First Tranche, Borrowed on September 22, 2015 [Member] Represents information about first tranche, borrowed on September 22, 2015. Second Tranche, Borrowed on June 15, 2016 [Member] Represents information about second tranche, borrowed on June 15, 2016. Share-Based Payment Arrangement [Text Block] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Net share settlement of restricted stock awards in satisfaction of tax obligations Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Accretion of preferred stock dividends Value of accretion of preferred stock dividends. Series A Preferred Stock Purchase Agreement with CRG [Member] Represents information about series A preferred stock purchase agreement with CRG. avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage Debt Instrument, Redemption Initial Prepayment Premium Percentage The initial premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. Award Type [Domain] avgr_DebtInstrumentFinancingFeePercentage Debt Instrument, Financing Fee Percentage The debt instrument fee required on the borrowing date for each tranche of borrowing, as a percentage of the principal amount borrowed. avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage The annual decline in the premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. Net Income (Loss) Attributable to Parent Net loss and comprehensive loss Net and comprehensive loss Basis of Presentation and Significant Accounting Policies [Text Block] Award Type [Axis] Noncash interest expense and other charges The amount of noncash interest expense (income) and other charges, net. avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum The minimum amount of cash and certain cash equivalents the entity is required to maintain under the terms of the debt agreement. avgr_DebtInstrumentFinalFacilityFeePercentage Debt Instrument, Final Facility Fee Percentage The facility fee payable at the end of the debt instrument term or upon prepayment in full, as a percentage of the amount borrowed. Restricted Stock Units (RSUs) [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] us-gaap_PreferredStockConvertibleSharesIssuable Preferred Stock, Convertible, Shares Issuable Antidilutive Securities, Name [Domain] us-gaap_PreferredStockConvertibleConversionPrice Preferred Stock, Convertible, Conversion Price (in dollars per share) us-gaap_PreferredStockConvertibleConversionRatio Preferred Stock, Convertible, Conversion Ratio Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Cash flows from investing activities us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued compensation us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_OperatingExpenses Total operating expenses Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Other long-term liabilities avgr_PreferredStockExcessFairValue Preferred Stock, Excess Fair Value Represents the excess fair value of preferred stock. Allocated Share-based Compensation Expense Share-Based Payment Arrangement, Expense Amendment Flag dei_CityAreaCode City Area Code Use of Estimates, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Accrued expenses and other current liabilities Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares) us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding (in shares) Common Stock, Shares, Outstanding, Ending Balance (in shares) Preferred Stock, Shares Outstanding (in shares) Preferred Stock, Shares Outstanding (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus us-gaap_OperatingLeaseCost Operating Lease, Cost Document Fiscal Year Focus dei_DocumentPeriodEndDate Document

Period End Date us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating Lease, Weighted Average Remaining Lease Term dei_EntityFileNumber Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount dei_DocumentType Document Type Entity Small Business dei_EntityShellCompany Entity Shell Company Document Information [Line Items] us-gaap_DividendsPreferredStock Dividends, Preferred Stock Document Information [Table] us-gaap_SeveranceCosts1 Severance Costs Entity Filer Category Debt Instrument [Axis] dei_EntityCurrentReportingStatus Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Accretion of preferred stock dividends Employee stock-based compensation us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Entity Tax Identification Number Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] dei_EntityAddressAddressLine1 Entity Address, Address Line One us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Issuance of common stock in public offerings, net of commissions and issuance costs ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] dei_EntityAddressCityOrTown Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code dei_EntityAddressStateOrProvince Entity Address, State or Province Concentration Risk Type [Axis] ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Domain] Material Terms of Trading Arrangement [Text Block] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other assets us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] The 2015 Equity Incentive Plan [Member] Represents information pertaining to the Company's 2015 Equity Incentive Plan. Nature of Operations [Text Block] Conversion of CRG loan principal into Series E convertible preferred stock Conversion of CRG loan principal into Series E convertible preferred stock (in shares) dei_LocalPhoneNumber Local Phone Number us-gaap_TableTextBlock Notes Tables Issuance of common stock upon vesting of restricted stock awards (in shares) Right of Use Asset and Liabilities [Table Text Block] Tabular disclosure of information pertaining to right of use assets and liabilities. Issuance of common stock upon vesting of restricted stock awards Issuance of common stock upon vesting of restricted stock units (in shares) Selling, general and administrative Issuance of common stock upon vesting of restricted stock units avgr_OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly Represents information related to operating expense excluding maintenance fee and other expenses on a monthly basis. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) Stock Issued During Period, Shares, New Issues Raw materials Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholdersâ€™ equity (deficit) Finished products Work-in-process Issuance of common stock in public offerings, net of commissions and issuance costs UNITED STATES Accumulated deficit Retained Earnings (Accumulated Deficit) Research and development Series 1 February 2018 Warrants [Member] Related to series 1 February 2018 warrants. Series 2 February 2018 Warrants [Member] Related to series 2 February 2018 warrants. Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense, net us-gaap_InterestExpenseDebt Interest Expense, Debt Changes in operating assets and liabilities: Conversion of CRG Loan Into Series E Convertible Preferred Stock [Member] Relating to conversion of CRG loan into Series E Convertible Preferred Stock, avgr_PreferredStockConvertibleBeneficialOwnershipPercentage Preferred Stock, Convertible, Beneficial Ownership Percentage Represents the beneficial ownership percentage of convertible preferred stock. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other non-cash charges Leasehold liability, long-term portion Subsequent Event [Member] Inventory Disclosure [Text Block] Schedule of Inventory, Current [Table Text Block] Leasehold liability as of June 30, 2024 Total lease liabilities Leasehold liability, current portion Subsequent Event Type [Axis] Subsequent Event Type [Domain] Right of use asset Operating lease Total right of use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid Total us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Imputed interest Fair Value Measurement, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2024 (remaining three months of the year) us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2025 Segment Reporting, Policy [Policy Text Block] Other assets Stock-based compensation Conversion of CRG loan principal and accrued interest into Series H convertible preferred stock Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) Amortization of debt issuance costs and debt discount Earnings Per Share, Policy [Policy Text Block] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Debt Conversion Description [Axis] Common Warrants [Member] Represents the common warrants Debt Conversion, Name [Domain] Operating expenses: us-gaap_AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) Placement Agent Warrants [Member] Represents Placement Agent Warrants. us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Reclassification of other long-term liabilities to accrued compensation Amount of reclassification of other long-term liabilities to accrued compensation in noncash activities. us-gaap_ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued Depreciation and amortization avgr_WaiverAccretionOfPreferredStockDividends Accretion of preferred stock dividends Represents the amount of preferred stock dividends waived (accreted) during the period. us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Net share settlement of restricted stock awards in satisfaction of tax obligations (in shares) us-gaap_ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] us-gaap_AssetsCurrent Total current assets Equity [Text Block] avgr_ProceedsFromIssuanceOrSaleOfEquityNet Proceeds from Issuance or Sale of Equity, Net The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of underwriting discounts, commissions, legal and accounting fees. Warrants Issued in the January 2022 Financing [Member] represents warrants issued in the January 2022 financing. Common stock, par value of $0.001; Shares authorized: 100,000,000 at September 30, 2024 and December 31, 2023; Shares issued and outstanding: 2,783,891 and 1,279,928 at September 30, 2024 and December 31, 2023, respectively Placement agent warrants issued in the January 2022 financing [Member] Represents placement agent warrants issued in the January 2022 financing. Customer, One [Member] Represents one of the major customers. Adjustments to reconcile net loss to net cash used in operating activities: avgr_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Nonvested Fair Value Represents sharebased compensation arrangement by sharebased payment award equity instruments other than options nonvested fair value. Common Stock, Shares Authorized (in shares) Common Stock, Shares Authorized Common Stock, Shares, Issued (in shares) Common Stock, Shares, Issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate Common Stock, Par or Stated Value Per Share (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Standard Product Warranty, Policy [Policy Text Block] Statistical Measurement [Domain] Supplemental disclosure of cash flow information Maximum [Member] Minimum [Member] Statistical Measurement [Axis] Preferred Stock, Liquidation Preference, Value Preferred stock issuable in series, par value of $0.001; Shares authorized: 5,000,000 at September 30, 2024 and December 31, 2023; Shares issued and outstanding: 30,229 and 62,881 at September 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $18,338 and $62,796 at September 30, 2024 and December 31, 2023, respectively Preferred Stock, Shares Issued (in shares) Preferred Stock, Shares Issued Geographical [Axis] Geographical [Domain] Preferred Stock, Shares Authorized (in shares) Preferred Stock, Shares Authorized (in shares) Inventories, net Total inventories Preferred Stock, Par or Stated Value Per Share (in dollars per share) Preferred Stock, Par or Stated Value Per Share Revenues avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage Represents conversion of warrants allowed maximum ownership of common stock percentage. avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election Represents conversion of warrants allowed maximum ownership of common stock percentage upon election. Customer [Axis] Customer [Domain] Warranty provision us-gaap_PreferredStockDividendRatePercentage Preferred Stock, Dividend Rate, Percentage Cash flows from operating activities us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Statement [Line Items] Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, net of allowance for doubtful accounts of $56 and $41 at September 30, 2024 and December 31, 2023, respectively us-gaap_NumberOfReportableSegments Number of Reportable Segments Additional paid-in capital Stockholdersâ€™ equity (deficit): Schedule of Product Warranty Liability [Table Text Block] Other income (expense), net Current assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Private Placement [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies (Note 6) Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Cost of revenues us-gaap_CostOfRevenue avgr_NumberOfWarrantsIssuedPerUnit Number of Warrants Issued Per Unit The number of warrants issued per unit. us-gaap_GrossProfit Gross profit Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Waiver of Series A preferred stock dividends Amount of increase in additional paid in capital (APIC) resulting from waiver of dividends legally declared (or paid) in excess of retained earnings balance. avgr_EquityOfferingCashFeePercentageOfGrossProceeds Equity Offering, Cash Fee, Percentage of Gross Proceeds Percentage of gross proceeds for cash fee of the equity offering. avgr_MilestonePaymentMinimumRevenueRequired Milestone Payment, Minimum Revenue Required The minimum amount of revenue required for milestone payment. Provision for excess and obsolete inventories Exchange of Series A Preferred Stock Into Series A-1 Preferred Stock [Member] Represents the exchange of Series A preferred stock into Series A-1 preferred stock. avgr_ClassOfWarrantOrRightExercisePercentageOfSharesIssuedInEquityOffering Class of Warrant or Right, Exercise Percentage of Shares Issued in Equity Offering Percentage of share issued in equity offering for exercise of the warrants or rights. avgr_LicenseAgreementRenewalTerm License Agreement, Renewal Term Period for renewal of license agreement. avgr_WarrantsAndRightsOutstandingTermPeriodFollowingPublicAnnouncement Warrants and Rights Outstanding, Term, Period Following Public Announcement Period following public announcement for term of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. avgr_StockAndWarrantsIssuedDuringPeriodShares Issuance of common stock warrants in connection with the Private Placement (in shares) The number of shares of stock and warrants issued during the period. Issuance of common stock warrants in connection with the Private Placement Issuance of common stock warrants in connection with the Private Placement Value of stock and warrants issued during the period. Series B Preferred Investment Option Purchase Warrants [Member] Represents the Series B investment option purchase warrants. avgr_DebtInstrumentBorrowingPeriod Debt Instrument, Borrowing Period Period for borrowing under the debt instrument. avgr_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice Class of Warrant or Right, Expired During Period, Exercise Price Exercise price per share of warrants or rights cancelled during period. us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Net share settlement on restricted stock awards in satisfaction of tax obligations Loan Agreement Amendment No. 7 [Member] Represents Loan Agreement No. 7. Change in right of use asset The amount of change in right-of-use asset during the period. us-gaap_ProductWarrantyAccrual Beginning balance Ending balance us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity avgr_StockIssuedDuringPeriodAveragePricePerShare Stock Issued During Period, Average Price Per Share Represents the average price per share for shares issued over a period of time. Proceeds from issuance of common stock upon warrant exercises Retained Earnings [Member] Additional Paid-in Capital [Member] Common Stock [Member] Preferred Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Total Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Total Outstanding and Exercisable (in shares) Class of Warrant or Right, Outstanding (in shares) Transfers between inventory and property and equipment The amount of transfers between inventory and property and equipment during the reporting period. Underlying Shares of Common Stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) One Customer [Member] Information related to one customer. Less: Amount representing debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Borrowings, current portion, as of June 30, 2024 avgr_ProceedsFromIssuanceOfCommonStockNet Proceeds from Issuance of Common Stock, Net The net cash inflow from issuance of common stock, net. avgr_DebtInstrumentCovenantComplianceMinimumLiquidityRequirement Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement The minimum amount of liquidity required at all times for compliance with the debt instrument covenant. Document Quarterly Report Securities Purchase Agreement [Member] Represents securities purchase agreement. Entity Incorporation, State or Country Code Accounting Policies [Abstract] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Selling, General and Administrative Expenses [Member] dei_EntityInteractiveDataCurrent Entity Interactive Data Current Security Exchange Name Title of 12(b) Security Cost of Sales [Member] Research and Development Expense [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] us-gaap_SharePrice Share Price Potentially dilutive securities (in shares) us-gaap_PurchaseObligation Purchase Obligation Statement [Table] Statement of Financial Position [Abstract] Weighted average common shares used to compute net loss per share, basic and diluted (in shares) Weighted average common stock outstanding, basic and diluted (in shares) Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] 2026 2027 Long-Term Debt, Maturity, Year Four 2028 Long-Term Debt, Maturity, Year Five 2024 (remaining three months of the year) 2025 avgr_LicenseAgreementTerm License Agreement, Term The term of a license agreement. Placement Agent Private Investment Options Issued in August 2022 Financing [Member] Relating to Placement Agent Private Investment Options Issued in August 2022 Financing avgr_AgreementToPurchaseCommonStockMaximumAmount Agreement to Purchase Common Stock, Maximum Amount The maximum amount of the company's stock under agreement to be purchased. License and Distribution Agreement [Member] Related to license and distribution agreement. avgr_ClassOfWarrantOrRightWarrantsExpired Class of Warrant or Right Warrants Expired Represents class of warrant or right warrants expired. us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated Restructuring and Related Cost, Number of Positions Eliminated us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Series A Private Investment Options Issued in August 2022 Financing [Member] Relating to Series A Private Investment Options Issued in August 2022 Financing Series B Private Investment Options

Issued in August 2022 Financing [Member] Relating to Series B Private Investment Options Issued in August 2022 Financing. Series A-1 Preferred Stock [Member] Related to Series A-1 preferred stock. avgr_PreferredStockParValue Preferred Stock, Par Value The par value of preferred stock. Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares Reduction in the number of shares during the period as a result of a reverse stock split. avgr_MilestonePaymentAdditionalAuthorizedAmount Milestone Payment, Additional Authorized Amount The additional authorized amount of milestone payment to be made. The Market Offering Agreement (the â€œATM Agreementâ€) [Member] Represents the market offering agreement (the â€œATM Agreementâ€). avgr_PreferredStockStatedValue Preferred Stock, Stated Value The stated value of preferred stock. Common Stock in June, 2022 [Member] Represents common stock in June 2022. avgr_CommissionPercentage Commission Percentage Represents commission percentage. Restructuring and Related Activities Disclosure [Text Block] Cash flows from financing activities Other long-term liabilities Series G Preferred Stock [Member] avgr_ShareOfferingAgreementAggregateOffering Share Offering Agreement, Aggregate Offering The value of the aggregate offering under share offering agreement. Series H Preferred Stock [Member] Series E Preferred Stock [Member] Pre-funded Warrants [Member] Represents prefunded warrants. Series F Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Gain on exchange of Series A for Series A-1 convertible preferred stock Gain (Loss) On Convertible Preferred Stock Converted to Other Securities The gain (loss) on the value of convertible preferred stock that was converted to other securities. us-gaap_StockholdersEquity Total stockholdersâ€™ equity (deficit) Balance Balance us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Periodic Reduction Class of Stock [Axis] Class of Stock [Domain] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] EX-101.PRE 8 avgr-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 9 avgr-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 04, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-36817 Â Entity Registrant Name AVINGER, INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 20-8873453 Â Entity Address, Address Line One 400 Chesapeake Drive Â Entity Address, City or Town Redwood City Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94063 Â City Area Code 650 Â Local Phone Number 241-7900 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol AVGR Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding (in shares) Â 3,196,791 Entity Central Index Key 0001506928 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 5,901 $ 5,275 Accounts receivable, net of allowance for doubtful accounts of $56 and $41 at September 30, 2024 and December 31, 2023, respectively 877 1,014 Inventories, net 3,759 5,298 Prepaid expenses and other current assets 947 575 Total current assets 11,484 12,162 Right of use asset 1,427 1,102 Property and equipment, net 466 487 Other assets 224 19 Total assets 13,601 13,770 Current liabilities: Â Â Accounts payable 921 777 Accrued compensation 1,962 2,311 Preferred stock dividends payable 653 0 Accrued expenses and other current liabilities 589 817 Leasehold liability, current portion 1,210 1,102 Borrowings 4,168 14,293 Total current liabilities 9,503 19,300 Leasehold liability, long-term portion 217 0 Other long-term liabilities 6 672 Total liabilities 9,726 19,972 Commitments and contingencies (Note 6) Â Stockholdersâ€™ equity (deficit): Â Â Preferred stock issuable in series, par value of $0.001; Shares authorized: 5,000,000 at September 30, 2024 and December 31, 2023; Shares issued and outstanding: 30,229 and 62,881 at September 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $18,338 and $62,796 at September 30, 2024 and December 31, 2023, respectively 0 0 Common stock, par value of $0.001; Shares authorized: 100,000,000 at September 30, 2024 and December 31, 2023; Shares issued and outstanding: 2,783,891 and 1,279,928 at September 30, 2024 and December 31, 2023, respectively 3 1 Additional paid-in capital 438,153 414,493 Accumulated deficit (434,281) (420,696) Total stockholdersâ€™ equity (deficit) 3,875 (6,202) Total liabilities and stockholdersâ€™ equity (deficit) $ 13,601 $ 13,770 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DividendsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_SecuredDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accounts Receivable, Allowance for Credit Loss, Current $ 56 $ 41 Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001 Preferred Stock, Shares Authorized (in shares) 5,000,000 5,000,000 Preferred Stock, Shares Issued (in shares) 30,229 62,881 Preferred Stock, Shares Outstanding (in shares) 30,229 62,881 Preferred Stock, Liquidation Preference, Value $ 18,338 $ 62,796 Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001 Common Stock, Shares Authorized (in shares) 100,000,000 100,000,000 Common Stock, Shares, Issued (in shares) 2,783,891 1,279,928 Common Stock, Shares, Outstanding (in shares) 2,783,891 1,279,928 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue of the difference between preference in liquidation and the par or stated values of the preferred shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_PreferredStockLiquidationPreferenceValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues $ 1,650 $ 1,817 $ 5,356 $ 5,746 Cost of revenues 1,224 1,429 4,209 4,117 Gross profit 426 388 1,147 1,629 Operating expenses: Â Â Â Â Research and development 1,086 1,044 3,052 3,388 Selling, general and administrative 3,009 3,377 10,980 10,261 Total operating expenses 4,095 4,421 14,032 13,649 Loss from operations (3,669) (4,033) (12,885) (12,020) Interest expense, net (48) (455) (698) (1,292) Other income (expense), net 11 12 (2) 16 Net loss and comprehensive loss (3,706) (4,476) (13,585) (13,296) Accretion of preferred stock dividends (349) 2,436 (652) 0 Gain on exchange of Series A for Series A-1 convertible preferred stock 0 0 1,908 0 Net loss applicable to common stockholders $ (4,055) $ (2,040) $ (12,329) $ (13,296) Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) $ (1.82) $ (2.92) $ (6.93) $ (21.48) Weighted average common shares used to compute net loss per share, basic and diluted (in shares) 2,224 698 1,780 619 X - DefinitionThe gain (loss) on the value of convertible preferred stock that was converted to other securities. + ReferencesNo definition available. + Details Name: avgr_GainLossOnConvertiblePreferredStockConvertedToOtherSecurities Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of preferred stock dividends waived (accreted) during the period. + ReferencesNo definition available. + Details Name: avgr_WaiverAccretionOfPreferredStockDividends Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands Preferred Stock [Member] Private Placement [Member] Preferred Stock [Member] Series A-1 Preferred Stock [Member] Preferred Stock [Member] Common Stock [Member] Private Placement [Member] Common Stock [Member] Additional Paid-in Capital [Member] Private Placement [Member] Additional Paid-in Capital [Member] Series A-1 Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Private Placement [Member] Retained Earnings [Member] Series A-1 Preferred Stock [Member] Retained Earnings [Member] Private Placement [Member] Series A-1 Preferred Stock [Member] Total Balance (in shares) at Dec. 31, 2022 Â Â 60,961 Â 522,177 Â Â Â Â Â Â Â Â Â Â Â Â Balance at Dec. 31, 2022 Â Â $ 0 Â $ 8 Â Â $ 406,514 Â Â $ (402,376) Â Â $ 4,146 Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) Â Â 0 Â 607,236 Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock in public offerings, net of commissions and issuance costs Â Â $ 0 Â $ 1 Â Â 5,173 Â Â 0 Â Â 5,174 Conversion of CRG loan principal into Series E convertible preferred stock (in shares) Â Â 1,920 Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Conversion of CRG loan principal into Series E convertible preferred stock Â Â $ 0 Â $ 0 Â Â 1,920 Â Â 0 Â Â 1,920 Employee stock-based compensation Â Â $ 0 Â $ 0 Â Â 703 Â Â 0 Â Â 703 Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares) Â Â 0 Â 56,896 Â Â Â Â Â Â Â Â Â Â Â Â Reclassifications and adjustments due to rounding impact from reverse

stock split for fractional shares Â Â $ 0 Â $ (9) Â Â 9 Â Â 0 Â Â 0 Net and comprehensive loss Â Â Â Â Â Â Â Â Â Â (13,296) Â Â (13,296) Exercises of pre-funded warrants for common stock (in shares) Â Â 0 Â 91,325 Â Â Â Â Â Â Â Â Â Exercises of pre-funded warrants for common stock Â Â $ 0 Â $ 1 Â Â (2) Â Â 0 Â Â (1) Issuance of common stock upon vesting of restricted stock units (in shares) Â Â 0 Â 2,294 Â Â Â Â Â Â Â Â Â Issuance of common stock upon vesting of restricted stock units Â Â $ 0 Â $ 0 Â Â 0 Â Â 0 Â Â 0 Net Income (Loss) Attributable to Parent Â Â Â Â Â Â Â Â Â Â (13,296) Â Â (13,296) Balance (in shares) at Sep. 30, 2023 Â Â 62,881 Â 1,279,928 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2023 Â Â $ 0 Â $ 1 Â Â 414,317 Â Â (415,672) Â Â (1,354) Balance (in shares) at Dec. 31, 2022 Â Â 60,961 Â 522,177 Â Â Â Â Â Â Â Â Â Balance at Dec. 31, 2022 Â Â $ 0 Â $ 8 Â Â 406,514 Â Â (402,376) Â Â 4,146 Balance (in shares) at Dec. 31, 2023 Â Â 62,881 Â 1,279,928 Â Â Â Â Â Â Â Â Â Balance at Dec. 31, 2023 Â Â $ 0 Â $ 1 Â Â 414,493 Â Â (420,696) Â Â (6,202) Balance (in shares) at Jun. 30, 2023 Â Â 60,961 Â 622,578 Â Â Â Â Â Â Â Â Â Balance at Jun. 30, 2023 Â Â $ 0 Â $ 9 Â Â 404,597 Â Â (411,196) Â Â (6,590) Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) Â Â 0 Â 600,454 Â Â Â Â Â Â Â Â Â Issuance of common stock in public offerings, net of commissions and issuance costs Â Â $ 0 Â $ 1 Â Â 5,136 Â Â 0 Â Â 5,137 Conversion of CRG loan principal into Series E convertible preferred stock (in shares) Â Â 1,920 Â 0 Â Â Â Â Â Â Â Â Â Conversion of CRG loan principal into Series E convertible preferred stock Â Â $ 0 Â $ 0 Â Â 1,920 Â Â 0 Â Â 1,920 Employee stock-based compensation Â Â $ 0 Â $ 0 Â Â 219 Â Â 0 Â Â 219 Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares) Â Â 0 Â 56,896 Â Â Â Â Â Â Â Â Â Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares Â Â $ 0 Â $ (9) Â Â 9 Â Â 0 Â Â 0 Waiver of Series A preferred stock dividends Â Â 0 Â 0 Â Â 2,436 Â Â 0 Â Â 2,436 Net and comprehensive loss Â Â 0 Â 0 Â Â 0 Â Â (4,476) Â Â (4,476) Net Income (Loss) Attributable to Parent Â Â $ 0 Â $ 0 Â Â 0 Â Â (4,476) Â Â (4,476) Balance (in shares) at Sep. 30, 2023 Â Â 62,881 Â 1,279,928 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2023 Â Â $ 0 Â $ 1 Â Â 414,317 Â Â (415,672) Â Â (1,354) Balance (in shares) at Dec. 31, 2023 Â Â 62,881 Â 1,279,928 Â Â Â Â Â Â Â Â Â Balance at Dec. 31, 2023 Â Â $ 0 Â $ 1 Â Â 414,493 Â Â (420,696) Â Â (6,202) Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) 7,224 10,000 0 75,327 330,000 Â Â Â Â Â Â Â Â Â Issuance of common stock in public offerings, net of commissions and issuance costs $ 0 $ 0 $ 0 $ 0 $ 0 $ 6,880 $ 0 5,155 $ 0 $ 0 0 $ 6,880 $ 0 5,155 Conversion of CRG loan principal into Series E convertible preferred stock (in shares) Â Â 11,000 Â 0 Â Â Â Â Â Â Â Â Â Conversion of CRG loan principal into Series E convertible preferred stock Â Â $ 0 Â $ 0 Â Â 11,000 Â Â 0 Â Â 11,000 Employee stock-based compensation Â Â 0 Â 0 Â Â 1,525 Â Â 0 Â Â 1,525 Net and comprehensive loss Â Â $ 0 Â $ 0 Â Â 0 Â Â (13,585) Â Â (13,585) Exercises of pre-funded warrants for common stock (in shares) Â Â 0 Â 867,457 Â Â Â Â Â Â Â Â Â Exercises of pre-funded warrants for common stock Â Â $ 0 Â $ 1 Â Â 0 Â Â 0 Â Â 1 Accretion of preferred stock dividends Â Â 0 Â 0 Â Â (652) Â Â 0 Â Â (652) Net Income (Loss) Attributable to Parent Â Â $ 0 Â $ 0 Â Â 0 Â Â (13,585) Â Â (13,585) Issuance of common stock warrants in connection with the Private Placement (in shares) Â Â 0 Â 0 Â Â Â Â Â Â Â Â Â Issuance of common stock warrants in connection with the Private Placement Â Â $ 0 Â $ 0 Â Â 127 Â Â 0 Â Â 127 Issuance of common stock warrants in connection with the Private Placement Â Â $ 0 Â $ 0 Â Â 127 Â Â 0 Â Â 127 Cancellation of Series A preferred stock (in shares) Â Â (60,876) Â 0 Â Â Â Â Â Â Â Â Â Cancellation of Series A preferred stock Â Â $ 0 Â $ 0 Â Â 0 Â Â 0 Â Â 0 Issuance of common stock upon vesting of restricted stock awards (in shares) Â Â 0 Â 368,503 Â Â Â Â Â Â Â Â Â Issuance of common stock upon vesting of restricted stock awards Â Â $ 0 Â $ 1 Â Â 0 Â Â 0 Â Â 1 Net share settlement of restricted stock awards in satisfaction of tax obligations (in shares) Â Â 0 Â (137,324) Â Â Â Â Â Â Â Â Â Net share settlement of restricted stock awards in satisfaction of tax obligations Â Â $ 0 Â $ 0 Â Â (374) Â Â 0 Â Â (374) Balance (in shares) at Sep. 30, 2024 Â Â 30,229 Â 2,783,891 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2024 Â Â $ 0 Â $ 3 Â Â 438,153 Â Â (434,281) Â Â 3,875 Balance (in shares) at Jun. 30, 2024 Â Â 30,229 Â 1,916,434 Â Â Â Â Â Â Â Â Â Balance at Jun. 30, 2024 Â Â $ 0 Â $ 2 Â Â 438,326 Â Â (430,575) Â Â 7,753 Conversion of CRG loan principal into Series E convertible preferred stock (in shares) Â Â 0 Â 0 Â Â Â Â Â Â Â Â Â Conversion of CRG loan principal into Series E convertible preferred stock Â Â $ 0 Â $ 0 Â Â 0 Â Â 0 Â Â 0 Employee stock-based compensation Â Â 0 Â 0 Â Â 222 Â Â 0 Â Â 222 Net and comprehensive loss Â Â 0 Â 0 Â Â 0 Â Â (3,706) Â Â (3,706) Issuance of common stock in public offerings, net of commissions and issuance costs Â Â $ 0 Â $ 0 Â Â (45) Â Â 0 Â Â (45) Exercises of pre-funded warrants for common stock (in shares) Â Â 0 Â 867,457 Â Â Â Â Â Â Â Â Â Exercises of pre-funded warrants for common stock Â Â $ 0 Â $ 1 Â Â 0 Â Â 0 Â Â 1 Accretion of preferred stock dividends Â Â 0 Â 0 Â Â (349) Â Â 0 Â Â (349) Net Income (Loss) Attributable to Parent Â Â $ 0 Â $ 0 Â Â 0 Â Â (3,706) Â Â (3,706) Balance (in shares) at Sep. 30, 2024 Â Â 30,229 Â 2,783,891 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2024 Â Â $ 0 Â $ 3 Â Â $ 438,153 Â Â $ (434,281) Â Â $ 3,875 X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from waiver of dividends legally declared (or paid) in excess of retained earnings balance. + ReferencesNo definition available. + Details Name: avgr_AdjustmentsToAdditionalPaidInCapitalWaiverOfDividendsInExcessOfRetainedEarnings Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares of stock and warrants issued during the period. + ReferencesNo definition available. + Details Name: avgr_StockAndWarrantsIssuedDuringPeriodShares Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock and warrants issued during the period. + ReferencesNo definition available. + Details Name: avgr_StockAndWarrantsIssuedDuringPeriodValue Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares cancelled during the period. + ReferencesNo definition available. + Details Name: avgr_StockCancellationDuringPeriodShares Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares of stock being canceled during period. + ReferencesNo definition available. + Details Name: avgr_StockCancellationDuringPeriodValue Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: avgr_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesNo definition available. + Details Name: avgr_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for shares issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: avgr_StockIssuedDuringPeriodValueWarrantsExercised Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic

942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Net Income (Loss) Attributable to Parent $ (13,585) $ (13,296) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 245 214 Amortization of debt issuance costs and debt discount 32 62 Stock-based compensation 1,525 703 Noncash interest expense and other charges 844 1,488 Change in right of use asset 16 42 Provision for excess and obsolete inventories 111 350 Other non-cash charges 14 (51) Changes in operating assets and liabilities: Â Â Accounts receivable 122 278 Inventories 1,205 (996) Prepaid expenses and other current assets (372) (188) Other assets (221) 21 Accounts payable 144 (82) Accrued compensation (349) (250) Accrued expenses and other current liabilities (228) 240 Other long-term liabilities (666) 422 Net cash used in operating activities (11,163) (11,043) Cash flows from investing activities Â Â Purchase of property and equipment 0 (8) Net cash used in investing activities 0 (8) Cash flows from financing activities Â Â Proceeds from issuance of common stock upon warrant exercises 1 0 Net share settlement on restricted stock awards in satisfaction of tax obligations (374) 0 Net cash provided by financing activities 11,789 5,173 Net change in cash and cash equivalents 626 (5,878) Cash and cash equivalents, beginning of period 5,275 14,603 Cash and cash equivalents, end of period 5,901 8,725 Supplemental disclosure of cash flow information Â Â Increase to right of use asset and leasehold liability arising from lease amendment 1,177 0 Conversion of CRG loan principal and accrued interest into Series H convertible preferred stock 11,000 1,920 Accretion of preferred stock dividends 652 0 Reclassification of other long-term liabilities to accrued compensation 0 796 Transfers between inventory and property and equipment 223 32 Private Placement [Member] Â Â Cash flows from financing activities Â Â Proceeds from the issuance of common stock and convertible preferred stock in a private placement, net of commissions and issuance costs 7,007 0 Public Offering [Member] Â Â Cash flows from financing activities Â Â Proceeds from the issuance of common stock and convertible preferred stock in a private placement, net of commissions and issuance costs $ 5,155 $ 5,173 X - DefinitionValue of accretion of preferred stock dividends. + ReferencesNo definition available. +

Details Name: avgr_AccretionOfPreferredStockDividends Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of change in right-of-use asset during the period. + ReferencesNo definition available. + Details Name: avgr_ChangeInRightofuseAsset Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase or decrease in value related to the right of use assets and leasehold liability arising from lease amendment. + ReferencesNo definition available. + Details Name: avgr_IncreaseDecreaseRightOfUseAssetAndLeaseholdLiabilityArisingFromLeaseAmendment Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of noncash interest expense (income) and other charges, net. + ReferencesNo definition available. + Details Name: avgr_NoncashInterestExpenseIncomeAndOtherChargesNet Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of common stocks, and preferred stocks identified as being convertible, into another form of financial instrument, typically the entity's common stock, after deduction of issuance costs. + ReferencesNo definition available. + Details Name: avgr_ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of reclassification of other long-term liabilities to accrued compensation in noncash activities. + ReferencesNo definition available. + Details Name: avgr_ReclassificationOfOtherLongtermLiabilitiesToAccruedCompensation Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of transfers between inventory and property and equipment during the reporting period. + ReferencesNo definition available. + Details Name: avgr_TransfersBetweenInventoryAndPropertyAndEquipment Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-

28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Organization 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Nature of Operations [Text Block] 1. Organization Â Organization, Nature of Business Â Avinger, Inc. (the â€œCompanyâ€), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (â€œPADâ€). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (â€œU.S.â€) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (â€œOCTâ€) visualization with interventional catheters and is the industryâ€™s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Companyâ€™s Lumivascular platform consists of a capital component, Lightbox consoles, as well as a variety of disposable catheter products. The Companyâ€™s current catheter products include Ocelot, Tigereye and Tigereye ST, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (â€œCTOâ€). The Company also has image-guided atherectomy products, Pantheris, Pantheris SV and Pantheris LV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California. Â Liquidity Matters Â The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Update (â€œASUâ€) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entityâ€™s ability to continue as a going concern within one year from the date of the issuance of these financial statements. Â In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2024, the Company had an accumulated deficit of $434.3Â million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $5.9 million at September 30, 2024, together with debt and other financing activities and expected revenues from operations will be sufficient to allow the Company to fund its current operations through the end of the fourth quarter of 2024. On March 5, 2024, the Company entered into a financing as part of a broader strategic collaboration with Zylox-Tonbridge Medical Technology Co., Ltd. (â€œZylox-Tonbridgeâ€) in which the Company received an aggregate of $7.5 million before any commissions, legal and accounting fees, and other ancillary expenses as described more fully below. On June 17, 2024, the Company completed a public offering in which it received an aggregate of $6.0 million before any commissions, legal and accounting fees, and other ancillary expenses. The Company had also received net proceeds of approximately $6.5 million from the sale of its common stock under an At The Market Offering Agreement from the time of activation through the quarter ended September 30, 2024. On October 17, 2024, the Company reactivated the ATM Agreement. During October and part of November 2024, the Company sold 107,080 shares of common stock pursuant to the ATM Agreement at an average price ofÂ $0.82 per share for aggregate proceeds of approximately $88,000, of which approximately $2,600Â was paid in the form of commissions to the Agent. The Company may seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives. Â The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for its existing stockholders. Given the volatility in the Companyâ€™s stock price, any financing that the Company may undertake in the next twelve months could cause substantial dilution to its existing stockholders, and there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern. In addition, the macroeconomic environment has in the past resulted in and could continue to result in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company. Â If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development and sale of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Companyâ€™s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding. Â Additionally, due to the substantial doubt about the Companyâ€™s ability to continue operating as a going concern and the â€œMaterial Adverse Changeâ€ clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively â€œCRGâ€), the entire amount of outstanding borrowings at September 30, 2024 and December 31, 2023 has been classified as current in these financial statements. CRG has not purported that an Event of Default (as defined in the Loan Agreement) has occurred due to a Material Adverse Change. Â Currently substantially all of the Companyâ€™s cash and cash equivalents are held at a single financial institution. The Companyâ€™s previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. The Company has regained access to its accounts with the new institution and is currently reviewing its banking relationships. Potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Companyâ€™s access to cash and cash equivalents. Â If the Company is unable to access its cash and cash equivalents as needed, its financial position and ability to operate its business will be adversely affected. Â Public Offerings Â June 2024 Offering Â On June 13, 2024, the Company entered into a securities purchase agreement with two institutional investors for the issuance and sale of 3,614,457 shares of its common stock in a best efforts public offering (â€œthe Offeringâ€) at a purchase price of $1.66 per share, or pre-funded warrants in lieu thereof. The Company received aggregate net proceeds of approximately $5.2 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Â As a result, the Company issued (i) 330,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 3,284,457 shares of common stock (the â€œPre-Funded Warrantsâ€). During the third quarter ofÂ 2024, a total of 867,457 shares of the Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 867,457 shares of common stock. After giving effect to these aforementioned exercises, as of September 30, 2024,Â 2,417,000 Pre-Funded Warrants remain outstanding. Â In addition, the Company issued to the investors in the Offering (i) Series A-1 warrants (the â€œSeries A-1 Warrantsâ€) to purchase up to an aggregate of 3,614,457 shares of common stock, (ii) Series A-2 warrants (the â€œSeries A-2 Warrantsâ€) to purchase up to an aggregate of 3,614,457 shares of common stock, and (iii) Series A-3 warrants (the â€œSeries A-3 Warrants,â€ and together with the Series A-1 Warrants and Series A-2 Warrants, the â€œWarrantsâ€) to purchase up to an aggregate of 3,614,457 shares of common stock. Each share of common stock or Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. Each Warrant has an exercise price of $1.66 per. Â The Series A-1 Warrants expire on the earlier of August 12, 2029 and 60 days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. The Series A-2 Warrants expire on the earlier of August 12, 2026 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. The Series A-3 Warrants expire on the earlier of May 12, 2025 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO investigational device exemption (â€œIDEâ€) application. Â Pursuant to an engagement letter (the â€œEngagement Letterâ€) with H.C. Wainwright & Co., LLC (the â€œPlacement Agentâ€), the Company, in connection with the Offering, issued warrants to designees of the Placement Agent (the â€œPlacement Agent Warrantsâ€) to purchase up to an aggregate of 216,867 shares of common stock (the â€œPlacement Agent Warrant Sharesâ€). The Placement Agent Warrants have

substantially the same terms as the Warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $2.075 per share and expire on June 13, 2029. Â At The Market Offering Agreement Â On May 20, 2022, the Company entered into an At The Market Offering Agreement (the â€œATM Agreementâ€) with H.C. Wainwright & Co., LLC (the â€œAgentâ€), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.001 per share (the â€œSharesâ€) up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Companyâ€™s shelf registration statement on Form S-3, which was initially filed with the SEC on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on May 20, 2022. On August 3, 2022, the Company suspended sales under the ATM Agreement. On March 17, 2023, the Company reactivated the ATM Agreement. During the year ended December 31, 2023, the Company soldÂ 607,241Â shares of common stock at an average price of $9.01Â per share for aggregate proceeds of approximately $5.5Â million, of which approximately $164,000Â was paid in the form of commissions to the Agent. There were no sales under the ATM Agreement during the three or nine months ended September 30, 2024. On October 17, 2024, the Company reactivated the ATM Agreement. During October and part of November 2024, the Company sold 107,080 shares of common stock pursuant to the ATM Agreement at an average price ofÂ $0.82 per share for aggregate proceeds of approximately $88,000, of which approximately $2,600Â was paid in the form of commissions to the Agent. While the Company may attempt additional sales in the future, there can be no assurance that the Company will be successful in acquiring additional funding through these means. Â Other than the ATM Agreement, the Company currently does not have any commitments to obtain additional funds. Â Strategic Partnership and Private Placement Â On March 4, 2024, the Company entered into a License and Distribution Agreement (the â€œLicense Agreementâ€) with Zylox-Tonbridge effective as of the Initial Closing (defined below), pursuant to which the Company will license and distribute certain of the Companyâ€™s products (including consumables) in the Greater China region, including mainland China, Hong Kong, Macao, and Taiwan (the â€œTerritoryâ€). Zylox-Tonbridge will lead all regulatory activities for the registration of the Avinger products in the Territory. Avinger will also license its intellectual property and know-how related to Avinger products to Zylox-Tonbridge so that Zylox-Tonbridge can manufacture the localized products in the Territory. Avinger will supply Avinger products to Zylox-Tonbridge until Zylox-Tonbridgeâ€™s manufacturing capability has been established and Zylox-Tonbridge has obtained the regulatory approval of the localized products manufactured by Zylox-Tonbridge. All sales of Avinger products locally manufactured by Zylox-Tonbridge with regulatory approval by the regulatory authorities in the Territory and commercialized in the Territory will be royalty bearing to Avinger at a rate from a mid-single to high-single digit percentage depending on the amount of gross revenue as defined in the License Agreement, with certain increases depending on the amount of product gross margin. The License Agreement has an initial term of 20 years, which shall be further automatically extended for additional 20-year terms, subject to certain conditions. The License Agreement may not be terminated by either party, other than for certain uncured material breaches or the other partyâ€™s insolvency. During the three and nine months ended September 30, 2024, the Company received approximately $0.2 million and $0.4Â million respectively from Zylox-Tonbridge related to inventory consumed for regulatory approval which is recorded as a reduction to research and development expenses in the Condensed Statement of Operations and Comprehensive Loss for the three months ended September 30, 2024 which substantially offset the related expenditures associated with the inventory consumption. Â In connection with the License Agreement, on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the â€œCollaboration Agreementâ€ and, together with the License Agreement, the â€œStrategic Collaborationâ€), which provides the opportunity for the Company to access certain Zylox-Tonbridge peripheral vascular products for distribution in the U.S. and Germany. The agreement also provides the option for Avinger to source finished goods inventory from Zylox-Tonbridge following registration of Zylox-Tonbridgeâ€™s manufacturing facility with the FDA. Â Private Placement Â On March 4, 2024, in connection with the Strategic Collaboration, the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the â€œPurchaserâ€), entered into a Securities Purchase Agreement (the â€œPurchase Agreementâ€), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Companyâ€™s common stock, and shares of two new series of the Companyâ€™s preferred stock (the â€œPrivate Placementâ€). On March 5, 2024, (the â€œInitial Closingâ€), the Company issued to the Purchaser 75,327 shares of the common stock at a purchase price per share of $3.664 (the â€œPurchase Priceâ€), and 7,224 shares of a newly authorized Series F convertible preferred stock, par value $0.001 per share (the â€œSeries F Preferred Stockâ€), at a purchase price per share of $1,000, for an aggregate purchase price ofÂ $7.5 million. Â Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of common stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock (the â€œSeries F Certificate of Designationâ€). Â Upon completion of the following as mutually agreed upon by the Company and the Purchaser: (i) the successful registration and listing under 21 CFR part 807 with the FDAÂ of the Purchaser and one of its designated affiliates to manufacture Avingerâ€™s products, and (ii) the Company achieving an aggregate of $10 million in gross revenue within any four consecutive fiscal quarters after the Initial Closing, excluding any gross revenue achieved by Avinger under the License Agreement discussed above (together, the â€œMilestonesâ€), the Purchaser will invest an additional $7.5 million (the â€œMilestone Closingâ€) to purchase shares of the Companyâ€™s new Series G convertible preferred stock, par value $0.001 per share (the â€œSeries G Preferred Stockâ€). Each share of Series G Preferred Stock will have a stated value of $1,000 and will be convertible into shares of common stock at a conversion price of equal to the lowest of (x) the Purchase Price, (y) the closing price of the common stock on the date immediately preceding the Milestone Closing, and (z) the average closing price for the last five trading days preceding the Milestone Closing, provided that the conversion price will be no less than $0.20. The Milestone Closing was determined to be a separate freestanding equity-classified instrument issued together with the common stock and Series F preferred stock, all of which are classified within equity. Â On May 22, 2024, the Company held a special meeting of stockholders to vote on the following proposals resulting from the Private Placement (i) accept conversion of the shares of Series F Preferred Stock in excess of 19.9% of the Companyâ€™s outstanding common stock, which may be deemed a â€œchange of controlâ€ under Nasdaq Listing Rule 5635(b) and (ii) issue and sell shares of Series G Preferred Stock upon completion of the Milestones. Both proposals were approved by the Companyâ€™s stockholders. There were no conversions of Series F Preferred Stock during the three months ended September 30, 2024. Â The Company engaged two financial advisors in connection with the Private Placement and agreed to pay them an aggregate cash fee equal to 7% of the gross proceeds to the Company. Additionally, the Company agreed to issue to one financial advisor warrants to purchase an aggregate number of shares of common Stock equal to 2% of the gross proceeds. In connection with the Private Placement, the Company issued the financial advisor warrants (the â€œAdvisor Warrantsâ€) to purchase 40,938 shares of common stock. The cash fee of approximately $0.5 million and warrants with a fair value of approximately $0.1 million are considered financing costs and are recognized as a reduction of the proceeds from the Private Placement. Â Series A Preferred Stock Exchange Â On March 5, 2024, the Company entered into a Securities Purchase Agreement (the â€œA-1 Securities Purchase Agreementâ€) with CRG to exchange all outstanding shares of Series A preferred stock for 10,000 shares of Series A-1 preferred stock (the â€œExchangeâ€). Among other things, the shares of Series A-1 preferred stock: (i) are convertible into an aggregate of approximately 2,729,257 shares of common stock at a conversion price equal to the Purchase Price, (ii) do not accrue or pay dividends payable solely on the Series A-1 preferred stock, (iii) will have no liquidation preference and (iv) will be junior in rank to shares of the Companyâ€™s Series E preferred stock, Series F preferred stock and Series G preferred stock. The Exchange resulted in approximately $1.9 million gain included in the net loss applicable to common holders for the nine months ended September 30, 2024. Â CRG Loan Amendment Â Also on March 5, 2024, the Company entered into Amendment No. 9 to Loan Agreement effective as of the Initial Closing (the â€œAmendmentâ€) with CRG, which amends the Loan Agreement to, among other things: Â Â - extend the interest-only period through December 31, 2026; Â - provide that interest payable through December 31, 2026 may be payable in kind rather than in cash; and Â - permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Basis of Presentation and Significant Accounting Policies [Text Block] 2. Summary of Significant Accounting Policies Â Basis of Presentation Â The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S.Â GAAPâ€) and pursuant to the rulesÂ and regulations of the SEC. The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Companyâ€™s financial information. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending DecemberÂ 31, 2024, or for any other interim period or for any future year. The DecemberÂ 31, 2023 condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rulesÂ and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Companyâ€™s FormÂ 10-K for the fiscal year ended DecemberÂ 31, 2023, which was filed with the SEC on MarchÂ 20, 2024. The Companyâ€™s significant accounting policies are more fully described in Note 2 of the Notes to Financial Statements included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended DecemberÂ 31, 2023. Â Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Companyâ€™s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Â Concentration of Credit Risk, and Other Risks and Uncertainties Â Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. Â The Companyâ€™s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, First Citizens Bank, which acquired the Companyâ€™s prior banking partner, Silicon Valley Bank, in March 2023. The counterparties to the agreements relating to the Companyâ€™s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Managementâ€™s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and DecemberÂ 31, 2023. The Companyâ€™s previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. Although the Company has regained access to its accounts with this institution, now a division of the acquiring bank, and is currently reviewing its banking relationships, potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Companyâ€™s access to cash and cash equivalents. Â The Companyâ€™s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Managementâ€™s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and December 31, 2023. At September 30, 2024, there was one customer that represented 38% of the Companyâ€™s accounts receivable. At DecemberÂ 31, 2023, there was one customer that represented 24% of the Companyâ€™s accounts receivable. For the nine months ended September 30, 2024 there was one customer that represented 17% of revenues. For the three months ended September 30, 2024, there were two customers that represented 20% and 11% of revenues, respectively. For the three and nine months ended September 30, 2023, there was one customer that represented 22% and 17% of revenues, respectively. Disruption of the Companyâ€™s sales orders or a deterioration of financial condition of its customers would have a negative impact on the Companyâ€™s financial position and results of operations. Â Product Warranty Costs Â The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Beginning balance Â $ 150 Â Â $ 128 Â Â $ 193 Â Â $ 109 Â Warranty provision Â Â 3 Â Â Â 18 Â Â Â 35 Â Â Â 52 Â Usage/Release Â Â (25) Â Â (7) Â Â (100) Â Â (22) Ending balance Â $ 128 Â Â $ 139 Â Â $ 128 Â Â $ 139 Â Â Net Loss per Share Attributable to Common Stockholders Â Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holdersâ€™ continued service to the Company. As of September 30, 2024 and 2023, there were no shares subject to repurchase. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive. Â Net loss per share applicable to common stockholders was determined as follows (in thousands, except per share data): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss applicable to common stockholders Â $ (4,055) Â $ (2,040) Â $ (12,329) Â $ (13,296) Weighted average common stock outstanding, basic and diluted Â Â 2,224 Â Â Â 698 Â Â Â 1,780 Â Â Â 619 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (1.82) Â $ (2.92) Â $ (6.93) Â $ (21.48) Â The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Common stock

warrants equivalents Â Â 14,425,040 Â Â Â 459,019 Â Â Â 5,844,318 Â Â Â 483,947 Â Common stock options Â Â 15 Â Â Â 20 Â Â Â 15 Â Â Â 20 Â Convertible preferred stock Â Â 30,229 Â Â Â 62,151 Â Â Â 35,121 Â Â Â 61,362 Â Unvested restricted stock units Â Â 112,459 Â Â Â 91,630 Â Â Â 114,730 Â Â Â 88,585 Â Â Â Â 14,567,743 Â Â Â 612,820 Â Â Â 5,944,184 Â Â Â 633,914 Â Â Segment and Geographical Information Â The Company operates and manages its business as one reportable and operating segment. The Companyâ€™s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Companyâ€™s long-lived assets, which are comprised of property and equipment, are based in the United States. For the three months ended September 30, 2024 and 2023, 94% and 91% respectively, of the Companyâ€™s revenues were in the United States. For the nine months ended September 30, 2024 and 2023, 93% and 92%, respectively, of the Companyâ€™s revenues were derived from the United States based on the shipping location of the external customer. The remaining revenues for the three and nine months ended September 30, 2024 and 2023, were primarily derived from Germany. Â Fair Value Measurements Â As of September 30, 2024 and DecemberÂ 31, 2023, cash equivalents were all categorized as LevelÂ 1 and consisted of money market funds. As of September 30, 2024 and DecemberÂ 31, 2023, there were no financial assets and liabilities categorized as Level 2 or 3. There were no transfers between fair value hierarchy levels during the three or nine months ended September 30, 2024 and September 30, 2023. Â Recent Accounting Pronouncements Â Recent accounting standards not yet adopted Â In August 2020, the FASB issued ASU No. 2020-06,Â Debtâ€”Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. Â As a result, after adopting the ASUâ€™s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under Accounting Standards Codification (â€œASCâ€) 815 or (ii) a convertible debt instrument was issued at a substantial premium. The ASU becomes effective for the Company, as a smaller reporting company as defined by the SEC,Â in the first quarter of 2024. The Company has not yet adopted this standard.Â This new standard isÂ not expected to have a material impact on the Companyâ€™s financial statements. Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) â€“ Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has not yet adopted this standard. This new standard is not expected to have a material impact on the Companyâ€™s financial statements. Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU No. 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, if any, with further disaggregation required for significant individual jurisdictions. The ASU is effective for the Company for fiscal years beginning after December 15. ASU No. 2023-09 allows for adoption using either a prospective or retrospective transition method. This new standard is not expected to have a material impact on the Companyâ€™s financial statements. X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Inventories 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Inventory Disclosure [Text Block] 3. Inventories Â Inventories consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $ 1,863 Â Â $ 3,203 Â Work-in-process Â Â 154 Â Â Â 25 Â Finished products Â Â 1,742 Â Â Â 2,070 Â Total inventories Â $ 3,759 Â Â $ 5,298 Â Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Borrowings 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Debt Disclosure [Text Block] 4. Borrowings Â CRG Â On September 22, 2015, the Company entered into a Term Loan Agreement, as amended (the â€œLoan Agreementâ€) with CRG under which, subject to certain conditions, the Company had the right to borrow up to $50 million in principal amount from CRG on or before the end of the twenty-fourth (24th) month period commencing on the first Borrowing Date (as defined in the Loan Agreement). The Company borrowed $30 million on September 22, 2015. The Company borrowed an additional $10 million on June 15, 2016 under the Loan Agreement. Â On February 14, 2018, the Company and CRG further amended the Loan Agreement concurrent with the conversion of $38 million of the principal amount of the senior secured term loan (plus $3.8 million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock. Â On August 2, 2023, the Company and CRG entered into a Securities Purchase Agreement (â€œSeries E Purchase Agreementâ€) pursuant to which the Company issued 1,920 shares of a newly authorized Series E convertible preferred stock (â€œSeries E Preferred Stockâ€) in exchange for CRG surrendering for cancellation $1.92 million of outstanding principal and accrued interest of the senior secured term loan under the Loan Agreement. Each share of Series E preferred stock has a stated value of $1,000 per share and is convertible into 93 shares of the Companyâ€™s common stock at a conversion price of $10.725 per share. Â On May 16, 2024, the Company and CRG entered into another Securities Purchase Agreement (â€œSeries H Purchase Agreementâ€) pursuant to which the Company issued 11,000 shares of a newly authorized Series H convertible preferred stock (â€œSeries H Preferred Stockâ€) in exchange for CRG surrendering for cancellation $11.0 million of outstanding principal and accrued interest of the senior secured term loan under the Loan Agreement. Each share of Series H preferred stock has a stated value of $1,000 per share and is convertible into 259 shares of the Companyâ€™s common stock at a conversion price of $3.86 per share. Both the shares of Series E preferred stock and Series H preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess 9.99% of the Companyâ€™s outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Companyâ€™s outstanding voting power on a combined basis (as CRG collectively holds all of the issued and outstanding shares of the Companyâ€™s Series A-1 Convertible Preferred Stock, Series E Convertible Preferred Stock and Series H Convertible Preferred Stock), unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). Â The Company has entered into several amendments to the Loan Agreement (the â€œAmendmentsâ€) with CRG since September 2015. The Amendments, among other things: (1)Â extended the interest-only period through DecemberÂ 31, 2026; (2)Â extended the period during which the Company may elect to pay a portion of interest in payment-in-kind (â€œPIKâ€), interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3)Â permitted the Company to make the entire interest payments in PIK interest payments through DecemberÂ 31, 2026 so long as no Default has occurred and is continuing; (4)Â extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2028; (5)Â reduced the minimum liquidity covenant to $3.5 million at all times; (6)Â eliminated the minimum revenue covenants for all years (7) changed the date under the on-going stand-alone representation regarding no â€œMaterial Adverse Changeâ€ to December 31, 2020; (8) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of the Company and its subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; (9) provided CRG with board observer rights and (10) provide that the board observer may be appointed or removed by written notice from the Majority Lenders (as defined in the Loan Agreement). Â On January 26, 2024, the Company entered into Amendment No. 8 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.0 million until April 1, 2024. Thereafter, the Company was subject to the minimum liquidity requirement of $3.5 million. Â On March 5, 2024, the Company entered into Amendment No. 9 to the Loan Agreement with CRG, which (1) extended the interest-only period through December 31, 2026; (2)Â extended the period during which the Company may elect to pay a portion of interest in PIK interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3)Â permitted the Company to make the entire interest payments in PIK interest payments through DecemberÂ 31, 2026 so long as no Default has occurred and is continuing; and (4) permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. The Company assessed Amendment No. 9 to the Loan Agreement and determined that this represented a loan modification. As such, the unamortized portion of previous issuance costs incurred will be amortized over the modified term, and costs incurred with third parties was expensed as incurred. Â On June 5, 2024, the Company entered into Amendment No. 10 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.5 million for the period commencing June 1, 2024 and ending July 31, 2024. Thereafter, the Company will be subject to the minimum liquidity requirement of $3.5 million. Â Under the amended Loan Agreement, no cash payments for either principal or interest are required until the first quarter of 2027. The interest will be accrued and included in the debt balance based (to the extent not paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of 12.5%. Beginning in the first quarter of 2027, the Company will be required to make quarterly principal payments (in addition to the interest) of $0.5 million with total principal payments of $1.8 million in 2027 and $1.8 million in 2028. Total cash interest payments required to be made are $0.4 million and $0.1 million for 2027 and 2028 respectively. The maturity date of the Loan (as defined in the Loan Agreement) is December 31, 2028. Â The Company may voluntarily prepay the borrowings in full, with a prepayment premium beginning at 5.0% and declining by 1.0% annually thereafter, with no premium being payable if prepayment occurs after seven and half years of the loan. There is currently no prepayment premium payable. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to 1.5% of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to 15.0% of the amounts borrowed plus any PIK is to be payable at the end of the term or when the borrowings are repaid in full. A short-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Companyâ€™s assets. Â The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for a pre-specified liquidity requirement and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents. The minimum liquidity requirement was temporarily reduced to $1.5 million until July 31, 2024. The Loan Agreement also prohibits the payment of cash dividends on the Companyâ€™s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may accelerate the payment terms of the Loan Agreement upon the occurrence of certain â€œEvents of Defaultâ€ set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a â€œMaterial Adverse Changeâ€ thereunder. Â As of September 30, 2024, the Company was in compliance with all applicable covenants under the Loan Agreement. Â As of September 30, 2024, principal, final facility fee and PIK payments under the Loan Agreement, as amended, were as follows (in thousands): Â Year Ending December 31, Â Â Â Â 2024 (remaining three months of the year) Â $ â€” Â 2025 Â Â â€” Â 2026 Â Â â€” Â 2027 Â Â 2,176 Â 2028 Â Â 4,060 Â Total Â Â 6,236 Â Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2024 Â Â (1,934) Less: Amount representing debt issuance costs Â Â (134) Borrowings, current portion, as of September 30, 2024 Â $ 4,168 Â Â In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of September 30, 2024 and DecemberÂ 31, 2023, the balance of the aggregate debt discount was approximately $134,000 and $166,000, respectively. The Companyâ€™s interest expense associated with the amortization of debt discount was approximately $8,000 and $21,000 during the three months ended September 30, 2024 and 2023, respectively. The Companyâ€™s interest expense associated with the amortization of debt discount was approximately $32,000 and $62,000 during the nine months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024 and 2023, the Company incurred interest expense of approximately $116,000 and $512,000, respectively. For the nine months ended September 30, 2024 and 2023, the Company incurred interest expense of approximately $0.8 million and $1.6Â million, respectively. Â While, as of the date hereof, CRG has not purported that an Event of Default has resulted due to a Material Adverse Change (as those terms defined in the Loan Agreement), due to the substantial doubt about the Companyâ€™s ability to continue operating as a going concern, the entire outstanding amount of borrowings under the Loan Agreement and associated aggregate debt discount at September 30, 2024 and December 31, 2023 were classified as current in these financial statements. X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section

50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Leases 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Lessee, Operating Leases [Text Block] 5. Leases Â The Companyâ€™s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The most recent amendment also provides an optional one-year extension of the lease following the end of the current term on November 30, 2025, which was not included in the assessment of the lease term as it is not reasonably certain the Company will elect to exercise this option. Rent expense is recognized using the straight-line method over the term of the lease. Â The current lease was to expire on November 30, 2024. On March 6, 2024, the Company entered into an amendment to the lease which extended the lease term for a period of one year, subsequent to the original expiration. As amended, the lease will expire on November 30, 2025. Under the terms of the amendment, the Company will be obligated to pay an additional $1.3 million in base rent payments through November 2025, beginning on December 1, 2024. In total, the Company is obligated to pay approximately $7.1 million in base rent payments through NovemberÂ 2025, which began on December 1, 2019. The weighted average remaining lease term as of September 30, 2024 is 1.2 years. Â In connection with the amendment the Company adjusted its right-of-use asset and lease liability to $2.2 million. As of the date of the amendment, the operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit rate. Â The Companyâ€™s operating lease expense, excluding variable maintenance fees and other expenses on a monthly basis, was approximately $105,000. Rent expense for the three months ended September 30, 2024 and 2023 was approximately $316,000 and $314,000, respectively. Rent expense for the nine months ended September 30, 2024 and 2023 was approximately $947,000 and $942,000, respectively. The Companyâ€™s variable expenses for theÂ threeÂ months endedÂ September 30, 2024Â andÂ 2023Â were approximately $90,000Â and $65,000, respectively. The Companyâ€™s variable expenses for theÂ nine months endedÂ September 30, 2024Â andÂ 2023Â were approximately $263,000Â and $233,000, respectively. Operating right-of-use asset amortization for the three months ended September 30, 2024 and 2023 was approximately $290,000 and $288,000, respectively. Operating right-of-use asset amortization for the nine months ended September 30, 2024 and 2023 was approximately $867,000 and $852,000, respectively. Â The following table presents the future operating lease payments and leasehold liability included on the balance sheet related to the Companyâ€™s operating lease as of September 30, 2024 (in thousands): Â Year Ending December 31, Â Â Â Â 2024 (remaining three months of the year) Â $ 313 Â 2025 Â Â 1,166 Â Total Â Â 1,479 Â Less: Imputed interest Â Â (52) Leasehold liability as of September 30, 2024 Â $ 1,427 Â Â The following table shows ROU assets and lease liabilities, and the associated financial statement line items, as of September 30, 2024 and December 31, 2023 (in thousands): Â Lease-Related Assets and Liabilities Â Financial Statement Line Items Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Right of use assets: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating lease Â Right of use asset Â $ 1,427 Â Â $ 1,102 Â Total right of use assets Â $ 1,427 Â Â $ 1,102 Â Lease liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating lease Â Leasehold liability, current portion Â $ 1,210 Â Â $ 1,102 Â Â Â Leasehold liability, long-term portion Â Â 217 Â Â Â Â â€” Â Total lease liabilities Â $ 1,427 Â Â $ 1,102 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] 6. Commitments and Contingencies Â Purchase Obligations Â Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $0.7 million as of September 30, 2024. The majority of this amount is related to commitments to purchase inventory components and services related to the manufacturing of inventory. Â Legal Proceedings Â The Company is not currently involved in any pending legal proceedings that it believes could have a material adverse effect on our financial condition, results of operations or cash flows. From time to time, the Company may be involved in legal proceedings or investigations, which could harm our reputation, business and financial condition and divert the attention of our management from the operation of our business. X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Stockholders' Equity 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Equity [Text Block] 7. Stockholdersâ€™ Equity Â Convertible Preferred Stock Â As of September 30, 2024 and December 31, 2023, the Companyâ€™s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of convertible preferred stock with $0.001 par value per share. As of September 30, 2024 and December 31, 2023, 30,229 and 62,881 shares, respectively, were issued and outstanding. Â Series A Preferred Stock Exchange Â On March 5, 2024, the Company entered into the A-1 Securities Purchase Agreement with CRG to exchange all 60,876 outstanding shares of Series A preferred stock for 10,000 shares of Series A-1 preferred stock. Consequently, there are no shares of Series A preferred stock outstanding as of September 30, 2024. Â The exchange was accounted for as a capital transaction constituting an extinguishment of the Series A preferred stock through the issuance of Series A-1 preferred stock with no net impact to stockholdersâ€™ deficit. At the time of the exchange, the Series A preferred stock had approximately $1.9 million excess fair value in comparison to the Series A-1 preferred stock. The difference in fair value is treated as an adjustment to net loss applicable to common stockholders for the purpose of calculating earnings per share, see Note 2 for details. Â SeriesÂ A-1 Convertible Preferred Stock Â Each share of Series A-1 preferred stock has a stated value of $1,000 per share and is convertible into 273 shares of the Companyâ€™s common stock at $3.664 per share. The Series A-1 preferred stock is convertible into a total of 2,729,257 shares of common stock subject to certain limitations contained in the A-1 Securities Purchase Agreement. Shares of Series A-1 preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Companyâ€™s outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Companyâ€™s outstanding voting power, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b).The Series A-1 preferred stock has no liquidation preference, no voting rights and ranks junior to shares of the Companyâ€™s Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock in terms of repayment and certain other rights. The SeriesÂ A-1 preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. As of September 30, 2024, 10,000 shares of SeriesÂ A-1 preferred stock were outstanding. Â SeriesÂ B Convertible Preferred Stock Â The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no voting rights and is subject to certain ownership limitations. The SeriesÂ B preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. As of September 30, 2024 and December 31, 2023, 85 shares of Series B preferred stock remained outstanding, which are currently convertible into shares of the Companyâ€™s common stock at $1.66 per share. Â SeriesÂ E Convertible Preferred Stock Â Each share of Series E preferred stock has a stated value of $1,000 per share and is convertible into 93 shares of the Companyâ€™s common stock at a conversion price of $10.725 per share. The Series E preferred stock is convertible into a total of 178,560 shares of common stock subject to certain limitations contained in the Series E Purchase Agreement. Shares of Series E preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Companyâ€™s outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Companyâ€™s outstanding voting power, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). The holders of Series E preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series E preferred stock or cash, at the Companyâ€™s option. The shares of Series E preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series E preferred stock rank junior to Series H preferred stock and are senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. The Series E preferred stock accrued additional dividends of less than $0.1 million and $0.1 million during the three and nine months ended September 30, 2024, respectively, which were recognized as a reduction to additional paid-in capital in the statement of stockholdersâ€™ equity (deficit). As of September 30, 2024 and December 31, 2023, 1,920 shares of Series E preferred stock were outstanding. Â Series F Convertible Preferred Stock Â On March 4, 2024, in connection with the Purchase Agreement (see Note 1), the Company issued 7,224 shares of Series F Preferred Stock, at a purchase price per share of $1,000. Each share of Series F preferred stock is convertible into 273 shares of the Companyâ€™s common stock at a conversion price of $3.664 per share. The Series F preferred stock is convertible into a total of 1,972,152 shares of common stock subject to certain limitations contained in the Purchase Agreement. Shares of Series F preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 49.9% of the Companyâ€™s outstanding voting power. The holders of Series F preferred stock are entitled to receive annual accruing dividends at a rate of 5% until the third anniversary of their issuance and 8% thereafter. The dividends are payable in additional shares of Series F preferred stock or cash, at the Companyâ€™s option through the third anniversary of their issuance, and at the holderâ€™s option thereafter. The shares of Series F preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series F preferred stock ranks junior to Series H preferred stock, pari passu with Series E preferred stock and are senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. The Series F preferred stock accrued additional dividends of $0.1 million and $0.2 million during the three and nine months ended September 30, 2024, respectively, which were recognized as a reduction to additional paid-in capital in the statement of stockholdersâ€™ deficit. As of September 30, 2024, 7,224 shares of Series F preferred stock were outstanding. Â Series H Convertible Preferred Stock Â On May 16, 2024, in connection with the Series H Purchase Agreement (see Note 4), the Company issued 11,000 shares of Series H Preferred Stock, at a purchase price per share of $1,000. Each share of Series H preferred stock is convertible into 259 shares of the Companyâ€™s common stock at a conversion price of $3.86 per share. The Series H preferred stock is convertible into a total of 2,849,000 shares of common stock subject to certain limitations contained in the Purchase Agreement. Shares of Series H preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Companyâ€™s outstanding voting power and in no case will such beneficial ownership limitation exceed 19.99%, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). The holders of Series H preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series E preferred stock or cash, at the Companyâ€™s option. The shares of Series H preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series H preferred stock rank senior to all other classes and series of the Companyâ€™s equity in terms of repayment and certain other rights. The Series H preferred stock accrued additional dividends of $0.2 million and $0.3 million during the three and nine months ended September 30, 2024, which were recognized as a reduction to additional paid-in capital in the statement of stockholdersâ€™ deficit. As of September 30, 2024, 11,000 shares of Series H preferred stock were outstanding. Â Common Stock Â As of September 30, 2024, the Companyâ€™s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 2,783,891 shares were issued and outstanding. Â March 2024 Offering Â On March 5, 2024, in connection with the Purchase Agreement (see Note 1), the Company issued 75,327 shares of common stock at a purchase price per share of $3.664. Â June 2024 Offering Â On June 17, 2024, in connection with the June 2024 Offering (see Note 1), the Company issued 330,000 shares of common stock at a purchase price per share of $1.66. Â Common Stock Warrants Â As of September 30, 2024, the Company had outstanding warrants to purchase common stock as follows: Â Â Â Total Outstanding and Exercisable Â Â Underlying Shares of Common Stock Â Â Exercise Price per Share Â Â Expiration Date Â Series 1 Warrants issued in the February 2018 Series B financing Â Â 8,979,000 Â Â Â 2,993 Â Â $ 6,000.00 Â Â February 2025 Â Series 2 Warrants issued in the February 2018 Series B financing Â Â 8,709,500 Â

Â Â 2,903 Â Â $ 6,000.00 Â Â February 2025 Â Placement agent warrants issued in the January 2022 financing Â Â 1,330,000 Â Â Â 4,433 Â Â $ 150.00 Â Â January 2027 Â Warrants issued in the January 2022 financing Â Â 16,150,000 Â Â Â 53,833 Â Â $ 144.00 Â Â July 2027 Â Series A Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â Â February 2028 Â Placement agent Preferred Investment Options issued in the August 2022 financing Â Â 171,233 Â Â Â 11,416 Â Â $ 32.85 Â Â August 2027 Â Advisor Warrants issued in the March 2024 financing Â Â 40,938 Â Â Â 40,938 Â Â $ 3.664 Â Â March 2029 Â Pre-Funded Warrants issued in the June 2024 financing Â Â 2,417,000 Â Â Â 2,417,000 Â Â $ 0.001 Â Â Â n/a Â Series A-1 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (1) Â Series A-2 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (2) Â Series A-3 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (3) Â Placement Agent Warrants issued in the June 2024 financing Â Â 216,867 Â Â Â 216,867 Â Â $ 2.075 Â Â June 2029 Â Total as of September 30, 2024 Â Â 51,711,792 Â Â Â 13,784,013 Â Â Â Â Â Â Â Â Â Â (1) The Series A-1 Warrants expire on the earlier of August 12, 2029 andÂ 60 days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. (2) Series A-2 Warrants expire on the earlier of August 12, 2026 andÂ 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. (3) The Series A-3 Warrants expire on the earlier of May 12, 2025 andÂ 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO IDE application. Â During the three months ended September 30, 2024, a total of 867,457Â Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 867,457 shares of common stock. After giving effect to these aforementioned exercises, 2,417,000 Pre-Funded Warrants remained outstanding. On October 3, 2024, holders of Pre-Funded Warrants opted to exercise a total of 306,000 shares of their warrants into common stock leaving 2,111,000 remaining. Â In accordance with their terms, the 2,853,833 Series B Preferred Investment Options, exercisable for 190,259 shares of common stock at an exercise price of $22.53 per share, expired on August 8, 2024. Â As of December 31, 2023, the Company had outstanding warrants to purchase common stock as follows: Â Â Â Total Outstanding and Exercisable Â Â Â Underlying Shares of Common Stock Â Â Â Exercise Price per Share Â Expiration Date Series 1 Warrants issued in the February 2018 Series B financing Â Â 8,979,000 Â Â Â 2,993 Â Â $ 6,000.00 Â February 2025 Series 2 Warrants issued in the February 2018 Series B financing Â Â 8,709,500 Â Â Â 2,903 Â Â $ 6,000.00 Â February 2025 Placement agent warrants issued in the January 2022 financing Â Â 1,330,000 Â Â Â 4,433 Â Â $ 150.00 Â January 2027 Warrants issued in the January 2022 financing Â Â 16,150,000 Â Â Â 53,833 Â Â $ 144.00 Â July 2027 Series A Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â February 2028 Series B Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â August 2024 Placement agent Preferred Investment Options issued in the August 2022 financing Â Â 171,233 Â Â Â 11,416 Â Â $ 32.85 Â August 2027 Total as of December 31, 2023 Â Â 41,047,499 Â Â Â 456,096 Â Â Â Â Â Â Â Â March 2024 Private Placement Â On March 7, 2024, in connection with the closing of the Strategic Partnership and Private Placement, the Company issued Advisor Warrants at an exercise price of $3.664 per share which were immediately exercisable. The Advisor Warrants will expire five years following the time they become exercisable, or March 5, 2029. Â The exercise price and the number of shares of common stock issuable upon exercise of each Advisor Warrant are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Advisor Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Advisor Warrants prior to the fundamental transaction. Â The Advisor Warrants can be exercised at the option of the holders at any time after they become exercisable provided that shares cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% of the Companyâ€™s outstanding common stock immediately after giving effect to the exercise. A holder of the Advisor Warrants may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%. Â June 2024 Offering Â On June 13, 2024, the Company entered into a securities purchase agreement with two institutional investors resulting in the issuance of among other things, Pre-Funded Warrants in lieu of common stock to purchase up to an aggregate of 3,284,457 shares of common stock of which 2,417,000 remain outstanding as of September 2024. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable, and have no expiration date. On October 3, 2024, holders of Pre-Funded Warrants opted to exercise a total of 306,000 of their warrants into common stock leaving 2,111,000 remaining. Â In addition, the Company issued to the investors in the Offering (i) Series A-1 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, (ii) Series A-2 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, and (iii) Series A-3 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock. Each share of common stock or Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. Each Warrant has an exercise price of $1.66 per share. Â The Series A-1 Warrants expire on the earlier of August 12, 2029Â and 60Â days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. The Series A-2 Warrants expire on the earlier of August 12, 2026 and 60Â days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. The Series A-3 Warrants expire on May 12, 2025 andÂ 60Â days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO IDE application. Â In connection with the Offering, the Company also issued to the placement agent Placement Agent or its designees Placement Agent Warrants to purchase up to an aggregate of 216,867 shares of common stock. The Placement Agent Warrants have substantially the same terms as the warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $2.075 per share and expire on June 13, 2029. Â The exercise price and the number of shares of common stock issuable upon exercise of each Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants immediately prior to the fundamental transaction. Â The Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants can be exercised at the option of the holders at any time after they become exercisable provided that shares of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% (or, upon election by such holder prior to the issuance of any shares of Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants, 9.99%) of the Companyâ€™s outstanding common stock immediately after giving effect to the exercise. A holder of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%. Â In the event of a fundamental transaction in which the holders of our voting securities immediately prior to such fundamental transaction will not, following such fundamental transaction, directly or indirectly own more than 50% of the voting securities of the surviving entity or successor entity, and in which the Company is not the successor entity or does not continue as a reporting issuer under the Exchange Act, then, at the request of the holder, the Company or the successor entity shall purchase the unexercised portion of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants from the holder by paying to the holder an amount, in cash, equal to the fair value of the remaining unexercised portion of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants on the date of such fundamental transaction, subject to certain limitations in the event of a fundamental transaction not within our control. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Stock-based Compensation 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Share-Based Payment Arrangement [Text Block] 8. Stock-Based Compensation Â Stock Plans Â In January 2015, the Board of Directors adopted and the Companyâ€™s stockholders approved the 2015 Equity Incentive Plan (â€œ2015 Planâ€). On December 22, 2023, the Companyâ€™s stockholders approved an additional 300,000 shares of common stock for issuance under the 2015 Plan, which was later registered in an S-8 registration statement filed on January 10, 2024. The 2015 Plan provides for the grant of incentive stock options (â€œISOsâ€) to employees and for the grant of non-statutory stock options (â€œNSOsâ€), restricted stock, restricted stock awards (â€œRSAsâ€), restricted stock units (â€œRSUsâ€), stock appreciation rights, performance units and performance shares to employees, directors and consultants. As of September 30, 2024, 15 share grants were outstanding with 71,442 shares of common stock were available and outstanding for grant under the 2015 Plan. Â The Companyâ€™s RSUs and RSAs generally vest annually over two years in equal increments. RSAs and RSUs largely contain the same contractual terms except RSAs have the ability to vote along with common holders as an RSA is considered an outstanding security at the time of grant, subject to certain vesting and other restrictions. The Company measures the fair value of RSAs using the closing stock price of a share of the Companyâ€™s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSA activity is presented below: Â Â Â Number of Shares Â Â Weighted Average Grant Date Fair Value Â Â Weighted Average Remaining Contractual Term Â Awards outstanding at December 31, 2023 Â Â 90,190 Â Â $ 18.45 Â Â Â 1.04 Â Awarded Â Â 394,105 Â Â $ 2.75 Â Â Â â€” Â Released Â Â (368,503) Â $ 4.89 Â Â Â â€” Â Forfeited Â Â (3,333) Â $ 18.45 Â Â Â â€” Â Awards outstanding at September 30, 2024 Â Â 112,459 Â Â $ 7.85 Â Â Â 0.30 Â Â As ofÂ September 30, 2024, there wasÂ $0.300 millionÂ of remaining unamortized stock-based compensation expense associated with RSAs, which will be expensed over a weighted average remaining service period of approximately 0.3 years. TheÂ outstanding non-vested and expected to vest RSAs at September 30, 2024 have an aggregate fair value of approximatelyÂ $0.1 million. The Company used the closing market price of $0.95 per share at September 30, 2024, to determine the aggregate fair value for the RSAs outstanding at that date. For the nine months ended September 30, 2024 and 2023, the fair value of RSAs vested was approximately $1.0Â millionÂ andÂ less than $0.1 million, respectively. For the three months ended September 30, 2024 and 2023, stock-based compensation expense recognized associated with the vesting of RSAs was $222,000 and $219,000, respectively. For the nine months ended September 30, 2024 and 2023, stock-based compensation expense recognized associated with the vesting of RSAs was $1.5 million and $0.7 million, respectively. Â Total noncash stock-based compensation expense relating to the Companyâ€™s RSAs recognized, before taxes, during the three and nine months ended September 30, 2024 and 2023, is as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of revenues Â $ 36 Â Â $ 36 Â Â $ 228 Â Â $ 99 Â Research and development expenses Â Â 42 Â Â Â 24 Â Â Â 397 Â Â Â 158 Â Selling, general and administrative expenses Â Â 144 Â Â Â 159 Â Â Â 900 Â Â Â 446 Â Â Â $ 222 Â Â $ 219 Â Â $ 1,525 Â Â $ 703 Â Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-

2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Restructuring Charges and Expenses 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Restructuring and Related Activities Disclosure [Text Block] 9. Restructuring Charges and Expenses Â In June 2024, the Company undertook an organizational realignment and cost reduction plan which included a reduction in force, lowering its total headcount by approximately 24%, or 17 employees, compared to March 31, 2024. Accordingly, the Company recorded a restructuring charge of approximately $66,000, relating to severance related costs at that time. As of September 30, 2024, all 17 employeesâ€™ severance costs related to the June 2024 termination had been incurred and paid. As of September 30, 2024, $4,000 of the total severance costs was included within accrued compensation on the condensed balance sheet. During the three months ending September 30, 2024, the Company recorded $14,000 in severance costs related to R&D and $53,000 to SG&A. For the nine months ending September 30, 2024, an additional $23,000 in severance expenses was recorded to SG&A. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 9 Months Ended Sep. 30, 2024 Insider Trading Arr Line Items Â Material Terms of Trading Arrangement [Text Block] ITEM 5.Â Â Â Â Â OTHER INFORMATION Â 10b5-1 Trading Plans Â During the second quarter of 2024, none of our directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangementâ€ (as each term is defined in Item 408(a) of Regulation S-K). Â Â Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Adopted [Flag] false Rule 10b5-1 Arrangement Terminated [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Â The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S.Â GAAPâ€) and pursuant to the rulesÂ and regulations of the SEC. The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Companyâ€™s financial information. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending DecemberÂ 31, 2024, or for any other interim period or for any future year. The DecemberÂ 31, 2023 condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rulesÂ and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Companyâ€™s FormÂ 10-K for the fiscal year ended DecemberÂ 31, 2023, which was filed with the SEC on MarchÂ 20, 2024. The Companyâ€™s significant accounting policies are more fully described in Note 2 of the Notes to Financial Statements included in the Companyâ€™s Annual Report on FormÂ 10-K for the year ended DecemberÂ 31, 2023. Use of Estimates, Policy [Policy Text Block] Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Companyâ€™s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block] Concentration of Credit Risk, and Other Risks and Uncertainties Â Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. Â The Companyâ€™s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, First Citizens Bank, which acquired the Companyâ€™s prior banking partner, Silicon Valley Bank, in March 2023. The counterparties to the agreements relating to the Companyâ€™s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Managementâ€™s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and DecemberÂ 31, 2023. The Companyâ€™s previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. Although the Company has regained access to its accounts with this institution, now a division of the acquiring bank, and is currently reviewing its banking relationships, potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Companyâ€™s access to cash and cash equivalents. Â The Companyâ€™s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Managementâ€™s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and December 31, 2023. At September 30, 2024, there was one customer that represented 38% of the Companyâ€™s accounts receivable. At DecemberÂ 31, 2023, there was one customer that represented 24% of the Companyâ€™s accounts receivable. For the nine months ended September 30, 2024 there was one customer that represented 17% of revenues. For the three months ended September 30, 2024, there were two customers that represented 20% and 11% of revenues, respectively. For the three and nine months ended September 30, 2023, there was one customer that represented 22% and 17% of revenues, respectively. Disruption of the Companyâ€™s sales orders or a deterioration of financial condition of its customers would have a negative impact on the Companyâ€™s financial position and results of operations. Standard Product Warranty, Policy [Policy Text Block] Product Warranty Costs Â The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Beginning balance Â $ 150 Â Â $ 128 Â Â $ 193 Â Â $ 109 Â Warranty provision Â Â 3 Â Â Â 18 Â Â Â 35 Â Â Â 52 Â Usage/Release Â Â (25) Â Â (7) Â Â (100) Â Â (22) Ending balance Â $ 128 Â Â $ 139 Â Â $ 128 Â Â $ 139 Â Â Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Attributable to Common Stockholders Â Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holdersâ€™ continued service to the Company. As of September 30, 2024 and 2023, there were no shares subject to repurchase. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive. Â Net loss per share applicable to common stockholders was determined as follows (in thousands, except per share data): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss applicable to common stockholders Â $ (4,055) Â $ (2,040) Â $ (12,329) Â $ (13,296) Weighted average common stock outstanding, basic and diluted Â Â 2,224 Â Â Â 698 Â Â Â 1,780 Â Â Â 619 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (1.82) Â $ (2.92) Â $ (6.93) Â $ (21.48) Â The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Common stock warrants equivalents Â Â 14,425,040 Â Â Â 459,019 Â Â Â 5,844,318 Â Â Â 483,947 Â Common stock options Â Â 15 Â Â Â 20 Â Â Â 15 Â Â Â 20 Â Convertible preferred stock Â Â 30,229 Â Â Â 62,151 Â Â Â 35,121 Â Â Â 61,362 Â Unvested restricted stock units Â Â 112,459 Â Â Â 91,630 Â Â Â 114,730 Â Â Â 88,585 Â Â Â 14,567,743 Â Â Â 612,820 Â Â Â 5,944,184 Â Â Â 633,914 Â Â Segment Reporting, Policy [Policy Text Block] Segment and Geographical Information Â The Company operates and manages its business as one reportable and operating segment. The Companyâ€™s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Companyâ€™s long-lived assets, which are comprised of property and equipment, are based in the United States. For the three months ended September 30, 2024 and 2023, 94% and 91% respectively, of the Companyâ€™s revenues were in the United States. For the nine months ended September 30, 2024 and 2023, 93% and 92%, respectively, of the Companyâ€™s revenues were derived from the United States based on the shipping location of the external customer. The remaining revenues for the three and nine months ended September 30, 2024 and 2023, were primarily derived from Germany. Â Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Â As of September 30, 2024 and DecemberÂ 31, 2023, cash equivalents were all categorized as LevelÂ 1 and consisted of money market funds. As of September 30, 2024 and DecemberÂ 31, 2023, there were no financial assets and liabilities categorized as Level 2 or 3. There were no transfers between fair value hierarchy levels during the three or nine months ended September 30, 2024 and September 30, 2023. Â New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Â Recent accounting standards not yet adopted Â In August 2020, the FASB issued ASU No. 2020-06,Â Debtâ€”Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. Â As a result, after adopting the ASUâ€™s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under Accounting Standards Codification (â€œASCâ€) 815 or (ii) a convertible debt instrument was issued at a substantial premium. The ASU becomes effective for the Company, as a smaller reporting company as defined by the SEC,Â in the first quarter of 2024. The Company has not yet adopted this standard.Â This new standard isÂ not expected to have a material impact on the Companyâ€™s financial statements. Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) â€“ Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has not yet adopted this standard. This new standard is not expected to have a material impact on the Companyâ€™s financial statements. Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU No. 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, if any, with further disaggregation required for significant individual jurisdictions. The ASU is effective for the Company for fiscal years beginning after December 15. ASU No. 2023-09 allows for adoption using either a prospective or retrospective transition method. This new standard is not expected to have a material impact on the Companyâ€™s financial statements. X - DefinitionDisclosure of accounting policies for credit risk and other risks and uncertainties. + ReferencesNo definition available. + Details Name: avgr_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock Namespace Prefix: avgr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration

X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for standard warranties including the methodology for measuring the liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Product Warranty Liability [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Beginning balance Â $ 150 Â Â $ 128 Â Â $ 193 Â Â $ 109 Â Warranty provision Â Â 3 Â Â Â 18 Â Â Â 35 Â Â Â 52 Â Usage/Release Â Â (25) Â Â (7) Â Â (100) Â Â (22) Ending balance Â $ 128 Â Â $ 139 Â Â $ 128 Â Â $ 139 Â Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss applicable to common stockholders Â $ (4,055) Â $ (2,040) Â $ (12,329) Â $ (13,296) Weighted average common stock outstanding, basic and diluted Â Â 2,224 Â Â Â 698 Â Â Â 1,780 Â Â Â 619 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (1.82) Â $ (2.92) Â $ (6.93) Â $ (21.48) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Common stock warrants equivalents Â Â 14,425,040 Â Â Â 459,019 Â Â Â 5,844,318 Â Â Â 483,947 Â Common stock options Â Â 15 Â Â Â 20 Â Â Â 15 Â Â Â 20 Â Convertible preferred stock Â Â 30,229 Â Â Â 62,151 Â Â Â 35,121 Â Â Â 61,362 Â Unvested restricted stock units Â Â 112,459 Â Â Â 91,630 Â Â Â 114,730 Â Â Â 88,585 Â Â Â Â 14,567,743 Â Â Â 612,820 Â Â Â 5,944,184 Â Â Â 633,914 Â X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Inventories (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Inventory, Current [Table Text Block] Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $ 1,863 Â Â $ 3,203 Â Work-in-process Â Â 154 Â Â Â 25 Â Finished products Â Â 1,742 Â Â Â 2,070 Â Total inventories Â $ 3,759 Â Â $ 5,298 Â X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Borrowings (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Debt [Table Text Block] Year Ending December 31, Â Â Â Â 2024 (remaining three months of the year) Â $ â€” Â 2025 Â Â â€” Â 2026 Â Â â€” Â 2027 Â Â 2,176 Â 2028 Â Â 4,060 Â Total Â Â 6,236 Â Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2024 Â Â (1,934) Less: Amount representing debt issuance costs Â Â (134) Borrowings, current portion, as of September 30, 2024 Â $ 4,168 Â X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Leases (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Year Ending December 31, Â Â Â Â 2024 (remaining three months of the year) Â $ 313 Â 2025 Â Â 1,166 Â Total Â Â 1,479 Â Less: Imputed interest Â Â (52) Leasehold liability as of September 30, 2024 Â $ 1,427 Â Right of Use Asset and Liabilities [Table Text Block] Lease-Related Assets and Liabilities Â Financial Statement Line Items Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Right of use assets: Â Â Â Â Â Â Â Â Â Â Operating lease Â Right of use asset Â $ 1,427 Â Â $ 1,102 Â Total right of use assets Â $ 1,427 Â Â $ 1,102 Â Lease liabilities: Â Â Â Â Â Â Â Â Â Operating lease Â Leasehold liability, current portion Â $ 1,210 Â Â $ 1,102 Â Â Â Leasehold liability, long-term portion Â Â 217 Â Â Â â€” Â Total lease liabilities Â $ 1,427 Â Â $ 1,102 Â X - DefinitionTabular disclosure of information pertaining to right of use assets and liabilities. + ReferencesNo definition available. + Details Name: avgr_RightOfUseAssetAndLiabilitiesTableTextBlock Namespace Prefix: avgr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Â Â Total Outstanding and Exercisable Â Â Underlying Shares of Common Stock Â Â Exercise Price per Share Â Â Expiration Date Â Series 1 Warrants issued in the February 2018 Series B financing Â Â 8,979,000 Â Â Â 2,993 Â Â $ 6,000.00 Â Â February 2025 Â Series 2 Warrants issued in the February 2018 Series B financing Â Â 8,709,500 Â Â Â 2,903 Â Â $ 6,000.00 Â Â February 2025 Â Placement agent warrants issued in the January 2022 financing Â Â 1,330,000 Â Â Â 4,433 Â Â $ 150.00 Â Â January 2027 Â Warrants issued in the January 2022 financing Â Â 16,150,000 Â Â Â 53,833 Â Â $ 144.00 Â Â July 2027 Â Series A Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â Â February 2028 Â Placement agent Preferred Investment Options issued in the August 2022 financing Â Â 171,233 Â Â Â 11,416 Â Â $ 32.85 Â Â August 2027 Â Advisor Warrants issued in the March 2024 financing Â Â 40,938 Â Â Â 40,938 Â Â $ 3.664 Â Â March 2029 Â Pre-Funded Warrants issued in the June 2024 financing Â Â 2,417,000 Â Â Â 2,417,000 Â Â $ 0.001 Â Â Â n/a Â Series A-1 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (1) Â Series A-2 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (2) Â Series A-3 Warrants issued in the June 2024 financing Â Â 3,614,457 Â Â Â 3,614,457 Â Â $ 1.66 Â Â See note (3) Â Placement Agent Warrants issued in the June 2024 financing Â Â 216,867 Â Â Â 216,867 Â Â $ 2.075 Â Â June 2029 Â Total as of September 30, 2024 Â Â 51,711,792 Â Â Â 13,784,013 Â Â Â Â Â Â Â Â Â Â Total Outstanding and Exercisable Â Â Â Underlying Shares of Common Stock Â Â Â Exercise Price per Share Â Expiration Date Series 1 Warrants issued in the February 2018 Series B financing Â Â 8,979,000 Â Â Â 2,993 Â Â $ 6,000.00 Â February 2025 Series 2 Warrants issued in the February 2018 Series B financing Â Â 8,709,500 Â Â Â 2,903 Â Â $ 6,000.00 Â February 2025 Placement agent warrants issued in the January 2022 financing Â Â 1,330,000 Â Â Â 4,433 Â Â $ 150.00 Â January

2027 Warrants issued in the January 2022 financing Â Â 16,150,000 Â Â Â 53,833 Â Â $ 144.00 Â July 2027 Series A Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â February 2028 Series B Preferred Investment Options issued in August 2022 financing Â Â 2,853,883 Â Â Â 190,259 Â Â $ 22.53 Â August 2024 Placement agent Preferred Investment Options issued in the August 2022 financing Â Â 171,233 Â Â Â 11,416 Â Â $ 32.85 Â August 2027 Total as of December 31, 2023 Â Â 41,047,499 Â Â Â 456,096 Â Â Â Â Â Â X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Stock-based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Â Â Number of Shares Â Â Weighted Average Grant Date Fair Value Â Â Weighted Average Remaining Contractual Term Â Awards outstanding at December 31, 2023 Â Â 90,190 Â Â $ 18.45 Â Â Â 1.04 Â Awarded Â Â 394,105 Â Â $ 2.75 Â Â Â â€” Â Released Â Â (368,503) Â $ 4.89 Â Â Â â€” Â Forfeited Â Â (3,333) Â $ 18.45 Â Â Â â€” Â Awards outstanding at September 30, 2024 Â Â 112,459 Â Â $ 7.85 Â Â Â 0.30 Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of revenues Â $ 36 Â Â $ 36 Â Â $ 228 Â Â $ 99 Â Research and development expenses Â Â 42 Â Â Â 24 Â Â Â 397 Â Â Â 158 Â Selling, general and administrative expenses Â Â 144 Â Â Â 159 Â Â Â 900 Â Â Â 446 Â Â Â $ 222 Â Â $ 219 Â Â $ 1,525 Â Â $ 703 Â X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Organization (Details Textual) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 28 Months Ended Oct. 03, 2024 shares Jun. 17, 2024 USD ($) $ / shares shares Jun. 13, 2024 USD ($) $ / shares shares Mar. 05, 2024 USD ($) $ / shares shares Mar. 04, 2024 USD ($) $ / shares shares Oct. 31, 2024 USD ($) $ / shares shares Sep. 30, 2024 USD ($) $ / shares shares Jun. 13, 2024 $ / shares shares Sep. 30, 2023 USD ($) shares Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) shares Dec. 31, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) $ / shares shares May 22, 2024 Dec. 23, 2023 shares Aug. 02, 2023 May 20, 2022 USD ($) $ / shares Retained Earnings (Accumulated Deficit) | $ Â Â Â Â Â Â $ (434,281,000) Â Â $ (434,281,000) Â $ (420,696,000) $ (434,281,000) Â Â Â Â Cash and Cash Equivalents, at Carrying Value | $ Â Â Â Â Â Â $ 5,901,000 Â Â $ 5,901,000 Â $ 5,275,000 $ 5,901,000 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares Â Â Â Â Â Â 13,784,013 Â Â 13,784,013 Â Â 13,784,013 Â 456,096 Â Â Class of Warrant or Right, Outstanding (in shares) | shares Â Â Â Â Â Â 51,711,792 Â Â 51,711,792 Â Â 51,711,792 Â 41,047,499 Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) Â Â Â Â Â Â $ 0.001 Â Â $ 0.001 Â $ 0.001 $ 0.001 Â Â Â Â Preferred Stock, Par or Stated Value Per Share Â Â Â Â Â Â Â Â $ 0.001 Â Â $ 0.001 Â $ 0.001 0.001 Â Â Â Â Gain (Loss) On Convertible Preferred Stock Converted to Other Securities | $ Â Â Â Â Â Â Â $ 0 Â $ 0 $ 1,908,000 $ 0 Â Â Â Â Â Â Exchange of Series A Preferred Stock Into Series A-1 Preferred Stock [Member] Â Conversion of Stock, Shares Issued | shares Â Â Â 10,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Gain (Loss) On Convertible Preferred Stock Converted to Other Securities | $ Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,900,000 Â Â Â Â Â Â Â Â Â Â Â Â Series F Preferred Stock [Member] Â Stock Issued During Period, Shares, New Issues | shares Â Â Â 7,224 Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Stated Value Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â 273 273 Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) Â Â Â Â $ 3.664 Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â 49.90% Â Â Â Â Â Â Â Â Â Â Â Â Series G Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Stated Value Â Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Par Value Â Â Â Â $ 0.001 Â Â Â Â Â Â Â Â Â Â Â Â Series A-1 Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Stated Value Â Â Â Â Â Â $ 1,000 Â Â $ 1,000 Â Â $ 1,000 Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â Â Â Â 273 Â Â 273 Â Â 273 Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) Â Â Â Â Â Â $ 3.664 Â Â $ 3.664 Â Â $ 3.664 Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â Â Â Â Â Â Â Â Â 9.99% Â Preferred Stock, Convertible, Shares Issuable | shares Â Â Â 2,729,257 Â Â 2,729,257 Â Â 2,729,257 Â Â 2,729,257 Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues | shares Â Â Â Â Â Â Â 600,454 330,000 607,236 Â Â Â Â Â Â Stock Issued During Period, Shares, Warrants Exercised (in shares) | shares Â Â Â Â Â Â 867,457 Â Â 867,457 91,325 Â Â Â Â Â Â License and Distribution Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â License Agreement, Term Â Â Â Â 20 years Â Â Â Â Â Â Â Â Â Â License Agreement, Renewal Term Â Â Â Â 20 years Â Â Â Â Â Â Â Â Â Â Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer | $ Â Â Â Â Â Â $ 200,000 Â Â $ 400,000 Â Â Â Â Â Â Pre-funded Warrants [Member] Â Class of Warrant or Right, Exercised (in shares) | shares Â Â Â Â Â Â 867,457 Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, Warrants Exercised (in shares) | shares Â Â Â Â Â Â 867,457 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Outstanding (in shares) | shares Â Â Â Â Â Â 2,417,000 Â Â 2,417,000 Â Â 2,417,000 Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 0.001 Â Â Â Â $ 0.001 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 0.001 Â Â Â Â $ 0.001 Â Â Â Â Â Â Â Â Â Â Series A-1 Warrants [Member] Â Number of Warrants Issued Per Unit Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term, Period Following Public Announcement Â Â 60 days Â Â Â Â Â Â Â Â Â Â Â Â Series A-2 Warrants [Member] Â Number of Warrants Issued Per Unit Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term, Period Following Public Announcement Â Â 60 days Â Â Â Â Â Â Â Â Â Â Â Â Series A-3 Warrants [Member] Â Number of Warrants Issued Per Unit Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 1.66 Â Â Â Â 1.66 Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term, Period Following Public Announcement Â Â 60 days Â Â Â Â Â Â Â Â Â Â Â Â Placement Agent Warrants [Member] Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 2.075 Â Â Â Â 2.075 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 2.075 Â Â Â Â $ 2.075 Â Â Â Â Â Â Â Â Â Â Advisor Warrants Issued In The March 2024 Financing [Member] Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares Â Â Â 40,938 Â Â 40,938 Â Â 40,938 Â Â 40,938 Â Â Â Â Class of Warrant or Right, Outstanding (in shares) | shares Â Â Â Â Â Â 40,938 Â Â 40,938 Â Â 40,938 Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â Â Â Â Â $ 3.664 Â Â $ 3.664 Â Â $ 3.664 Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â Â Â Â Â $ 3.664 Â Â $ 3.664 Â Â $ 3.664 Â Â Â Â Class of Warrant or Right, Exercise Percentage of Shares Issued in Equity Offering Â Â Â 2.00% Â Â Â Â Â Â Â Â Â Â Â Â Maximum [Member] | Series F Preferred Stock [Member] Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â Â Â Â Â Â Â Â Â 19.90% Â Â Â Maximum [Member] | Series A-1 Preferred Stock [Member] Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â Â Â 19.99% Â Â 19.99% Â Â 19.99% Â Â Â Maximum [Member] | Pre-funded Warrants [Member] Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares Â Â 3,284,457 Â Â Â Â 3,284,457 Â Â Â Â Â Â Â Â Maximum [Member] | Series A-1 Warrants [Member] Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares Â Â 3,614,457 Â Â Â Â 3,614,457 Â Â Â Â Â Â Â Â Maximum [Member] | Series A-2 Warrants [Member] Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares Â Â 3,614,457 Â Â Â Â 3,614,457 Â Â Â Â Â Â Â Â Maximum [Member] | Series A-3 Warrants [Member] Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares Â Â 3,614,457 Â Â Â Â 3,614,457 Â Â Â Â Â Â Â Â Maximum [Member] | Placement Agent Warrants [Member] Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares Â Â 216,867 Â Â Â Â 216,867 Â Â Â Â Â Â Â Â Subsequent Event [Member] | Pre-funded Warrants [Member] Â Class of Warrant or Right, Exercised (in shares) | shares 306,000 Â Class of Warrant or Right, Outstanding (in shares) | shares 2,111,000 Â Securities Purchase Agreement [Member] Â Proceeds from Issuance or Sale of Equity | $ Â Â Â $ 7,500,000 Â Payments of Stock Issuance Costs | $ Â Â Â 500,000 Â Agreement to Purchase Common Stock, Maximum Amount | $ Â Â Â Â $ 15,000,000 Â Milestone Payment, Minimum Revenue Required | $ Â Â Â Â 10,000,000 Â Milestone Payment, Additional Authorized Amount | $ Â Â Â Â $ 7,500,000 Â Equity Offering, Cash Fee, Percentage of Gross Proceeds Â Â Â Â 7.00% Â Warrants and Rights Outstanding | $ Â Â Â $ 100,000 Â Securities Purchase Agreement [Member] | Series F Preferred Stock [Member] Â Stock Issued During Period, Shares, New Issues | shares Â Â Â 7,224 Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Par or Stated Value Per Share Â Â Â $ 0.001 Â Â Â Â Â Â Â Â Â Â Â Â Securities Purchase Agreement [Member] | Common Stock [Member] Â Stock Issued During Period, Shares, New Issues | shares Â Â Â 75,327 Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share Â Â Â $ 3.664 Â Â Â Â Â Â Â Â Â Â Â Â Securities Purchase Agreement [Member] | Minimum [Member] | Series G Preferred Stock [Member] Â Preferred Stock, Convertible, Conversion Price (in dollars per share) Â Â Â Â Â $ 0.2 Â Â $ 0.2 Â Â Â Â Public Offering [Member] Â Proceeds from Issuance or Sale of Equity | $ Â $ 6,000,000 Â Â Â Â Â Â Â Â Â Â Â Â The Market Offering Agreement (the â€œATM Agreementâ€) [Member] Â Proceeds from Issuance or Sale of Equity | $ Â Â Â Â Â Â Â Â Â Â $ 5,500,000 Â Â Â Â Â Proceeds from Issuance of Common Stock, Net | $ Â Â Â Â Â Â Â Â Â Â Â Â $ 6,500,000 Â Â Â Â Stock Issued During Period, Shares, New Issues | shares Â Â Â Â Â Â Â 0 Â Â 0 Â 607,241 Â Â Â Â Â Â Payments of Stock Issuance Costs | $ Â Â Â Â Â Â Â Â Â Â Â Â $ 164,000 Â Â Â Â Â Stock Issued During Period, Average Price Per Share Â Â Â Â Â Â Â Â Â Â Â Â $ 9.01 Â Â Â Â The Market Offering Agreement (the â€œATM Agreementâ€) [Member] | Subsequent Event [Member] Â Proceeds from Issuance or Sale of Equity | $ Â Â Â Â Â $ 88,000 Â Â Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues | shares Â Â Â Â Â 107,080 Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share Â Â Â Â Â $ 0.82 Â Â Â Â Â Â Â Â Â Â Â Â Payments of Stock Issuance Costs | $ Â Â Â Â Â $ 2,600 Â Â Â Â Â Â Â Â Â Â Â Â June 2024 Offering [Member] Â Stock Issued During Period, Shares, New Issues | shares Â 330,000 330,000 Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share Â $ 1.66 Â Â Â Â Â Â Â Â Â Â Â Â Share Offering, Shares Issuable in Best Efforts (in shares) | shares Â Â 3,614,457 Â Â Â Â 3,614,457 Â Â Â Â Â Â Â Â Share Offering, Purchase Price Per Share (in dollars per share) Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Â Proceeds from Issuance or Sale of Equity, Net | $ Â Â $ 5,200,000 Â Â Â Â Â Â Â Â Â Â Â Â Common Stock in June, 2022 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) Â Â Â Â Â Â Â Â Â Â Â Â $ 0.001 Share Offering Agreement, Aggregate Offering | $ Â Â Â Â Â Â Â Â Â Â Â Â $ 7,000,000 Commission Percentage Â Â Â Â Â Â Â Â Â Â Â Â 3.00% X - DefinitionThe maximum amount of the company's stock under agreement to be purchased. + ReferencesNo definition available. + Details Name: avgr_AgreementToPurchaseCommonStockMaximumAmount Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of share issued in equity offering for exercise of the warrants or rights. + ReferencesNo definition available. + Details Name: avgr_ClassOfWarrantOrRightExercisePercentageOfSharesIssuedInEquityOffering Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants exercised during period. + ReferencesNo definition available. + Details Name: avgr_ClassOfWarrantsOrRightsExercisedDuringPeriod Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents commission percentage. + ReferencesNo definition available. + Details Name: avgr_CommissionPercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of gross proceeds for cash fee of the equity offering. + ReferencesNo definition available. + Details Name: avgr_EquityOfferingCashFeePercentageOfGrossProceeds Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe gain (loss) on the value of convertible preferred stock that was converted to other securities. + ReferencesNo definition available. + Details Name: avgr_GainLossOnConvertiblePreferredStockConvertedToOtherSecurities Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X -

DefinitionPeriod for renewal of license agreement. + ReferencesNo definition available. + Details Name: avgr_LicenseAgreementRenewalTerm Namespace Prefix: avgr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe term of a license agreement. + ReferencesNo definition available. + Details Name: avgr_LicenseAgreementTerm Namespace Prefix: avgr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe additional authorized amount of milestone payment to be made. + ReferencesNo definition available. + Details Name: avgr_MilestonePaymentAdditionalAuthorizedAmount Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe minimum amount of revenue required for milestone payment. + ReferencesNo definition available. + Details Name: avgr_MilestonePaymentMinimumRevenueRequired Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of warrants issued per unit. + ReferencesNo definition available. + Details Name: avgr_NumberOfWarrantsIssuedPerUnit Namespace Prefix: avgr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the beneficial ownership percentage of convertible preferred stock. + ReferencesNo definition available. + Details Name: avgr_PreferredStockConvertibleBeneficialOwnershipPercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe par value of preferred stock. + ReferencesNo definition available. + Details Name: avgr_PreferredStockParValue Namespace Prefix: avgr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe stated value of preferred stock. + ReferencesNo definition available. + Details Name: avgr_PreferredStockStatedValue Namespace Prefix: avgr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe net cash inflow from issuance of common stock, net. + ReferencesNo definition available. + Details Name: avgr_ProceedsFromIssuanceOfCommonStockNet Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of underwriting discounts, commissions, legal and accounting fees. + ReferencesNo definition available. + Details Name: avgr_ProceedsFromIssuanceOrSaleOfEquityNet Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe value of the aggregate offering under share offering agreement. + ReferencesNo definition available. + Details Name: avgr_ShareOfferingAgreementAggregateOffering Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents purchase price per share for share offering. + ReferencesNo definition available. + Details Name: avgr_ShareOfferingPurchasePricePerShare Namespace Prefix: avgr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issuable in best efforts under share offering. + ReferencesNo definition available. + Details Name: avgr_ShareOfferingSharesIssuableInBestEfforts Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the average price per share for shares issued over a period of time. + ReferencesNo definition available. + Details Name: avgr_StockIssuedDuringPeriodAveragePricePerShare Namespace Prefix: avgr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: avgr_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod following public announcement for term of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: avgr_WarrantsAndRightsOutstandingTermPeriodFollowingPublicAnnouncement Namespace Prefix: avgr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion for each share of preferred stock to be converted. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionRatio Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_ConversionOfStockByUniqueDescriptionAxis=avgr_ExchangeOfSeriesAPreferredStockIntoSeriesA1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=avgr_SeriesA1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_TypeOfArrangementAxis=avgr_LicenseAndDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA1WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA3WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_AdvisorWarrantsIssuedInTheMarch2024FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_TheMarketOfferingAgreementTheAtmAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_June2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_CommonStockInJune2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 shares Sep. 30, 2023 shares Dec. 31, 2023 Warranty Period (Year) Â Â 1 year Â Â Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation Â Â 0 0 Â Number of Reportable Segments Â Â 1 Â Â Customer Concentration Risk [Member] | Accounts Receivable [Member] Â Â Â Â Â Number of Major Customers Â Â 1 Â 1 Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â 38.00% Â 24.00% Customer Concentration Risk [Member] | Revenue Benchmark [Member] Â Â Â Â Â Number of Major Customers 2 1 1 1 Â Customer Concentration Risk [Member] | Revenue Benchmark [Member] | UNITED STATES Â Â Â Â Â Concentration Risk, Percentage 94.00% 91.00% 93.00% 92.00% Â Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] Â Â Â Â Â Concentration Risk, Percentage Â 22.00% 17.00% 17.00% Â Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer, One [Member] Â Â Â Â Â Concentration Risk, Percentage 20.00% Â Â Â Â Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer, Two [Member] Â Â Â Â Â Concentration Risk, Percentage 11.00% Â Â Â Â Â X - DefinitionRepresents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. + ReferencesNo definition available. + Details Name: avgr_NumberOfMajorCustomers Namespace Prefix: avgr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the typical period of product warranty for parts and labor. + ReferencesNo definition available. + Details Name: avgr_WarrantyPeriod Namespace Prefix: avgr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13 + Details Name: us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=avgr_OneCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=avgr_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=avgr_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Beginning balance $ 150 $ 128 $ 193 $ 109 Warranty provision 3 18 35 52 Usage/Release (25) (7) (100) (22) Ending balance $ 128 $ 139 $ 128 $ 139 X - DefinitionRepresents the aggregate decrease in the liability related to payments to satisfy claims for standard and extended product warranties and adjustment to release accrued amounts. + ReferencesNo definition available. + Details Name: avgr_ProductWarrantyAccrualPaymentsAndRelease Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrual Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase in the standard and extended product warranty accrual from warranties issued. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualWarrantiesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net loss applicable to common stockholders $ (4,055) $ (2,040) $ (12,329) $ (13,296) Weighted average common stock outstanding, basic and diluted (in shares) 2,224 698 1,780 619 Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) $ (1.82) $ (2.92) $ (6.93) $ (21.48) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-

1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Potentially dilutive securities (in shares) 14,567,743 612,820 5,944,184 633,914 Common Stock Warrants [Member] Â Â Â Â Potentially dilutive securities (in shares) 14,425,040 459,019 5,844,318 483,947 Common Stock Options [member] Â Â Â Â Potentially dilutive securities (in shares) 15 20 15 20 Preferred Stock [Member] Â Â Â Â Potentially dilutive securities (in shares) 30,229 62,151 35,121 61,362 Restricted Stock Units (RSUs) [Member] Â Â Â Â Potentially dilutive securities (in shares) 112,459 91,630 114,730 88,585 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avgr_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avgr_CommonStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Raw materials $ 1,863 $ 3,203 Work-in-process 154 25 Finished products 1,742 2,070 Total inventories $ 3,759 $ 5,298 X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Borrowings (Details Textual) 3 Months Ended 9 Months Ended May 16, 2024 USD ($) $ / shares shares Aug. 02, 2023 USD ($) $ / shares shares Aug. 10, 2022 USD ($) Feb. 14, 2018 USD ($) Sep. 22, 2015 USD ($) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Aug. 01, 2024 USD ($) Jul. 31, 2024 USD ($) Jun. 05, 2024 USD ($) Apr. 02, 2024 USD ($) Jan. 26, 2024 USD ($) Dec. 31, 2023 USD ($) $ / shares Jun. 15, 2016 USD ($) Preferred Stock, Par or Stated Value Per Share | $ / shares Â Â Â Â Â $ 0.001 Â $ 0.001 Â Â Â Â Â Â $ 0.001 Â Series E Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Par or Stated Value Per Share | $ / shares $ 1,000 $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio 93 93 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares $ 10.725 $ 10.725 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage 9.99% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Series E Preferred Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage 19.99% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Series H Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Par or Stated Value Per Share | $ / shares $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio 259 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares $ 3.86 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage 9.99% Â Â Â Â 9.99% Â 9.99% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Series H Preferred Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage 19.99% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Conversion of CRG Loan Into Series E Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Conversion, Original Debt, Amount $ 11,000,000 $ 1,920,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares 11,000 1,920 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CRG [Member] | Loan Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Agreement, Maximum Borrowing Capacity Â Â Â Â $ 50,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Borrowing Period Â Â Â Â 24 months Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement Â Â Â $ 3,500,000 Â Â Â Â Â $ 3,500,000 Â Â $ 3,500,000 Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â Â 12.50% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Periodic Payment Â Â $ 500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt, Maturity, Year Four Â Â 1,800,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt, Maturity, Year Five Â Â $ 1,800,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long Term Debt Maturities, Repayments of Interest in Year Four Â Â Â Â Â $ 400,000 Â $ 400,000 Â Â Â Â Â Â Â Â Long Term Debt Maturities, Repayments of Interest in Year Five Â Â Â Â Â 100,000 Â 100,000 Â Â Â Â Â Â Â Â Debt Instrument, Redemption Initial Prepayment Premium Percentage Â Â 5.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage Â Â 1.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Financing Fee Percentage Â Â 1.50% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Final Facility Fee Percentage Â Â 15.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum Â Â $ 3,500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Â Â Â Â Â $ 1,300,000 134,000 Â 134,000 Â Â Â Â Â Â Â Â $ 166,000 Â Amortization of Debt Discount (Premium) Â Â Â Â Â 8,000 $ 21,000 32,000 $ 62,000 Â Â Â Â Â Â Â Â Interest Expense, Debt Â Â Â Â Â $ 116,000 $ 512,000 $ 800,000 $ 1,600,000 Â Â Â Â Â Â Â Â CRG [Member] | Loan Agreement [Member] | Series A Preferred Stock Purchase Agreement with CRG [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Conversion, Original Debt, Amount Â Â Â 38,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Conversion, Fees and Prepayment Premium Amount Â Â Â $ 3,800,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â CRG [Member] | Loan Agreement [Member] | First Tranche, Borrowed on September 22, 2015 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â $ 30,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â CRG [Member] | Loan Agreement [Member] | Second Tranche, Borrowed on June 15, 2016 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 10,000,000 CRG [Member] | Loan Agreement Amendment No 8 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,000,000 Â Â CRG [Member] | Loan Agreement Amendment No 10 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,500,000 Â Â Â Â CRG [Member] | Loan Agreement Amendment No. 7 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1,500,000 Â Â Â Â Â X - DefinitionMaximum borrowing capacity under a debt agreement on the amount that could be borrowed with a combination of, but not limited to, a line of credit and term loan. + ReferencesNo definition available. + Details Name: avgr_DebtAgreementMaximumBorrowingCapacity Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of related back-end fees and prepayment premium being converted together with the original debt in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: avgr_DebtConversionFeesAndPrepaymentPremiumAmount Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod for borrowing under the debt instrument. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentBorrowingPeriod Namespace Prefix: avgr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe minimum amount of cash and certain cash equivalents the entity is required to maintain under the terms of the debt agreement. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe minimum amount of liquidity required at all times for compliance with the debt instrument covenant. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentCovenantComplianceMinimumLiquidityRequirement Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe facility fee payable at the end of the debt instrument term or upon prepayment in full, as a percentage of the amount borrowed. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentFinalFacilityFeePercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe debt instrument fee required on the borrowing date for each tranche of borrowing, as a percentage of the principal amount borrowed. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentFinancingFeePercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe annual decline in the premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe initial premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of interest payments on long-term debt sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFive Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of interest payments on long-term debt sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFour Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the beneficial ownership percentage of convertible preferred stock. + ReferencesNo definition available. + Details Name: avgr_PreferredStockConvertibleBeneficialOwnershipPercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -

Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionOriginalDebtAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion for each share of preferred stock to be converted. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionRatio Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtConversionByUniqueDescriptionAxis=avgr_ConversionOfCRGLoanIntoSeriesEConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=avgr_CRGMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=avgr_LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtConversionByUniqueDescriptionAxis=avgr_SeriesAPreferredStockPurchaseAgreementWithCRGMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=avgr_FirstTrancheBorrowedOnSeptember222015Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=avgr_SecondTrancheBorrowedOnJune152016Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=avgr_LoanAgreementAmendmentNo8Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=avgr_LoanAgreementAmendmentNo10Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=avgr_LoanAgreementAmendmentNo7Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Borrowings - Schedule of Debt (Details) - CRG [Member] - Loan Agreement [Member] $ in Thousands Sep. 30, 2024 USD ($) 2024 (remaining three months of the year) $ 0 2025 0 2026 0 2027 2,176 2028 4,060 Total 6,236 Less: Amount of PIK additions and final facility fee to be incurred subsequent to June 30, 2024 (1,934) Less: Amount representing debt issuance costs (134) Borrowings, current portion, as of June 30, 2024 $ 4,168 X - DefinitionCumulative paid-in-kind interest treated as additional principal and added to the total carrying amount of the debt. + ReferencesNo definition available. + Details Name: avgr_DebtInstrumentCumulativePaidInKindInterest Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX

210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_SecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LineOfCreditFacilityAxis=avgr_CRGMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=avgr_LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Leases (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 06, 2024 Dec. 31, 2019 Lessee, Operating Lease, Renewal Term (Year) 1 year Â 1 year Â Â Â Lessee, Operating Lease, Liability, to be Paid $ 1,479,000 Â $ 1,479,000 Â $ 1,300,000 $ 7,100,000 Operating Lease, Weighted Average Remaining Lease Term 1 year 2 months 12 days Â 1 year 2 months 12 days Â Â Â Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Â Â $ 2,200,000 Â Â Â Lessee, Operating Lease, Discount Rate 6.50% Â 6.50% Â Â Â Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly Â Â $ 105,000 Â Â Â Operating Lease, Expense $ 316,000 $ 314,000 947,000 $ 942,000 Â Â Operating Lease, Cost 90,000 65,000 263,000 233,000 Â Â Operating Lease, Right-of-Use Asset, Periodic Reduction $ 290,000 $ 288,000 $ 867,000 $ 852,000 Â Â X - DefinitionRepresents information related to operating expense excluding maintenance fee and other expenses on a monthly basis. + ReferencesNo definition available. + Details Name: avgr_OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Leases - Future Operating Lease Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Mar. 06, 2024 Dec. 31, 2023 Dec. 31, 2019 2024 (remaining three months of the year) $ 313 Â Â Â 2025 1,166 Â Â Â Total 1,479 $ 1,300 Â $ 7,100 Less: Imputed interest (52) Â Â Â Leasehold liability as of June 30, 2024 $ 1,427 Â $ 1,102 Â X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Leases - ROU Assets and Lease Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Operating lease $ 1,427 $ 1,102 Total right of use assets 1,427 1,102 Leasehold liability, current portion 1,210 1,102 Leasehold liability, long-term portion 217 0 Total lease liabilities $ 1,427 $ 1,102 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Commitments and Contingencies (Details Textual) $ in Millions Sep. 30, 2024 USD ($) Purchase Commitment [Member] Â Purchase Obligation $ 0.7 X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=us-gaap_PurchaseCommitmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Millions 3 Months Ended 9 Months Ended Oct. 03, 2024 shares Aug. 08, 2024 $ / shares shares Jun. 17, 2024 $ / shares shares Jun. 13, 2024 $ / shares shares May 16, 2024 $ / shares shares Mar. 05, 2024 USD ($) $ / shares shares Mar. 04, 2024 $ / shares shares Sep. 30, 2024 USD ($) $ / shares shares Jun. 13, 2024 $ / shares shares Sep. 30, 2024 USD ($) $ / shares shares Aug. 07, 2024 shares May 22, 2024 Mar. 07, 2024 $ / shares Dec. 31, 2023 $ / shares shares Dec. 23, 2023 shares Aug. 02, 2023 $ / shares Feb. 16, 2018 $ / shares Preferred Stock, Shares Authorized (in shares) Â Â Â Â Â Â Â 5,000,000 Â 5,000,000 Â Â Â Â 5,000,000 Â Â Â Preferred Stock, Par or Stated Value Per Share | $ / shares Â Â Â Â Â Â Â Â $ 0.001 Â $ 0.001 Â Â Â Â $ 0.001 Â Â Â Preferred Stock, Shares Issued Â Â Â Â Â Â Â 30,229 Â 30,229 Â Â Â 62,881 Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â 30,229 Â 30,229 Â Â Â 62,881 Â Â Â Common Stock, Shares Authorized Â Â Â Â Â Â Â Â 100,000,000 Â 100,000,000 Â Â Â 100,000,000 Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares Â Â Â Â Â Â Â Â $ 0.001 Â $ 0.001 Â Â Â Â $ 0.001 Â Â Â Common Stock, Shares, Outstanding, Ending Balance (in shares) Â Â Â Â Â Â Â 2,783,891 Â 2,783,891 Â Â Â

1,279,928 Â Â Â Common Stock, Shares, Issued (in shares) Â Â Â Â Â Â Â 2,783,891 Â 2,783,891 Â Â Â 1,279,928 Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â Â Â Â Â 51,711,792 Â 51,711,792 Â Â Â Â 41,047,499 Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â Â Â 13,784,013 Â 13,784,013 Â Â Â Â 456,096 Â Â Series A-1 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term, Period Following Public Announcement Â Â Â 60 days Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Number of Warrants Issued Per Unit Â Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Â Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Series A-2 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term, Period Following Public Announcement Â Â Â 60 days Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Number of Warrants Issued Per Unit Â Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Â Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Â Series A-3 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term, Period Following Public Announcement Â Â Â 60 days Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Number of Warrants Issued Per Unit Â Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Â Â Â 1 Â Â Â Â 1 Â Â Â Â Â Â Â Pre-funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercised (in shares) Â Â Â Â Â Â Â 867,457 Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, Warrants Exercised (in shares) Â Â Â Â Â Â Â 867,457 Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â Â Â Â Â 2,417,000 Â 2,417,000 Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â $ 0.001 Â Â Â Â $ 0.001 Â Â Â Â Â Â Â Pre-funded Warrants [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercised (in shares) 306,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Outstanding (in shares) 2,111,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Series B Preferred Investment Option Purchase Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right Warrants Expired Â 2,853,833 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â Â Â Â Â 190,259 Â Â Â Â Â Â Class of Warrant or Right, Expired During Period, Exercise Price | $ / shares Â $ 22.53 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â Â Â Â Â Â Â Â $ 3.664 Â Â Â Â Warrants and Rights Outstanding, Term Â Â Â Â Â Â Â Â Â Â 5 years Â Â Â Â Advisor Warrants Issued In The March 2024 Financing [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â Â Â Â Â 40,938 Â 40,938 Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â Â 40,938 Â 40,938 Â 40,938 Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â Â Â $ 3.664 Â $ 3.664 Â Â Â Â Â Â Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage Â Â Â Â Â Â Â Â Â Â 4.99% Â Â Â Â Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election Â Â Â Â Â Â Â Â Â Â 9.99% Â Â Â Â Placement Agent Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares Â Â Â $ 2.075 Â Â Â Â $ 2.075 Â Â Â Â Â Â Â Pre-Funded, Series A-1, Series A-2, Series A-3 and Placement Agent Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage Â Â Â 4.99% Â Â Â Â 4.99% Â Â Â Â Â Â Â Â Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election Â Â Â 9.99% Â Â Â 9.99% Â Â Â Â Â Â March 2024 Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues Â Â Â 75,327 Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share | $ / shares Â Â Â Â $ 3.664 Â Â Â Â Â Â Â Â Â Â June 2024 Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues Â 330,000 330,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share | $ / shares Â Â $ 1.66 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maximum [Member] | Series A-1 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â 3,614,457 Â Â Â Â 3,614,457 Â Â Â Â Â Â Â Maximum [Member] | Series A-2 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â 3,614,457 Â Â Â Â 3,614,457 Â Â Â Â Â Â Â Maximum [Member] | Series A-3 Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â 3,614,457 Â Â Â Â 3,614,457 Â Â Â Â Â Â Â Maximum [Member] | Pre-funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â 3,284,457 Â Â Â Â 3,284,457 Â Â Â Â Â Â Â Maximum [Member] | Placement Agent Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â 216,867 Â Â Â Â 216,867 Â Â Â Â Â Â Â Series A Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â 0 Â 0 Â Â Â Â Â Â Â Series A-1 Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â 10,000 Â 10,000 Â Â Â Â Â Â Â Preferred Stock, Excess Fair Value | $ Â Â Â Â Â $ 1.9 Â Â Â Â Â Â Â Â Â Â Preferred Stock, Stated Value | $ / shares Â Â Â Â Â Â Â $ 1,000 Â $ 1,000 Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â Â Â Â Â 273 Â 273 Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â Â Â Â Â $ 3.664 Â $ 3.664 Â Â Â Â Â Â Preferred Stock, Convertible, Shares Issuable Â Â Â Â Â 2,729,257 Â 2,729,257 Â 2,729,257 Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 9.99% Â Series A-1 Preferred Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â Â Â 19.99% Â 19.99% Â Â Â Â Â Â Â Series B Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Par or Stated Value Per Share | $ / shares Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0.001 Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 85 Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â Â Â Â Â $ 1.66 Â $ 1.66 Â Â Â Â $ 1.66 Â Â Â Series E Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Par or Stated Value Per Share | $ / shares Â Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â $ 1,000 Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â 1,920 Â 1,920 Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â Â 93 Â Â Â Â Â Â Â Â Â 93 Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â Â $ 10.725 Â Â Â Â Â Â Â Â Â $ 10.725 Â Preferred Stock, Convertible, Shares Issuable Â Â Â 178,560 Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â 9.99% Â Â Â Â Â Â Â Â Â Preferred Stock, Dividend Rate, Percentage Â Â Â Â 8.00% Â Â Â Â Â Â Â Â Â Dividends, Preferred Stock | $ Â Â Â Â Â Â Â $ 0.1 Â $ 0.1 Â Â Â Â Â Â Â Series E Preferred Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â 19.99% Â Â Â Â Â Â Â Â Â Series F Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â 7,224 Â 7,224 Â Â Â Â Â Â Preferred Stock, Stated Value | $ / shares Â Â Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â Â 273 273 Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â Â Â $ 3.664 Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â 49.90% Â Â Â Â Â Â Â Â Â Preferred Stock, Dividend Rate, Percentage Â Â Â Â 5.00% Â Â Â Â Â Â Â Â Â Dividends, Preferred Stock | $ Â Â Â Â Â Â Â $ 0.1 Â $ 0.2 Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues Â Â Â Â Â 7,224 Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share | $ / shares Â Â Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Preferred Stock Dividend Rate, Percentage, Thereafter Third Anniversary Of Issuance Â Â Â Â Â 8.00% Â Â Â Â Â Â Â Â Â Series F Preferred Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â Â Â Â Â Â Â 19.90% Â Â Â Â Series F Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Shares Issuable Â Â Â Â Â 1,972,152 Â Â Â Â Â Â Â Â Â Series H Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Par or Stated Value Per Share | $ / shares Â Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Preferred Stock, Shares Outstanding (in shares) Â Â Â Â Â Â 11,000 Â 11,000 Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Ratio Â Â Â 259 Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â $ 3.86 Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Shares Issuable Â Â Â 2,849,000 Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â 9.99% Â 9.99% Â Â Â Â Â Â Preferred Stock, Dividend Rate, Percentage Â Â Â 8.00% Â Â Â Â Â Â Â Â Â Dividends, Preferred Stock | $ Â Â Â Â Â Â Â $ 0.2 Â $ 0.3 Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues Â Â Â 11,000 Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share | $ / shares Â Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Series H Preferred Stock [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Preferred Stock, Convertible, Beneficial Ownership Percentage Â Â Â 19.99% Â Â Â Â Â Â Â Â Â Exchange of Series A Preferred Stock Into Series A-1 Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Conversion of Stock, Shares Converted Â Â Â Â Â 60,876 Â Â Â Â Â Â Â Â Â Conversion of Stock, Shares Issued Â Â Â Â 10,000 Â Â Â Â Â Â Â Â Â X - DefinitionExercise price per share of warrants or rights cancelled during period. + ReferencesNo definition available. + Details Name: avgr_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice Namespace Prefix: avgr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionRepresents class of warrant or right warrants expired. + ReferencesNo definition available. + Details Name: avgr_ClassOfWarrantOrRightWarrantsExpired Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants exercised during period. + ReferencesNo definition available. + Details Name: avgr_ClassOfWarrantsOrRightsExercisedDuringPeriod Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents conversion of warrants allowed maximum ownership of common stock percentage. + ReferencesNo definition available. + Details Name: avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents conversion of warrants allowed maximum ownership of common stock percentage upon election. + ReferencesNo definition available. + Details Name: avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe number of warrants issued per unit. + ReferencesNo definition available. + Details Name: avgr_NumberOfWarrantsIssuedPerUnit Namespace Prefix: avgr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the beneficial ownership percentage of convertible preferred stock. + ReferencesNo definition available. + Details Name: avgr_PreferredStockConvertibleBeneficialOwnershipPercentage Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock after the third anniversary of their issuance. + ReferencesNo definition available. + Details Name: avgr_PreferredStockDividendRatePercentageThereafterThirdAnniversaryOfIssuance Namespace Prefix: avgr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the excess fair value of preferred stock. + ReferencesNo definition available. + Details Name: avgr_PreferredStockExcessFairValue Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe stated value of preferred stock. + ReferencesNo definition available. + Details Name: avgr_PreferredStockStatedValue Namespace Prefix: avgr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: avgr_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: avgr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod following public announcement for term of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: avgr_WarrantsAndRightsOutstandingTermPeriodFollowingPublicAnnouncement Namespace Prefix: avgr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -

Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsPreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion for each share of preferred stock to be converted. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionRatio Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA1WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA2WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA3WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesBPreferredInvestmentOptionPurchaseWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_AdvisorWarrantsIssuedInTheMarch2024FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PreFundedSeriesA1SeriesA2SeriesA3AndPlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_March2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=avgr_June2024OfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=avgr_SeriesA1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=avgr_SeriesFConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConversionOfStockByUniqueDescriptionAxis=avgr_ExchangeOfSeriesAPreferredStockIntoSeriesA1PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Stockholder's Equity - Outstanding Warrants (Details) - $ / shares Sep. 30, 2024 Mar. 05, 2024 Dec. 23, 2023 Total Outstanding and Exercisable (in shares) 51,711,792 Â 41,047,499 Underlying Shares of Common Stock (in shares) 13,784,013 Â 456,096 Series 1 February 2018 Warrants [Member] Â Â Â Total Outstanding and Exercisable (in shares) 8,979,000 Â 8,979,000 Underlying Shares of Common Stock (in shares) 2,993 Â 2,993 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 6,000 Â $ 6,000 Series 2 February 2018 Warrants [Member] Â Â Â Total Outstanding and Exercisable (in shares) 8,709,500 Â 8,709,500 Underlying Shares of Common Stock (in shares) 2,903 Â 2,903 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 6,000 Â $ 6,000 Placement agent warrants issued in the January 2022 financing [Member] Â Â Â Total Outstanding and Exercisable (in shares) 1,330,000 Â 1,330,000 Underlying Shares of Common Stock (in shares) 4,433 Â 4,433 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 150 Â $ 150 Warrants Issued in the January 2022 Financing [Member] Â Â Â Total Outstanding and Exercisable (in shares) 16,150,000 Â 16,150,000 Underlying Shares of Common Stock (in shares) 53,833 Â 53,833 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 144 Â $ 144 Series A Private Investment Options Issued in August 2022 Financing [Member] Â Â Â Total Outstanding and Exercisable (in shares) 2,853,883 Â 2,853,883 Underlying Shares of Common Stock (in shares) 190,259 Â 190,259 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 22.53 Â $ 22.53 Series B Private Investment Options Issued in August 2022 Financing [Member] Â Â Â Total Outstanding and Exercisable (in shares) 171,233 Â 2,853,883 Underlying Shares of

Common Stock (in shares) 11,416 Â 190,259 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 32.85 Â $ 22.53 Placement Agent Private Investment Options Issued in August 2022 Financing [Member] Â Â Â Total Outstanding and Exercisable (in shares) Â Â 171,233 Underlying Shares of Common Stock (in shares) Â Â 11,416 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Â Â $ 32.85 Advisor Warrants Issued In The March 2024 Financing [Member] Â Â Â Total Outstanding and Exercisable (in shares) 40,938 Â Â Underlying Shares of Common Stock (in shares) 40,938 40,938 Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 3.664 Â Â Prefunded Warrants Issued in June 2024 [Member] Â Â Â Total Outstanding and Exercisable (in shares) 2,417,000 Â Â Underlying Shares of Common Stock (in shares) 2,417,000 Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.001 Â Â Series A-1 Warrants Issued in June 2024 [Member] Â Â Â Total Outstanding and Exercisable (in shares) 3,614,457 Â Â Underlying Shares of Common Stock (in shares) 3,614,457 Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 1.66 Â Â Series A-2 Warrants Issued in June 2024 [Member] Â Â Â Total Outstanding and Exercisable (in shares) 3,614,457 Â Â Underlying Shares of Common Stock (in shares) 3,614,457 Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 1.66 Â Â Series A-3 Warrants Issued in June 2024 [Member] Â Â Â Total Outstanding and Exercisable (in shares) 3,614,457 Â Â Underlying Shares of Common Stock (in shares) 3,614,457 Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 1.66 Â Â Placement Agent Warrants Issued in June 2024 [Member] Â Â Â Total Outstanding and Exercisable (in shares) 216,867 Â Â Underlying Shares of Common Stock (in shares) 216,867 Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 2.075 Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_Series1February2018WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_Series2February2018WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_WarrantsIssuedInTheJanuary2022FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_AdvisorWarrantsIssuedInTheMarch2024FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PrefundedWarrantsIssuedInJune2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA1WarrantsIssuedInJune2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA2WarrantsIssuedInJune2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_SeriesA3WarrantsIssuedInJune2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=avgr_PlacementAgentWarrantsIssuedInJune2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Stock-based Compensation (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Dec. 22, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share Price Â $ 0.95 Â $ 0.95 Â Share-Based Payment Arrangement, Expense Â $ 222,000 $ 219,000 $ 1,525,000 $ 703,000 Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Â 300,000 Â $ 300,000 Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Â Â Â 3 months 18 days Â Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Nonvested Fair Value Â 100,000 Â $ 100,000 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Â Â Â 1,000,000 100,000 Share-Based Payment Arrangement, Expense Â $ 222,000 $ 219,000 $ 1,500,000 $ 700,000 The 2015 Equity Incentive Plan [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized 300,000 Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Â Â Â 15 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Â 71,442 Â 71,442 Â X - DefinitionRepresents sharebased compensation arrangement by sharebased payment award equity instruments other than options nonvested fair value. + ReferencesNo definition available. + Details Name: avgr_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=avgr_The2015EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Stock-Based Compensation - Stock Option Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Awards outstanding, shares (in shares) 90,190 Â Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) $ 18.45 Â Awards outstanding, Weighted Average Remaining Contractual Term (Year) 3 months 18 days 1 year 14 days Awarded, shares (in shares) 394,105 Â Awarded, Weighted Average Grant Date Fair Value (in dollars per share) $ 2.75 Â Released, shares (in shares) (368,503) Â Released, Weighted Average Grant Date Fair Value (in dollars per share) $ 4.89 Â Forfeited, shares (in shares) (3,333) Â Forfeited, , Weighted Average Grant Date Fair Value (in dollars per share) $ 18.45 Â Awards outstanding, shares (in shares) 112,459 90,190 Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) $ 7.85 $ 18.45 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Allocated Share-based Compensation Expense $ 222 $ 219 $ 1,525 $ 703 Cost of Sales [Member] Â Â Â Â Allocated Share-based Compensation Expense 36 36 228 99 Research and Development Expense [Member] Â Â Â Â Allocated Share-based Compensation Expense 42 24 397 158 Selling, General and Administrative Expenses [Member] Â Â Â Â Allocated Share-based Compensation Expense $ 144 $ 159 $ 900 $ 446 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Restructuring Charges and Expenses (Details Textual) 1 Months Ended 3 Months Ended 9 Months Ended Jun. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 24.00% Â Â Restructuring and Related Cost, Number of Positions Eliminated 17 Â Â Severance Costs $ 66,000 Â Â Restructuring and Related Cost, Number of Positions Eliminated, Severance Paid 17 Â Â Severance Costs, Included in Accrued Compensation Â Â $ 4,000 Research and Development Expense [Member] Â Â Â Severance Costs Â $ 14,000 Â Selling, General and Administrative Expenses [Member] Â Â Â Severance Costs Â $ 53,000 $ 23,000 X - DefinitionRepresents the number of eliminated positions for which severance costs have been paid. + ReferencesNo definition available. + Details Name: avgr_RestructuringAndRelatedCostNumberOfPositionsEliminatedSeverancePaid Namespace Prefix: avgr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount of expenses as part of accrued compensation on balance sheet, for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesNo definition available. + Details Name: avgr_SeveranceCostsIncludedInAccruedCompensation Namespace Prefix: avgr_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe number of positions eliminated during the period as a result of restructuring activities. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
<)X/K>C#H..^P(O[M6>E#NJ=Z_0;*^+H]:HI:36 CBX.X,Q M[2&UV,2.$@A/2#KT ET+_LB,<@+A!ME-J6QJEF\DSZG2,3Q"P^+"P2H'_V?(MP[/?
6@4)8$#.^ZP8R_V7\WZE[PZ>'EZ5M:_E[3P9'6^?N*^3TT'E)KY*'O4;&V-.1ZN M%N[W0XL1GKGV;4?0H9?7EA^>*?;$@BSHJT&+U7CAT@YA1XJAGQ77@E:$9<<6 M*$] [8"VTX#D4EA7YD/[&T6R05(M5Z.R&'4V&?IYL-JH'W)#!H9\$VY*LR#=G/5K8;\ C%J/QW-6>._H+_?P'\$1] 3^'0QH;1 _&BC]%B MA5U]&'=DA_UD=P3I*#CX?
4!@4P[\&W6.'8A;YC0.QGP*8XA#JEL/)WVN=IB%6-'->".\+"?\'ZY9#2P@K9P&[#'T-.K#MMH%L4/%X8X& M\FGWQ35V)6_G2>BH%ONI%O1\2FEVW&;'610J#BBD)DO]=2'Z@HNGX@0I-0S M%14IDX[L#%FW3\P6$U=7[G@9^WE95Y\$04\1B :5F^-#9,YWI1(L55"2320$ MHLB,OM;L*+ZN2@]@ M&82S^79YQ5]&UQ V[].JQ2P)9XY>'G5T'_GIWD!OYUL3&A(YBYD)WLD>2ZQ,N MZQ'DD,&GN,^=%J-Q,G=I^Z@C^LA/]"L7TC=H0W>L+'7B=6NFO@',"G_(Z@F> M]>6_Q2J,IZZ3D*AC_\C/_A[\5 LN+_(AL2>+H+^1+5;SV:QH;V; \N.']@>OA&//P%? M:1^*Z2-
]6(4MA4GBT/2MP5I&\S (^LK#9K; KH [[1'Y9W,] M$C\?300LGK M#N_X+2L:CMS3I#^76XQ:YE!O;,O2]@";NV-T+Y<=4=#SL>X/RY9C"+' MD!=URB#R*X.U@+ZN*%KGT(",
[/GS(RTV5/S;BM/K[,5]\4K>SG_6ZY1%/PM M"C[V":I:7)N%:WLZ3T,F4^-D3^1,%#QO2K>*-&'"W22W/B&ZZIIZJ8SV],3\Q M'GR!;RV.C:OS7ZZLB1Y*FUD0]!G%8N7H5G&G?F*_^%G7H.13].L6 M0%X=L3 M?E3L/O!-/\$U<53-?R=IZ$DQ_\GSDY^7_>$\-W!9(P&;Q0 M8+,:S&*3D]=M"BIVYBTDB\K=6Z:UZ<^ M$@&SC@3]N 67P=L9;%/1O)'4?
%"\,B_U;+A2O#"7>THR*K0! 'W+N3I^T%_0 MOA>V_!]02P,$% @ L(AG62Y/"GT%&P *50 !@ !X;"]W;W)K2?I]?T<'Q3% 1(2 E^1#$11U6+N211!I
M3\1N[$.ANP"4U>AJ]T$2_O7[9695]0F(]H[W8<8BT%V5F97'ET?A^WM;?"DW M6E?1PS;-RA^.-E65?_OT:1EO]%:54YOK#-^L;+%5%?XLUD_+O- JX9>VZ=/%
M;';Q=*M,=O3B> [L4_'B>UM7J$_=.I:IRDM!#)^A2WIQ?:__>IOF'?P MLE2EOK;IOTQ2;7XX>G84)7JEZK3Z;.]_U(Z?5 MW;J70<'69)/?]>#DT'KAV6S/"POWPH+IEHV8RE>J4B^^+^Q]5-
#36(W^P:SR MVR#.9'0H-U6!;PW>JU[\9"L=S:.3Z&.Q5IGY79&LOG]:86EZX&GLEGDIRRSV M+/,\^F"S:E-&K[-$)]WWGX*D0-?"T_5R<7#!&YU/H]/9)%K,%F<'UCL-?)[R
M>J<'^"RCRD9O3*:RV*@TNJE4I:%?53G&KRQW-KXO'/O\\O9M\=(/8L$'MV:/47/ZFJ+G1D5]"7!=\)&7TW[?ZH8I>IC;^\C]C M!!]<32$6O=*KN%5:(;9';PJUZK\G(9XCG>"/Z(,JX0U>G8Y MC6ZQIEL,UE6:=59.H!/9O8(!@YXR4ED2P:Q3K+.%WSA9UP8Z-XEB!7HJ79R0 ME>*178GCQ9EO5!41&35]NMQ%^697&FA QOI0P95540[J2!-@?=4F@M!-OH'D
M4[R(%4&)*356C8X=NY^N7GE6I]&GSLOX*MJH.PT)+&N3)B=U3C+,4_5;K8E; MDAHO:[2CKJSS/-U%R]3:A&@"M9 2A+>+5H7=\AL;C76.S]_76W*F2^2#)5!1=H!L; SV@ M%=<%[V]S,
(ME8XO3T%FL(9VMQ9,_XA4-DB."G.Z@9B4"D4I/*L0E6KA0@0O211A' ME-0% 8=69=4B!Q-!UYD@")S4 XO%.J"#Z0@[#X]'@=@'H;"$]+"* A^YJ5@T MVJQFV&02O:<(M+0/_*1--0P'DK_'D=-
_572GH'+5CMZ'/N>V5,M4!X$$51BG M*:Z+@E@9/$[6G-:)CC[&.&&0<6O@(O1.LX#'S>W_GS)%L6RM6A["F30LTI@ M#EV1#H#LRA*?2W\);=2/94YNYQ$7S)
[GPE[\::PF8G=\S8&50P=O)Y!U EO/Z'/3_F=T\POSVGSP_I<_Q"RV@7^! MQA5Z:^^\=P 3C=-@M7%^IDN]";;+:E6R?CAS(TW,$#9.UI"G>. (8HCBPI8E M:ZN^,[$$QDH5:X!
>&;8"5P>/3=JSM@09^%]JV>=W)/;NC85CN,:Q@=ES8R: M0AU_@R3Q,?Q[Q19'JZ@XEG5H^U4(QF4(QN(\EUIG)!CX.SJ+$J!1S JV6+6(MN3D1OR9:TF#S9L?<39%!E"4;Y&.G;$E^4
MY#G=UZE12Y.:BERVDW9&H)#VKHN27>G214F15H,SKL!Q302NR:UFB2J2,GII M\9^@FF^N;EX&'S;Z_,]Y0M;@7[BZ^3D_Y.=(G;.ST[FYU!*"NY9%?@:@SM
M>V]91M(+XSCPUSY+490;,,JITSV$A()P>!(3- M(([K;9VR/@*.PZPJ>ON;L].SZ2D@Z/=\07-X! M_X44-;O'54W1L_O^4J<&!N:B-Q'/'!+/_\-Q;]3*$P*V,,V9A M?' >$K,2O:QX.AY.=:E)9R)Z
>YM:TJ*/# 30#("D9"8:JQZI3DTA^,E[L%9(8J9L?D08BKC MPBRQ\Y:67M5IRIIG[UF^_U%G2-PNQ^1+#C;5!!8JRNME"M'9U4HS+@D\PDKV MLW8QQ?U5K/6A82+A-]"N"^!3"">"+\]8#
(7%& !&6-T ,V+F%KWDD1C?@. MB7/\)8)&,Q'15<7;?N!X%GWTTK@"T^P3F[48VM&^9&FB:6WE]ZJN*<\=L60^ MFX] #?3A^/$@\LC:6F+U>V'AI!I]$H I%^#9.F-XB>]YMN"CP7A+-9Y>3
MV;-95&X4 7Z\T9%&#F=>*_$ @XW),9$>W,'FUX0E@ M8%V;39PO*B&15]I&- MLAPXJ6?/)K,9I()O'!3J?K^87,QFG [FRB0^JC+2=80[50ODKED^W?P&G&O] MA1XI%#!4I!
(@#D'ZY,\X6HL+9Z_/Z%<.GJ?=4MV+U";X.KR8,4?BS05D%_1N MX:(G2< !0H^SMHR_8R3=['TJ F]N!?"A"PK 6P4SC8:QV:7OVJN3O6L(U:9 M3SP -Q@%%8J5(([D[+>\>$_*#CR!^21)LC"R]JFWI..E44BP"4ZXC#@(*6M@HIAL;W=@O]UMF=05;!;D; HN0KJJ0@5-:IRR7$8/@H M_&YDV/P$*S:29B3.G_66^<<30:[J:!?^'0%2\E(+TP&'I<=/8)Z@D)^I4D[
M7((S\7K7%*O8MZV,RPG\SA[C.U(=&25"&QU3DVP0#X"6!1>-!$F7[,*]1\'[M3T%S:K9&1* NE$D]R:T'G?-S)P-1KSJZA&2LSABHCKE OPB5:QJJ45L*UVSH MI-
JZV!*V)_3M%S+59&!'G);A.\E=#9:"'G'&2H+INM!2O$JJD!"6,<7FI8+) MTH>F;$YVH]ON4\I?+1!;8!LLI'Q?5N=6(T<71^R-R<9TM;AULKC5DZR6/L:$VS\1;KK!!;=D9!81?=59_K-T8TX&>1=
MX;,41Y>(^3' ^C_Z#*<: O%[WB/DW Z=?U"N^'&5 (N ZNN-R@)*1Y!E+^V, M^KTEZIVLC84B#=ZSNG;Z^D614= MXX&! B=5#-M-"6EREKJ4\5!/7%OQDPH6CH-(B1W-!- "GJE"I^)L-
R;']IJLI<4^'=J%JRWJO/(>I1'4,&HI5-5 M :AID0DO3-SXX%D4=."L=I/@H>^I,,XMXQQ+$.1>W3D<'MT"A^LU9$; _]10H@<;ZG-;FG! +2B'=JAFPMB/QZ>1B?C8Y.[]L)96#-)N@&
[@%PMKK:QJ%=V M*47VL)$P5O_OZ<<[)8&& M8 ,D.D7X0#*]}[&?X!DC?;E#\NF7 ZCSX(5>YVP@O3K0Z63QK'_XG27:'>!/ MV/J-;/TOMW73;GG5ZHIM3)'T2X:3T.?!!\\N+GN;TGLCZT?
WY+WT ^&@DJN@)$57YNJH-!USC[GA+FW6<"Y\]FM#+6_2:VIV"APB\Z*:V%::BCH))$C';4_M M>C$YFU_R,8ZQ@N48FC188B2MZJF&0V>-*3NV@QLAW;F11O/5R;Q1B?:YM;[O
MG]NC5&3H'T9T,VRR^ H1B[^&"+(-$-*FY/0KE)P&2B8>>S)2[13]Z<41 ?*3 M(SQ-VD#W+V!T&KU6R#^E4M(Q*.+B89[AV'X,P+%5A10 MJP(NAZW[JEXCUD?
S!9O!9/?]_9Y84A0/^G<2:_8R*5S5K7Q5V2@-7 MOV6 &S#-NU>O&RB3YZE3( )ZKVVI?)9'@@O.&$Q(C9IDD_ $^@+E17:VK A_Z MO\ZZVGG"\^G7.UW$3?K'T&G7[2GU;?GM)2>$(N
M&ON9^_M(>G+N-5],Y,DR/D3H5.*:_?&YXA)8_NM!ILH)V>Q+H.B :N0[S25TY8+/IW. M_N$I7E.4Z&99>,CQP98BK=F1_N=MP_"A!R.!."M6UV!_1;GH'FTT>F*:C.& MNV^&U<$5TLB8:-
([NCDY]95\F58USAFL3-J6U\WK:WK'3:\^%WMB6A(=ISRX M)'D#B0\/7N%PTNC2VQWGBB2CDH8XZE+&0'4HAG-7H#TMU7I4JC\4+5UO=-Q. M]Q'VYAYL-UO4__3->;OMD!*[C^^]!0.M+T
MOIA=3A9G\WU!8E];^_FT8_*/;FN?-P,(^WO;\XLSMOX_U=VFBAK]7V:CCPT& M',QW8K/1=6H9K!![M>CAH>X:UXPL>+4V;]8"?4 M::FIL%IO";7:4,3,TSWNRH>L26D;Z<#Z#[?!9GZ72"L;]?
TX-^=84/)-)TZO4 M-4L>S8 ;T\,(53Y2_N?!NUH2&&]4+DO)(<&D*;&=6H0J"2L]=?GS@Q;L'.D M[>-K)39[&&W)@GL@O>7!-['KP<> 85XQW7UM&3'4,QF-=-7ZCFPB@ONQ\
(E(58.E7G$PCF+5%@YJ)8>U2#DB[Q(L#E#ER%P1/&N5X<&33*GC#/SDT#[MYOKZ8,9W%;IQ?];N'6!E?' 6/@ ZR4-SF?6P;S4MGT?5AXS5VTV9R&F,F92;
MYR1%C&V12.=8R62&'UZB>68.UX).FS&$,'$:IJT@@*ST5X#\]$+K'AK'),BA MT!NZFWE'S>.RB1P&F0T[4-8S#\]IM";35=3&W9@!C*KU#F+GD# MT-**ZM>=V>
<^,J*M^C/D>QANI[8MJENK-[FWG%*X^L0&EM-T09U1S()'WIHA M=RU6;Z]JV;4NUC7WFWQL63[4:]"H239UR3X0>ER(Q\DP(?/J:OHH0+VG M0K?GU+ZNN'XV_CW-G%%_6^& L<3NQ-
Y3T")K-(FA^N>0O6ZQS97MBD95^@;1 MM*3]PWO _O#K9M%QD!YV]P6,5B&1I4;-[HI*V1MJR(V7%K^9-W/D-!W7:34. M9E4&O:36\]B,1CA**8'OS0HT4G(2T%CCM*<+#7 ?WJ-
HO]CS%Z.%WEZKL)'= MY?GD=-'OL0XRYWY;ODF828:GTXN+L_'3_$2/MZIXD!G2=`C^9D-%?[GSBWT*"]S0 BVJOLKA7&;8&0BU-6AD6J%U':3? MAMM'B> UJ4 ECJ6PJQ$:LI/;:&
(G770Q^+R]% 1Q+W.Y3NA6O]6-P.FW9/K MH#L.ZUS^]MI-5- 7]I,M5O#&:&V%#ASAK.\1N:D-T<]EZQU>^&&S!PW/1965HQM]L2422[@@W93:QPF$C2'4Y=\&V%)=V://?KI0)P/
M)J71B*RIX$]Z0N?L47I]+),FW>E<\#H>6[3O>3LMK<,AA4*&T^NW_TYO]W:? MM]OCDP;/BT#<#Q@<\$P^ZQXXI3_D@O!4QPO!1K4,RA_/!GU2\<[^3QV(#FL M,XA?
+I/F7K+9TH2U^$FZ;JT3GP8.#M-9SN^RC2\<=[?SR#>E&PPKL@+X %Z2 MF]2W<&AU:3I"PXDX^6;V2CEL4?*A2G!G G^:S*Q>9$2U8M$7_)9TAWJ*7T MH7684Y;K/R>M<6,:#RQJ25
\9NCG$JT3S5H!>Z"V;O2WN07?VLJY$Z%A&CJ2 MB]%;OCP)3%[5$(:3 MCY>[$.TC<>K5J/;>N$5L/?A;^//GT^?_V.YU" M/1Y5&_Y!=;M?33B/RSQI%_2^4KMH7<5G,)*R.4AX M9TK ?7EPJN1L-
GE^^FSOK!SI03B38:=OU@K_'/"U*G,C:V4*9K0.'AYWKS, MOX&4(;GF%+FYKTB7PJ2@1H]0^6Z=<1[4*^#Y22BO'?O]US2,8@WLY/6#9/QIW^R-*2&
[AS[N5H/9S=R]DFEXOGD\7^">L_D;FQBW=W MX1#*BIKOTI%+2@RA#KX4K'9*X)^)HA*KUD[&QMA<.*F9QMP2+B$?^!%] MMGWK=SK6KD%#5PE#0X>N#M!OA?
@Y/W>QQ)V8QR(>'3ZFKR"7M^3Z%8PDD=$P MJFC:QYMI\R;]%QS(JEW,>Y1/?*V,?L5!T8;?MAHRXK$R5EWKXIZTP-C^O9O M)W^3QI(KW!/]977"O[1%=6'ZZ3/W0PO]L8^+
[_"ROP@O=]_=ZT&1][[J<91_ M$"?YQ="-7M6TF"C*(PYP&9UV(@@ML!QO^19(8SS6_JQ25P==$"--IVL'3C8T&OMUP*>MGV_'T6%_#"E_%'9G\,2K*<*&YG@7E88!_B2!9Y>3_/?>2\HN-
=3=^I500 M7\O"^)>'JQ#6SXZ/?;92I?0#NU8&3Q;6E3+@UBV/_=HIF?.DLCA.A\.3XU)J M'NN)62ZU(9KZT13BU>'EZ,GEU.:#P/>$VKC>]<"[)D;NT-W;S-7QX. M22%5J"R0!
(E_M^I*%04)@AI_U#(/VR5I8O>ZD?Z&;85?' NTI3A](MH&>#&^3?RMPXE^?U-<@+@N;W?R[SZK]ZZ:# MOP 2T:_EIY5"(F:V7$MS1^,K(ZM/WZ M:O!]9FH3E-/E=YL+!]$"7I:*B
C>E9Z_D<94F-TK!UHFY"@:9]?:4!"@:2D- M*)>&)$2MQ)$"CA(R_P+.X:F)V*QTML+DK*ARS#;PHR$F+# EJYPCPW8F&)4I M[PD@J!9"BH74;JM,XZ&KZ!9R\>CTN>_HK4VL,E R^A#0
;MZ%D=3P\HIQ9XW M *J5T/=8'<&H?Q&AX],\6 M5PLX'C(:>&'J S@TZ;>1E"$%AK1*D*.QU#OI\#RMP5Y1=7]IWV'I+O4U+$T9
M4EI\+"J*?:Y\YO0\FE*W!G76[BV1WW3!10321[6V+I#R#WVRSQD#\=ESOK[V M09?,[61MA& $-AX^$AR*)"6 #G?WT>G4'Y4F]&_YD$PLY0W(H%V*4"(]VM9U
MA&-827ASL2#29/XMR:]Q7#>E'%N[=4H_9-]MEZZ\V@W9ERI?\I/-"AD$M2AX M6\4X+R"?T@+KHUG,;HZH1R7@E^C;/?LFH= [^']GQNX(TN]6%E7K3/H"0T"Q M42Z Z)QDFE\
[>ZL]NX*"E]MJ'H"?!F"T2J;TK9P7D:O55Z)?OK1S;PL%7&ES M"[NL P@3D:'5T)00P9%W&FT3GJ)9(#=1<3TO"[8=A&JBU%JU.RCL[[F4O.%9 MQM9M,&FE2U.:Q+I0PWB+M;0P
]@[\K7G/XP\HX8K=#J-CHRXOH M(QY;1"V@//TC=!!+:>2>BU8\T'8W5U$$+=QOPI8EKE"SH,I'[6\BP'YE1]!] MG/X9$[APLB??=+H3'UP58\+^78,2,8AU\M7\2\,'M8,XR>)B#L*)AA!C;H,R
MZ5>\%E\0"2&B'8<]S*.Z]43_WNFD&N+!.)3?;81V^@???QFX!*#:^UA4D5R! MN?(QS9)&?\(?=9#6*(J*NT&+LD!0V^][Z/48P6BE"B;#QD&MH9)JPOV9.E21
MF]YH!^6N@_P_05C869B;ICK*C D\[P4F&GQ+>W;#"07L!VP'$NQ<8#D\)1L" M!Q.B.+VMIU1N/C'[5=1KT#P=2Q_[?(D6>)K4;4OZUH]>C6,[P>^UDI-YI9%_ M-62(-ZCOW(E>I-Z\)D?T)
[;@XPUFVAH,7"H\&EDJ(HTTS,.8DL*@O>HR9*OM M-H<>E[WMYF0.;&!T3*%.^:R9L:$@["FZ!:V3#UUI, F)M-"T00N]G;SI[0IZ
M@>W4+=/WOM:W4*_[NJTW\4\.!4;J%S'0MLF/*M/RLP9M5P??4.ZH"&R M7;&VM$CC@0A4@&REUU2_&]YJ=B5H6ES5E#C[&$!+*=V[;-%WC$%L"&+ZQAS
M38Z@\+Q5XCYS0^CEX\.=51]V2*CW,J/2;7)L,-T=\0]UZ ;^I-T;[52@Q2[E MMB#8.OM10NM'3V\/0RZJ5+WEXO9 !3X$62F)N&D^D7?8.ZJ"%7248.X MX^9PMZ8VL*!XHJN
VVCFP2<^:>@>6^XN?_">#B#V/"?UZ&/BFEZ\-DC!,)).CUX M*IZ&[162HN,C[;N7Z/^OV+1;*@+#1;7*\+R14 C/J" MTWET#*.?)372^ER$;@RB:R9XGRWN3NYN(9C)Q%OQ?A&R3
M,"=3S\U%&RO%WI%R94N=Z*@K/D5J!/-* _&*OE?Y_ZIGXAZV-FUK[7_C1^2L MN=L=7XMIFV5+>V1L0%:$8W(1MHKQ'*%I[D';1=8>!-4'GH@+^JX*PZC!JAM2 M7Z%
[JQ=@+_)1!V^KUW5?7'NGYL&.F+K:W&OD8 ";_A)Q5.:FH 4[[4XF>Y' M_9O!(O;*L2EV96P4?-UT>/&$ZPB:&:R'(DH;Z77HR*:CP:?/_AZR>O_]:/M1 M/)DDPRG1$"
[39#@9QLM1FHS3,Q&OQTEZ=@)>^OT^*!^#5,*[XFR+2T8G-57)P,0<_Q-)C,<$D59-L9 M=C>";?)X.B./N_%NFFPK80_6.?.W[Q,:M1ZD<9:,:ESE(>=USJO\)D!=]9TF[6Q^1Y-
DDDX)(FR/4N&HS,Q36:3 M23)&Z9O,QLG9Y'17C*W[Q]$4Z1@_,0#[+A>[&72:*.K4\,?QT"T%($_29#0= MH9HFHW0$#"7C$U15WJXI.GI&PZGY14"<51GJID= ,]029Z/D9(S%H.TI_L]F
MR70V/<#=].0T.9V,(2]-9E!G"GTGR6@&O(ZA^V@")\7C/,+<3\HNG5RO^!#J M;>>(OMN=V#55G[IWC*U7/,V:5QXA\$R)U.F\H5I5+:4]1]PC=F0%H,YSGS=784-IR"^I^$ -
^V]X&]7H3A0DPG=K6GSU!)'? M]^;)]'P-93XJ.HS:>6'JK,%U5L>K'M YJ^<,ER[W?)9W!Z?*W/*[S+=&7%1+ M@]Y(^#">,+GF?U+Y$^?-4U2ZN/XOW=L!/CX8G"3P]#_&#=YTQ47SS6BB>@_U:
M9]23ZVH>+'IC,3D='J7#IW6L')!!%!*C\+/*EZ0D1,&S63QO?PW%T;IZ\>L& M-\ 2;K;B9J/IT63X]%G7"=1:==/V;??@",OLB)?]*[RE-Q:WT>$MBA[SQ_AH M>)JTZ1A?2Y B3SZQCND,]KXMJ?
FNXP*6C*.XHC037W5.^[%^B^3O6?\LP10P MOA*?Y%=Z!QV7/F7?W%)[.[*[9M^/"8X[OP4IE5OR+UY\/,R*/PMIOVU_5',1 M?TNR'1Y_D?-..@37(QD6F#HY-
A:)G=D7"O_JSDF;%:GTQ?;]^OR=SW?3C39/-D"D+ M96=>3E1-?-^F.9;"#G2%BBTK;4I!+)JU;RN#(FN"RL(/@^#4+X547C)M=']:"JGPSH"MRU*8USD6>C/SAMY.
<2_7.3F%GTPKL<8%TL_JSK#D=RB9+%%9 MJ1487,V\B^%D'CO_QN&7Q(W=.X/+9*GUDQ-NLID7.$)88$H.0?#VC)=8% Z(M:?
S=8GK=E2YP_[Q#OVYRYUR6PN*E+AYE1OG,&WN0X4K4!=WKS7?*DN M;+/"IO6-8@_2VI(NM\',H)2JW<7+]AWV L;!.P'A-B!L>+<7-2RO!(ED:O0& MC/-F-
'=H4VBFF9Q4KB@+,FR5'$?)#TT($9S C7I&1=I(M%.?&-G9_72+,F]1 MPG=0SN%6*HM?%,99F_C?6;4T0IWM.;A4< %5@.(@CZ$01@?P8NZ-*,&+SJ2
MI@72<"V54*D4!2Q($/+WHH/YMG#Q83C7*1-;B11G'K>"1?.,7O+IP_ T^]$ M;-R1C8^A)[M2O,*5M&FA;6T0?C_@"\&\T.G3GT.$CT(>)AP-]JO^YIQJ;CM+ MF(%>
>4(*UUP_TJUAL]2L4;75JC,?IGTN%3\CDLTKEZ]*TRWPK#?<\5S2]2[M%QO^M82&7][*1QCVQZ<1[U$_#*+>(S?NB50GE=$I6@O#40SAJ,>UDORS,V!] M5J?$AOY9'$+8#\Z"WH,FKJ+
<(^W@SD;GO(_ZX?D8#I7"WVN5$LVZ&0@NWUI1 MVS6=MILY%VVK_7=O!]:M,&NI+!2XXM!@<#;RP+I#H!5(5TWC+35Q&S?'G.*(@\>=&/5=91H3 QJ=(B8DX$L^,Q59=7+DGQQZ$Z>?
C)!)Y%HB,=A Y$^],X1=. MO"Q2E7;W'X-JS=6HXNK9Z$Z"EVK9%^-!3XP&H\D=],:UE&.F-[Y#2B>\$:]T M(8M$RTQ<>ND5O,MOE3>0FVPG1X'RT"UEHI[N(1*,[F)W4
MS$[NHG[^0LV\>*%=DAE76B7^]5%]]N)99I+K?V_C]6YJDW[+M.+YA[^+GPL! M_4+XF;)B-"(E#T]ZPB^4>&[RI2QN!=2BK$J%+J S*3XJFXNW1A;BXLHJUEI/ M2"-
Q=QE\.'Q_"J_V"3R^QPXK50B>+'J!@]CO"DRR3 M*.N!(2Q(1:HI8%V7I85,^=E2F-&&4LERB4[])\,$!U91H$.(DNK8>4ES"QS M4Q9>S*W>)^7C\;A#"G"FF!XD$&;.'-
(7AR(GSQ9+9;5) MP5P.J1*HD@C1GKFVSC<:%@A")0Z@&R #+$$JY'5=M1SVQ<>6;$$4+-X?-V*8 M;6;:L0^T91K4!IGWAQTJ/Y:%$F1A$)A&_6^RU">_>*5FM@0VB^&$EYJV;2"A
M*U+BG!0$*I7]-ZF1&9/26OK(IJE$ MSC)V ZN\.:SDB2N U[0*AN;+$#T ZN6;]7917 M@&S!QAJ-MRMO+;8N22A8#O3?ES99(,.TU'@0HRIR\'++FCK$EJ5UI2PX.#B^
M.L=KYTJ<.NR=C0;"+21PB]2[6]J7=TF[A;%ZP24MJ+F"/=1GL%Q<(5A@1%*! M8\^ 'U+$T)<>)0!F)67*BWA_VST9MUT MX3S4IZM;+@)]RB2Q9= E=.J^[#*[MO?^EA,)8+T2D%FM=
[@7!'CXCS%-Q([.2E^\/>X/!@% BDB#FM.MHD.U]-F[I MOF4>4M?PX6/'" .IPV'2XZQ6U$#X))XWZ#\]DPC<:4B:]_&]PG 4 M?Y4'OO[?/3#HZCXN^/IK7/#U-
W7!87_PUW#!U]_:!4B0RD"_MBIU,.0"F9<5Z 5@76ITB!W1AO ?=RP\["$^,K(,C&G-#0EZVV;O M;RZ8/QC8D1D0@<:F%+ZAU/A)NE1^$F^U8^5]*'',R71\5E:]5-
N^"]J!=O%KM.$U>M,JXNX9I=/2IVJ*!D/J+&JM,?B8/A M87#MJKZJ\.7(%#!QK$?]PIKR:B%>]"0<,!XR_$\?HWQ=(Q"WI"5#WB8\Y\@> MW"R3S*B6X&Q+8WT$P!K>J+H.I=21+HZN-0Q; ?'[-
^H5-!K-L35;C>SPAE M(YB"/1!3+T)/?8\]FBUH$BXTTQ;@P>XEA(02QH^MD@C4@X>'(N3@L"\EB9I<:(JC^\.@1.AT)*%$]'J*V^LBPJ=55](R>@(?@U8O8BI0P%.9T0^WZ6, ,4X/.[W+?
0XGJ[5_?GFC0H/R%>[:"+" M;90E'}6D=2K;XH^Q=M'U.LBXB& M1#"S2E[3ON<___KFQ='P+&0RRKUP3J"G+V$CN8M9Z/$,X064UJ1(PCL&OIF! MD,+,>"YB0\,>VK"#X:#>$*3DK-
E=3S@TXV1N*/!2DAD]6Y4+5I:"F9*OIT*$ M&WNB\D[^;CA4WG)9Y^[5A*-H_E$6W/&.MA;.G?108[;XR?3%Z8[<4(%_+V+L MW8%G%3[9L#-
<(T>2]B)28K1=GV*3EG#.*C,,A%\?,))!N:=@_VN1^OIVF.7 M>W'5/CUV&N>Q,E7:NSLGAK[*^>^;Y,/_H]2&\?]I.(U6"..8]#:5!,6%"A7 M(YJM]P*Q= 4&T*=0/F++_7R/V$L5=6=LC A*D*&&?
Q(K M=&ZY237*>\X'?7'A&*V#]Y<%BC@X##6O+<\!B1MM2A>8IUHP,8ZU'Q7&@$MH M5^\V-S$CAM-BZ]AC1CJ(W(9FV .AH$?FW0#@=_ M,LXUSU10M**Y-8P-(\X@&6M*A0[GQQ)X,?
XR)D8K_&^X^$M=S%2UQ?K(/#2, MBR;82"*EN?!OI@KDZU584B,?#TTCSC=3YT](7)X:PSG)]S#$0;VU=JTXH A- M:Y*5:0,Z*5TUS&3&KDF76S3+[_355 PLI4X/A=D;U2J=JRM=%#PB#W:N
MV.2BIN'/4@&()<-1_^3[OGA6;]/%;AFWVZW64 5]<1"S'BBL$F+!R_=Z3.QR\L,I;,2DV TVP;HD<@%P M-&E* CEM6XX#@%GG52:11[74$WB,7 0XWNHHNZE("O3$9 M?
*%)JN=!NZQO*MOGT!^7F99+RA5;AO+-]X#=SGI#[Z/")UDFK]%!3@,WZ)L MHWF.;\4TDT60-<1X>B)O.6_H>?M SEDH2VDG-_Y!L0N9S6/'$I5$T!^A@W-; MN-7
R>&@=0'B:7&:YRU':\$*K_70LG*3#'M5 FR6D:5Z84 Z#]>6-*I4"$VX M=T8N G"LQTCU71"GJMI5*W3FC$9SDI 7)#*O2_B.)48 04%?O&E"HT?GRD1G MY#7=8]DN\=P*">KS^4J&?
(+K"Q==N3)"!(GVK1M-1@U=":IBW6$"_!^5+Z# MO"O< LGR*$Q4M9P%#G%2,#?AG:*L73IZY-.X94(T-"&7*[] #JE22D?0.@4'

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`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{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`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|(\K1P,S6^ %:G1;O"V %M0,\@WI@'DM2]A8$J%BZ1 ,)P[0 M$2-:!G]@(<]D#BZ;*YYH;N(Z[+O.95[DR#-/@ 9^*J1>D\3 $*JF5X1\K=)BMM:9!N%$0%,1N*8P2@>,$,%/"5H0YJE,[3F:] .%!AC('^\II@1SPK.2HE-7; MS=^:@^5DF4H_2, @,"IVQQ\L KB&*4'*D)KMN2RM&J)*@&NE-1PW5K&KCU! MQ4=R"3*E!WFN]3#P'L<1=P!P!&H[\ E4BUN5%\G (#P&(,SH[.!S\# QM8 MW%4);2*RDA40!S2I(<5@*RV]R:W-H965TJ%6KB\`)$M9"_7*UGBS5SI0RC#0F1E[^,*/?OO-U>JLGE6R@=_IBH*H;=W,E>;ZU[4.QX\M9HNEY0>#FZN56,B9M%]6#QIW@]9*FA6R-)DJ2\VNK@;L;P3^#.3&].Y M)L[D6:FO?/,IO>Z%')#,96+9@L#76M[+/&=#".:,;;/7NF3%[G5C_:/+';D\ M"R/O5?Y7EMKE=6_2HU3.197;1[7YFZSS&;.]1.7&?=+&RX[&/4HJ8U51*R."-M(BO]MWBI<>@H3,(W%.):(79Q>TG.CP^:X,2[,2B3RNH>^,%*O9>_FŸ^BL_#R2+"C M-MC1,>LWLZ?0\O3.U>5!,#E&NM5:E L7+_WC2;Y8NLM1O7\>BOVH]<.Q3_HU M&^Y>L<&_H(=2)G%T?FG(L,VERE/)PN55FOI)=DL_?JM9NP6W&+DBQ9VWND7M5H_#2R?"3]Q]=/F^3W^4]$$FLGB6FN+8T688_(!G6!=IFG&^H,8P#(,P#,EP M(0QGEJBB !1.F3 7*3.F I$D56"\WD7.806T66,)DC;"4 Z2:8RR169P 4]9 MR$O'>':'DHIT=@.3 T,;E)MP)@*Y M,LW*!:.\7=)Y%(Q&\5O,>]:X,KXJAQ@G.?'JW1G])P=!I@6 MLI1:Y/F6UD 8S\$POD,/P I&T58*9 V.RF]XPT32?D,VO0%OZ0OS6B\D-&. MQ1[@0C&BD.Z!QL'+ZF!\84B^)(#+ZR\%2,FRXCG+N<4! _)K/(Y&K!J(:D;9' MV2MKH^=<+P?@Z0$"2ZOE2]"G[2Z1V(3,$K.E0 MAHIN:\.59[1D<5@'$Z&5Z4GW[WO+1 W%<5EII, M0?Q,I4T,K@/!Z&8[[BY/EJ,]]X&A\\I=;MA"!P"X_8Z^@W%_H'#OTC@_4G@_5.[%'R#LF1W7=8\P36G-SZ\=",K,&SOAA MY&<\3<,@FH,TCJ))?S2FJ!^.O"[<#*>C(K'>!GWS\?DP(XO3QZQ'[I3[!?A MV208A\.3]Q 9]2?35@3;WUQFULD$PZ&7\!X:D<,!OAX,%$5Q,!/8>"\QE3 MV!^&1Z8(\U"ZD^,=2X98 /.<1QKD=0M758!":>N88#!,7 -(]MQM^"&,4#T.\ M=_W%A&V/*%A'61O9U'_&8!#5!1)UJ7.^>6-@4N_(Y${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e!;]!:/PAX@PO6._&/DHM=":%@H47'BGK_%E[&[CA>3@NH'M7B0PG$56(M0_N&T?3J77^4/%P@.VS)#B^A3T\CQ)&9HR*R.3QR:DLOR99GZ3)E7&T1_OX= MMQYFRF2O_YRSY:*V\[,<]7X@3^3AE]KC2%(7? %PI,I*Z%W4%,>6$\E2@)MG41H^9_@ZB3'4TM1RE+'@)S.H,W9W1)]LD ME,Z6 \DW29W#-[24C-CL8N,)5,$0,,?!HJ=&$\$ AV#@:7G$H-!?HQ2F8H=RB]B(]0 2]Z{Q$=#H43*/QY]#D(9-/.AMW6VGZV,S5+Y>;T8S5&ULG95M;YLP$,>_RHE)>]4&0AZ:=0E2 MT@KG5Y[OL]SK$@JB-*Y&8E%,(@VI@R\U4ID21U4,'\, B&?D$H]Z)Q M/;>4T5A4FE&.2PFJ*@HB_\R0B>W$ZWK[B17+WB! MC%DA@_&\T_3:+6W@X7BO?EWG;G+9$(47@OVBBK%@JG["MO$=F!WC2FE1{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},,+Z,039M'R4Q3DOA._5__J;]>7.0FO>D4_XD, MKDGXPDN.FT\KA=A)S7HCBSLR55G(,M->92(U<&SA<+70A2Q2+7/AL$TA,+T3 M*WFKQ%RI0L.&VFQ3A=,RV98K0!UOQ*?"Z8UHWU.+%6AK,SS.UJG G1'[KRT ML11<-CD!\U_?39)D\,KST>Q(_'A^?LW?XU?/A2PRL2FM*PG3W@@/!6Q)>^B.M5WMY]#0U=>&5U>LGJPOS$0,GUXIR!ZPK'?\BBZ+$[DXZD#(B-M0}$ZL]$%.0&2KF6!-$E+(DJ'E-8$#"5D]@5I@K=&8KO2Z0J;T[S,L+N`0M*.M7CFVI*6UI-C>AD*ERCGD8X$,+Z182&UWPM06N@QF(1/!Z]<2VY=A,H (8,_ M 1TD1,?D:*M?6:78\@7@)M8A(RC*"&)&#E[/E6V"6L!LD-@WQ*\ M'5](G$=*"RJZ@@^PJB]JV+)./3VI,)(,I0]W,F6>$0BH'2&=L/5+681RSTH1 M(#]IM"W6!7"J^"(>O/AW@ZL%# \. ;RP]0$98CX"&D48!J?W<_>]SZH]04G;M\32Y8RQLDJX85H5@ZM,*;$"Y^)>'M MQ8*2.M>'-?D]K&N'O&5O{)S6'5(?=JQ+I_8A]:7,EGQGNT*$0RP"UTXPCEO0 M[%?_2?Z8!1S;)B)H6N!C;\?^"!+O5N9E8TSZ 4M0 @)=!(JU MDLO0QH;[=@4!*[,E',/?-#G9,ZZ(^$7@6HEVAT$=O=,2M9P3&-G JBT MTHZ8$T\J2A'#*7K)&=#MH=^R=+L& MZ7[NN2G,%OESR0%*?0NQ4+=_ 9!,)[VT.TN&,A3A.5AP:6;0.1+[GV"C7AM M'J2 \/2/T$%95"/V;-#B@;3[L=J7V$Z:Q';2FWHN#1Q8^%V>N415AC(?M;MA M?K^P)>EKXA9Z[DS8%<\,?W]?1FB)PCQKM4#8F(J {(8)1L4'BQBR[IR_J7. M.I6;.54$9I841C(%4KG93*5;,2^^H%0*7+;<_C ;5 T^+-'J5^OTB75H "T&QZG$6GQ2@8 M5BKGE%X;J%%44N6]OU/[,F38=]I"NOYY](N^)"%C=U#R)3+D-99WAAC#)T MF%%P6D $>PQ=D9@AU*&+^!6.@PJ!G-YU+2CJ;#&635G:IT.#P39?HM$/*K6, MOR[^P:IA;5&#@@N

;Z3=98+':>]Z9ID!&U@=0]C5!%3YO4ZDF-S:9;D5 M#VUJ4 F!M_T!OO.>:GHZKVZ@6W5+1>A>X[G?K7!RQSH*T(B[_0' 8)GGP7, M8+9$I^1.:"MW(?4@8.R](M!XBT8C+$(]"?,]U?*JXVB@7_7.VNUC!4!8VJF M0[O0!#R+3\+,&;5B4&I B MPQAO[RC_T!Q4P)XT{},\"'GV4VX#@IVQ'TUHW>CI[,3(1*6J!EMN'WE!88NY2%_E/NZ;__Z$ 2A(/:,"L6O!C*ABSJ_A_J/:%^WK68>T-"E71< M0.H_OS7TOZ>%.6U:F-/>]F%&:.5C:3%Q;DY7PW&]5Q_RM0UHOF^XCU?LL 0TT MZ7L@\7<;.L5S0B,Z.SB=]#[XQ*=1[6/I?>,=7 $A5<]],BY]#%M7%VJIBR(D MG]!??"_B\8 ^DPE]3H?T.9@>-.(W\XX8BG@BAF,Q3@X^.^M?^",";VQ>)., M#YZ+9Z?T$0& O^21#P_>!O.MEJL I/A=-.^ZQ\63QL637A>_E9:T>GK?N\RS) SFB$ITY)[Z>PZ10[TM(]\W.]XL[VUN#Z#U9JH4P$WI0_VCXL(VIDS5D,2H Y7[R& K[=CRDR *XUME MX5%1E P?I$46B3N:O3D8PUC=Ü2"?VIIU.)*,N!+2O,:M$CB%CITRU*Y@81HK M^82T)LR$$LDK[BN=T<=7A];]T%M6,3*$,KT-[YJ16SXEG M7+W10H(?6A(RB0:C0;B,DVB8 M3$6X'D;)] 3Y]+?[H'P,4A&?]*0[3&)/$B4P_\ET(N+H=#(0)_'TH,OH?QUJ M7=1)S*.)4NEQ-*VN3HY04,)O\=%H@DNJ?+M^O#U^.\'CZ/E/,.EIA\FN_^C M.D?^[EE9+=.#,*[#L45WKE)0(HI"&.QX,S}CRF\?M$(5S6LU$O".F2\UEGG M/P2HRZZ3R+TCAW@4C9(QP4>,QM-H$$_%.)],1M$0)7LT&4;3T>D^&5-U[?$8 MX1@^L0#3K@T]),HDDT@3AC MR#N*X@GP.H3L\.BO1Y@V/<*TOPU4X30Y/",X&X^D>\EWMP@U3PJ5'Y596KE9 M\,GC^]93LW8S.#94 *M!(_3IX0!W7CHP=)S}J3WN,4@\V+U1,>@UR3MZA/HK M':>*#^CD,$>&A[;?9I=^)MV&Z>;L^NM&QV.L!X=O7$]HCDEAQJ6Q^L]0&'[& ME).+.(R1X2"'#MNZ#\&^PB&]4K-;@!\YG^X4+:'Y.IR'M&AYQ+KCJ6"N_):2 M'S_VYB-PL=(."MST';_Y$3"=?N),+#;)\VK/LHN-G'.'LM9[.W$09RJ[4=N^% M'6L*7*2UL<{W@JV?UT=%)\6/LQ/5@M;C2E>-AXX?%]P!!3(S_#K'^T*,+&(#S&>'<^NT"7Y*CY.9]]%E?FB.^^&)Q$@,,8/03H]/BV3PO *7!92IT@38_*2R)0D)4ORJ#Q]+O(7@F,R<^&6+ M+P -ONS(3>+QB]'@^/:)94PFT/?]FF,+RB\HIF$5-Q[UQA]:#Q3!OPF]I_"?1MB"QD") M3_(KO8836)^R,>[SWJUL\^R"_W'K#;:ULDM^3\^%D^;P,EOS:._NX'EX VZW M/+Q(^$%:._A?8.C@Z'1*&][-"U_@4'X?;FZ\ VN^7"F']'HP6X#Z]U^_M(0;_&Y)C_P502P,$% @-L{AC65:TV\T@! 0 Ĥ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tGP6!R4NLF#E6-4K- M62M=_4NAW@2FULB*%E2)(K#DZ!B7'K9K%V[T]E_<5@3%-53+\N4*CM MW!M[;POW?%-.MQ!DLYIM<(GV1WVG*0H&EH)7* U7$C2NY][Y^&R1N/PVX2?' MK=F9@W.R4NK)!3?%W N=(!286\? .'C&"Q3"$9&,/SVG-QSI@+OS_,KUCMY M63&#%TH\\L*63.KY<"=-^8=OEIJ$'>6.LJGHP*:BX M[$;VTM_##F#Z'B#] 5&KNSNH57G)+,MF6FU!NVQB[I%1Q>]0W<*MTK:TL"5 M+++#X'Q^0M$%?]*9O$1TD7&}]#"'H0Q1&R0&^>/ ;MWSQ ,\&.G_[[']7H9#_:M=51KE:,Q,$X3B+1-9><.K, 6B^:W-*& M/TDBB/QP$HX>E&4"^$[A.;)>DICZD>G4]AWJ<%.L5>H-VU+&\A5(VU7]\J M\&]<=\WR+[U[NLE*5&;*&PO M=V]R:W-H965T_KM,"*Z1-9HZ"37*J*&3+5TM>U0I8Y4%7Z41 D?L6X\"8CMS=3 MDY%L3,D%SA3HIJJ8>IEB*5=C+_1>-^[XLC!VPY^.;K;&.9J?]4R1Y-]9,EZA MT%P*4)B/O6:*L3?P(,.<-.6YDZNOV.5S:ÕE2 M666KW"ZO6-TX\2!MM9-6!24'%1?MESUT=-@"#X_U $BI[L_Y%1>,\,F(R57 MH*PWL=F%2]6A21P7]E+F1M$!)YR9_) &H0^?8"H50;E8:CBZ9XL2]?'(-Q3! M^OEIQS9MV:(/V,

[A5@I3:/@L,LS>XWVB7\N+7N5-HYV$C;8,,=”OTPGW^&Q@6LKTX=\VR3M)MTO^@TS9*Z+,ID@I5@M4 M$(>]/5ME.%)HN]D>FD(A0M7>*Z82)%2*4VU-6A [WU10]
<1,+64EF%/6”N*EMB'E”R83*,;<_”-MW^C6”M72S21-44E6V[CKW?78NVR[_<5V^(MVL_5M28K:E%R7J{T?$G0N%F$Y\EL-7;^WN%?CGMSL-:G9*W4-MO3,N\D48.T(H,+,.@=‘G!{Y'(1P0T?
C>8(9M2A=XN'Y”_^BUDY8U,_A>B?]X M;HM%>!9”CANV$_9&[?_&1H\GF”EA_”_L:]_I)(1L9ZPJFV!B4')9?]E#M/,F-+?P4GTTD>/2%>76:CKE%&>7_RB+ M,(83N$329N#HCJT%FN-Y9
G=^419@[2]D=+?{+V%*R5M8> OF6/^:WQ$K%]J MZ1.U5=H+>(O5*0SC :1Q.NK!&[92AQYOV”/50*VO2UX=/>]_=G^.F;E8AHN0 MNM^@_H'A\LVK9!*_Z^$V:KF.-^7”EV@,X@
^5:B9Y7);UV, EYRMN>#V<0!6 MP1KAFO%\ %?,[C3MPE>O!^[PP<)*J.S^6Y>TWN3=TKX@TZZ4CLL'S+!!(H_O'NT-;:$0HZ]JK#=D(CQ1\#*_)?^C\QY ,DLDDN%.6”5J/IF\#
MIW@&%V6ULY@#EQ8IM86C<1H%>\TG-RB8NQ”?W#S/'GSD MDLF,TRW>6O*CZ6CI7”),+QZ'!J[JE] MDSAMJJE?HKWP]+-:4I*.E_DZ*CZ@^:>U4U@#[4>XPTN3^%?T)=5/9 MAJ7)%-
Z\.DN3]%U#6CPG])QR9S-%!V.V1+WUCXF!3.VDK2=NN]N^5^?UF/[I M7C]V5TQON31$9$.A\>F4&D,?+TAM6%7YH,U6EIX ORSHS47M'.A\HVB:.89+ MT+[BR_\!4$L#!!0 (-+”
(9UGE[$N\'P0 (D-9 >&PO=V]R:W-H M965T%GN@I;$M1!)=DHJ3?[]#2G;4KFWL5[&77D12FGEO'LD9D>,M%_ =RC:C@ ML2IK.;'72FTNAD.9K;%B^ZHV'%BMJ> MCLV[6S$=\T:518VW
F1354P\76+)MQ/;LWSU02M9<'ZO!V_RB>WJ@+/#$3&D$ M1LT#7F%9:B *XW.':>\IM6._OT._=+)RX))O.+EIR)7ZXF=V)#CDC6E^L”W MK[‘3$VF\C)?
2/&’\VL:Q#5DC%.\Z9XJ@*%JV98_=//0<$O>(@]\Y^”;NELA$ M^3HI-AT+0@6AK0E-=XQ4XTW!%;5+E+D2]+4@/S7]A2N$&,YAKGAVO^9ECD+^ M!->?FT(]P*W6$JK'/,O_8<4XSY0 M0?2
HI7\2<(Z,-02N-[[KAR?P@KWPP.%)X1+:/4=DM=ZAX>]=:I THJ5N=%O0)JX/H1159(S6E]I(46 MY9/^_%\SBH1)”>\%+H+.^A&51LSK3 21.&J>.Z[K@.VD:P L8Z=‘
M=:V>KQ_MF/Q_P12[J1.U3.X)IMN29I2JF0*J=?3<’B9\R^]=C]^C\9R]KX6 M%#IAH&F\R)#T[&/KB(ACF”.’0 QH%#A)BQJ&!K4I.\A.\HS6#)G!AJZ3!LFN(=3!
M:!:>]/4HL#/;QI=^H[AOFUJ_!K6IR#C;MON>B] K*_\:&8<0@<\< MD4>[)HI[/5II”ID $6K]!WCIG3VC\V&?XSN]]”#_QP]..MMG)G9.\GTBD/
MDE&\;VEG#MPXLG:VJ=76/F8*&OV&%%8+*EVI?Q%$GA/3_HI3'[S-B9/0<_W M^EXPOQ?,;U\P]QA\C=B>[2;S @@]QPUC)TQ3””/:1ND(M#IV^AKWC<85B92X!$C+>U*H]*>_?
[N\9L_9X_6S>7E*HQ**DE?BDES=01S9 M(_J#?SM0?&,.VPNNZ.ANNFNZ*Z'0!O1]R:ED=0 _L+]]3?\ 4$L#!!0 (M +”(9UF$ 1Q1B@, X(9 >&PO=V]R:W-
H965TR%K)BFK3QXJ\'(B..OV$7CP68B5+9+YPZ6=-^[*BT]#IE M0E#QNOUE3]T[_(Q”V”F$%G?KR*+\A6FVF$EQ FFDR9I9V%”M-H'CM4G*5DNZ MY.2G%[=”(TSA”K9:9]7)L WP
M/VRG\$74NE#PJ;’@&NPH'#6ZQ&4/DNQ#Z83Q@+^]#CZR]:”!X M!6U\E\)KM>/+VJ9<;E3#,IP[5 *Y2,ZBW=O@HG_<0!;W&.+AZPOM@63>+6R M^;ACSU0’&I92LOJ 9NW”!166//-
T;W,’7VM.QTM#$SXQ*^L?*(_Q,; MH.D:O#X0X6HMJ4”/K”3 LAHM3TSF”JB+*,WJW,@PLH@96MJ18#D00>]{0>K# M6PBFXSB!8.S’K2ZYB=+8#?R$+L/Q=0+OWDS#
(/PXVE!’L* Z/!I,W<2/1A](M)!Y/TUZ$ZGV/7%L9 XI:B=;#<6>0<V- MD4>[)HI[/5II”ID $6K]!WCIG3VC\V&?XSN]]”#_QP]..MMG)G9.\]GTBD/
MDE&\;VEG#MPXLG:VJ=76/F8*&OV&%%8+*EVI?Q%$GA/3_HI3'[S-B9/0<_W M^EXPOQ?,;U\P]QA\C=B>[2;S @@]QPUC)TQ3””/:1ND(M#IV^AKWC<85B92X!$C+>U*H]*>_?
[N\9L_9X_6S>7E*HQ**DE?BDES=01S9 M(_J#?SM0?&,.VPNNZ.ANNFNZ*Z'0!O1]R:ED=0 _L+]]3?\ 4$L#!!0 (M +”(9UF$ 1Q1B@, X(9 >&PO=V]R:W-
H965TR%K)BFK3QXJ\'(B..OV$7CP68B5+9+YPZ6=-^[*BT]#IE M0E#QNOUE3]T[_(Q”V”F$%G?KR*+\A6FVF$EQ FFDR9I9V%”M-H'CM4G*5DNZ MY.2G%[=”(TSA”K9:9]7)L WP
M/VRG\$74NE#PJ;’@&NPH'#6ZQ&4/DNQ#Z83Q@+^]#CZR]:”!X M!6U\E\)KM>/+VJ9<;E3#,IP[5 *Y2,ZBW=O@HG_<0!;W&.+AZPOM@63>+6R M^;ACSU0’&I92LOJ 9NW”!166//-
T;W,’7VM.QTM#$SXQ*^L?*(_Q,; MH.D:O#X0X6HMJ4”/K”3 LAHM3TSF”JB+*,WJW,@PLH@96MJ18#D00>]{0>K# M6PBFXSB!8.S’K2ZYB=+8#?R$+L/Q=0+OWDS#
(/PXVE!’L* Z/!I,W<2/1A](M)!Y/TUZ$ZGV/7%L9 XI:B=;#<6>0<V-

)#.D<~Z9)#>B3FDUA 8B&)1206'W7.$VC(7K#~ML$V MDP:.;9U%F]5S)4/8223OG/0"R_B/*~AN)+2HZ~+Q+329.?\K)X-/@YWO_">A3B:3_O\1-
\VSZD9A)8A:)V23FD)A+8AZ)^206D@%A(8A&)Q2260%@O__/E.EEU-]^~+N]45TZ5:.;#3L2,TG.(C&;0!P2 MB?DD-M%!!82&(1B<4DED!8+!Q@OM\%X^2>"\;/(Q=?L-
DL72O0]KR/R(7MLSHAO15ZE-M]V(H-Y^&:.^YDV'VM],KJ:B\$I9LU]N5"$C-(S"0QB\1L$G-(S"4QC\1\$@M(M+"2QB,1B$DL@K!>55]NHO/ISEUC]^6&0_LB6ZZ7TJHMTE+%774A,)S&#Q$P2
MLTC,)C&'O%P2\TC,J!& Q$(2BT@L)K$$PGHQJDZV:~K_O(*.6<[WMZD4SV< M=,HW;&Q:CFHU] :B&]1:@6HUI":?WPW+G;7#UF M%F]/NM%';HZ=>6R^K+3I6HS.ZSO)Z:
M\Y53XLBW5>#4;IU>$M2:4= M+]C+MW5T-](%(52S4.Ü&-0?57%@35.U'M0#50E2+4"U&M832^F\ZWI6%-'E9-MZ" !V[EE/9]T\E55KI?U>?G[TWV:*\59K=;U=YJKZ4\7S9M+Z"]?/F_'GN^!
MY%Y"#BU6)^1>/,IW9&P\HI]):A;JV:CFH)]+:AZ]^:@6H%[(:A&]Q:B64%H_ M'KLZD":O S4GX#O7@S;GXA_N2R&:6)2>:\OAL>?:]*:CFH%{])JI9]&:CFH-]
M+]JYJ.:C6H!](:I%]!:C6D)I 2C5NBB5=X(V;\UM=!YNKZUO/!=']N4GKX;/] MC\$)6_SOT$U'=4.5#.UP^K4?#+T.H6%CFNCFH-]+JJYJ.:C6H!](:I%]!:C M6D)I .:CL:D":O
:TB!#4XOT4{0]CFHYJ*:AVH^]@6H%]):A&HQJB64UL_,KA!4/QR5F3?%-Y&G M>?/]YO)QD:7YK:@GG5F^F73ZV>_K[*Z>:RJ?1/VHW,Q)!U-5.NKH5"4U'=6, M5MN=*4[G-Q-
%$QW60C4;U1Q4BP .;%Q^Y$A X;HUI":?W@ZZH[MFKRZ]"]*8G7D=>^YX,\%DOY&* C#NWT:(.5$W7_#=T-=%03U2Q4
MLU'-0347U3Q4\U$M0+40U2)4BU$MH,1^7G:\'TW>^SG(RZ=3ZNQ6B=,_7IP& MHB4?5--,[? EOOU\1.L]$:&MHU]#Y]J:.AFH]] :]%]!:A6HQ]":7U\[&K M[VCR^HY?
Y/=__T64R_8>R"""MUF5]!GRJ_(=(2\4LUN5@0I)WX=^@FMYJO1N, M+@:N>O1R3:K$$U"]5L5'-0S44U@#]5\5 M0+42U"-5B5$LHK1^1-M7;-
&DS=KFHA4MA'YG)"96)TJG\3CTXGV]JDX;E^MS)/7)ICH!_N@FHY]!JJ9 MJ&9IAVVFV.ZJ*C>]CFHU] :B&J1:@6 MHUI":?U8[&HV4WG-YN":S"=O)Y./5?.V&$Y>!V2Z:.[HH@W(YN$R6R]?N:8M
M'W-T.J(-9VG9KWFY^YYKV9/^2-CJHB6H6JMFHYJ":BVH>]OFH%]!:B&H1]L6H MEE!:/SZU+CZ/J-.\$\)?\GR]>3^+VV:M9CHY/DC1[@VJZ:VV'Z3]?I"BI1I4 MLU#-1C4'U5Q4\U#-1[4 U4)4BU
M1K6$TO!!VA5OIB.+-V:6I_EM4[PQA7@M-M)M$"#JKIK;;_MMWJP803K=@FH5J-JHYJ..BFH=J/]H%]!:B6H1],:HEE-,/ MR:YL4S\9B5Y*.FJEFH9J.:@VHN.MJGFHYJ-:@&HAJD6H%J-
:0FG]K.SZ.=.1_9R!8J)RDZX>E#2_4VY$6:7U2?KF_M">/W=?8M76RN";7 O<$L1+HNRROY;W"EZMKIMWK!7^:E]8?/G3:8^_MK;.:K9^BMEA5JU.E%(-%'-GPH[.4+?
J@FH%JYO2PA*1.AJYF]%VP=\UZ.ANX M4HVY>(X7Y<.:,P3:M1^7G:1

12;2KWT#J3G37NB;Z!C#Q.M(#'GT9DU_M/;I9TJ0S(#UOW! 1'QUCBMTF'Z"5?EM0DZ+)&IZ@S.[#$N9X)1+LAJ;ME=)^CC@J&.,)LNRNN_#M1,<[C.'((.$R@TE>K: M]4$1MQGLEFMU+_\>-R\@KT^" A-)4V:%[OG3H3=TA5H(^V@PP)SMC_*AO03_M]JGT(JI$O+K>#%VWN;=GSK?S7_"4]F5YL0VFY/;C;W78KI_#44M+U;)VPC MA$;Y ^U7@*(%4&@JN]+KV#WW*VR];T H]O1VA3F1SK0!H;FT2;)C]]S2L/7N MP@[;0 T*%)I*FS0HI]GT/JI$ZDII#2T+_]D%M2A0;.K%O=+(T,/;)&?XQZ72
M'*1+S=;Z@7@8*3:576A[;C#$%%IB&C/#1;JMSIV+'E0IP.%IM(FG0[MN0U#]8[(#MI_+0P4FDJ;_MM##T5_HU5.^5"G X6FWG0GG8[3<\O&T=LB[;29$^E\XUT?#L.1#L8YE:_HS=& M6I32G&YG/HS1J"_MW;&K+7M0MP.%IK(FW8[3<[?&T=LP[:R!FA@H-)6UVIW=[]+5UW(390Y3D*&9S 6\-/1$MVSS\9/.!IZOR<2#W*>?I_MLGR[8*&8]\4!XO_S-.7/'XHGC&P?03/Y'U!+_P04 "
"PB&=9>Q]8.\$ M "_&P &0 'AL+W=O8F_M71 $ ZF4Q*9C60TS@5%]J#JR;TQZ';QD<92B,0%TF220;!Y0C-==PS:V'<_1 M/&2BP^QU%G".)HB]+,;$M\P"]8@2E-((IX"@6=?
HV_8)3=7<,^UT,@5&M+W MF;.DIX>0P5Z'X#4@0IJCB0<9+JG-'1RE@ED31OC;B.NQWA-F"+3 +9@P[+_ = MBB %8(3SEP*9>ROAHC!**;@.WIG2QA?<^&7R1!<_7K=,1D?@@
R_=S<(#/G MG#!7 X\X92$%7AJ@0*'O5>NW*_1-/O5B_LYV_@],)> 0^7? <6Z 8SDUU7RJ MU2=H<0=]EE2O*]2'YZNKK'N?LS[ZS];W?%DKN%23>/53>"$D"(O)Y"/%8!XJ ME44&O:
<+Z*.NP5,D162%C-YOO]@-ZW=56#*PE@03V7/5L^[:,L=!C;\ GQ&/IZGT3^(O^@G>)DR%2DJAW I M*3(PM\1XP?>C=:,3IM8;Q4[KF5 M8[V4,JVC7&"K&=6Y0)-
O')#DEIZ[>;&OW>6O]M**X&OK2&.5H M'Y;%*CE57;R0LUV5;Q6"S2K?EHX.[$K??@\1_W2TW=T2\;E+HQ7_!HSYT]@J MCJN1+W;M3K2A5C1/*]I(%]I^QO)U=O)V?G4Z?EH(4 ,]
/PAD.07C3)Z"_I*% MF(C22\D9YZQZ=U-]AXO9H!/-TXHVTH6VSX;=<8]]QGG/Y]A0;)]?N ;?64O; MYQ>"]-J"?*@>U<6Y0R?:4"N;EZ/M[8J')TZZ+.YS8'?F9)]_Z/3IC+!_RL8 MQ7 :
(_GA)9FAY('60ZLSKIEVO.X>[LTZCWGE&1[J.9C$V2[<%"2)S>:]# M@2_.+++#WJ*WN#OJRQN3@_Z!?3^T%?V>N&N2MQ.[^.RBZA&2>+0_D6(TXZ:L
MNR:?.&ULM5?;:N,V$/V5@5H466!CW7R14]N XW3;/]0-[&871=$'1AK;1"112]+V MYN\[!3%MVB]:M8/%BG.&NJ^(E9DRU M1($YC8BLW0\9WG%U.^6&KSPAT."K:
&>K[XDY2SZV!)#S#7'&1@\3YT!G[5Q,_M-.!K\9'C1FVUP5!Y$.+1=']Y/AHYG(L(48VU<,']L<8)I:CQ1'\\KITX]IP%N MMY^.]?[#DB>Z.70B1Q(<,Y6]9Z*S6]8$>H8?[%(E?V'367K.1"O
ME!99!;8(.IZ73_:E$F(+X/=> 005(-@'=%\!A!7 *N>6D5E:.TRST4"*#4AC M3=Y,PVICT<2&YR:._RUIE!.C_X0&B&"2YAI$3]>7I,B"4Q$1LM$,2MT-01_M%K8[-KIS_007-
Z@93J4[LIBBTI+'FK"E\7W.M8*+Z>R>QO^YQ>P!Y;]D^"_X MH)9.HAJXFL(W0:AQ%>IU&6KP2JA]N!6Y7BKX)4\P.8*?-./]H,&!2[K5X@7/ MXET'C1YG6+0@!Y#X
7M8P$UPV\P)KAOX6%#.&&=R]#Z;[_B;[QA,E% FU5I MEB<\7[ROQ(8+GE?-=\>$+_UVK%^S\=>CON?WO8&[WF;3.+LY;ZY4P6(<.G2@ M*)1K=$8__>!WO9\,N+5K;NUOYO;)[E%.
<^,U2CISX%?)<@VT#Q ^,"[A(TM7 M;+DG(DV95%"@+'4X*D,90K0E@Q^UVIT]&1H#/5.&3BU#Y__+,$5S?M,8;>1< M2SHI5RR%OU!F_.\(63EUO$C2-C3L=T[:?;@PO_#7[!"'Y'BFXM M1??
K4F!RZA+O'BSOL_VO?WD-LYY9G)[.;>:8S>?&'W#A9VT.KM4V\,[DSJ M44T];J0^I>^Z^?2.$>]\99S^34KSGU3^3TYOGL'^2SW8KZ
M>]P;HSN3N^^]W"N\1O9TR9HCUZ>GM/*WFU/Z[:%]GO9<6EO7)?]46M\AK]7D M7_L"-<=XK@:!BP;!=[IG5(ZW<^S[0;NSOW2/V.U>2'8C?[D@^=]^0WK[)(8' M2>RUHH.
<'EKMIK]DZ&Y=[3.4"UOQ*(C%*M?E+;]^6U=58UM+N"_F94EVR^2"_MYPI2G!/4HP^ [*L&PO=V]R:W-H965T;U,.1;#!NY2OR>$C5'H2E*F_MZ%!A#0V%,\9)5@6+%61)7O[BQRH/1P&"ISO
K +.9H#]3(!5!5@OG<&N NR7 MSN!4 4JZ7FI7B?.PQXL9)0=$)JPR0^5?14M\17DTB4YNB5YB%GV,1_E ^ UI!B+@8Y*;'H5 MDNM2B?F.$@O=D)S'#/EY!%%'O-F[V$ 107R#+.D&F8
M=L=ZEB\(M[KD_+_9_=^>_2095NTS2_'9S_!=I2D)E3F"&%/H<5'7SI?<8\4M M3[!]PC3-F;X_SF8'9N2>8KPV9N28SBG(;X,FAE5C3M3;M7J[5_V2,((!@4X
M!8;^N8'L'NB_74I[>>2E<7P88D\X8D\P[,4KH1!W/]\A#YG]E+_JC.')/.&)/,'(CO9GTF]/Y-7=.:DY1>[>4:V M(?)N.'%F&V*YDX8SVYB1,^VVYK26/NV5'HBG8I)OS]
'R('B5%GT*A(OGH1Q MBN5K\DE[_P':.\OVG1(,F](,G\@LI.]F^]7OKPNA*U0._NO1Y7+4T>^) M0JJL>W[0EU78#:,;)&&ULM9==;]LV%(;_"]$-0P=XT8=E.\YL M
XG5;2V0PHC7[6+8!2,=6T0ITB,I._OW)2E%D6I%B1#UQA(ION\A'Q]2.HL3 M%U]D"]J#00T:97#JI4HU..],$%] M/FR$;KF52T(R8))PA@3LELZU?
Q7Y5F!"_$7@)&OWR"SEGO,OIO$A63]>F1%0 MB)6QP/IRA#50:IST//XK39TJIA'6[Q_=?[.+UXNYQQ+6G/Y-$I4NG4L');## M.55W_/0'E
N:&+^84VE_T:D8.YL[*,ZEXEDIUC/("'NN^*$$41,$P3."H!0$ MKQ6,2\'XM8*P%(263+$4RR'"']\6@I^0,*.UF[FQ,*U:+Y\P\[]OE=!/B=:I MU2>N
,W1+^@.I!)YK')!V!ZM4RSV(!%F"7K_H)-,ZL:["!0F5*(_X4'EF/Z\ M<)6>@C%RXS+<31$N>":<7:"Q-T*!%X3H\S9"[WYLX[+NMMG"X54VT9MM&JL<5UDRMK[A,[[- MY#!)
<0<4*TC0FDLU0I_R[!X$XCNTX9*8#:T)4Z+SU0P:H0T(PA-SB8&IMK0I MXOO%PLQA=5QY%T&X<(]UB)VS-$?]DE3S@&):./@,EB",XJY]^*?>KVTH!S)K M TKH.%W!-
H&L(@W]?'S9]_0ZYQ27WH#F37H32IZDTYZ6SB"P"P&2TNVX2@, MIC4=\0Z0S3E\A 9@TBTXK(]+MNT">B&TQ:\VOZXX?=$-ZA8-Y=9D7*L(_+?F7;=#;WK^6>9-QN>9US(L
M&)\?7&ZM&,I 5S&F])0HYCE315U4]5:%Z[4M]URGX475>ZN+(*+?E!1V6NI=_MS/3K3Q2%9-%0_&!+]WNN=*%F;U-=?(,P _3S'=?E5=DP :IR?O454$L#!!0 M (+"(9UDR? 7"1 ,
,X4 - >&PO?;V)1GZ[>C:]ZS< M.$_HT'^\>/]SD:N;=YZ]GWTX.VL]7M[LQB\,<.D'3M'N :)7K18N#" F'ATF MOD\;D^YM2S=]_ME7WTT^;Y+/,7+L(&^8&*W7.F@M]BR%$0ZJ4AD-
TEQL*B;T M;4!G)AGUG@@?^F/"V40R8*4D8WQEPQT(3',>2T_I4M56VA IGRW@5[RM7G_MA9Z.,'VH%7HG:AM7)T7!5Y\XFXF,VLD?G' T(&N>-\\E>],9 MH%2F.D"E[SU1]=BT&?
DE2?% EVI=3LL4]]PY0<__=IUG5%!)>-.TKOUC7N57 M.PY[;V79?*OL&G9ZK-[;QVZR>PHFHU,P>1(UV3]^DV%_!ZKT^"1F^R]V3?[M7I-!=1)]'+>V#EMUU(-#
[=#_#L=GODGJ31:,*R;]WIPE"14OSEQ:7I&)_F-M M2U^/3VA*%EP]U.#0W!2_T80MLK@>=0<+48W:M+_"]-I1?:+6N9A(Z(FXZHK
M9Q/3]'1#9ZTN(.PBM^9R(QC'8FX$,"P/Y@#C6!:6YW^:3Q^=C\4P;WTGTDAX['0PQM8MBN#'K89Y P:6!S+]W5KC MNXU7R/XZP/9T7X5@,\4K$9LIOM: N-<-
&"'LWFTL#S"P7<.>8!R)8PR!6G37:!0AJQ/!Q[T_V%,2AG'L1@!S.PA##(&G$4 M-8?20$3;8T.P6BP^0"X99K>]9!:GD/KX M8NS3QI@G\KU4VBV2O?>'R\G$Y7M1[.0@-=
[;&EMS#I=U-W,$*7KB]$+Y4 M$SJ=SBZET3!8#WR3XL6]W:\OR;-TC/5?KW!JE%DG:WO@FK)?Y?X;7->0CW[AF MQ// P>013*?PH);;9UO9C3K!IYB M$CQ&$X?NLPWBI?
T_833;K*>J0D2728,T!:VG*4OHV83E8#S+9RY[I M,(ND(VNDP3RK\Z*M=JH0UGT@G_^I0,TA)&:1=&2--)#G'>3IAM=U$.(*2[J^ M1E+,(^G((FDP+P#S03AO]JQ7%A*%+/?
<[H0C(29FDG1DE:RTD_ KDT?+BYKO MRE]N=ZU20D9,).G()@E*,IG*Z"^RVQ R3QE?,KQ@IYAH:US6_Y,.D0V-(9ZB:DY,0$]VZQ)#.4#WO MI0W%M$-C:.=].TM.;H3G4O7J.
<6T0V-H9[(L1 3TPX=63LX9A9B8N:A,?8P M@YBS$!,S#SVJ>>8A)F8>>@SS #0L752]=Y2"N8<>PSU=GC^&F S3#XNAGW>8
M;\$,"Q+#+,1B6"BTY%LDO_N*AYB8A5@,"P68I^2V@I9=_'LZ%6*B1V@Q+-3# M?+C[BUPY)YH-98B)68C%L-#0?K=_'HE9B,6PT%"'U,?$+,1B6.@=Y@?7-7*G M(29F(1;#0H.-7-
AZ,.Q"+(:%WC"O^YAAZ\$P"[$8%AJ,9MAZ9)B%LA@6&CKF MZ*50AEDH:U_=>^<"K&56A1?X2L6U!_M&5DVJW>GVTJD8S=Z2^& M%]TKK.[UVZ>?4$L#!!0 (+"
(9UDI78B@DP$.(8 : >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'/-V4V.@D 0AN&K& Y@6U7X-U%7LW$[\0)$ M6S&"$+HGH[PS,H8
MVP_GPK;T=1&&3>O/MS/[IJN+>%MV![<6VU-Q\$Y'HXGK7F=D]\7KS,'FVOK_M3&SV^^/6?S;,[IJ?XQ^#W4_3G4+I?0]"WHMV*H+>BWDJ@M_9>M@GT5M1;"?
16U%L)I%;46PGT5M1;"?16 MU%L)I%;46PGT5M1;"?0VU-L(I#;4VPCT-M3;"/2VWL<2 KT-]38"O0WU-@*] M#?4V KT-]38"O0WU-@*]#?4V KUSU#LGT#M'O?-WZAWBM?+AV?
-8X_W?276\ M7>N?M[\O'YN]AW#'V<$OC=4O4$L#!!0 (+"(9UF(C*DWI0$ "\9 3 M 6T-O;G1E;G1?5'EP97-=+GAM:,V9S6Z#,:\"$7P5QC8)C.TU_E.32]MKF
MT!=P80DH@"W;29.WKR$_4JL4-4JES@4+O#LS>*7O -.WG2$7;>NJ<;.X\-X\ M,.;2@FKE$FVH"3NYMK7RX=8NF5!2BV)B=%HPE+=>&K\T+<:\7SZ1+E:5SYZ MWH];'KM3-
++94N3AZW!>V7K-8&5.5J?)AGVV:[)O+\."0A,ZNQA6E<8-0$+.S M#NW.SP:'OM<-65MF%"V4]2^J#E5L6S'G=Q6YI%_B3$:=YV5*F4[7=6A)G+&D M,E<0^;I*]J*#?FH?
C_=!VUM5W_]";]=DUJ5S=&?=?)Y]H02P$"% ,4 M " "PB&=9!T%-8H$ "Q $ @ $ 9&]C4')O M<',O87!P+GAM;%!+ 0(4 Q0 (+"(9UFU[R[2[P "L" 1 M " .\ !D;V-0&UL4$L! A0#% @
L(AG68E#42K&PO=V]R:W-H965T&UL4$L! A0#% @ ML(AG691N*-&6!0 "A8 !@ ("\$1@ 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ L(AG62Y"GT%&$X?*50 M !@
("!4#P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L(AG64> ^\N/Y#@ =C !D ("! MF6< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ L(AG661XF]BT$ "%$!D ("!EX$
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L(AG688T;\;D M @ M < !D ("!Z)T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L(AG6:RI4DM^ @ 5P4 !D M ("!I+(
'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ L(AG6>7L2[P?! B0T !D ("!'+P M 'AL+W=O&PO=V]R:W-H965TN @ 9 M " @3/$!X;"]W;W)K&UL4$L! A0#% @
ML(AG659*E]@Z!0 P20 !D ("!>,D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L(AG647+3S?(P M[Q !D ("!5/4 'AL+W=O&PO=V]R:W-H965T#[!X;"]W;W)K&UL4$L!
A0#% @ L(AG69,9/M/H @ RP< !D M ("!Z@P! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ L(AG67Q#3:5Y @ R 8 !D ("!WQ&PO=V]R:W-H965T&UL4$L! A0#% @
L(AG M677Z4U+7!P CD8 !D ("!P4 ! 'AL+W=OQ]8.\$ "-&P &0 M @('/2 $ >&PO=V]R:W-H965T&UL4$L! A0#% @ L(AG63@U^YN(P :@X M !D ("!VE$! 'AL+W=O&PO=V]R:W-
H965T7!E&UL4$L%!@ Q #$ 3@T %9E 0 ! $! end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 246 283 1 false 72 0 false 8 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.avinger.com/20240930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Balance Sheets (Current Period Unaudited) Sheet http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited Condensed Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited Condensed Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited Condensed Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Organization Sheet http://www.avinger.com/20240930/role/statement-note-1-organization Note 1 - Organization Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Inventories Sheet http://www.avinger.com/20240930/role/statement-note-3-inventories Note 3 - Inventories Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Borrowings Sheet http://www.avinger.com/20240930/role/statement-note-4-borrowings Note 4 - Borrowings Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Leases Sheet http://www.avinger.com/20240930/role/statement-note-5-leases Note 5 - Leases Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Stockholders' Equity Sheet http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity Note 7 - Stockholders' Equity Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Stock-based Compensation Sheet http://www.avinger.com/20240930/role/statement-note-8-stock-based-compensation Note 8 - Stock-based Compensation Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Restructuring Charges and Expenses Sheet http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses Note 9 - Restructuring Charges and Expenses Notes 15 false false R16.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 16 false false R17.htm 995460 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies 17 false false R18.htm 995461 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies 18 false false R19.htm 995462 - Disclosure - Note 3 - Inventories (Tables) Sheet http://www.avinger.com/20240930/role/statement-note-3-inventories-tables Note 3 - Inventories (Tables) Tables http://www.avinger.com/20240930/role/statement-note-3-inventories 19 false false R20.htm 995463 - Disclosure - Note 4 - Borrowings (Tables) Sheet http://www.avinger.com/20240930/role/statement-note-4-borrowings-tables Note 4 - Borrowings (Tables) Tables http://www.avinger.com/20240930/role/statement-note-4-borrowings 20 false false R21.htm 995464 - Disclosure - Note 5 - Leases (Tables) Sheet http://www.avinger.com/20240930/role/statement-note-5-leases-tables Note 5 -

Leases (Tables) Tables http://www.avinger.com/20240930/role/statement-note-5-leases 21 false false R22.htm 995465 - Disclosure - Note 7 - Stockholders' Equity (Tables) Sheet http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables Note 7 - Stockholders' Equity (Tables) Tables http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity 22 false false R23.htm 995466 - Disclosure - Note 8 - Stock-based Compensation (Tables) Sheet http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables Note 8 - Stock-based Compensation (Tables) Tables http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation 23 false false R24.htm 995467 - Disclosure - Note 1 - Organization (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual Note 1 - Organization (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-1-organization 24 false false R25.htm 995468 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables 25 false false R26.htm 995469 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Sheet http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Details 26 false false R27.htm 995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Sheet http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Details 27 false false R28.htm 995471 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 28 false false R29.htm 995472 - Disclosure - Note 3 - Inventories - Schedule of Inventory (Details) Sheet http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details Note 3 - Inventories - Schedule of Inventory (Details) Details 29 false false R30.htm 995473 - Disclosure - Note 4 - Borrowings (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual Note 4 - Borrowings (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-4-borrowings-tables 30 false false R31.htm 995474 - Disclosure - Note 4 - Borrowings - Schedule of Debt (Details) Sheet http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details Note 4 - Borrowings - Schedule of Debt (Details) Details 31 false false R32.htm 995475 - Disclosure - Note 5 - Leases (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual Note 5 - Leases (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-5-leases-tables 32 false false R33.htm 995476 - Disclosure - Note 5 - Leases - Future Operating Lease Payments (Details) Sheet http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details Note 5 - Leases - Future Operating Lease Payments (Details) Details 33 false false R34.htm 995477 - Disclosure - Note 5 - Leases - ROU Assets and Lease Liabilities (Details) Sheet http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details Note 5 - Leases - ROU Assets and Lease Liabilities (Details) Details 34 false false R35.htm 995478 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies 35 false false R36.htm 995479 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual Note 7 - Stockholders' Equity (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables 36 false false R37.htm 995480 - Disclosure - Note 7 - Stockholder's Equity - Outstanding Warrants (Details) Sheet http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details Note 7 - Stockholder's Equity - Outstanding Warrants (Details) Details 37 false false R38.htm 995481 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual Note 8 - Stock-based Compensation (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables 38 false false R39.htm 995482 - Disclosure - Note 8 - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details Note 8 - Stock-Based Compensation - Stock Option Activity (Details) Details 39 false false R40.htm 995483 - Disclosure - Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) Sheet http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) Details 40 false false R41.htm 995484 - Disclosure - Note 9 - Restructuring Charges and Expenses (Details Textual) Sheet http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual Note 9 - Restructuring Charges and Expenses (Details Textual) Details http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses 41 false false All Reports Book All Reports avgr-20240930.xsd avgr-20240930_cal.xml avgr-20240930_def.xml avgr-20240930_lab.xml avgr-20240930_pre.xml avgr20240930_10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "avgr20240930_10q.htm": { "nsprefix": "avgr", "nsuri": "http://www.avinger.com/20240930", "dts": { "schema": { "local": ["avgr-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["avgr-20240930_cal.xml"] }, "definitionLink": { "local": ["avgr-20240930_def.xml"] }, "labelLink": { "local": ["avgr-20240930_lab.xml"] }, "presentationLink": { "local": ["avgr-20240930_pre.xml"] }, "inline": { "local": ["avgr20240930_10q.htm"] } }, "keyStandard": 219, "keyCustom": 64, "axisStandard": 22, "axisCustom": 0, "memberStandard": 23, "memberCustom": 46, "hidden": { "total": 36, "http://fasb.org/us-gaap/2024": 14, "http://www.avinger.com/20240930": 13, "http://xbrl.sec.gov/dei/2024": 5, "http://xbrl.sec.gov/ecd/2024": 4 }, "contextCount": 246, "entityCount": 1, "segmentCount": 72, "elementCount": 440, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 752, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.avinger.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R3": { "role": "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited", "longName": "003 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "longName": "004 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Condensed Statements of Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R6": { "role": "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited", "longName": "005 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R7": { "role": "http://www.avinger.com/20240930/role/statement-note-1-organization", "longName": "006 - Disclosure - Note 1 - Organization", "shortName": "Note 1 - Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.avinger.com/20240930/role/statement-note-3-inventories", "longName": "008 - Disclosure - Note 3 - Inventories", "shortName": "Note 3 - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true,

"unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "longName": "009 - Disclosure - Note 4 - Borrowings", "shortName": "Note 4 - Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.avinger.com/20240930/role/statement-note-5-leases", "longName": "010 - Disclosure - Note 5 - Leases", "shortName": "Note 5 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "longName": "011 - Disclosure - Note 6 - Commitments and Contingencies", "shortName": "Note 6 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "longName": "012 - Disclosure - Note 7 - Stockholders' Equity", "shortName": "Note 7 - Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "longName": "013 - Disclosure - Note 8 - Stock-based Compensation", "shortName": "Note 8 - Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses", "longName": "014 - Disclosure - Note 9 - Restructuring Charges and Expenses", "shortName": "Note 9 - Restructuring Charges and Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995460 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "995461 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StandardProductWarrantyPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StandardProductWarrantyPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.avinger.com/20240930/role/statement-note-3-inventories-tables", "longName": "995462 - Disclosure - Note 3 - Inventories (Tables)", "shortName": "Note 3 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.avinger.com/20240930/role/statement-note-4-borrowings-tables", "longName": "995463 - Disclosure - Note 4 - Borrowings (Tables)", "shortName": "Note 4 - Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.avinger.com/20240930/role/statement-note-5-leases-tables", "longName": "995464 - Disclosure - Note 5 - Leases (Tables)", "shortName": "Note 5 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables", "longName": "995465 - Disclosure - Note 7 - Stockholders' Equity (Tables)", "shortName": "Note 7 - Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables", "longName": "995466 - Disclosure - Note 8 - Stock-based Compensation (Tables)", "shortName": "Note 8 - Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "longName": "995467 - Disclosure - Note 1 - Organization (Details Textual)", "shortName": "Note 1 - Organization (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_ConversionOfStockByUniqueDescriptionAxis-ExchangeOfSeriesAPreferredStockIntoSeriesA1PreferredStockMember", "name": "avgr:GainLossOnConvertiblePreferredStockConvertedToOtherSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:NatureOfOperations", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R25": { "role": "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995468 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-OneCustomerMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "avgr:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-OneCustomerMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "avgr:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "longName": "995469 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details)", "shortName": "Note 2 - Summary of Significant Accounting

Policies - Product Warranty (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "longName": "995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "longName": "995471 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details", "longName": "995472 - Disclosure - Note 3 - Inventories - Schedule of Inventory (Details)", "shortName": "Note 3 - Inventories - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "longName": "995473 - Disclosure - Note 4 - Borrowings (Details Textual)", "shortName": "Note 4 - Borrowings (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-05-16_2024-05-16_DebtConversionByUniqueDescriptionAxis-ConversionOfCRGLoanIntoSeriesEConvertiblePreferredStockMember", "name": "us-gaap:DebtConversionOriginalDebtAmount1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R31": { "role": "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details", "longName": "995474 - Disclosure - Note 4 - Borrowings - Schedule of Debt (Details)", "shortName": "Note 4 - Borrowings - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "i_2024-09-30_CreditFacilityAxis-LoanAgreementMember_LineOfCreditFacilityAxis-CRGMember", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_CreditFacilityAxis-LoanAgreementMember_LineOfCreditFacilityAxis-CRGMember", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual", "longName": "995475 - Disclosure - Note 5 - Leases (Details Textual)", "shortName": "Note 5 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R33": { "role": "http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details", "longName": "995476 - Disclosure - Note 5 - Leases - Future Operating Lease Payments (Details)", "shortName": "Note 5 - Leases - Future Operating Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details", "longName": "995477 - Disclosure - Note 5 - Leases - ROU Assets and Lease Liabilities (Details)", "shortName": "Note 5 - Leases - ROU Assets and Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual", "longName": "995478 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)", "shortName": "Note 6 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2024-09-30_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "longName": "995479 - Disclosure - Note 7 - Stockholders' Equity (Details Textual)", "shortName": "Note 7 - Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-08-08_2024-08-08_ClassOfWarrantOrRightAxis-SeriesBPreferredInvestmentOptionPurchaseWarrantsMember", "name": "avgr:ClassOfWarrantOrRightWarrantsExpired", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R37": { "role": "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details", "longName": "995480 - Disclosure - Note 7 - Stockholder's Equity - Outstanding Warrants (Details)", "shortName": "Note 7 - Stockholder's Equity - Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_ClassOfWarrantOrRightAxis-Series1February2018WarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R38": { "role": "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "longName": "995481 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)", "shortName": "Note 8 - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:SharePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R39": { "role": "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details", "longName": "995482 - Disclosure - Note 8 - Stock-Based Compensation - Stock Option Activity (Details)", "shortName": "Note 8 - Stock-Based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R40": { "role": "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-

espp-and-rsus-details", "longName": "995483 - Disclosure - Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details)", "shortName": "Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_IncomeStatementLocationAxis-CostOfSalesMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "unique": true } }, "R41": { "role": "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual", "longName": "995484 - Disclosure - Note 9 - Restructuring Charges and Expenses (Details Textual)", "shortName": "Note 9 - Restructuring Charges and Expenses (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2024-06-01_2024-06-30", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-06-01_2024-06-30", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "avgr20240930_10q.htm", "first": true, "unique": true } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r34", "r558"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r509"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for doubtful accounts of $56 and $41 at September 30, 2024 and December 31, 2023, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r614"] }, "avgr_AccretionOfPreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "AccretionOfPreferredStockDividends", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Accretion of preferred stock dividends", "documentation": "Value of accretion of preferred stock dividends." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r37"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r47"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r420", "r602", "r603", "r604", "r605", "r657", "r708"] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Net share settlement of restricted stock awards in satisfaction of tax obligations", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "negatedLabel": "Accretion of preferred stock dividends", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": ["r7", "r72"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Employee stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r29", "r30", "r269"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "negatedTerseLabel": "Issuance of common stock in public offerings, net of commissions and issuance costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r7", "r72"] }, "avgr_AdjustmentsToAdditionalPaidInCapitalWaiverOfDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalWaiverOfDividendsInExcessOfRetainedEarnings", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Waiver of Series A preferred stock dividends", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from waiver of dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "avgr_AdvisorWarrantsIssuedInTheMarch2024FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "AdvisorWarrantsIssuedInTheMarch2024FinancingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Advisor Warrants Issued In The March 2024 Financing [Member]", "documentation": "Advisor Warrants Issued In The March 2024 Financing" } } }, "auth_ref": [] }, "avgr_AgreementToPurchaseCommonStockMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "AgreementToPurchaseCommonStockMaximumAmount", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_AgreementToPurchaseCommonStockMaximumAmount", "terseLabel": "Agreement to Purchase Common Stock, Maximum Amount", "documentation": "The maximum amount of the company's stock under agreement to be purchased." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details"], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r297", "r302"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r104", "r174", "r178"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfDebtDiscountPremium", "terseLabel": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r4", "r59", "r239", "r663"] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [

"http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs and debt discount", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r239", "r543", "r544", "r598", "r663"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Potentially dilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r145"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r16"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r16"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r314"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r75", "r85", "r100", "r120", "r148", "r152", "r166", "r167", "r175", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r315", "r317", "r333", "r393", "r457", "r535", "r536", "r558", "r581", "r625", "r626", "r668"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r96", "r106", "r120", "r175", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r315", "r317", "r333", "r558", "r625", "r626", "r668"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r65"] }, "avgr_CRGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CRGMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "CRG [Member]", "documentation": "Represents information about CRG." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r11", "r98", "r524"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r62", "r116"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r62"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "auth_ref": [] }, "avgr_ChangeInRightofuseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ChangeInRightofuseAsset", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Change in right of use asset", "documentation": "The amount of change in right-of-use asset during the period." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r93", "r101", "r102", "r103", "r120", "r138", "r139", "r142", "r144", "r150", "r151", "r175", "r208", "r210", "r211", "r212", "r215", "r216", "r247", "r248", "r251", "r254", "r260", "r333", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r445", "r466", "r484", "r502", "r503", "r504", "r505", "r506", "r590", "r599", "r606"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r25"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical

option is measured in months." } } }, "auth_ref": [] }, "avgr_ClassOfWarrantOrRightExercisePercentageOfSharesIssuedInEquityOffering": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ClassOfWarrantOrRightExercisePercentageOfSharesIssuedInEquityOffering", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ClassOfWarrantOrRightExercisePercentageOfSharesIssuedInEquityOffering", "terseLabel": "Class of Warrant or Right, Exercise Percentage of Shares Issued in Equity Offering", "documentation": "Percentage of share issued in equity offering for exercise of the warrants or rights." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r261"] }, "avgr_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice", "terseLabel": "Class of Warrant or Right, Expired During Period, Exercise Price", "documentation": "Exercise price per share of warrants or rights cancelled during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Underlying Shares of Common Stock (in shares)", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r261"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Total Outstanding and Exercisable (in shares)", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "avgr_ClassOfWarrantOrRightWarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ClassOfWarrantOrRightWarrantsExpired", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ClassOfWarrantOrRightWarrantsExpired", "terseLabel": "Class of Warrant or Right Warrants Expired", "documentation": "Represents class of warrant or right warrants expired." } } }, "auth_ref": [] }, "avgr_ClassOfWarrantsOrRightsExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ClassOfWarrantsOrRightsExercisedDuringPeriod", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ClassOfWarrantsOrRightsExercisedDuringPeriod", "terseLabel": "Class of Warrant or Right, Exercised (in shares)", "documentation": "Number of warrants exercised during period." } } }, "auth_ref": [] }, "avgr_CommissionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CommissionPercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_CommissionPercentage", "terseLabel": "Commission Percentage", "documentation": "Represents commission percentage." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r43", "r79", "r394", "r444"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r69", "r195", "r196", "r510", "r616", "r621"] }, "avgr_CommonStockInJune2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CommonStockInJune2022Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock in June, 2022 [Member]", "documentation": "Represents common stock in June 2022." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r571", "r572", "r573", "r575", "r576", "r577", "r578", "r602", "r603", "r605", "r657", "r707", "r708"] }, "avgr_CommonStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CommonStockOptionsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Common Stock Options [member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r46"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r46", "r445"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued (in shares)", "terseLabel": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r46"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r46", "r445", "r463", "r708", "r709"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, par value of $0.001; Shares authorized: 100,000,000 at September 30, 2024 and December 31, 2023; Shares issued and outstanding: 2,783,891 and 1,279,928 at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r46", "r396", "r558"] }, "avgr_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CommonStockWarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Represents information about common stock warrants." } } }, "auth_ref": [] }, "avgr_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CommonWarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common Warrants [Member]", "documentation": "Represents the common warrants" } } }, "auth_ref": [] }, "avgr_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block]", "documentation": "Disclosure of accounting policies for credit risk and other risks and uncertainties." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r18", "r19", "r31", "r32", "r172", "r509"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r18", "r19", "r31", "r32", "r172", "r413", "r509"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic,

customer, employees, supplier, lender." } } }, "auth_ref": ["r18", "r19", "r31", "r32", "r172", "r509", "r592"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r18", "r19", "r31", "r32", "r172"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r18", "r19", "r31", "r32", "r172", "r509"] }, "avgr_ConversionOfCRGLoanIntoSeriesEConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ConversionOfCRGLoanIntoSeriesEConvertiblePreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Conversion of CRG Loan Into Series E Convertible Preferred Stock [Member]", "documentation": "Relating to conversion of CRG loan into Series E Convertible Preferred Stock," } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": ["r12", "r13", "r14"] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockNameDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": ["r12", "r13", "r14"] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesConverted1", "terseLabel": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r12", "r13", "r14"] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesIssued1", "terseLabel": "Conversion of Stock, Shares Issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r12", "r13", "r14"] }, "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage", "terseLabel": "Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage", "documentation": "Represents conversion of warrants allowed maximum ownership of common stock percentage." } } }, "auth_ref": [] }, "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection", "terseLabel": "Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election", "documentation": "Represents conversion of warrants allowed maximum ownership of common stock percentage upon election." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Cost of revenues", "label": "us-gaap_CostOfRevenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r56", "r120", "r175", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r333", "r535", "r625"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details"], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r207", "r623"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r207", "r623", "r624"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r66", "r172"] }, "avgr_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CustomerOneMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer, One [Member]", "documentation": "Represents one of the major customers." } } }, "auth_ref": [] }, "avgr_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "CustomerTwoMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer, Two [Member]", "documentation": "Represents Customer Two." } } }, "auth_ref": [] }, "avgr_DebtAgreementMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtAgreementMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtAgreementMaximumBorrowingCapacity", "terseLabel": "Debt Agreement, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under a debt agreement on the amount that could be borrowed with a combination of, but not limited to, a line of credit and term loan." } } }, "auth_ref": [] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": ["r12", "r14"] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Conversion of CRG loan principal and accrued interest into Series H convertible preferred stock", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r12", "r14"] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": ["r12", "r14"] }, "avgr_DebtConversionFeesAndPrepaymentPremiumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtConversionFeesAndPrepaymentPremiumAmount", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtConversionFeesAndPrepaymentPremiumAmount", "terseLabel": "Debt Conversion, Fees and Prepayment Premium Amount", "documentation": "The amount of related back-end fees and prepayment premium being converted together with the original debt in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionNameDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r12", "r14"] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r12", "r14"] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying

arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r70", "r117", "r183", "r184", "r185", "r186", "r187", "r206", "r207", "r217", "r223", "r224", "r225", "r226", "r227", "r228", "r233", "r240", "r241", "r242", "r343"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r8", "r36", "r37", "r76", "r78", "r121", "r218", "r219", "r220", "r221", "r222", "r224", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r540", "r541", "r542", "r543", "r544", "r555", "r600", "r617", "r618", "r619", "r662", "r664"] }, "avgr_DebtInstrumentBorrowingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentBorrowingPeriod", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentBorrowingPeriod", "terseLabel": "Debt Instrument, Borrowing Period", "documentation": "Period for borrowing under the debt instrument." } } }, "auth_ref": [] }, "avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum", "terseLabel": "Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum", "documentation": "The minimum amount of cash and certain cash equivalents the entity is required to maintain under the terms of the debt agreement." } } }, "auth_ref": [] }, "avgr_DebtInstrumentCovenantComplianceMinimumLiquidityRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentCovenantComplianceMinimumLiquidityRequirement", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentCovenantComplianceMinimumLiquidityRequirement", "terseLabel": "Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement", "documentation": "The minimum amount of liquidity required at all times for compliance with the debt instrument covenant." } } }, "auth_ref": [] }, "avgr_DebtInstrumentCumulativePaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentCumulativePaidInKindInterest", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Less: Amount of PIK additions and final facility fee to be incurred subsequent to June 30, 2024", "documentation": "Cumulative paid-in-kind interest treated as additional principal and added to the total carrying amount of the debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r218", "r343", "r344", "r541", "r542", "r555"] }, "avgr_DebtInstrumentFinalFacilityFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentFinalFacilityFeePercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentFinalFacilityFeePercentage", "terseLabel": "Debt Instrument, Final Facility Fee Percentage", "documentation": "The facility fee payable at the end of the debt instrument term or upon prepayment in full, as a percentage of the amount borrowed." } } }, "auth_ref": [] }, "avgr_DebtInstrumentFinancingFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentFinancingFeePercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentFinancingFeePercentage", "terseLabel": "Debt Instrument, Financing Fee Percentage", "documentation": "The debt instrument fee required on the borrowing date for each tranche of borrowing, as a percentage of the principal amount borrowed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r39", "r219"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r8", "r121", "r218", "r219", "r220", "r221", "r222", "r224", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r540", "r541", "r542", "r543", "r544", "r555", "r600", "r617", "r618", "r619", "r662", "r664"] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r8", "r33"] }, "avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage", "terseLabel": "Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage", "documentation": "The annual decline in the premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument." } } }, "auth_ref": [] }, "avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage", "terseLabel": "Debt Instrument, Redemption Initial Prepayment Premium Percentage", "documentation": "The initial premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Less: Amount representing debt issuance costs", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r229", "r243", "r342", "r343", "r344", "r541", "r542", "r555"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r148", "r156", "r167", "r535", "r536"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r268", "r270", "r298", "r299", "r301", "r549"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-3-inventories", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-5-leases", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Preferred stock dividends payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r37"] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsPreferredStock", "terseLabel": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": ["r2", "r72"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r585"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r586"] },

"dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel":
"Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the
supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-
operations-and-comprehensive-loss-unaudited", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-
details"], "lang": { "en-us": { "role": { "label": "Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)", "documentation": "The
amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r112", "r127", "r128",
"r129", "r130", "r131", "r132", "r136", "r138", "r142", "r143", "r144", "r147", "r310", "r313", "r327", "r328", "r391", "r402", "r529"] }, "us-
gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock",
"presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share,
Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock
and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account
stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } },
"auth_ref": ["r16", "r17", "r146"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-
period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-
condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Total of the carrying values as of
the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and
bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } },
"auth_ref": ["r37"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement,
Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment
arrangement." } } }, "auth_ref": ["r300"] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment
Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition","documentation": "Weighted-average period over which cost not yet recognized is
expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one
year, five months, and thirteen days." } } }, "auth_ref": ["r300"] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-
information"], "lang": { "en-us": { "role": { "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1
such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-
information"], "lang": { "en-us": { "role": { "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or
Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressPostalZipCode", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": {
"label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince",
"presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label":
"dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation":
"A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r583"] },
"dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": {
"role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number
of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic
report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or
Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus",
"terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have
been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related
disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain",
"presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited",
"http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals",
"http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-
statements-of-operations-and-comprehensive-loss-unaudited", "http://www.avinger.com/20240930/role/statement-document-and-entity-information",
"http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-
summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-
policies-details-textual", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20240930/role/statement-note-3-
inventories", "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details", "http://www.avinger.com/20240930/role/statement-note-
3-inventories-tables", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-
details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details", "http://www.avinger.com/20240930/role/statement-note-
4-borrowings-tables", "http://www.avinger.com/20240930/role/statement-note-5-leases", "http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual",
"http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details", "http://www.avinger.com/20240930/role/statement-note-5-
leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-tables",
"http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-
contingencies-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-
stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details",
"http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-
compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-
note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details",
"http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20240930/role/statement-note-
8-stockbased-compensation-tables", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses",
"http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual", "http://www.avinger.com/20240930/role/statement-
significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in
a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies,
grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." }
} }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityEmergingGrowthCompany", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": {
"label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r583"] },
"dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity
File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8
digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype":
"filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.avinger.com/20240930/role/statement-
document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the
following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information
should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r583"] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": {
"role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } },
"auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent",
"presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label":
"dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files)." } } }, "auth_ref": ["r589"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-
information"], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity
filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r583"] }, "dei_EntityShellCompany": { "xbrltype":

"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r583"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r583"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r583"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r94", "r109", "r110", "r111", "r122", "r123", "r124", "r126", "r131", "r133", "r135", "r149", "r176", "r177", "r181", "r263", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r334", "r335", "r336", "r337", "r338", "r339", "r345", "r347", "r355", "r401", "r407", "r408", "r409", "r420", "r484"] }, "avgr_EquityOfferingCashFeePercentageOfGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "EquityOfferingCashFeePercentageOfGrossProceeds", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_EquityOfferingCashFeePercentageOfGrossProceeds", "terseLabel": "Equity Offering, Cash Fee, Percentage of Gross Proceeds", "documentation": "Percentage of gross proceeds for cash fee of the equity offering." } } }, "auth_ref": [] }, "avgr_ExchangeOfSeriesAPreferredStockIntoSeriesA1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ExchangeOfSeriesAPreferredStockIntoSeriesA1PreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Exchange of Series A Preferred Stock Into Series A-1 Preferred Stock [Member]", "documentation": "Represents the exchange of Series A preferred stock into Series A-1 preferred stock." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "avgr_FirstTrancheBorrowedOnSeptember222015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "FirstTrancheBorrowedOnSeptember222015Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "First Tranche, Borrowed on September 22, 2015 [Member]", "documentation": "Represents information about first tranche, borrowed on September 22, 2015." } } }, "auth_ref": [] }, "avgr_GainLossOnConvertiblePreferredStockConvertedToOtherSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "GainLossOnConvertiblePreferredStockConvertedToOtherSecurities", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Gain on exchange of Series A for Series A-1 convertible preferred stock", "terseLabel": "Gain (Loss) On Convertible Preferred Stock Converted to Other Securities", "documentation": "The gain (loss) on the value of convertible preferred stock that was converted to other securities." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r55", "r56", "r84", "r120", "r175", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r333", "r531", "r535", "r608", "r610", "r611", "r612", "r613", "r625"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r182", "r188", "r192", "r330", "r331", "r332", "r404", "r406", "r469", "r522", "r550", "r679"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r188", "r192", "r330", "r331", "r332", "r404", "r406", "r469", "r522", "r550", "r679"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r597"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "terseLabel": "Accrued compensation", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r597"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities", "terseLabel": "Other long-term liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "avgr_IncreaseDecreaseRightOfUseAssetAndLeaseholdLiabilityArisingFromLeaseAmendment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "IncreaseDecreaseRightOfUseAssetAndLeaseholdLiabilityArisingFromLeaseAmendment", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Increase to right of use asset and leasehold liability arising from lease amendment", "documentation": "The increase or decrease in value related to the right of use assets and

leasehold liability arising from lease amendment." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r587"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense, net", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r148", "r152", "r155", "r157", "r167", "r341", "r535", "r536"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r59", "r237", "r245", "r543", "r544"] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-3-inventories"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r179"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Finished products", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r68", "r526"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Total inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r105", "r525", "r558"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r68", "r528"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Work-in-process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r68", "r527"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Provision for excess and obsolete inventories", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r180"] }, "avgr_June2024OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "June2024OfferingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "June 2024 Offering [Member]", "documentation": "Represents June 2024 offering." } } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.avinger.com/20240930/role/statement-document-and-entity-information", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20240930/role/statement-note-3-inventories", "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details", "http://www.avinger.com/20240930/role/statement-note-3-inventories-tables", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-tables", "http://www.avinger.com/20240930/role/statement-note-5-leases", "http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual", "http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-tables", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual", "http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": ["r556"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-tables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r667"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual", "http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r353"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2024 (remaining three months of the year)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r353"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r353"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r353"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r666"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r346"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities",

"crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r8", "r36", "r37", "r38", "r41", "r42", "r43", "r44", "r120", "r175", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r316", "r317", "r318", "r333", "r443", "r530", "r581", "r625", "r668", "r669"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r51", "r80", "r398", "r558", "r601", "r615", "r661"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r38", "r97", "r120", "r175", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r316", "r317", "r318", "r333", "r558", "r625", "r668", "r669"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "avgr_LicenseAgreementRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LicenseAgreementRenewalTerm", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_LicenseAgreementRenewalTerm", "terseLabel": "License Agreement, Renewal Term", "documentation": "Period for renewal of license agreement." } } }, "auth_ref": [] }, "avgr_LicenseAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LicenseAgreementTerm", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_LicenseAgreementTerm", "terseLabel": "License Agreement, Term", "documentation": "The term of a license agreement." } } }, "auth_ref": [] }, "avgr_LicenseAndDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LicenseAndDistributionAgreementMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "License and Distribution Agreement [Member]", "documentation": "Related to license and distribution agreement." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r35", "r40", "r600", "r623", "r624"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r35", "r40", "r600", "r623"] }, "avgr_LoanAgreementAmendmentNo10Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LoanAgreementAmendmentNo10Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Loan Agreement Amendment No 10 [Member]", "documentation": "Represents loan agreement amendment number 10." } } }, "auth_ref": [] }, "avgr_LoanAgreementAmendmentNo7Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LoanAgreementAmendmentNo7Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Loan Agreement Amendment No. 7 [Member]", "documentation": "Represents Loan Agreement No. 7." } } }, "auth_ref": [] }, "avgr_LoanAgreementAmendmentNo8Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LoanAgreementAmendmentNo8Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Loan Agreement Amendment No 8 [Member]", "documentation": "Represents loan agreement amendment number 8." } } }, "auth_ref": [] }, "avgr_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LoanAgreementMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Loan Agreement [Member]", "documentation": "Represents information about Term Loan Agreement (Loan Agreement)." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r8", "r78", "r230", "r244", "r541", "r542", "r555", "r677"] }, "avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LongTermDebtMaturitiesRepaymentsOfInterestInYearFive", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFive", "terseLabel": "Long Term Debt Maturities, Repayments of Interest in Year Five", "documentation": "Amount of interest payments on long-term debt sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "LongTermDebtMaturitiesRepaymentsOfInterestInYearFour", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_LongTermDebtMaturitiesRepaymentsOfInterestInYearFour", "terseLabel": "Long Term Debt Maturities, Repayments of Interest in Year Four", "documentation": "Amount of interest payments on long-term debt sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "2024 (remaining three months of the year)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r121", "r235"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "2028", "terseLabel": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r121", "r235"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "2027", "terseLabel": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r121", "r235"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r121", "r235"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r121", "r235"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r8", "r617", "r618", "r619"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper,

asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r8", "r23", "r617", "r618", "r619"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r172", "r547", "r567", "r570", "r629", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706"] }, "avgr_March2024OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "March2024OfferingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "March 2024 Offering [Member]", "documentation": "March 2024 Offering" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r267", "r303", "r329", "r359", "r403", "r405", "r412", "r435", "r436", "r489", "r492", "r496", "r497", "r499", "r520", "r521", "r539", "r545", "r548", "r551", "r552", "r553", "r568", "r627", "r670", "r671", "r672", "r673", "r674", "r675"] }, "avgr_MilestonePaymentAdditionalAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "MilestonePaymentAdditionalAuthorizedAmount", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_MilestonePaymentAdditionalAuthorizedAmount", "terseLabel": "Milestone Payment, Additional Authorized Amount", "documentation": "The additional authorized amount of milestone payment to be made." } } }, "auth_ref": [] }, "avgr_MilestonePaymentMinimumRevenueRequired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "MilestonePaymentMinimumRevenueRequired", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_MilestonePaymentMinimumRevenueRequired", "terseLabel": "Milestone Payment, Minimum Revenue Required", "documentation": "The minimum amount of revenue required for milestone payment." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r267", "r303", "r329", "r359", "r403", "r405", "r412", "r435", "r436", "r489", "r492", "r496", "r497", "r499", "r520", "r521", "r539", "r545", "r548", "r551", "r552", "r553", "r568", "r627", "r670", "r671", "r672", "r673", "r674", "r675"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r588"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": ["r172", "r547", "r567", "r570", "r629", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r87", "r92"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r115"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r115"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r62", "r63", "r64"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 0.0 }, "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss and comprehensive loss", "terseLabel": "Net and comprehensive loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r57", "r64", "r81", "r95", "r107", "r108", "r111", "r120", "r125", "r127", "r128", "r129", "r130", "r131", "r134", "r135", "r140", "r175", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r310", "r313", "r328", "r333", "r400", "r465", "r482", "r483", "r579", "r625"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Net loss applicable to common stockholders", "totalLabel": "Net loss applicable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": ["r113", "r127", "r128", "r129", "r130", "r136", "r137", "r141", "r144", "r313"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r588"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r588"] }, "avgr_NoncashInterestExpenseIncomeAndOtherChargesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "NoncashInterestExpenseIncomeAndOtherChargesNet", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Noncash interest expense and other charges", "documentation": "The amount of noncash interest expense (income) and other charges, net." } } }, "auth_ref": [] }, "avgr_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "avgr_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "avgr_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "NumberOfMajorCustomers", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers", "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A

reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r532", "r538", "r609"] }, "avgr_NumberOfWarrantsIssuedPerUnit": { "xbrltype": "integerItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "NumberOfWarrantsIssuedPerUnit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_NumberOfWarrantsIssuedPerUnit", "terseLabel": "Number of Warrants Issued Per Unit", "documentation": "The number of warrants issued per unit." } } }, "auth_ref": [] }, "avgr_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "OneCustomerMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "One Customer [Member]", "documentation": "Information related to one customer." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r84", "r531", "r608", "r610", "r611", "r612", "r613"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseCost", "terseLabel": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r350", "r557"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r665"] }, "avgr_OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly", "terseLabel": "Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly", "documentation": "Represents information related to operating expense excluding maintenance fee and other expenses on a monthly basis." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "Leasehold liability as of June 30, 2024", "terseLabel": "Total lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r349"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "Leasehold liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r349"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "Leasehold liability, long-term portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r349"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "verboseLabel": "Right of use asset", "label": "Operating lease", "terseLabel": "Total right of use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r348"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense", "terseLabel": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r598"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r352", "r557"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r99"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r42"] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNoncashIncomeExpense", "negatedTerseLabel": "Other non-cash charges", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r64"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r60"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r10"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Net share settlement on restricted stock awards in satisfaction of tax obligations", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r114"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r61"] }, "avgr_PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Placement Agent Private Investment Options Issued in August 2022 Financing [Member]", "documentation": "Relating to Placement Agent Private Investment Options Issued in August 2022 Financing" } } }, "auth_ref": [] }, "avgr_PlacementAgentWarrantsIssuedInJune2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PlacementAgentWarrantsIssuedInJune2024Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants Issued in June 2024 [Member]", "documentation": "Represents Placement Agent Warrants Issued in June 2024." } } }, "auth_ref": [] }, "avgr_PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Placement agent warrants issued in the January 2022 financing [Member]", "documentation": "Represents placement agent warrants issued in the January 2022 financing." } } }, "auth_ref": [] }, "avgr_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PlacementAgentWarrantsMember", "presentation": [

"http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]", "documentation": "Represents Placement Agent Warrants." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "avgr_PreFundedSeriesA1SeriesA2SeriesA3AndPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PreFundedSeriesA1SeriesA2SeriesA3AndPlacementAgentWarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Pre-Funded, Series A-1, Series A-2, Series A-3 and Placement Agent Warrants [Member]", "documentation": "Represents Pre-Funded, Series A-1, Series A-2, Series A-3 and Placement Agent Warrants ." } } }, "auth_ref": [] }, "avgr_PreferredStockConvertibleBeneficialOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PreferredStockConvertibleBeneficialOwnershipPercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_PreferredStockConvertibleBeneficialOwnershipPercentage", "terseLabel": "Preferred Stock, Convertible, Beneficial Ownership Percentage", "documentation": "Represents the beneficial ownership percentage of convertible preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionPrice", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionPrice", "terseLabel": "Preferred Stock, Convertible, Conversion Price (in dollars per share)", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": ["r249"] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionRatio", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionRatio", "terseLabel": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": ["r249"] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleSharesIssuable", "terseLabel": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": ["r249"] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockDividendRatePercentage", "terseLabel": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": ["r248", "r490", "r493", "r495", "r500"] }, "avgr_PreferredStockDividendRatePercentageThereafterThirdAnniversaryOfIssuance": { "xbrltype": "percentItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PreferredStockDividendRatePercentageThereafterThirdAnniversaryOfIssuance", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_PreferredStockDividendRatePercentageThereafterThirdAnniversaryOfIssuance", "terseLabel": "Preferred Stock Dividend Rate, Percentage, Thereafter Third Anniversary Of Issuance", "documentation": "The percentage rate used to calculate dividend payments on preferred stock after the third anniversary of their issuance." } } }, "auth_ref": [] }, "avgr_PreferredStockExcessFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PreferredStockExcessFairValue", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_PreferredStockExcessFairValue", "terseLabel": "Preferred Stock, Excess Fair Value", "documentation": "Represents the excess fair value of preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreferenceValue", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference, Value", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares." } } }, "auth_ref": ["r118", "r251", "r262"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r571", "r572", "r575", "r576", "r577", "r578", "r707", "r708"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r45", "r247"] }, "avgr_PreferredStockParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PreferredStockParValue", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_PreferredStockParValue", "terseLabel": "Preferred Stock, Par Value", "documentation": "The par value of preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r45", "r445"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued (in shares)", "terseLabel": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r45", "r247"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r45", "r445", "r463", "r708", "r709"] }, "avgr_PreferredStockStatedValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PreferredStockStatedValue", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_PreferredStockStatedValue", "terseLabel": "Preferred Stock, Stated Value", "documentation": "The stated value of preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Preferred stock issuable in series, par value of $0.001; Shares authorized: 5,000,000 at September 30, 2024 and December 31, 2023; Shares issued and outstanding: 30,229 and 62,881 at September 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $18,338 and $62,796 at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r45", "r395", "r558"] }, "avgr_PrefundedWarrantsIssuedInJune2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PrefundedWarrantsIssuedInJune2024Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Prefunded Warrants Issued in June 2024 [Member]", "documentation": "Represents prefunded warrants issued in June 2024." } } }, "auth_ref": [] }, "avgr_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PrefundedWarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Pre-funded Warrants [Member]", "documentation": "Represents prefunded warrants." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r595"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-

cash-flows-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "avgr_ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ProceedsFromIssuanceOfCommonStockNet", "terseLabel": "Proceeds from Issuance of Common Stock, Net", "documentation": "The net cash inflow from issuance of common stock, net." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r1", "r415"] }, "avgr_ProceedsFromIssuanceOrSaleOfEquityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ProceedsFromIssuanceOrSaleOfEquityNet", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ProceedsFromIssuanceOrSaleOfEquityNet", "terseLabel": "Proceeds from Issuance or Sale of Equity, Net", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of underwriting discounts, commissions, legal and accounting fees." } } }, "auth_ref": [] }, "avgr_ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from the issuance of common stock and convertible preferred stock in a private placement, net of commissions and issuance costs", "documentation": "The cash inflow from issuance of common stocks, and preferred stocks identified as being convertible, into another form of financial instrument, typically the entity's common stock, after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock upon warrant exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r596"] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ProductWarrantyAccrual", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": ["r77", "r201", "r203", "r205"] }, "avgr_ProductWarrantyAccrualPaymentsAndRelease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ProductWarrantyAccrualPaymentsAndRelease", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details"], "lang": { "en-us": { "role": { "label": "avgr_ProductWarrantyAccrualPaymentsAndRelease", "negatedLabel": "Usage/Release", "documentation": "Represents the aggregate decrease in the liability related to payments to satisfy claims for standard and extended product warranties and adjustment to release accrued amounts." } } }, "auth_ref": [] }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details"], "lang": { "en-us": { "role": { "label": "Warranty provision", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": ["r204"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r354", "r392", "r399", "r558"] }, "avgr_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "PublicOfferingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Public Offering [Member]", "documentation": "Represents public offering." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": ["r43", "r79"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": ["r43", "r79"] }, "us-gaap_PurchaseCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment [Member]", "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments." } } }, "auth_ref": ["r43", "r79"] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PurchaseObligation", "terseLabel": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r266", "r267", "r293", "r294", "r295", "r303", "r329", "r357", "r358", "r359", "r403", "r405", "r412", "r435", "r436", "r489", "r492", "r496", "r497", "r499", "r520", "r521", "r539", "r545", "r548", "r551", "r552", "r553", "r554", "r568", "r573", "r620", "r627", "r659", "r671", "r672", "r673", "r674", "r675"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r266", "r267", "r293", "r294", "r295", "r303", "r329", "r357", "r358", "r359", "r403", "r405", "r412", "r435", "r436", "r489", "r492", "r496", "r497", "r499", "r520", "r521", "r539", "r545", "r548", "r551", "r552", "r553", "r554", "r568", "r573", "r620", "r627", "r659", "r671", "r672", "r673", "r674", "r675"] }, "avgr_ReclassificationOfOtherLongtermLiabilitiesToAccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ReclassificationOfOtherLongtermLiabilitiesToAccruedCompensation", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Reclassification of other long-term liabilities to accrued compensation", "documentation": "Amount of reclassification of other long-term liabilities to accrued compensation in noncash activities." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r304", "r522", "r535", "r676"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r189", "r190", "r191", "r193", "r194"] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": ["http://www.avinger.com/20240930/role/statement-note-9-restructuring-

charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated", "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "avgr_RestructuringAndRelatedCostNumberOfPositionsEliminatedSeverancePaid": { "xbrltype": "integerItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedSeverancePaid", "presentation": ["http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_RestructuringAndRelatedCostNumberOfPositionsEliminatedSeverancePaid", "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated, Severance Paid", "documentation": "Represents the number of eliminated positions for which severance costs have been paid." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r48", "r72", "r397", "r410", "r411", "r419", "r446", "r558"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r94", "r122", "r123", "r124", "r126", "r131", "r133", "r135", "r176", "r177", "r181", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r319", "r321", "r322", "r324", "r326", "r345", "r347", "r407", "r409", "r420", "r708"] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "terseLabel": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": ["r86", "r656"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r82", "r83", "r148", "r153", "r154", "r165", "r167", "r169", "r170", "r172", "r264", "r265", "r360"] }, "avgr_RightOfUseAssetAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "RightOfUseAssetAndLiabilitiesTableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-tables"], "lang": { "en-us": { "role": { "label": "Right of Use Asset and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to right of use assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r351", "r557"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r588"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r588"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r172", "r591"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r16"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r607"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r28"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-3-inventories-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r9", "r52", "r53", "r54"] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": ["r202"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r73"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r25"] }, "avgr_SecondTrancheBorrowedOnJune152016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SecondTrancheBorrowedOnJune152016Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Second Tranche, Borrowed on June 15, 2016 [Member]", "documentation": "Represents information about second tranche, borrowed on June 15, 2016." } } }, "auth_ref": [] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebt", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Borrowings, current portion, as of June 30, 2024", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured

by assets of the borrower." } } }, "auth_ref": ["r8", "r78", "r677"] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Borrowings", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": ["r36", "r76"] }, "avgr_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Represents securities purchase agreement." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r582"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r584"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r170", "r171", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r432", "r433", "r434", "r491", "r494", "r498", "r501", "r508", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r523", "r546", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r573", "r629", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r158", "r159", "r160", "r161", "r162", "r163", "r164", "r168", "r170", "r533", "r534", "r537"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r58"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "avgr_Series1February2018WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "Series1February2018WarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Series 1 February 2018 Warrants [Member]", "documentation": "Related to series 1 February 2018 warrants." } } }, "auth_ref": [] }, "avgr_Series2February2018WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "Series2February2018WarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Series 2 February 2018 Warrants [Member]", "documentation": "Related to series 2 February 2018 warrants." } } }, "auth_ref": [] }, "avgr_SeriesA1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesA1PreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series A-1 Preferred Stock [Member]", "documentation": "Related to Series A-1 preferred stock." } } }, "auth_ref": [] }, "avgr_SeriesA1WarrantsIssuedInJune2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesA1WarrantsIssuedInJune2024Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Series A-1 Warrants Issued in June 2024 [Member]", "documentation": "Represents Series A-1 Warrants Issued in June 2024." } } }, "auth_ref": [] }, "avgr_SeriesA1WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesA1WarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series A-1 Warrants [Member]", "documentation": "Represents Series A-1 Warrants." } } }, "auth_ref": [] }, "avgr_SeriesA2WarrantsIssuedInJune2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesA2WarrantsIssuedInJune2024Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Series A-2 Warrants Issued in June 2024 [Member]", "documentation": "Series A-2 Warrants Issued in June 2024." } } }, "auth_ref": [] }, "avgr_SeriesA2WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesA2WarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series A-2 Warrants [Member]", "documentation": "Represents Series A-2 Warrants." } } }, "auth_ref": [] }, "avgr_SeriesA3WarrantsIssuedInJune2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesA3WarrantsIssuedInJune2024Member", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Series A-3 Warrants Issued in June 2024 [Member]", "documentation": "Series A-3 Warrants Issued in June 2024." } } }, "auth_ref": [] }, "avgr_SeriesA3WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesA3WarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series A-3 Warrants [Member]", "documentation": "Represents Series A-3 Warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r593", "r594", "r628"] }, "avgr_SeriesAPreferredStockPurchaseAgreementWithCRGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesAPreferredStockPurchaseAgreementWithCRGMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual"], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock Purchase Agreement with CRG [Member]", "documentation": "Represents information about series A preferred stock purchase agreement with CRG." } } }, "auth_ref": [] }, "avgr_SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Series A Private Investment Options Issued in August 2022 Financing [Member]", "documentation": "Relating to Series A Private Investment Options Issued in August 2022 Financing" } } }, "auth_ref": [] }, "avgr_SeriesBPreferredInvestmentOptionPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesBPreferredInvestmentOptionPurchaseWarrantsMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series B Preferred Investment Option Purchase Warrants [Member]", "documentation": "Represents the Series B investment option purchase warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r593", "r594", "r628"] }, "avgr_SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Series B Private Investment Options Issued in August 2022 Financing [Member]", "documentation": "Relating to Series B Private Investment Options Issued in August 2022 Financing." } } }, "auth_ref": [] }, "us-gaap_SeriesEPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesEPreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series E Preferred Stock [Member]", "documentation": "Series E preferred stock." } } }, "auth_ref": ["r593", "r594", "r628"] }, "avgr_SeriesFConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeriesFConvertiblePreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series F Convertible Preferred Stock [Member]", "documentation": "Series F Convertible Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_SeriesFPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesFPreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series F Preferred Stock [Member]", "documentation": "Series F preferred stock." } } }, "auth_ref": ["r593", "r594", "r628"] }, "us-gaap_SeriesGPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesGPreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-

organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Series G Preferred Stock [Member]", "documentation": "Series G preferred stock." } } }, "auth_ref": ["r593", "r594", "r628"] }, "us-gaap_SeriesHPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesHPreferredStockMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Series H Preferred Stock [Member]", "documentation": "Series H preferred stock." } } }, "auth_ref": ["r593", "r594", "r628"] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SeveranceCosts1", "terseLabel": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r4"] }, "avgr_SeveranceCostsIncludedInAccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "SeveranceCostsIncludedInAccruedCompensation", "presentation": ["http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_SeveranceCostsIncludedInAccruedCompensation", "terseLabel": "Severance Costs, Included in Accrued Compensation", "documentation": "Amount of expenses included as part of accrued compensation on balance sheet, for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r287"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Forfeited, , Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r287"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Awarded, shares (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Awarded, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodStartLabel": "Awards outstanding, shares (in shares)", "periodEndLabel": "Awards outstanding, shares (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r282", "r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share)", "periodEndLabel": "Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r282", "r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Awards outstanding, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r74"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Released, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Released, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r26"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r278"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [

"http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296"] }, "avgr_ShareOfferingAgreementAggregateOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ShareOfferingAgreementAggregateOffering", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ShareOfferingAgreementAggregateOffering", "terseLabel": "Share Offering Agreement, Aggregate Offering", "documentation": "The value of the aggregate offering under share offering agreement." } } }, "auth_ref": [] }, "avgr_ShareOfferingPurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ShareOfferingPurchasePricePerShare", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ShareOfferingPurchasePricePerShare", "terseLabel": "Share Offering, Purchase Price Per Share (in dollars per share)", "documentation": "Represents purchase price per share for share offering." } } }, "auth_ref": [] }, "avgr_ShareOfferingSharesIssuableInBestEfforts": { "xbrltype": "sharesItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "ShareOfferingSharesIssuableInBestEfforts", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_ShareOfferingSharesIssuableInBestEfforts", "terseLabel": "Share Offering, Shares Issuable in Best Efforts (in shares)", "documentation": "Number of shares issuable in best efforts under share offering." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharePrice", "terseLabel": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] },
"avgr_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue", "crdr": "credit", "presentation": [
"http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label":
"avgr_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue", "terseLabel": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Nonvested Fair Value", "documentation": "Represents sharebased compensation arrangement by sharebased payment award equity instruments other than options nonvested fair value." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation", "negatedLabel": "Net share settlement of restricted stock awards in satisfaction of tax obligations (in shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyPolicy", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": ["r622"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization",
"http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings",
"http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity",
"http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]",
"documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r93", "r101", "r102", "r103", "r120", "r138", "r139", "r142", "r144", "r150", "r151", "r175", "r208", "r210", "r211", "r212", "r215", "r216", "r247", "r248", "r251", "r254", "r260", "r333", "r415", "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r445", "r466", "r484", "r502", "r503", "r504", "r505", "r506", "r590", "r599", "r606"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited",
"http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r46", "r49", "r50", "r94", "r109", "r110", "r111", "r122", "r123", "r124", "r126", "r131", "r133", "r135", "r149", "r176", "r177", "r181", "r263", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r334", "r335", "r336", "r337", "r338", "r339", "r345", "r347", "r355", "r401", "r407", "r408", "r409", "r420", "r484"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r170", "r171", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r432", "r433", "r434", "r491", "r494", "r498", "r501", "r508", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r523", "r546", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r573", "r629", "r678", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited",
"http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20240930/role/statement-note-3-inventories", "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details", "http://www.avinger.com/20240930/role/statement-note-3-inventories-tables", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-tables", "http://www.avinger.com/20240930/role/statement-note-5-leases", "http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual",
"http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-tables",
"http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details",
"http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details",
"http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses",
"http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual", "http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": ["r122", "r123", "r124", "r149", "r347", "r360", "r414", "r431", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r459", "r460", "r461", "r462", "r464", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r574"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited-parentheticals", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited",
"http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details",
"http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20240930/role/statement-note-3-inventories", "http://www.avinger.com/20240930/role/statement-note-3-inventories-schedule-of-inventory-details", "http://www.avinger.com/20240930/role/statement-note-3-inventories-tables", "http://www.avinger.com/20240930/role/statement-note-4-borrowings", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-details-textual", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-schedule-of-debt-details", "http://www.avinger.com/20240930/role/statement-note-

4-borrowings-tables", "http://www.avinger.com/20240930/role/statement-note-5-leases", "http://www.avinger.com/20240930/role/statement-note-5-leases-details-textual", "http://www.avinger.com/20240930/role/statement-note-5-leases-future-operating-lease-payments-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20240930/role/statement-note-5-leases-tables", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies", "http://www.avinger.com/20240930/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses", "http://www.avinger.com/20240930/role/statement-note-9-restructuring-charges-and-expenses-details-textual", "http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r122", "r123", "r124", "r149", "r173", "r347", "r360", "r414", "r431", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r458", "r459", "r460", "r461", "r462", "r464", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r574"] }, "avgr_StockAndWarrantsIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockAndWarrantsIssuedDuringPeriodShares", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "avgr_StockAndWarrantsIssuedDuringPeriodShares", "terseLabel": "Issuance of common stock warrants in connection with the Private Placement (in shares)", "documentation": "The number of shares of stock and warrants issued during the period." } } }, "auth_ref": [] }, "avgr_StockAndWarrantsIssuedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockAndWarrantsIssuedDuringPeriodValue", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock warrants in connection with the Private Placement", "terseLabel": "Issuance of common stock warrants in connection with the Private Placement", "documentation": "Value of stock and warrants issued during the period." } } }, "auth_ref": [] }, "avgr_StockCancellationDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockCancellationDuringPeriodShares", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Cancellation of Series A preferred stock (in shares)", "documentation": "Number of shares cancelled during the period." } } }, "auth_ref": [] }, "avgr_StockCancellationDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockCancellationDuringPeriodValue", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Cancellation of Series A preferred stock", "documentation": "Value of shares of stock being canceled during period." } } }, "auth_ref": [] }, "avgr_StockIssuedDuringPeriodAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockIssuedDuringPeriodAveragePricePerShare", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_StockIssuedDuringPeriodAveragePricePerShare", "terseLabel": "Stock Issued During Period, Average Price Per Share", "documentation": "Represents the average price per share for shares issued over a period of time." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Conversion of CRG loan principal into Series E convertible preferred stock (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r7", "r24", "r46", "r49", "r72", "r234"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in public offerings, net of commissions and issuance costs (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r45", "r46", "r72", "r415", "r484", "r503"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock awards (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r7", "r45", "r46", "r72"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r7"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r7", "r45", "r46", "r72"] }, "avgr_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Exercises of pre-funded warrants for common stock (in shares)", "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised (in shares)", "documentation": "Number of shares issued as a result of the exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Conversion of CRG loan principal into Series E convertible preferred stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r7", "r46", "r49", "r50", "r72"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in public offerings, net of commissions and issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r45", "r46", "r72", "r420", "r484", "r503", "r580"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r7", "r72"] }, "avgr_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r27", "r45", "r46", "r72"] }, "avgr_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Exercises of pre-funded warrants for common stock", "documentation": "Aggregate change in value for shares issued as a result of the exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r46", "r49", "r50", "r67", "r447", "r463", "r485", "r486", "r558", "r581", "r601", "r615", "r661", "r708"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity (deficit):" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r71", "r119", "r246", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r263", "r325", "r487", "r488", "r507"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r340", "r356"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r340", "r356"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before

financial statements are issued or available to be issued." } } }, "auth_ref": ["r340", "r356"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited", "http://www.avinger.com/20240930/role/statement-condensed-statements-of-stockholders-equity-deficit-unaudited", "http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20240930/role/statement-note-3-inventories-tables", "http://www.avinger.com/20240930/role/statement-note-4-borrowings-tables", "http://www.avinger.com/20240930/role/statement-note-5-leases-tables", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-tables", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "avgr_The2015EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "The2015EquityIncentivePlanMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation", "http://www.avinger.com/20240930/role/statement-note-8-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2015 Equity Incentive Plan [Member]", "documentation": "Represents information pertaining to the Company's 2015 Equity Incentive Plan." } } }, "auth_ref": [] }, "avgr_TheMarketOfferingAgreementTheAtmAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "TheMarketOfferingAgreementTheAtmAgreementMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "The Market Offering Agreement (the \u201cATM Agreement\u201d) [Member]", "documentation": "Represents the market offering agreement (the \u201cATM Agreement\u201d)." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.avinger.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "avgr_TransfersBetweenInventoryAndPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "TransfersBetweenInventoryAndPropertyAndEquipment", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Transfers between inventory and property and equipment", "documentation": "The amount of transfers between inventory and property and equipment during the reporting period." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization", "http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r314"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.avinger.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r20", "r21", "r22", "r88", "r89", "r90", "r91"] }, "avgr_WaiverAccretionOfPreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "WaiverAccretionOfPreferredStockDividends", "crdr": "debit", "calculation": { "http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "avgr_WaiverAccretionOfPreferredStockDividends", "negatedLabel": "Accretion of preferred stock dividends", "documentation": "Represents the amount of preferred stock dividends waived (accreted) during the period." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r658", "r659", "r660"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r658", "r659", "r660"] }, "avgr_WarrantsAndRightsOutstandingTermPeriodFollowingPublicAnnouncement": { "xbrltype": "durationItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "WarrantsAndRightsOutstandingTermPeriodFollowingPublicAnnouncement", "presentation": ["http://www.avinger.com/20240930/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_WarrantsAndRightsOutstandingTermPeriodFollowingPublicAnnouncement", "terseLabel": "Warrants and Rights Outstanding, Term, Period Following Public Announcement", "documentation": "Period following public announcement for term of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "avgr_WarrantsIssuedInTheJanuary2022FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "WarrantsIssuedInTheJanuary2022FinancingMember", "presentation": ["http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity", "http://www.avinger.com/20240930/role/statement-note-7-stockholders-equity-outstanding-warrants-details"], "lang": { "en-us": { "role": { "label": "Warrants Issued in the January 2022 Financing [Member]", "documentation": "represents warrants issued in the January 2022 financing." } } }, "auth_ref": [] }, "avgr_WarrantyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "WarrantyPeriod", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "avgr_WarrantyPeriod", "terseLabel": "Warranty Period (Year)", "documentation": "Represents the typical period of product warranty for parts and labor." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "presentation": ["http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "terseLabel": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation", "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall)." } } }, "auth_ref": ["r15"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.avinger.com/20240930/role/statement-condensed-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.avinger.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Weighted average common shares used to compute net loss per share, basic and diluted (in shares)", "terseLabel": "Weighted average common stock outstanding, basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r136", "r144"] }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-product-warranty-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "avgr_statement-statement-note-3-inventories-schedule-of-inventory-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-3-inventories-schedule-of-inventory-details", "lang": { "en-us": { "role": { "label": "Note 3 - Inventories - Schedule of Inventory (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-3-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-3-inventories-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Inventories" } } }, "auth_ref": [] }, "avgr_statement-statement-note-4-borrowings-schedule-of-debt-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-4-borrowings-schedule-of-debt-details", "lang": { "en-us": { "role": { "label": "Note 4 - Borrowings - Schedule of Debt (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-4-borrowings-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-4-borrowings-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Borrowings" } } }, "auth_ref": [] }, "avgr_statement-statement-note-5-leases-future-operating-lease-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-5-leases-future-operating-lease-payments-details", "lang": { "en-us": { "role": { "label": "Note 5 - Leases - Future Operating Lease Payments (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-5-leases-rou-assets-and-lease-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-5-leases-rou-assets-and-lease-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 5 - Leases - ROU Assets and Lease Liabilities (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-5-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-5-leases-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Leases" } } }, "auth_ref": [] }, "avgr_statement-statement-note-7-stockholders-equity-outstanding-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-7-stockholders-equity-outstanding-warrants-details", "lang": { "en-us": { "role": { "label": "Note 7 - Stockholder's Equity - Outstanding Warrants (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-7-stockholders-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-7-stockholders-equity-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Stockholders' Equity" } } }, "auth_ref": [] }, "avgr_statement-statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-8-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-8-stockbased-compensation-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-note-8-stockbased-compensation-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-Based Compensation - Stock Option Activity (Details)" } } }, "auth_ref": [] }, "avgr_statement-statement-note-8-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri":

"http://www.avinger.com/20240930", "localname": "statement-statement-note-8-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Compensation" } } }, "auth_ref": [] }, "avgr_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.avinger.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":

{"Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r413": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r590": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r708": { "role":

**"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 60 0001437749-24-033979-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-033979-xbrl.zip M4$L#!!0 (-+"(9UE>10 OE 1 879G2KRDE!L@ER_MEGU(T"4G(1X$* M /K(KU\!TP%,B*5*"Q!!8+S9%-("^T.AN'/SVUY>Y;STARG! SEK=SYV6A8@; M>)A,SUH/]W;__F(P:%F,.\1S_("(@LQ8)6G_]!;__Z]O_V/9W1!!U,/*LQU=K M/ N)A^AE,$?6/\Y'-Y9M=8Z_=@_O;]V'\875Z_0.
]6[7!GRQ[=^^O3#O*W-G M:.Y8 @/"OHH79ZT9YXNO[?;S_/GYX// 9VV>YU.M_V/VYM["=N*@)VG*PL70HB /R*G-7Q>(Y="758!<4=R&8JC3L3M=N!>-:R+7*^Y"%.2Z M0"2<_*@8.]3AN!<$08?O21#6 @/"%X9O<^)^Q"+-"ZI'-1DNO)Q^2/8C]$ MV I:4/SH,!2#$P>[K+AI691KFV&W&%04Y $!3P G#GN4_8N7RT!+:,^"]]\ M!;Z@=?
V+DAQHR.RIXRQ66XX*EH%+\(A+++A-DY:]O"+"BND 8F,(C= M1!HO*]*+AESW]/2T+4M;EL,YQ8\A1]07U:,/C9GWG;5BMWK-5XA];8)"Q M#+6Z3^#ETQ8=I^:U5K\Q.#PTZ[7
LE3VN -+?1CYGTMAL(>C\U%-/TMDZR;\- MD%@Q.S5'6EP!AMC19G1G3&XMFA-X^,2YH',&>5-QRS:;X,#>>)2A#9EU-^9MM M(OAUSD,MC-
8ULZ%Z)\Y!/>V(P.%A&YN7N%WU3%X$#@\;:N22AU!(;-.B%'+ MN)G-L"C-D^3Bs'J622?TEPM,sNG,/-WCY?Q< @) MN&Q*OHO?+A:83(++HE7@)GM+7V-
<=H8DE?:>O#G6AGVH/]fV@P0)1CH54,^ZR M;&!&T>2L!:&.'3M'__2=Q_"?8M!5CK(NSB23E$%^3G%=T(&S%A/,lE%$
MJ4\GOW7\IN2(*F]H2ZD82I2')DV)$E4PP0;3M*'H*4VB"A-QP4;2@@;& L#" M(N85'CJ7(8;M!6XH'QSBB;F#8_Y]PUBD<]E+RX)Z#Z/!VB!#85B_X02]&,%4
M8"]F:JA,%_];I="S;NHSZRC[VB6==R6ZM0=KMM_927RMHA_QY0_*;?%X:&%'E M"**]8E[YZM=;%G!QS>AM+-%Z@G8#X@D?05CG1\>7\1F;(<29K?Q7;@=O=Q8%G
MA\0)/2QM_Z:B;]Z5+F7'H"@VXC_0SQD^@)6?K"N)MEO7I4N'UYITB54G4==C,GOC!\YM:HL)>=*G)44TUN1!(6-> Q%XE0%@DX,CN
MVH*G#L'_V3(&*FI,EX"/(=C!S!535DB1^/%#=&:! SS,=/?!!=FS63B?,_15 MVFD\)5B8/P>"4E>NT @1VHO %R81;>&^-N]*EQ)*50"Z<4J9.1,D")C]1-D
MK+L(F0^N(@F2X6FA#,&7.T\Z^^ B/+)])+BUK?B29C2)KMLI%WX5S>RHP\NMF,(H>>8 M*[=6A=1R@0%$PZRZKG5=0NX6"OE8.LY)_U%0GNG_@\O^2U'LNZ7$B]O4)>=>
MH9R_R&!I-5[^X,(4:(WJE$F0@@=41$Y>W]$O-!H9A/8C';LFN97XN[_N"B M/K5%\YR&+@\I1"KN#/88*HN+7H!+6YOR6EWH4H##0@4 +VR41<*Z4$A(RWX5 M(?%Q56%-
V*HA5*[=@QY%.#TI.CQ><>#6!,36I_CIH^?!FN0T;.X\^C\UBQ+W MJ%%5BMW 9OD4Z]-8XO71E2>7#-&C'85-;A1_L7>XE&G9RW\&O";;U
M"'JM\QH5H'C)LRJWRM!T1JT]2'N8%^88_3"0\?7NL"JTKA&!2A>]EQ>\X9= M+A(%;ZQ0^.C2;Q14Z=6-K;K6]#G%;ZA- [N]7FTNW 4-O-#E]K-#J8!YC;7] M,Q6L% >-
FE:\TMW0TVSK3[%_1ZAFBC??ND:)"P@KO;T+A"UV?,5I[&$_Y+'OG"$WD)AG)KF?]7_K M4-&HA%H2J+;5%/Y&QZO"UIW_$JH=Z_0J;2!.,@ M!WE22(Y_YV!00"Z:_ JN#GO
=3A**!N3JQ46,#2"0"N'$G771<05 M!X,K.LU]DK0=DMFC\B MFG)M@YJ,_';Y1.U7+Y@+3B^SIKD;32F2K\;?2A0%?8*$E !D4/AUGG!\W#>-MG\/6BH381E7>1?SJTR&\D?
0O1M_S0LV^,$)68F804]V C/!TQH.),*8RIYS@ M6UK\AC+PT.,61NS"=\!J1.-F2"'7J5R^(NIBA,_$/YI I&D[D_K%D7*E,QG B MC+884
GIFAK;3M8+U5&5L"NT3$4DS;VCKO3R.L7##X6ETZ MVA):BLO>FR-FS7B"[9Q0"9"(97@@JT\%<-+EH:.D,MV!K2AX6 M ;GRD2O9KXT_2ZV:.6V'C
=S1(<$+8V6@@(S)X (T?%S4$Q!ML"(,0S[8I-\ M0*1+R2,:."V?AN/(B/T5%76#34@8Y;M.Q=(T0S$/"Q$:[$L73''JG2QK6,2Y, MEB-^0"!3#>\3N>5#EG5
FY,7XZA%95,4+X(G1!SX/U_X&!@%%)D+$5THYP)^ M08;@R?$A)WJ+"6AM,;D;M_4>^9FZ^EY%7D3!#19$"=5Z'<'.%RH;]"- M\+J6\94Y^YJT%<(:2-<(>6@N8_P^(:'C7R+7QP0-
R,]\M(]J#5LRFB<#6/!T M_"UX4:L%(WWH^*N'8M*ZDM\\'&0_X1A170VS11J20SYSZPD^G["'23:RL"^:,+)+)NKNY&S65?M-AQ&%O*_'_I+35B9-Q@%[93)3F($2+HV?"]B"81-M736(
>'K,H)$+\[UJ66,.:<8IOU'B4V:.HI55U@(^<ER!<;.H>6W MV]><%QR++A=(]^+V0SX+*/X/AO(K#8UJF",%4K]C!/$(/2$2HB@=]I)717-IM MKD,=`3*)QUJTY5\$%,$HC,!/]+-
GHUKE;8'M'38PK&(<1"E4QT_^X0?2"8+^-?!O1N9)3JUY"@E,_YB;RH MP(@I/+DF2*9W(A-]]>+Z(1RIQX6M:[.;Z)KE-CL"\HV('SF)SLGM+2T,S/ MG>^X*I*:RK43_"3L)S)J
XF1;M3X_W[_7 JI_[;TL.Y^AKSL@@+D_>\A&D M."%7Q9*U=7:0[O$,_*_O>B M_P>P:ZH.K=NW8PH_5I=:8 WF'!$TP> V)7LV5Q>F-ZYMQ,)\\7'!C9>!?YY@^%1A+BUK3M:@-
;HR= MS:&[AAK3L%?3+6 -.;92N1W\F8Q135C3HB1!5XPLJU.:==<06 .\$M6)N M^A08[''PNVPAR$LGKHN I5FE-VG99#['[VY_BK]_I1\A7&>AEC@$G2,D+XG- M<*- "@9Y
MV=N88A*W;\;M,\81V/]V"G54; @-O*$=-F54Pl2'JW(!X*UL3P\P*\/ M;F2V)]U<&-\Y4]QH0Z@H11"@']C1ZIRCEU3XI]TCJ !E/8JTMA-:#!%%;O MK=[%C=,QSO5"P-
K01G@=R]A6TV($[NODU&LDI_70)LFI5RFGU5*3Y7302$[K MH14V2TT&EG%9+39;34M)QV; X'?/9RNUQFU4UFPM;+L1]:,=@_IPGHEZF+)9Z MU8C8H+;9O-
"B*UNU85]_KFO>\U;,VA#+'^4&9%9P0&![BA12>;ZF617]>9GF M-,(22YP^2[^)\?35"Q[!V4]]<&-W9";(R$V1O+&R+MHQ:F0V#)(.|:I0UC;=+D?27?9T=.'R6,J0<[?4Y!XJ_BS0SVU
M+I*>9V.20RNC\":8:1M[+6_)/[-`>L1(LG>4\]>T^GTIV$;_7AW_UV MS_6XYE6B-KBYV7:U>P:.\M7E^6LDN1;4#"&6H;DJOW60AHMN5>?ZX&Y,2Z:O M1E4,N2NY!&FE<>D]R-
&-P6M(+:]EAN*6V! X[4.94CMQ%CIF; V=Y.5V3]$E M*4WE7%K).()+XZCQ#,'-&[' -OJX#(MT5D^@JH!9V2(/R-$(-XG/*"0\]Y$^ @TAT>0X@})DN0VKV>< MBB=,4)15]?
\!FP;PQFY526ZC)9ZZW#[S;4HXFZSLU74 E]7*H!)VK_0)"4*B MMG"GS-B^(0/OR=CH6,.'F2(=UPI02V1DKXU4$;I=\:6OCC6LUDXGPNVV\'$
M9GA*Y)8D4>JX+AS#AJ^0+>#B;)9L8TD_W*8;\K2-7L'EM AW!AS&P_8,P6^-C2-7T;!E?V\XOR=]&V3L;?.GY]&\Y6]/*+\I4#49JYF+2Y
M.SPH,"DW0$!S)TA+_01$!N_KZ]QS=K;51[55)R22KM#]:'l&%\TGA>F\$UY M;9VHVJ.\]6F.A37V1V:CVRY/9_9DY"'8M8-XI/SZKT=7VY46RTV:'-'N270 MLAW8#*V^AZM(\]-
=T17S=&T"K\[M'Y1G^B&*TL193:2&30[2,/J MV 6KKQP;-?DK*$+G(;KN9A7A1+&\+*RV/OG]N4W4&R.:! A6S MG5R%MQ%;+*0=IRRL/][? :%?05I92D7TQO$3;A!-;J[NK\"
[FF.^1@,[P8VU MV9+HH8HA#=KX,35YU@:60!0V=\3/_P=02P,$% @ L{A6?82T]%'''> MDH8 !4 !A=F=R+3(?P.C0P.3,P7V-A;"YX;6SM75MOX[82?B_O_^#C/BO. M9;
<]66Q:9)UD8<"[*1SG;,]304OCF%A)=$G*CL^O/T/Y$CL1)>H2B@L4*#:- M/!S/-YPA9X9#Y>,?3U'860 7E,47W9.CXVX'8I\%'Z\Z#(<>Y?W_<&@VQ&2 MQ
$)60P7W9AU__C]YV\^_LOS/D,,G$@(.I-59SQ+X@#X%8N@\^>GT;#=C=8Y_M_7#RINY+YV'<[YP>G[!S3DZX]\\[_>/(8V_?U#_3(B #@H1B_37B^Y,ROF'
M7F^Y7!X}37AXQ/AC[_3X^*RWI>YNR-6G@=P-V"=^WUM_N'-]Q7IYEM*>G)^?`MH)+=Z2"9A$BTY/>GU^&]_X,N+16&G$5](("D&D#X?,)S)58R&$CI9"_>9M
MR3SUR#LYIT?GQ^ M=MQ3A#T46D($L?1\AG,5"PB\"0D5$D_ ,*3P_(1S13 '3EG@3%) HHSC$C3 M+YYQF%YTR>*1>UO>2K9?&F
M5W.T+T&C>0C=WAY8GX1^$J;*'>+O&W'*%R!{N MM7#P) $9:*9B*U_(_/M*)G$UB2G1$S2^4V$]TC((/6M!Z$4VR>I(E,E:Af\ M=>G[+
(FEN",K,@FAOY9M*TI()A!>=,V(UW*RC89WVCUS>4>@0]TH:3Y"M), M^KPAMC'P!((A)1,:4DE!% +(I[\G\ M[SH8Q@/MXA$"O5,G\\&'+/Z[P3=*T1)Q*7L$\]Y7-MN%C^AX0):*0O-
=8NJF>;S 6@(,JZQ5=4-QP K.EO(#;JN37N VS%%'4$:H(MSW@-!:YG%!:)51GW5*41,8.B+0EQ:4A=:\9"#/]%6B+D MJECLW&%M8>[-]<%6]%^[&:#7,#QE<5^%2BOQ[6(9D0?
M9_)V^B @W?N-D&G&V$4A9\#7X4KQ/.31VI=ZSSO-1,\=8%7^_V0#^/5!82B3 M0VE;XCEF']=]YVE]"VCDW5=LV'RPP+BAZ(DDBE*>'I40-M,
<=/.8N*$EA6I7B#7V1$Z\0%%/L,P!3&]0LP2]^YINC.7$!7H3YABL^>;V4Z M5?T)LN=%60!*Q+?N^5.V(YGN^.YY4.8$%8?P+KE*3@*>L1?EE,SPQ/V?-QEXS0#&'9:I!+F[(9
MPL(RJDMN9GQHEKWFN^MO58 55\7WLO80WQ-_?I'-N]TQX;.JQJ2;%8N&1 M.$"R:,YAAI1T 5[(A*C72U?IR^QVUS4DKEF_W6L-JB=_?<;E;(C,;^.BQ>8
MP%/,+Pf7@,T'$(Q9NA6G\5_6"7QS#,N4IC7 OA'4&U#X,HS&6 M4:2[R W&I[AQ2TY\^8W*63\1$O7+4,R9,66V5.EL_60V3W MN+ZX$^),7 81C:F0RK
6!798:G"M,YWOS=*/K+V9&847+B51!2AJFZ-+E.!^ MKV&5%A>7]YM$(6Q6_]S"\;^=S>;MO5ITW.ZAPSM@*X>3F/2[5,8LGID1@Z*S%EW/"(HVB-.>,S9-LN]=F) V4)559[<(
M]\7NLC;]:?,E2L$?0;QN+_]`H0'1,4+Q 0*A\H7Q# 9"),IN_.UTST=5KZ7. M_U":V^EVE.]@,DO/;_KQ&[/.#3:*3/4\]'#2YV_:,G4'D,8 MCG,$S?-EA]*.7@]M']-+-
L7M/O(<TRKR<9HRW#K)T73GS# M1!2NV%*WG^L),1]QT=0*8W154 @^K1XPFQO$=T_CTTI=TD6>)Y1FX@$]I7]@: M^'(8N(!OM]!6Q09?#X)!&$>WQ_C]--
S_9U]+;.O0Q/5M$ZVTK#ES$;DR=U;*C* M*4'S,I6Z[%K!/F;7/F:3'+27_@K0FC.P_:*#?7'E M&^&L9=E"'*9(OW5TH%O#:B& .$IXM_<
M1UR^6FH*_M_(GAMM;>YOS(6#'NQGCUB_O&2G _^&N@T;_-+2"O/KQ_-;UB]*&=>\P!=U()=DE7VFIQXG56I6=K5KLYXZ9!._,H_IN:?^[%>0A* :G;?/5UZ@7],3[@0M[NFN
MRME&7W<]V2S]M:Q=>?!78I#Z3XS%(@T]%"W ODBIWO&>.0 ?ZU$^).(++^@ MO7!*PG)*+QS84L,.X]5ICK0&+%4/%(-X]=_TTJ_YN.&,NAOC&V$PGSZ6= MVQBT-
JYTT8YVRIWC=WL+,$,)$5M])2/*UMHA6DLK1]#EG\ 8>J9>> M:E:X+!*[?ZQI3P!<@3:7^T8PWR2&ZEHDQ8![3L)!_!45-UY^N(O+)8S[1_3 M:H*GXNUK+Q!^0Q>ZSK-
:O!Q'S1+>&.HI7FZC\N,7-S;9!\PW,+K6"-8[W]9KM4MM7\W!?,+O7D;R?>UO1*P,T5=E;B^WK"6@KS%N MEAUN-V@P%,XT,ZC)SDGL;%2-2Z.ADEE;94U/?
=.14\6M%$05&FWH3 D3<& |4 !A=F=R+3(P.C0P M.3,P7V1E9B$X;6SM?5MSY+:2YOM&[^H[7TN=TMMN^T3Q[-1NO7HC%JEE=3' M_OBH$B4BF,6(?.BR_GU"_!25P)
(D""8K$:$W9*J /#[0%PR$YF)O_^?UV7T M[IDD:4CCW]X?_?#Q_3L2^S0(X\??WG^[FTSO3B\OW]!+,R\.O(C&Y+?W,7W_M?_[M?
_Z/O_^OR>0+B4GB921X]_#V[GZ1QP%)SNB2O/O/D]NK=Y-W'W_^V]&/ M-U_??;L_??7!\?C'R='1Y./GR>3?_AZ%\9]_X_!\>"EYQT#$:?'G;^\76?;T MMP\?7EY>?GA]2*(?:/+XX?
CCQT\?ZM+OJ^+|VR!;5=@L_.'\LM5T;VF7SX5 M98]^_?77#\6W]Z)IV%20-7KTX3^_?MWY"[+T)F',>|3G6-+P;VGQX17UO:SH M1B6%=\(2_*])76S"/YH<'4\^?
WPF@;O6:^_>U=VG9?X"8W(+9F_]W!]=GNY MWQ=AG'T(PN6'IJF+XH8Y**%14+F0JAU!W(&/_%G_^-+FMG;$QL&:,A\BL(F M#]U!!73IA?%D298/)&D)K[$-
XT##)8GY3)F4CVN+5="_:,;@+UE[BXP]DLGIB M2\22EGKL8S+W\BCKWLG;!0@!UVAWH?)G><]L023)#SY=?N +V<=?/WW4.!F
MZT!&V*,R]C+]O/B%+943]C/,WM@Z,:?)LE@6MGEXSX_)I&ZI *S=D) ((QS& M(2]ZQ?ZL2G.P?5$]D9#7C+ -H%]F:C 1]?=>8%H/@)3X/SS2YP\!"0L_)>B M5\]72,(_INSQ
8=P$7F/]?,B[X%$OFT?2E_BB?AZ3),]:PSA.65=,$V(=TH# MT@"GZ>L^T>*1)0KM:UBK]4R]=3.. _SC_*V>+0L00!=/LU$N2-[8U M_]. +-UH+7#@NMNG99L9D49LL"#@-(8VY.
{[/%@P1%W4-ZPRJM4#Z"@3%K&(] M"Y]#)] %L"U44=H]\G,FM=(WPH3RB"?O .]#X'I6V5S&$^S1-'ECN[H >%,1 MJQ@WNDH L:$4 C92E!,K06-F%Z;\D4NVW55RUZTV%!?
Y@$8R@O=A*#92=06K M^&=// L0VSFNB)>2&MR;O.IAE3#PN*;QWX;*?KT!V=R&CXML-O^6DD(* Ss1 MU+'+(EN0![0]!5M8^ZHU9"H,NK6 5_PUKAK#"!TI13%+2-
N(GIE6>OSYQ MFQG;BS8&@WPAT]AIF1%ELS%[NXD\MK[' =]0G[BH+I9S(%6L^]&(";RB53Z%-P:!\"P.8D+VL5;6Y.O!$EBU 6'
MP=N4)D9>R#).H'R,1"+>AZ&0,-457#A:W^%HBO'N M$0!{!UE,*6\DLOSKQ MF;$>)8"-U^XT S"38Z:=3+_H7B.8+/S8#.K?@(^CV# {Y-2_SYLV)VU]!DBU M?R_YUG+J M(=\'8"
(+U}],3FX! &_8SV4'D.BD%3V*F@>4Z,:K'EO0D3(Z.49[T$)E15AE%T(HT>/4,#U9XT8V2@CD:\T60+/)0#TNS?O;_SF$6^ M=\#D.;!3&[!= VHUA-GFTY0%Y :<]K-+@/*237UUA
MF==Z=SKO3>7=^G]Z=[747A 9-".,V @Y"8Z8^5;GL@]" MV99BDVB$T(#9EE[7E(#V3MK,<(3J4NC.W>%'F5KV%'0G[MH\C:P[]HH[.6_+K ML.A8N**@(SG
DF/O|&3U63]A\PDM'5AHG$X80%9L^920!9=KG\]+2@!
R3/[ZP,7C%&I_%IS1^)DD6,@%$R>XVOOB#!/2T\@+T$K+6D7])6$KSDU"Y*$!@TE+&?) MRIAPG&956)@ I:"45;37).-WH)#^\^8]M?1(MH1#D-4!W+++(J=^X)I<=SOF8_CW\-
L<9JG&>O?A'5SE'.U MC$?OL?^"">^]5R*UU2Y8$\D01O[Z$Q&PH1>Q-3(,E4Y3X',:W!8_5%6ZS^9]A0K9KMVK#G:BZ$U5WHNI.5'@6Z5;4=. MI/ZC6W2TZ$GMD.B<,_3>G(;M
YV++AA93B9$6G3L&B%B'LSET?AEPP@8/5-%Y M;!0?$IK&>GS.'5K< 4=M4(9(:.0.1IWAW5K2C<$W(460,C<'\!SDPXM6H\9 M#]U!7)6E!L&-V!/.1 M!AQ=[DC"
^6/MK>$KUOSU%M. M[4:(FG6MP&T*,&Q3U1384QX'$$6%RYA&M*]J0U2WIF@6J8@B@97_3K/7TGB MA^E>N%^%0J#^7O00M^HE*2D]0I^B<.]VS0XM] R]2Z?+&
[",IZ!Y@VA,6N%'#NW.%0/"'=[?8&B MH;1!4SQ(A]V7^0M%PA3)@$R0>0Y!$DY>6^)3Q!+J506R6_KL?CZ@[4**6L8VZO/G1:1:>;^])?OUGJD&J><7:J5L4L(K'@[?
05<<;$X:)%EH"A1>;*:%@?-&\>O MPA!8LXWBZ8=K\E)\U8KO7F4\O&Y)FB6AGU7"X?3%2P(FW,fF;/V=DS#+]TW! MQMO%U!L*PW''5O
PU=NFV[>$@7%AV#*\D.FUB:876BYCS771L#*_B&DWBZ8O M3$QL0$/V^8[IMO/\(0V#T$O>-A1/F:RM*C]4]):!D*<6 ^@0ZCWZY9568&ZS) M\F.9FSS
2^_=T%9&6W11"^"7J3@!0!>< ";F<=",+D@!3!)BAK4[-DTNIK - M]U"JF%7WEI5U2[R,UDF<:6X('0W<<8LM2 MT.:@!%TL<2>J,F,JNM!B
R]5TTJ.+N:X^\ONIP>PY8JWZYJ,+J#9P$Q1'1RB M"U^6<^X<98,O9AE N-= 27PQSK!AWST5PQ$V^@B9K=< <46I8W5)"M,KXJY\KOP003Q<> MZ[W+^)8G/I/S/"4\R?
3N12F0H@:_7,,.9L@9Z3\63QI-O{6/8G)1U^)8SZE MKD+0(8QX1O0D3/G\8K.V^'+*7FZP>.BW2;&7!Q@@?DUC/A1W,IZ6UAH&JLBG MR+H_>>3',XW,VK5@/I-
0GU"@I3WS_V"U"86;F1?N>XQ ,*TD<56*,LFT?-3 M3'1!_A"%_FS.GL<&BCCIF:R< 1BWQ.?>$>$\]+UR^2C> ^A6-']F@6-8#.B3< MD,#6F%SJGFZR20/D"O> .4^K2;
(70N)+[]>CUMH;>^ML<#RQM\Y_Y8>T3Z+9 MWI;-UG[K[F9%$ZC&<;/BEIV.'YO%?AB1+9O[/3UE2S0;:?P,#T]>V+837,.K
M!*53/V;/)1.BMP^GR4W3Y;4K98_ZM:6B["F*W.#%%VQ-D_&'JTSP6YQ?2 MK&XWQPWK?_X_7TV>O^%A6I-D'_!$&Y_L%%R=>,'X_!$4R_ZDM#[J>;$!GK, M5MK9ZJY>0?\,
6$\?5RJZ+L2X8KV^:M?R+NW3%X9UNV<#8. \)Z/U\P+6DE M9#XS/GP9B8/5K%LO*7R ,*T\3XAB'3/5K-6^.",/V=]79)7T ,*#)FF'*^)K-5
MB2TZ1P+.NM4M\JE5.^W.+"-K%MG#CO4F2 M0H#K(6'#Y #"5I4VA/:K#L^)QQ;ZD6MP]XDF(WO=/BV:;;@OCA?/D7TC9#* MKMB&M[])@3G6BI@.J88Z
[-8#:+-J5%ZQ^^DW,#2_ZM(:/T\2OE%QBQG\?4EK MXV+69HZIFQB8XTU"GKPP.*NL8I6!L%X -5^F3F.6>5$@>]:M6GY/B4-(.77[GT"&L+ M\&0IL=3 MT@!2?
NW>)S:+XSCR"]^$B<{JTG SX YB97FI[&8:]-Y/7-71M;A#N_#CLKSQ. M2'VN=]-Y<28YH&K?@,L>#<*]/C^N?"QK/W'1,@"I@D 6/T:KF@ MQVQWZ$0"DYVW/G!ODZL#G;!@?
%SD]JA$)R$8[Q&C>?+021#&NZM;(KYU__2=M(S>F&9D<35BW>?&.@XTZ%:ZDLH6,M]G=TML&SR"4\VVLJ5?QDSY_,K>SH)7 M6(T,<3[.]JV82'R[UHTOXW_D,6%%CL58 <4-
@*HEX=F[\NKUV>WV]9},$=`#2;^[ODGP)F>K%Y>=<U>,)7,D(0+V5 MP]*R4#]&/93D);R/Q7,.F3J>++>^I.-*,?FC:)C M*X?/=-
!W>\IM1U78JC3QA;C@6/!BZ.=*4)HEA3U8%,Q>],J$ZT[D)"H]!FS%:D(>6'1BI?MGE3EQXE^V#W59BI+X^AY)\[F&Y9!"7)IV<$2<)KRI 7K79:=9+^/!*/-)RJ4 M<02"B0%<7J-
PZS5J@E)QCFI9!3#RU+;QT18&-93$E3;^_1&L-JAC9"K?T3:3 MIW4Y),3(7"7%4FVA$2M+EZZZZ84>?KKJ-KZ$ED-X7-IJG&FK+2:0U6?9R6_0
M]FLVO&8IK2[X5BSEUBFF./SKTUB?NHH2G18EBYD-]:)VC!A &A&HPFK80C$06U7FI MD(<=&)H"X+2,!]T&W<+@M+@(7SOZ#KK#C@@$AW-%@(8.$K9+EF#>R7@7 [=

*M/MG6H%J_U19!QRAWTKXLT)UV5D-9HTRJ_W-7(G1#77[\M75H)/6,1SE^S1P&_M=AJMAE)RJ3%:Y2YIZ$;JY#1ZDQW4)13W@&UW/#\NC07T)@&NL6CXJ8PZXFAB-MNUN?88F]:U8@('E#V=]-FH%:Q5GA6U@!{B#UNS::G-CE$MR38TVGI=FZK46P-M-&MFF0&R,W2;@;N'M\=[>(6,'@[L'EY[RR[$I7-)FB^7-M7O(VH?-)&C[&12I-]JU77@?$FID\T2CT-_)MU,PMFG:5H+&]M@Z16_<4+YG-M3^)<&]"R9E,Q]M-=*0N;-)2G&5V29!8W)X.1%S((X/Z%{@'L%3(@)&]FQ<# M$!;]G).J&/S)6QG44?VQCN>H/OCCVIT.JOTO<.3LPH7&91K7"+^FR;UZ&T*-MZ)07ZAU?>>*S!:#QY8+*C@.M^<@V!>]f4JS\0NACXCTMV,X,"5$KRXX#K?T^-MK@6>32R"Z:8L:ST\$0$/:A,S0.M=@A!L\3M@GM;P9/G6P-5&Y]+(G<$H,.P#)0Y& UQLM@V)E1"?Y[-M^.39%&&U7,X[+08:2:70Y)5:7XM7(/D6ATSPOOLF!0^]8SWS&M,7GDF-[:Y(@0T0NPB3?$M<$C)Z2_(2?&J2#"+[\A35CSI^/CXX[%/8AHM-MJAL S7MKE3YUROX)^"-7].BC&"FT3H_P/NNC^VP-W"_ZX'I[%QP0D'$0=X1M-MM,'>H.;IF(]^8N/Y9S$PS:I&P#;D7=N[/^KW,%M(U\P.S> P'>[\"\WT8,10I*

*M.AIN+=G*SB&\U:1'5'OWDVP@$EP3TS<:80\)[Y+%@&C8 $1A8L+=F$/%I;7X-M\0[;SVPO"+,+SP^CY@5&77! O/*>EA0=$^9!Q\<9>;L=*

*[K5#H'+H+/-CBL:&4F6?.HTM(B@Z*6=[[MTL)CPSWH6*DLYQK94 U!F#P[HJL#*6&<3P0W5\XR7 7P%DMZPA9^<0,1^DNGH=5GYP(Q+5-=I@I"Q1GJB.>1,C-ZD83_4$ M9Y3\5.HO;:MFCLX-4,\B@,ZQ#/QV]-PM"96S8Q_#%$. K,GAJC0TX!NJ\L62-M0KUJ<-[53CO&@>2(@9XJH!N:2L&3=G4T1#EHNTGE&%94D^^VE=<=-*

@Z1@/SP9.&0N/2BF74BBSE5^-DBCFEC0$X&1S)PV&K,J,,,-N-M4MD_R>; *;MB>:?\L&P.P@"1_1K,2 HX.<"V+H%,,<1NNVA_C=%I$/Z,9E"X/ M@##8CEP? 4AX D$_YFJ25%

32+BI=I$WVS&2+M=#WN60/^ <\BTC^=:T MK:2/_Z7,NO[! ^:> NF#0D@=!+]N8BL 4\IV2G!HY$' NF42OY^08X'OU4 MOM7+V&G&NG%+(K; !!QD>K?P$G+"EY8;

[ZVX'D05SVVH59<- M1XL!6U_IDJQE$/Y4>:HH0 T,#*3QTZ ZV8Q['V7,+/FCF"R2UH;B@R"4=K% MS86PXQSTW=^2E/ 3O.U)$84

N)8""T.0>L[U^2C79_!'#9OSQ&6'0F!P0&V;:>)3 Q:2L#C_0H M >40-RDZ8EC1^WBOVD8TNY.U#\H=K%) \GB2 3@_'FU&SH_'DA^/T1-G25L^/_J88.X_SK_F,_6O*

*M<1X0S@,"*0MW"F[^%+S>.!BX:E>?^DS&9AL42>%7=W1IRIV9NS-,=X;ISC#= M&28.@\1W:#KMR\3FC*G8WG3_ED4\9X/.LN@LBU@MB]T5!GOFQ#1\C,-YZ'OL*

M=_W.:)1Z#.DJU_@0#3=%BT8$!M!ZA1>$H+/Y.D6>)G\1.$!&%V MK"79_LO$PRQ8DX,^G{(JOK%R2L1'(\B+-,{F4DC--XS3#(D+C3.;[@8EKF,.#$%"/M+[MLAKC93#L2-K4U2(.&B,;9A,W&2K#\M->;,-

*H,9X&;AK>;KY!WH1V>C3V9RGUTL9 M&M;7TE<"KW@H?!! <6S+5OO1#6F, !B?:#*0U!F P_]MC+K092&L,P,!=?N,N MOQG4_[T'G&L?IO/"A>F:9@0>DJ5=WRZ[_"$E3'Z.L_-*

*G5;B'M.R0]'>SALMQ M[^48'QBY7/A1E1\G^F$E-H8J#$(O>=L0+17C1UK>Q>.X>!QW&5?WK+SX"6K; MGV@+8P]*XD]+*

[OZ,59M;,3)520M4>W&RE^[!'V%]71AO2U,R^CBXV!&+1U MZE6C?OJH KQZ7K,/)&A/TYB!;ZQKL@'F%Q1CF!WV8&V7S"0'9X+P-Q5!X=U MU8&I6P!T5D# D0V0G[W_|-*

<9V/H.B+#_ #'/4!^ABYY;,FNZ_G(GD:NL(! M[64]^*[' YI+T>QJ+;3<>MR"@G11[7T]Z?\C$3%;O&)(3+C=+<6DO0/FIXEN-MJD(,C-M[\"S@0$^5L-65]'4C-LD'@ 2_A4S M8:V<

*5"!!K/ JA?O#V6,4X9KGUP)RANG/ =)U0%EB%-6@Z35@#)$+95)4V! M&>(4MD)ENR*DX;ME4KG8'0&$+7GD9CB:*P>)CRQNED\<(K\)G*]0'L J=S? M1WY);)?@5 S4&6*A_'#] ?*

LB5 3'T[IWVS&2+M=#WN60/^ <\BTC^=:T MK:2/_Z7,NO[! ^:> N8BL 4\IV2G!HY$' NF42OY^08X_'OU4 MOM7+V&G&NG%+(K; !!QD>K?P$G+"EY8;

[ZVX'D05SVVH59<- M1XL!6U_IDJQE$/Y4>:HH0 T,#*3QTZ ZV8Q['V7,+/FCF"R2UH;B@R"4=K% MS86PXQSTW=^2E/ 3O.U)$84

N)8""T.0>L[U^2C79_!'#9OSQ&6'0F!P0&V;:>)3 Q:2L#C_0H M >40-RDZ8EC1^WBOVD8TNY.U#\H=K%) \GB2 3@_'FU&SH_'DA^/T1-G25L^/_J88.X_SK_F,_6O*

*M<1X0S@,"*0MW"F[^%+S>.!BX:E>?^DS&9AL42>%7=W1IRIV9NS-,=X;ISC#= M&28.@\1W:#KMR\3FC*G8WG3_ED4\9X/.LN@LBU@MB]T5!GOFQ#1\C,-YZ'OL*

M=_W.:)1Z#.DJU_@0#3=%BT8$!M!ZA1>$H+/Y.D6>)G\1.$!&%V MK"79_LO$PRQ8DX,^G{(JOK%R2L1'(\B+-,{F4DC--XS3#(D+C3.;[@8EKF,.#$%"/M+[MLAKC93#L2-K4U2(.&B,;9A,W&2K#\M->;,-

*H,9X&;AK>;KY!WH1V>C3V9RGUTL9 M&M;7TE<"KW@H?!! <6S+5OO1#6F, !B?:#*0U!F P_]MC+K092&L,P,!=?N,N MOQG4_[T'G&L?IO/"A>F:9@0>DJ5=WRZ[_"$E3'Z.L_-*

*G5;B'M.R0]'>SALMQ M[^48'QBY7/A1E1\G^F$E-H8J#$(O>=L0+17C1UK>Q>.X>!QW&5?WK+SX"6K; MGV@+8P]*XD]+*

[OZ,59M;,3)520M4>W&RE^[!'V%]71AO2U,R^CBXV!&+1U MZE6C?OJH KQZ7K,/)&A/TYB!;ZQKL@'F%Q1CF!WV8&V7S"0'9X+P-Q5!X=U MU8&I6P!T5D# D0V0G[W_|-*

*<9V/H.B+#_ #'/4!^ABYY;,FNZ_G(GD:NL(! M[64]^*[' YI+T>QJ+;3<>MR"@G11[7T]Z?\C$3%;O&)(3+C=+<6DO0/FIXEN-MJD(,C-M[\"S@0$^5L-65]'4C-LD'@ 2_A4S M8:V<5"!!K/ JA?O#V6,4X9KGUP)RANG/ =)U0%EB%-6@Z35@#)$+95)4V! M&>(4MD)ENR*DX;ME4KG8'0&$+7GD9CB:*P>)CRQNED\<(K\)G*]0'L J=S? M1WY);)?@5 S4&6*A_'#] ?*

*LB5 3'T[IWVS&2+M=#WN60/^ <\BTC^=:T MK:2/_Z7,NO[! ^:> NF#0D@=!+]

*7_HA3/S$BVUXGCC-$/.[#B0,')&8EHNF;6]S!K6L]:I 3)!T);JHR MR(PH?QCV 83@9ZSD&I(,W&(%W%L%\S##V07CN)VF9?"'!5N0=QY?<< F2VN:+ MMPT4^,,N=:"ZZ(82>!-_!%67'(88->??<5>+YJL8^5$$X5H,6C2.XLWXKM$Y M-= .&F?3-/;8;-N9/S4S3X]G'F!?U&4^9D+]D](@5^?=IDF:[*GVD9UT^@/NM M41%PN/UQ!L'3W"27_)NS!FORL;=%82?E0F3^LT7I.RI5#,9U62=<35|SVE.=ER[-80C:U!G.UCGX"M_*"<2;++*.P7S?>X&P7$N [# 2?AAX@2!&.GQDEF]-8XG;3Q@EE+S?!"C07RMG;3/S:$ASC<9QTO2/IAQ/JP)#&+ND|51L_>;M'^Z=/COE;2?KOXG9]]=SGY? M[:%H^XVOH>7]3 IY%&4);{IH+3Q^#'"!@_<#V$7KS%,T>O973BV!76PJ3 MJXG=?9;&\R&?4|^A+AT&OQ-^PR!@6HCUM(.\';V!G$_B_-)K!=*U">M,'. \0V$"|6ZI&^1U-\?L];2BEC1W<3=Z'(A*>$!7XA[<",7+=("9_(3>-U?>Z*M6AV!M.I9)[CU4I43H$59%+U=1>6]H,VN/'N(HNVW(s#?T]PJFV^$2 EQJK_X M\[LTND\S87%=2//S0#3F']1D_$!7;/L,&2=?<$F_M5(.=2)28@*]NU1(>N0M\"I5"ES!U$EE&I39.$K!H5I>Y>) EESERS@N=N!F[2*W!^,R]5[\A6:J@_$3 MG:F.CWZ,33TP]#, %SZ*>MH1MRFC M0OP8U=/O)SB A^8^R@3%RC6EU4){Q^YK^\7RWO9^\'2Z@^(QZ M'IN6+$5]J<=?8#B(JH_'9S4@8/&(<+ MH1&=UT044,GR[+N.Z= %45M3,:*#LPJB)$UR2-,@K>G#[-A#@[,;CN!95? 4?!C,YM&ON ?"DA4]:!,@'1G[$;UCKLS)6 MM1E,-&HG&K43K>,\?PP2>Z#&5@Q#5?^E2,3W9VPK_JB|&;A@2T,8G@]73.+B MN9[)ZZ-Z)LU/Y%H@2)8U@B=[JYLNN$$A%{U5=+3QG+_ 4WWD.W[&X]31CA]OJ MSE_:WWSP\W*^^YR_/*'MYXBWYO:?8<+ZWX!R/N&H7(_^7GO+SVIG^5G%][2?.MG^/+f5;XOHMW.KA4+.TY;G9A++!-WJ!B0(YL_%'+N74V02IBNWMK^6"'7'Z\.MN9'1OKQILT#VXSK0V2A:5Y?6]%8Q<%(?!PIH]+S_3(DXYPF[$ M<+;L>3ND3C#OHRKJ:\#Q:M0W:*O-/85OQ#8_J M8SIDDSFQ7^;C@5UWS3O(&.(MWR :9@7M+,W,0@V_!A,B4.D7WN+[2*R+"I*T+MRKS&LXV=IVA:2#.D)R_EM=GHR],ND*O=-2]A@S3X%*CO;6);WI0B6T]M@#M^RN]$THP?=<,BO#1I^K]ET M*3^_!PV3TTZDPBOE2(61)PTB%5X%BE1X92}2P7@*]B(57!U I,(8CS -JOF+ M5M+:.YG^NZD91<4_/]Y>Z3.-%KRHU(B(ZZNI%8 MOU X>M!D"2&O#_26;J(TY]]?=#'.D)!]\>#XX:1RQL1BG-!?7RD8@7I)>X-F" M-+B1&CG28D=ZZ,D:#R&@&!VO@_(DUVDP(.64$'2Q*9\K;HC3QILRN>[-N'S5 M>YNR\13L;Q=31-G0BE.!P0<'(HU[#'D]69K-6YKKC\V:06K)=.7^2D'ZJ9!EG+WMT_)S.N:D0(^#M'"TX;DO"57?;G1@%Z3%B0!29^)4W_U.?@7$PB2 X->+65L$ MRP=E[9U#\4T;!^G .|>YVYW#^C1='+Y/;Q-1Y;VQ_]7NXF\8>!%L[&-[(_D M8R.1$$]R*Y&H?0&;R<&]8;>3H:4PK6"91;&,GG_@_T%TV$*\CZIXJ0".,:\V MN!"!C*N.6TYG;+S;Z! A1&U-#*%\R8|('W'X&953U<6L;B;],M$>]A:*@>=L-MCEE+CVB6"W)H'Q04WI11L"/P0>$!MP<%ZI,T=#%-3_<$JGWHG0ZTR&O(;6.5+$A.JV8L/K9HOP5#M7!$WRU$C]7PL8I%XXM$#KD]0)AYNN4EE*\YZ*]B#=7!?0!0.J3\K.)2O&#X-[MO3S2]F9G03C&:1QE4 >3HP;C5L^_*_?0X%BL^/&*)#39Q;+>Y.I@!8,TC74F M_,P3FYFW>WXKVM\V!]_F+]%1^!RW80-]L@^TE3&1#:*-8'OH"TF$5ST7(B]MSZ]ZG(\3HCMZ]C-I+ ^V92.8'8(MT"].=VHY(,"=+^!L(O/I9FJ5U:,,%!7*7X M\0TW*\+%8B'Q.[GP+,UY>(F !J5P%/8L<"& 3^^:!Y7^]L4%^6!Y$4OH-.?A6E'=4=0W\TE15F"Q"A^-]/4]UEQ8]FT/NI/M#TUA4'NY'24SB1<*Z@:%|!0_Z.CC#G-BX+"LT^ 0MW#9+CE.K9(XZKV=G9K*MTZH4DV_JE6K6]K8*Q;@5/=-P)C;\;?.N2=X#QHJLH>W(5Q^TR MP6'1<@2:^QM HC#;E@O" M2KC5NFIE*]$KK+O)T+^9=CM=9&NUAX>"/L!V']]!TN'R[5'LZ6VMG+9)?522 MB/"_=YFXAQ-W/#6^_;IN(2ZS42S+S!?F-V#=?X_;)SC@G)YMKX_:R5GVZE/X M\G-.U>=Z6AFN+M=(EK3\6$5%4[?H3U7TL/>;>RW1_/+/#EIBG]QYU^$-O9RM^L6RTF[@[VY]-8US,I3[{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{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}R[=19*;86U;47\%SYIX-G4DD3LWZ&43V MBS>)!F=U4G:2);J'-9[J7%FX[N]-X[=E3$U+LP\+2X%5#"]IWZ9%6=UQ%HC7 M]'7=SOXZ_\A)+DKLO7KUZN7Y[^/U1&O8ZYL-<"X5F_"%5+CLB --G MUN)#M7KV"UL'GW^-+(3N=L8/BR"M!EJHAR_TD60)< 6(8E9FNA6G5%2IT>7($&)I3 MGW_/8?Y^]CVPUJNHZBMJ(%S+HT1C6"!"%&^_S[P73_=ZD2["CF3J0PU*28U 0M]\@1HC]+)E,R$_I(:/'!=K_K[>=W.#K;U\B@#8[:IEZ51T6WGC*]E_EI M.S9\&S%;]<<++8F_"),VNK>L$;UC=']'G7]]#2PLQ7Q$;"P+ M'K*W !@\BJBH&2;4,8G:!{>?]%3&-\;JRJ1Z$-VORZI(XZH+81.',HAZEP'M M=8]IB%Z+/A-VGZ4/ N] (3L6F)XY6#=_"=5\YTIV&==]2F?M92:D6R2.'YZF MA:,VMUS!O.^W(;G M5$AQH1+J<$#L8/$F],#507WCU.M!6DK\[5XD2>.&.&8F7B$//# B7=HI#QQFW(>'5$IB*.(S\L UA(92O8;>E]= MY?R4(=;PEB9T(WH77<$M3I1QO.],&OYID^XV7<+(D("CX.1/2T M!=XG)1 7NX >Z?!;D Y#4J-(.AQ)C23Y0@ABT@!)SGU;3[B7[U8Q6D.DT\@!QZ"W&@4KYM;=7!SM(\L M9(_>GF51EW[>%BF?Z19R?:7ET%S%!S<.9J1TV Q063E'1Z9EGN^B[V-^1#T M*K=T=-(?U>812AUZ*4.IK63A N*6/Y;'51)36N<'GHYY#EDD1X51D;B0= M-:0;_&[|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f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|-BWC*/L3C0JNMJY$U>!MYA*J&G-<\L1XB9S19/1O@OX :Q< M%DT!"G-S-(61^362W?G:N%-J,(+R2%#Y4B"EW(!RQV3$C>.7CBIDSR@>UZT M[$V3-_4>5$<-4[!95G240>;V6#67/$]0,.YX%6PL^-VMTR'GR0=U/64L!0;HTW_+O#H59Z5F$33,_X@Z:IO^V WG_6\A& MR;\&^&/2H]!?P$?ZD_.X>\Z]?>8(X9R?T?(Y$4MPO%)32D>/6FL$ML1?2M$ M<98V7!W MO<|'\]],.P13II.W+?XV?5A7UZM/W#P%L_3Z'OIT0LVMR_Q&A)|WK)B7TLW MD2'/(]:A1&11H.!9%_6A0&*&#/$*T40,>#N7+O#V$J6O9FN.,,$ T)E !4HH*V W-V=-F9"EV< MLNOEAA8/7%9^+MA3M8:\]2@_-$D5GT8S\>"HKOFY9HL&-I'-20TI$<(M,TY=I M$BW0O?7;**9+TPN&\>G5 GA89Q8.5Q,?UCRV#AU7>RO,YDCA M=(?_N(FRI(6NY_P4D??&\W33BY@0@9HH UF(Q,D39N^6'I-LVS, MP!MZ"|,%O<\'4_Z4'$'%#.!|4<4 3>P!3K(&R-.HXWU:M\Q8J-R,![QX7G MJ]*;J;O&J<<--MVA8;W=.O: DU\|/!'P_6;B*Q.9Z5+.WX$EA<8H>5+NQXN/ MG5>FG\8>5X9!79:&0:/.JS8F@G&W&M@+\A!2D.8D\H,JS!-]OE3]7<#_3Q4 M'K6C2N]\=.T85J,"!$EHT+O#CA;JQ/*7.@TYW)'^!U%&Y=AUU.A3V+3I_=&|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fF(>%#@N7.4<32X04JIN) R\8\TTZ(T=SB#H(6'#,#-RF3S5YZ"-MM[U_B&LF=_Q1HCERE]6.OH_/FWN6'0C#Z,|(}C>.*Z9O/&>2FC>O3W#-&.S MA4Y=YZ-O3N=+?LW=1OC=|@%N(8X2=9;XJ:JJP7/3X4@H]>_O3=2|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|'^W"I6 M19F>=7 'K_2#684Q5/:0^:=_ ^/'5^0|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|MILDNH]>K%KD+]2N5^FIOHV58(I@G.NT&@_P%;28+$B-BW;3%5>Z3G=1F"FE M0YMR>@:<&[,M@+%&HA(X\3]V.Z?G%(!?]M&-K1@B70)W##(#[%XVG9'1J MF)JG)187F./-A<9,9^0H0XT=QSN1+F2F:?M'&J: M4;T?:P!PR+(E<]0=/]L,DRPD$TT6H9QIWAXC^2D[.<)*(F+2=8H05N()X(\V M-9MYU1X**D7M*;J(T.,'I(FN!A2GKI2M(S)2$IZ%B M/N?0AAC*8M#D\C/4ZUENX"^,OID,RX7R&8-Y$IHH##GK95!5H5;CMS<)?QNEA:A2[))Y€N2M$)-(-R]+X6?YW(@)$M^WVD)"0#<5[;CR-"|":DA|"2#3(K_6_H>]-]->%&1/+-;EW]Y@>-YIT2S M1!G0;+2F!/_'%N7MBAN)_,(CJ:^AG9]PUVBYE"T MS'&B_?U)2^TATR&$=9"><_FXYZ_@&^&)!@K18 MG)PIJ;<4S(B^?G,'A NWG ^&GGK6)&?@<$SGUPDBJCZD\WV2DH=Q]-/D\:?& M)IO=\'^]4R8>OBFIP4.>:"7+FSNY%M]FX!_>$6LD.:AT%8GFMT-6E7M<)B#2YMRLNJ$&F=T@-T/L)-N]\;U//\2 >,_H('(TM\6:1ZGVR@3)3FB."YV/8?A7A+_ MOT_EL0;K"Z;UA,QT74[C#/#^]G8%_U(!'W&EZ/> >-X{JX,H8-GA MU%;KX)M5AU;3Z;)\@ZG!-*

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{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f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f=O:0G:%^[B[+ZSW0V D?G9;175P6(I_+BSV0+M%=/*4+D@+0IQ0"@P/0% $86]PLK]6Q7ZO-(B>Z7TQQX/Q^,4MFCQZ-]&#E-K,E3MI1A$F2 M,:N2-"(=0G+-->)A97!)#N7Y[#QNXO*P*L6:O65'(0Y90(T/B]_0"1DHG!_9RMFIG$0%O>+,\'81 :]I1#84%;),AIS,G877[?3FB7)_P< JHC@5FG+9(!M(,: MB#![FKJ)1]A"I%W?>FAO{HT'CQ;& UD,=Y@&F#(^()IS&Q=D=N>O^WX 8$?MD0C6*JRK#N.:#N*F$GTS/V_ MSMKXJQI87?3YE!1.0^XUE_&WK\"'>T-?\Y)) < ML T49]M3HR-\@AW.4.1TP?H61UW\3$35(2U^DK3(Z0- T!-D*)(F]|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}[ATV1E6GK3RQC?OF,S:A[#V%789>@3))?VA?#GR^S Q+GI+GS#]B^[@ ME2 '[7?'MZQH509F$A&595)2=BU>K8H)G\KBJ0&B91JY.6D9\SZRN5EC%,6%ISSYO4P'X ML+E'&3BDJ3U/Y3EV"VAS#^(S:7DKO&&3K?Q8X1.,%=(<5Z'U",%-_U\&<7K_6=UF!SKDU6U8'OZ^1@C*@U"\@M=>Q:0UW/ MY Y;(M&%@GZ \-%,IZ,@4'(PIT;PRQ=6V?0J^^GHDH'7;*J*WO"N-8$XBO?+ M@XKB1+6%*^I-(BO$9N@76'N3UUYJC[E=8C7Y1 1QE+Z&,8%W=:W2\C6MGBC- MVOXWRSRY*1@]57P$=Q-V[*QM@Q,-&!NK"<2UN##[F7"+6IC]Z%W&UKG,0?MM,%*.VC. ,;1MY+!4*&+TLUMDF=J@=0K0W,RLK-6IFN]'/A$[AOK8J'L,]$/H MKI7%)Z@@E(FBTA ,6J9[T0PNMF:7_=JAH]X*$]N:T>P.]X:GUY#0^O@.J<7MN]DB&UJ,YUN//H39WX\&) ^]H/)]5 M7",48 \=9PFF1C!ON^!^.;1/.3=FN/WQ=Y]\2Z"AM"=5S&@9?D'LI168]NB #9%65>OB6J/L56!O,_?1N'$'IJD MP9.\]#'}6EC,\IV]^D)\SYQ+?'>T\]EB<>9HW?P%R<&63).)89)2!)[!<-U(MKJ6TK1++)>8P#+>"@)LYF+%^02!AP_[*CN\QW+Q<$:!(F#&Z LDR!7(9FT6#>MY]H7YWN\,VB_AS&>.5,.WDC.I@HBVC>5F=A85D?>/<@JJV=LD#;IOT{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f'1X9-$AL*$^#+2R;1167GI?0 M7&%(G'3>PTB3ROA>MG 51+1%R 7;]5=8LA426&NPI3)]S,[*[+ MB:N#&UJD#/[+;..Q ^%,+(WM5%'L8G+;6V$/5GPHQ)!W?,(@$F.B1*F3TB_#MXF"L,"96T/#P\I&/3,NEU9I/6V-B#CVFL-W7"0;\R++(0]=_XIC?;E@@&(C& M6)8D@#E9.2LZX[4#G6$^)EYGX&%[TAFO ^H,G\)2QIC-,"!:DFYXE$6!.ELZ.MH7%_PQ^B14$3>]UN:C_%-0F^*VW;* MXO8NF$3-\|#3)]1IS-$>@)NH^*|HVQWF32@\B8HI&AS1RRW ,&C]0!U+,|"4 M2MN767Y,C0H2=A;X& EF&\45 3X@A<2W#O4H6/1A7XE>A>Q/,KJ>D'Z6Z1C*F$WS60G M)@8V*$2[Y*U3K"XSE4CW&?RVE0ZQB).4$ZK<996,Y!T@6HA]%L?PS,+Z& K[M^S3C1C'+Z8T_ E\F22]9;,FKU]Q(TZ3\9_;+-PRB;HI1-\4N,&_34J5.F*G#\#910@/H'H0. M,D/Z& ^<3N3W4?%76EVON"T#UP!M(.":+JN-0B0><@B,]M$$Y;S+&N=0B0]I M$.H%YKV O?*?_N''5Z]>_G%Y][[I7QW_L>O\>=LYW0P#LN11!RM(UK2!.I MDR: [&+9F-E8$ZNG>%$N*%$\R \\;'Z6[PT:X#C?@VYX%C;:AXU#O43 RKG> M:"[X';R4,SC9T_T0_P\?I\$<):!JRV\797^7_I*

- *+_'MUN%QU$!NN/#NN]] MU.64P/D3H"_D%0AZA[0Z'?,@U7XMXG[&8H(A8E(5^(?I4M&"'"*1ER:E;AY5$ M#X-;U]1S6*8_',]/%/H 8!2/FV:/B3)O9/@Z%N1S7HRVQ.0'(YRMM,F6:A M@S^7T-M=%+%XDY89QOLI=0>_HY^HU1^"O!S)M8RBIX9V3(-K!%"3NT2(<7M^14P(P*U8(UU\>LV'X>HL1C>N/X#K;#8]$W!'M.$)]^?/Y40MM &*W0XSU38 MQ0^$Y'A]@,IM/B@lOA*EQ\6ERZH-$(I:7(+PM<','L$!\;3HJ/HNS2Z3S.!MS@=.H1T_]HQ&Y\^_@.31\8%=\Z+LJH!]4!1FB;KD C"@@HD9OIT\U<(7\2O M_*P07Z7Q!K;H_?C(GF*L?D9&6+FJ;Z] .H:@GVFL UPT'SE/EP_\TP,W!YI? M:H.<|%Y%13>H@?!R>E3$13\VP=41/^%TM9!"EO?M3>NR3>.,J!D3UM7/!^BAO7-$F/-M-BX%^GGFKDMM{II\PXB!D?VQ%V7!A=TZ0^XBX%^EFXVP7EGS0E(":J/$X_MBKW7'1C2>17&@IY)N%WA$GPY15MS,/8U;QM,VN(D@>X_I[B$Z9#-L^I\JZTZ M)]\P4IV#(WM2G6]/475.D_I(=2K0SS-W+;6Y;_(-(^X:'-EC0OC)<=>&!:.M+0@9/[TA[>9/2(7OJ ML,&[!\X$A3)!(2,3IEHOW@2O\ ROH[^=-M^]AMH]@&/?H@=E\^&M!7^;/CR)AJ8#;PKU@597!.Z@Y>D7)5 X<4@O,?_DBH M[*7]{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j:@"$G+PD-!B'O3",?' M);&8YSD%1T1:'+88$9$=$8Z*M#ALY_G--V#"X9 6A.V$@V.>A&/AD.PKMB## M(9&6=BW>0V2\!. (N2?TPFY:X0A)"BOA73_<@C>L>]P {dR;6S@BCEAZ-MP,XT<&\|+,#DB[UZ(02CAF#@BJ,*"6. "P,"+_@\L)1 MX*Q%X8O %AA+|<9$?.WA$1,TM\7B[^^.H" #_JDQ9-+'9$^+"2*3!R^BP9^3 M=(E0ED[\2OQ>%\]LDL=>'H09VG M#)4\M(6&5+ZCH)M+RPRIW;O.O?W$L? MBC5%,.%YZU+PE"4I?5?MA16?_ACZOOT;BV\\5ZHNTRS2R^L<2}TWR(?A8^4 MFN\H@U'/ZV*:[P*+!M>A]Q!&81:B5,@ O[U9ZH.@\'(@IY(7!E?QN;<.,R_: M$8=9,([FN4G3#CYT"-E@KFQV\8&.J=>NIS& M ?WGXJ^<; P1H2B=~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{RI!]AU0,4W./"H,&]M176.NKHP'@N;&V8\HRH"6E6Q;4S*=YKI6,K4B'V.\I*[,B>SR!UKTU/-MTV&/ANFC%T;4-G;/=P2HRD&++MP0E1^F)UTUL1C4W6-_E)TM] H6J[!]/]0+ MUT%#RI%0IV+7=QSC?8KX.PZLD^%TD2DBB@W-I_.%G.,1+I(4\-D]3',12&" M7!++]C\9]T)G|>Y@MS_,T(_@F!.8HIPH=C; G_PONO68!JLP#NDJIB5*^1]0KO/H;N! JLG?$4W0@H(I4AS,/H8VK]SM.@ES-I*

*+_'MUN%QU$!NN/#NN]] MU.64P/D3H"_D%0AZA[0Z'?,@U7XMXG[&8H(A8E(5^(?I4M&"'"*1ER:E;AY5$ M#X-;U]1S6*8_',]/%/H 8!2/FV:/B3)O9/@Z%N1S7HRVQ.0'(YRMM,F6:A M@S^7T-M=%+%XDY89QOLI=0>_HY^HU1^"O!S)M8RBIX9V3(-K!%"3NT2(<7M^14P(P*U8(UU\>LV'X>HL1C>N/X#K;#8]$W!'M.$)]^?/Y40MM &*W0XSU38 MQ0^$Y'A]@,IM/B@lOA*EQ\6ERZH-$(I:7(+PM<','L$!\;3HJ/HNS2Z3S.!MS@=.H1T_]HQ&Y\^_@.31\8%=\Z+LJH!]4!1FB;KD C"@@HD9OIT\U<(7\2O M_*P07Z7Q!K;H_?C(GF*L?D9&6+FJ;Z] .H:@GVFL UPT'SE/EP_\TP,W!YI? M:H.<|%Y%13>H@?!R>E3$13\VP=41/^%TM9!"EO?M3>NR3>.,J!D3UM7/!^BAO7-$F/-M-BX%^GGFKDMM{II\PXB!D?VQ%V7!A=TZ0^XBX%^EFXVP7EGS0E(":J/$X_MBKW7'1C2>17&@IY)N%WA$GPY15MS,/8U;QM,VN(D@>X_I[B$Z9#-L^I\JZTZ M)]\P4IV#(WM2G6]/475.D_I(=2K0SS-W+;6Y;_(-(^X:'-EC0OC)<=>&!:.M+0@9/[TA[>9/2(7OJ ML,&[!\X$A3)!(2,3IEHOW@2O\ ROH[^=-M^]AMH]@&/?H@=E\^&M!7^;/CR)AJ8#;PKU@597!.Z@Y>D7)5 X<4@O,?_DBH M[*7]{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j:@"$G+PD-!B'O3",?' M);&8YSD%1T1:'+88$9$=$8Z*M#ALY_G--V#"X9 6A.V$@V.>A&/AD.PKMB## M(9&6=BW>0V2\!. (N2?TPFY:X0A)"BOA73_<@C>L>]P {dR;6S@BCEAZ-MP,XT<&\|+,#DB[UZ(02CAF#@BJ,*"6. "P,"+_@\L)1 MX*Q%X8O %AA+|<9$?.WA$1,TM\7B[^^.H" #_JDQ9-+'9$^+"2*3!R^BP9^3 M=(E0ED[\2OQ>%\]LDL=>'H09VG M#)4\M(6&5+ZCH)M+RPRIW;O.O?W$L? MBC5%,.%YZU+PE"4I?5?MA16?_ACZOOT;BV\\5ZHNTRS2R^L<2}TWR(?A8^4 MFN\H@U'/ZV*:[P*+!M>A]Q!&81:B5,@ O[U9ZH.@\'(@IY(7!E?QN;<.,R_: M$8=9,([FN4G3#CYT"-E@KFQV\8&.J=>NIS& M ?WGXJ^<; P1H2B=~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{RI!]AU0,4W./"H,&]M176.NKHP'@N;&V8\HRH"6E6Q;4S*=YKI6,K4B'V.\I*[,B>SR!UKTU/-MTV&/ANFC%T;4-G;/=P2HRD&++MP0E1^F)UTUL1C4W6-_E)TM] H6J[!]/]0+ MUT%#RI%0IV+7=QSC?8KX.PZLD^%TD2DBB@W-I_.%G.,1+I(4\-D]3',12&" M7!++]C\9]T)G|>Y@MS_,T(_@F!.8HIPH=C; G_PONO68!JLP#NDJIB5*^1]0KO/H;N! JLG?$4W0@H(I4AS,/H8VK]SM.@ES-I*

*M"!X<\|#K\BX JK*Nf#%B=K&2HN;*:22%CXH>Y-1>(X66T-C5W<8S&&C8=]D. MO)L^E^#$1,K,JK9VPB.RM+OBWB0W9R2,@=WY-MF^LK@W'QWX-%F_IMI=K{OB M{@2'2J,W17>,48-:A?*W=G#ATB7I&^!M ?&);&{A1W9!A^|=&>Z3U"9C"0H M4]OH]+Z3>DVO?G<*E+;RN)L&_YVG9:*W>|S(RE2>D+/YYBB\BB^>?43.@?EA MAJ*#VXXN7Z'!*^\,)30ESLG^$?8-T374Q FDO0ZRZ*A$@_[=2Q*/H%8Z%G\A MYVB\N"G2OI3+NY%%$8- .}5&"FY(;]'0=!+'ZL3VG<7515.P\$O, U[UK(OEP M@GKI(I&U&NH/>O&,$Cl,CS(CM!BA.](+A*@5/TE1Z7._CL*,/1ND1^B8]#:@ M\P=\,/RQ.4H MO-1'IEYK'Y,;G8_^EQZ3].*VS>QB#3F)/_<"PWGDT1E>VMF:(DK$##?O*1,;= MWIGMS89S%-HC71$XM).""S"WK=TN_,.@4DTGT)PIBSMI=2FU&F@.`XFXR)5IYY?:&2\30/>T2P_MP QO1<TF/P^,WH\]TDL%"R+ Ml),15(;]2_[=N%#M^B,-0:?@)OU0?W#2IQ . M>'W&B 98 D5QOG9V!D5HV9$Q3N. 3HI!KKRH3HL,_YW;;&8Z ;V#VH/#=_14 M/%+B]ZBS/7S={(K)"0C^KY-GIDY<$1'*?SEAKL-"QL $#F>=W3[#C M\;-?*
LZBIJ2A$=P6=11J<,XB . M),Y,&)EM5_;.W#E)QL),-F7I7/+^)+,Q'8G0+Z&[A60[,D(KF',2C!@/R;LY
*MYS88%8IX9G_GCG#U*21Y#>1*ZHGV4ZLKX)PHMV/6IH[^#O!868]O]^MZ5A!9\ MJ%H'Q'67NL(ZF#H-W>XPDT5&/Z"-$BPW)]"+#!;[.7CN;<5%;_02',=!;P&M M@Y+A. U:%V@;1PR':1CIYO2M2)5H53B;+FL)<`]#.%Y.* =M';?@<+#DA[W,B M(>%(2(OSUHE7K5+?P(&2ST4W4*:T]C ;;M#N0UM#9$]0+;?<`$!DLDO! ?'M$:%<(K$1')M!"^(=Q=? T7/98J_HV\'#RZ.VZ_<:(D]AD,'E\SMATYG6BGF3?1%;B:$PDA\.C+3L;C-ZHO:.D M%1/6+@.M4E%I>"\-60S/EQY![RJ^1,F6\3Q/$2TH=1BX#VF]@1BB[R>(;*U?.M4/EO\;,9_$? UJ]*T7-_.TU5T'7H/4#5%,3>#"6_M*&2P_CYP3;KZ/0DSJ-4.L208=]CN$"0-(C&##_@ /> D3< (%^Z;Z0#;P MNU5X%+\HH]PVI?=$& M6^*& @&_AM,&7*|=DP@%U?5- XNK#Z0W:5<>]%R(U<4 M]I*&XO8'%#/;]U7KB2C/.JO+J0[7ERQ2TTNO / *PP35=VDWD1=GG$LY^0%Z M8W&@=7MVK\TK?^\Z$HRU"T"ZC#5\VM:8D:HB8TM"Y\$6**F-\J}C'=)E+$2?YIGB<)%GF^#)UY^!HPD6O/=I",)\.U/7YM3(S; AB@&Z8S MDX6Y>H2^?,Y, "XN3==H8@M?6LN4*6BUPT)W#P&Z@%%*N=.)(Z\K$ZQ2IG2\B M]HSDHRUZA,":TI0K!ZIE+5FSK$\!T'7F+,.) ,#;7FZ B- @^(#P8A:GE+, MU'8@\G4A5WMB8QXG>ZD10>P@\>*=" D-MN@-CNV
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|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`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dB

[KT3\'>S;N8T;MJQ&TE@]^2{GP_,5^6QD,9,8=!AZ'GU$/&H>CVH3%CEPCP^Q.M[ZXV;%\ M>\DLV5&KB7!6"}XLAL0]^^>IE)RG>,;,$";TP*>;EL(?L3A7SGZ@E(_"0OMER>*2';OE[?OW@KQ)1-QCWXY**=- MI>RC@"F%B/K9,MMVU[$D,U6GGCBIK=[IOK6%P0*C=4^T,Z\GMD@WN8C(=K>7-MNUOJKJ3.7=!=-NZVBX+CO _L,05OS?=*(,;:NUK!E;3X">ML!6= (93?R2). MN*(HNX-%'(@%4D&OON*FO CMR%^S^3U1)E.O<%'BBF_PCF,Y;7)6X@;> 7KT MP,&9- ?<'CUP<'"-;=!#QQ<2G/ [=$#!_\NS0&WAUD.=C;Z0L85'-_,!GU" ML.[>?!*#>V'[.9[6?#QM!W1R[N._HZ?B$1MK2.>^YGO^D**_V M[9/J>_)NWAKEM^Z;0%"#/;6^4>1$7"H,)43?8RAU6 MI/$8XS_&^#+4/G&BfLI;P!D>N,*Z{7W!AA=LD9\ 2.B8=SR"Q M%Y KZ(@$-2PM%[5#%^0PNI&/=T=_$N9R4+N,=R7=A\I.K3^JU!4T)3*\&U# MS@$"D8[JGOG$LWPT)$,WG(.FZ.EQ''>'_JRX;I2G! #YS)3P[<+P&59=ZFI MK4<'C<^@ +OG Z/SB #K*H9%@E'YU "7I:U;G=F>V= NS[0)F);2 MP.$Y9)P1W<"P0-+\.'=ZLRT1L A%5U8/R.X)SA3ARN*11H6;M,*5HT<:%6[^ M#%>V%#@JH'0TSFD"7#E%Z/WARCZK?H/B\B21W5';I;EQ18V$HR;.A.J*T@C' MI&V^8S!BGUQ!#)[$$(S-9V>PT9H$TI4=RD3[LLWI+%^@4K] JD(N`YDPX$ M! VJ[$XM'PA0O"C!KG3S08'#B9N%ER&,.4HZR, ^ MX[H\E7G,"HL3G[/&Q#*C*_7H2LUUI98T2(U>TJ_'2[K9,'"8"+G3#=85*!N5 M0@Q3QUS!0'RMR5:=7;FT8\T#!>NQ*Y"(IP7'0.D*';*M5L+PX=PM;8>>)08[M#MGL"6)M*CIKNMA_WT(5;(KK;P-Q#5=(PUMW&:"VTQB[fN@NX>GW8@Nf\ MN@O:L@[PWEUN@OPL@YKL5&UNV@MN\'H_6;QN_@N:X%76BRDR1TI(T4+HU+>R/[I&VN$<.PHEP="?B MG[-$F)ZC<.>H->Y#=$3!)/[D)L@YK5J%.$0(T7H>4>(M4*&.? R&[9\'^7"K$ M.?)=]JU.QI\O?KV3V-HWI17I<<3&)TE)H'/V#[T]^'O'M%-/^KN)KW\8" M)W=63_HK^+:,6MF)>3]@_A9I1S'64+T#MR+:*DXI?[&?=++HR%?:-W@: M_P# IKW=/!=OGS[!]29$^NfI.Z*0_NL [XP+?I1E[=)8?G>5'9_G1(W@P\L&6 M8S+FAK/:(WA=2+3D_4EFHR=%;S;.[l.?B+BTZI[ARC7]>L5W>1 G\JZ4(:I9!_$;^R22]P;(K58IZ[.L%7/KBW*)H@QC' MOI(Y,.[]GRTPE*U^L)T6LF29H?%0EM':,0+7DVQ#>8X-!T M8$2W/!+6,I# !^!B*84LH1O>9JGOAB\8 S^9W7H12;L &LYU1:]]BLL+0]KRF M;Z6',#L\!M##!@ZXGAJ@/J9#?A"1/9;3./B"'E&$UY2P:AZ+ G^@/D6$NFFP"N.0R&P>S055$%?E:;S!:9'<+KV(0G)2%(L T7N7V$4#OJ]>^3[:5O:7W.F90MMPZ.)N?1I.R42=G:W.D=Z#G=2'4!R+ ^H@4M.ZN M2*U#1"NS=?7QN?V),)4#KDOJY[0_U!'+?*7_Pl02P,$% @ L(AG6; S MI?4ICP$ +DT4 !0 !A=F=R.C R-# Y.S!?.3!Q+FAT;>Rl;7?B2+8N_+GK.M5^BENTYEK@5.)&9G%G>1-LITJ4S;#7_I'_Z-+/)8^11W? JU,K/MQ>6'#R\O+QOM#^13_T'Z@8]7SZX_YW[H/ZK+6+'6G[20W'D%!H?L&[9L]Z@Y?.6&K8R\]SXX?}^_S969F@N^P_C5[M&AE[[M@C\5K&M81__W\'C;!H=4=6MJF'/9)KM+WB6V:O5NK2$N\R6/_AF]H?33P)#A MJ]DUGE2OU:6:*/DO<:R. ,9]TVR%V8X7N@G:W##9(L0Z M6NC'$]E:H@5;1E,2.[OPY3ZQ!G, [%.8M%^;V"HEX/Q)KF_BU9XZN(E,UYFCM MVZ/K+S>83/_)NE",>8!0|^:B(AR^[>2#M5U'NC.7PC9%JG]`KS;2 M+3S14(T^ADP&;JLF7=3]K\O/3^O+D)_)0I%)5\K&J?<:RX?- ""B8YB;F0|&^ M-F_%,4TB)=_"W^A_NO85"RL14,3*^]Z[*K/P)^DGZ],P'-TVHV;A?KC^;D6- M>+6BKCU(F.I)EA>AW$8_6'M8M(-[<+D3?AT$?]- M$"\|\&*8M:T)-$,4/'38YH7TI-B]%47CX+M1J1(/-D2T+=\XU|)>#GW^M7!DZ M09A=>R1SJPB*^[N0%9L [P-391_ZGSZXT_PT,=0WP;+?_=2)<4_)DS<+_19>" M6%_8'P7VAZD\Q]K;I?_?SF&_? $1SY$EW*$7863,9=WIXT=A(;M4L5X*=:P+ M]0L1ZQ\%@A;+,.'\%V;&-CV1C5/SLCZ1B.Z')Y*6ZH/Z&7Z7H!-'IOLC5E6D MD]F1G\D3=Y1)L.*NY- 4>40VL_ION!=WTNNCl\V*M1GM!E*B<(/UY>&PKYHF[? M8$N1M0?R"D.](7^S*@(F:,&OS[6.6.]6^OIL?/JP-E*Z(.\+R>;YN+U*GWXY.MY9&O& (<&!A[]ZC7!57!HL5[!UXCN)/HDY=$'9-$]6[@/F/ZT-21AC*FL62GG MH4XXZ>V*C&C*VBUAFM??T-O:P%*E7R$#]E??/IGGD^&ULT M4(T%$7+K<^IDN$>A$VHGG="- *2M4EWMOJK5)EO6_?0/ MV23&K7UOCO#8!5Z\8JEV)BJ\U/H2!

^Z)\) M>X2|G=. %L TIGR4/- M^DEXZ"B-LZ^?'7 . < X'G"_FYIQC+[Y+@XN(N5D56\|+P$MGG7:$G[.I)6:F MQ/?FI[$$RO>)%

M"7XB_YT8ZAN=K4SVO/_33RL_>M#1'>$YH&.0H01%DRU"IX7QCTV9\] M_8UWW?WXOGQ9D%L4(J21^5%8&V#WSFVLF"RAN=RCV3*"\S#X,JQ]'@'T`OJ4& M-X_#T;4@:R_RF^6S#XU.Z&ACX!ER5R!11'AQF;_7V?^%A6R\CRH?-E?|!7H4 MNEJZ96M#KK:?+>#Q\+|C7 U&'\5;K[=_S'F M9ZIO"%UVR#$"J>_YF=0GW'IW]POVS'

*L65]TTDYW=$T*JR8+/=$ M W/8*4C3/$6Q _-U:R,KR=_?[4ZP_TJ^&2\K$*F!3AZV5W]29F494$=64KBZR MS<'$OB+9)YA]PC!UM(5XTC&(?">T)F9[>Z?2XB IY*QQ_%@,?*

D=.6L)W M\OV9)0P)8M7U/^2U2."_"=-4'E3S7(PWXYP3\(P'_',H_;A8,1TP']L'D:AI< MH8:CI+HSU6K[Y[IH.L?PR3;"CQQ39F0E3S7BQA*EIS_5C@4S9O3)C03]*_E&=L8*

*M6>>"RWGDR:?ED9$M"X8"(F4Z%$?RK_!)QE><0I2X:9'3 MC-=+K<0E"R6*PN4'M6$-SQHKU#:R0*W4:W.)6H[47WE:-7F=YE>]PP3;$$Q$ M0*M@#0FZIO?*

*I7^G/"CTD./0.3ZR'GA-NBW,\./T8(5)J9^N./*VM*&/P0B.._MI&-Y#@>LD5VE?XT61"1BF6EVVKY.GAMDZ_\KPP7&&=E;X>96*]Z5=+-O-K2"Q MR<\:NX%EH*N# ,T3YC!)3:*

L."]PJ;2X#6MF=^@OX92X%9O\XI8CQ5B>8X.G M&(/8HI=4]6AB"]BR'%:MKQ@6.4.I0?`3WTQNL M$^^30^$5I3Z1/]<>V9-

VEFYPU5B:.RR5%KIA30XA=:WO]Y\X,98MX=RP%X2HO5L':(AZK"_M5+':]6=7`IPGS5>Z ^.=H;,0$]8YB$; MECH45SV>#[YBM=GM\@M@CK1FZEA6G8;9,'Z<-

T8=H$+RF<%4.T MWH-I/&.+XI; B1P4Z7VE[CEQ8AD:LJE"]$;Z;9@8CHL M/2Q<>[\YX/T&9I6@E+L+N<'6 +&BGPWRAN!.6YW.\GCPABD6^$NQY5"E*

*M.T"Z"1:@(!F3+F'Y%:L'1G0X(PT_G_V7O7YL:1'%W\X_:O8-1NGZV*B-R2-M2^[NXPB5RZ!V23TI98;MFXGV_,%!BRF(W1:IYLG M71+%$8@"2)/*@PNLJK6-XF_^9J-K>*

*<5\;NF:7[S/@2Y9ANJF/:G?-2*ID2 M<-7I,O'\;Y.!LEXD[<;^Q7+5J93PI3]%GI)-RP35D+%6_.D-+I'[>)E5',$1, M[<@;G%M9QI'%<[75*N:?%3@DXI?@9.X>OWR:+Y^WYNH-*

*]0DIUPI8V-'MR#BF_MK+0<^ZGN,W=V.F=]X3;K)=10A>>>=I*_3;90ZDYIBZ=QKU>B/,6D2?MA)RHQ63P-NE(VQ:3B\X>:[%4LG!0)_]I_-;M'LWC6Y&F]\=]]I=26>6>UH-M*

*MY"W!KE_"IA,"GL&,CZ_?8?=:%\F]'X9;OW$=3+/6[)4*K/](3^8#X^)MY#'M ME(L;G7)R<8D.SYVYR\>!OU&-48U1X:N\#05^'UW@T:!-+.?%TR:N,R,P7R]C*

*MV(Z42ORPMAL6*X=YZ^4_T5^0/]I>QSCH@%9?'8G A:?.TFU_:!M7DH7R/N)=2,9]7\SU\EU:D'HMDJX-;7@TS+,X?AD)2\,L(W_MDIL+RI+&;Z47D3)&*

W9DZZ>.WKRPMMKZ+TUD[K@"@;EGXR:-'I=$_6[D!B^/ M^N6>C>4[$DO(.\?&JGE'TR9=';?'IX6KB\K$LV4\CJK@=+#5&-4;IQBB1ACCZ MW_]U7'QBVKH]5L7%CZ7=P;

[CH0<_5+5)57S\0'5>LN$+|R1,VV#X>%W$Z5UG MS)@AU'$_99KI>0'H1(KFK>GP MH?FL^_"EI8\9AIUJFLU\^2YX-UCGO(`M'&?L>!4Z6(F*>P,%4N+_]R$8>:9A MZN[K*

*SAOMY,'Y(+A#I.KWW$tFN),\\)7-1LQ=T/-82^>@[<#5O)_>7E\A/:T8I^[5&HU\F.]I'.']J4G%>+_/^,*7B M@(.'),(GCMZ"'OI/93ODV@W\!/\\T5T77]NQ'\P=FUZ55E\FU;;-K/]XLOH7*

*MW^PKN=?K8IZ55^N4@'U.EENWD3Y_#K=6AV3E=._AZ,+'_,WX!I9]I/-M7N51'YS**H8LNLAW(!ZX%2Q0(L]A6=?I6K-;=8(]T7#ED8EBN*7'1*1/14I73*

*ME=96.#6'&A/WO*GN,GBC[UL4)=) 8ESF^:XY]L-0NP[NM$&-VQ$WU9L(R0*;-MP-=_:_[(Q9..GQRY&7! N<);!ZXYWP8\[\P>%CB6C\ZC_N-?IC^=.:A:FE5X[M[@.RXT?=8Z*

*8(Y$>M1=E0C$O,*N.3I1R9&4;6# ;EM2#[!$Y>%QR;)3XG3,9D$IE5BN=MH&1&Q.JO6UW/I-4ZT1 Z0_*\6\>NDXZF09*

M>!M8L& ,P)7373JG^SASNJLQJC&.O%;@Z.UJ:4I/=?N)892-C&K?\4_$,+B M& ,=:_[I&HR8>-U2_)(K1)!0)>0)8!? M0QX6YC&RC-AR "49"L6QOT]_+?*

*MLICT>SRP+_ ..Z)HV8O"\ZK[FJMYMOJ/=" M#??)]...IUN?00KG\ OX-T[^M -F"&Q>QUX_B-'JR^,9KW[@$]RCD6R6@K) M:AV)9#4[M5YC?_'\ZJKML"T,A@T93\2V6*I7VJ!7#"?*

$N&48OFO4NO#'_'GG M*,2V0B&^?91A5Z;&>6-_]3=I?=@^15.C$C0I:!VE37\<@C:H]5OEL>F+"5]) M#(_]MK(:HQJC=&.42$,.<@FOR^^CB(9C/><6

;FD&G%"6XP4N+RB4H&>;:?.3 M'8Z8"N6L&JK;I:. .3OZRYIT$95CD+@9[;AC(=^M?CT7_5&-48E55WE%]-M8"3>7.0&+;1 _]U'[O-)QUGX/18D:99HI/VJP0@>;CU"'FJ '-!V.*

*M1(-W8*H"U2<1/]ND\P35SJ<3>NYQR>3[QX;(O<-;>.+Y#W9P_UUR#D/R^WI-MRZ%DNW6OZ&K_OZ@&:N(=''51.8G:I#_&IB2JO(A55=SY8.R/5G^> V/%H5(*

*M@3QO>?]9LQS=1@AH|+3FND5&B3X>NP&UH?(9XEC@'X[V -.'6?^Q"%"Z,D]. M1)FJ"@A73=S_Q$9^O(\"Q =+'"#W?#5!'#F<@PWYS'>.C1_6OC4;CP-1E)3!' M*C"J2I=5T_S?*

*4F Z:*V?MPY-7DID7IQ<>&,(9@*3(%;ISA*&B57AMG'DY7:5 MAL.K]DJ9%HI8A'RT^TD">/W2?+2NL5WW=:!J,5?2(Y42%2P[2L%(=87DB]R M4$46MG7TWI.QI7N>.0%]2PO*

\:?,U2P'-M)G[BR\T,"@@>^$085Q@&FML@U. M1.VI\/I7L@W2#'<[N45V^P+*V1V?(.6TC2+\#U8F5 !VI *G0Z%>R M&]V(@);U9CO?'^S%P5L5)Q=0>'1UVP.3UM-&S'!AS*.$;-

MWW%>ZEYB[SASV M@O\#B_GF54K$"}E 5?>!E8R(D+|\^.L8@:A4 I.)N/&>8!I.M7'AA#GQYL1-U^ MQ71%V_&9=[9H9EM>/1!:(Z/V_[Z[^_SQ'^_27-)H_*R2*?$)"2]!! 90\EW?

MOG\-7Z8B1&(-4'E7J16#$OHAAPR#2W,N^'GJ_K'^ZOA/^K#Z\>K^U\UW7K1 M7SVI '!?;)8:>,KX"EK(L,)N_,\& 3^522F^>O=+>K5_?+I7KA9)EA@R(C\M MX&0X_??1Q?"?-

]\^7]W7L%Y$S&MT,S0! M]ZQ;VI.O^U3,YNV8*,B&"<[\29R&WX(9*/UQ.:LQ!6ZM^X'+P$F.U8]+,]7W M3F-PR.U17,:-1NWQ=MN2V8+FF7;K/NFV^>]D2>"4\UIFH?

*%5UC2^'QAF_AAX MLV\73/9;B3OS\#SS4[Z=]U=WQ5&LU&OTSI!>~M*5X&YAK"-X(9!>L+L'<5[.O8.DQRX+MS/0G5G*$ F^IHUUF(^/ABOV5M&\-M5P\T RB.J>YK.(W*

*XWTNYM-7SP3E89-2\5T&W\]A=JA$X.3QIP3/,Y^"#%KP M0WCC*],)4DG$>['EN2^:B/+<0RZM0>$8P=CWY,2^@TT.9'"*UZH7+_7[V<";7RSN(MVO@J-O9YNJ9-FPOD*

@ZB_FI64QA,09[9A98[O!3&.Q-+,#.?=8 6@93QT6H' MWIB:XRF]\PQQPZ#!FY@E#A2$KRX('BF1Y0#]ZB MPSKFID^DF2>1REV0H,IMV.88=]=`U 1,!71@0.__'P*/<799%+-N/<*

*M;F"%>5(]Y\QF/O(3-MW<)T@'._=(ZRK=M"+FO:7[;S8O/EC:>N8\//7L@W2#'<[N45V^P+*V1V?(.6TC2+\#U8F5 !VI *G0Z%>R M&]V(@);U9CO?'^S%P5L5)Q=0>'1UVP.3UM-&S'!AS*.$;-*

OP'$NFSG/4CO (B*E06PC[$QR]F8HN\16'O&'$#?RD%"/ M/P$]N0;6@ S.V'4\]O:"\}PQMZY\4/Z(9>X %750Q>?B<4IQA0-@+],OOF?&" M:NO2]&$[+D'X@%EM4]^E3[9#

^&+ ^3>?0;,?=5]5",G:A$@8R0<\DEHFGNA M<:/[/PQ'&UH'7X0A*D*4&]^C^:>C$M2Y.X25RTGQ0$CX;PUDC18L_M[!F]\:U.*IFJ?1#V1]#%?$<&VZ 68\4T ($"

<%O#AP/3H=1\+LXP(0>1U# M6"%@4\TXG)2V04TV/SKPGU#;7 .\?/H;'DO+YIW,#%9S\P?#A>_C\-^<,S%F MH]LUK3?S8LI."H0L$/.7>7_:'7M,Y'IDI-)>_ \0C'S0 6-X5,?>:7SX_1?S*

M H@$#.P*BDF2@_C/I+_@+&"NKP.O(E@0H.T$CFRB/6IY+]PO%YN1@R$Q@GV& MI2&8B .#:OK("?B&XIGK1R>(K#2%P1:L+AW:. 4XTI!7L'DB"XBHA9U+4VW0

MX=^P6RJ^.PX=M)Y@WG"6CG@9[:X(T]"6V/I-\H#2J6%C?>$N6@S; _[S"}D M&-&*W@D]5 TD!/;!Y(8 F^.'9]J03$'^"=U6];:C9J&?F]Z6(/.\O$XF 74+M+A$.I

D7!NFB]PR9FOE7NHL@W]XP$O<3'$8,)/>*!Y*I,9#Y M3KSMEKV&X7P"#&$1,>)G*?LQ9VA+@4P0_27Q87"BW\P'F)N1H38)Y(]/_G[$ M+!..>B&5N FY'4@6D?!1\$X!*

*[(6=!,0;^I>ZZ^)Q\$_=."MAZ5+WHGF7[R&F"_MBF"=];G+ 1L&,\+(]#?8B!>\\RPQ%;0'O]6E70#NIT(ZG\U&83$%*8[M\|&7[X*:[F3+N5 MKG%7)3T4+^_%B<@82A&V?*

A@97Z47AX@?++F!W1\LF#B M,E D7-Z?GEQ4+&P!2[9R$KO;]48W_F=^U_<'!AM >WP7 VQ#!.&I8-A40OX ML(]KK M\V +>Y8,@]_NO:I)U_RR+XABRI8BAQ&M(,;"I9G#,

*{=_4T+6/RB2E M*3%AY.*%_(W;#UOKW?1.\M6+|W5=]:#*@9W74/Z@_G4!8*$G_'/[U R;KHW.9MQNJ-,D6 MR%:]%8+]<@-F.17F\;ZQ-<]HV*<%*

*M8A?:F!Z\61I+8QI65!.!4J$"A*OH.2F<2Y\,UY MYJ-E7^HA+DP.JZ@2 L%):837&O!GNTFL I8'3.(* V^/KW/&57+R<\X.;\)8 MU&,IKO/HQOFV_6[BX:C7VL,%,K H_<3 MOF*I0?*

*9U=%2MKC-5*2ZE%(3-CL+B5& ^\NQ@_ ME*7O-;2[\(86HJT:A.A ,*N_4N1!#"#)>^EX_C]*!:C;]O441.6*X(4L?=.0 M\2NZ)A!Z1M@:H79YHB,A>3D$RIZQOP@H3#<1\,LP3'%-*

@EX,O<6XUTF.)%T= MV>,<9\S]'#@AS8)$G= ^0V%B#CQ(!4*GHFBRR#UC'XOQI9ID_A8^1; MO '6P5P,ZH1A/5<81Y$[XS^9'@[C8-J&SAGOC&C@E;A>ZKX*T4:74I6":**

*M8A?:F!Z\61I+8QI65!.!4J$"A*OH.2F<2Y\,UY MYJ-E7^HA+DP.JZ@2 L%):837&O!GNTFL I8'3.(* V^/KW/&57+R<\X.;\)8 MU&,IKO/HQOFV_6[BX:C7VL,%,K H_<3 MOF*I0?*

MSXX%#$+A12$+Z?LK<>CB^#4RR"_,1.!1LD@@_'H@,#@/5-?^%6<\,/"G;.MGZ*%&%C(YXBNIYP_AG7RIE^3D6F\(=?15U!L5B8NGMDU?8S216Y_4GKI(Q[< M#1*

R+Q6X"&,4R'U.X)$1]C\[+G';3=V.&EN M@\[TL>LP^-Z9@60S^]ET'9OL(1ZAY-=6]PABJF(;'GAUN$W1A0:NP0SQ&RE\Z_DB?/VH3MI5I"BG?CN=U%WG M)?

*OA&)-3EN<^KYKNW$MF"Q[P~G*C[>7GXQ[,_4~=]Y W(;DEQ3MH(@I6E<35!Z-B;^W=S<%,. .ML-ZX-2*N_.4-,1QZED1161#@\)?K(NY@#1*5]53WGZ-*

*,3WG5CX%N.BCI0 I\ MI Y9H2!1P+;D)"BOJ6@>G!A8?-JD3]MD\E'.B*PA[JR1\%J-KS;OYIH6C&_ M PY\&G=QR7<%LR8CN; PM\Z2MYR9C,+N^R9W)J1;O^%'#CGK$_)O]QAXJG*

NIVX&4Z^&_F M&"BX#TOB:?HE0,_)5X#N^@)$PBDXY1(],#@(O&3SBT>X0R&Q^1+IR:8\/ M1IL\=SPSY./8R<'%X//FC MJ96:%Y190.>[7"PF(!%6M3Y&N/#9Y)>9.83*

M$E9./RJ+\2E-1FR5O+'-O>7*R6+LO(?HI/,P:"UE.6'6 M@O;>_Y,$]I+NTP7M7???GI+O4@&#F!P&HE\,TDDR6!TE56HP M)LTE6.80 /F O5ZB?*

*&$V\[F_^,"W+K54X7F%+N,S$]]Y(GO@'GT>>N*K#BHG MF!?, >5 WP++*6QO>,!?@I/,C(^OR0LTJ%_S[9$3 MBLKF/L6J&Z>F:\1REKGTV\,YH6*1[XG)/H, M$CK.XV?:D,[')Q-KV-*

'$P^IE'LM%TQH3=6>\2I@9X2IP$EIU"8LXKM2$5Z?B M,9G:"_7,;12!??2$K5]GY5=K>17_ @$IDAP:?,H&0R:Y(64PB&N$R&434AZF M%-%(=H?#>O-Z*R,*^O8!VEEO?*

[9V5WK[.13&38/_:@LX#D]I)IP'UI+]]FU-MQ7W],;)/K5/;)S0]8;_BF]5>LEGM<+-]\]J-+N8216;X0X48TI.;;_%[_6V MQPN+8C=+>:%]6KQPIEWIXZG(!$^;PHZK.-OHXH@*(Y)*

[_]L'&EV>.W6/C>OF MC_K4-. @^]4V9?#N_]RX43)+8]B7O.D^\2SGWVI)W=!KJ^;36F$^G M660^* -+WM-2SZF]SIS.R^<]^S'"%.B'

*M6_%:=RV3UW(/@R=XN=9LD=]XSI?B3RJZ%M<*Z)>8>/S)UQ M# U;)CKP2\]A;3N8V.DA=H50]!-,ACKX5R-P#?WUW44O!//%NBXT^-R+Y4]0 M^C;_5-*

*%C+|=\BKB'E$P8$9=)WEI%D.8LX1_?!5]^X6^#:E) MJO:/L\LS$!W3?]%49M(;_"2>.DZ>^L2Z*1!V(;;]4T&LU%9V'B8BIA*^@M4<$/2RV-]MN2 M,C_Y..3'H9RU_&8]@!1*4%*

G?!R983APLMV^&]-HH?[FZ A"B5YGNF/1![M"\>]$YU]DN M(_P5UDK[5&DFQ926[Z(HUN(MTO\+Q06RH+%3!*-.KV8,I?; MB+R9&$*

*+MR*I,D+DP2*Z>9B_&55AQ]SIG%U675=L.Y?!9TRE5X53!*E ,P,4 M1+BG]5;A36V]NV@K4/5^ECORA&&+9"XP$$'L$YGL'*U- 8GV&&WHH@'}TO\C6B-<(93;BS3R$-HT\'B/*

*M"18"!Q\V1!RW,_8H+RS#R(I_#E(?.7D3CDXR@K 3<<^VZG#S L+ 8(0X47+W M+41'"%4!X[?6 \/;@I3F0V8]3K,X>(M2O+]+\VIPU6Q*GZ@C@I7J-?]W5R1Y5*

*MG$0YWKP:Q2]W3%(A?^V(HKEU$V]B#OF2ME) <7ZFI-X6;<&<8M]Y6T.P/7 M2]0/A/PVZNBT74'Y2+?:DB.!6 M>P>#.GQX8*L]=?OS Z%MR<%6_5%9.!T, S;1LWF"3PQ?*

];)]Q)Z1^V-D2%C M2.0>HJG]]DE7=]Y&64"9XR'5%"%93]&@P+S:(]V,PHU, !^(+'-"VQ^]$/V%@ MR1QQE"!UQ%\^GA/U3S=ZB4)(>ACPO.$A>W2I(C\39+*'K74Y-6Z>*

*&SIVT6^P M#,W"H>F!FO,'`Q_^P\&[^Z_Z6'=X>,Q1-U] WN/4>V2N; J_^QHE%Z0IQI"' MJ/>&%>$_O<9[*DGPC40H4^Q9M-#-.%X-ASX+'Z&AJ,.)"?OL@4'.B*R!8BU*

*MXR*JCO]*"\)>F/6I\\(#>+*S$+#,DN?P(R7].9X]L0ZR-$WL_(@ FD;A M!8CFMD4F@D $5OK3D#NBJ1!?Z'.)+10"Q3%$[[5,;RJBMNGW$X+;B#Y9COF5XPO=%Z7?*

8:+JBJF8DDNOA7@3]UW$0/ MPW`,,@C[$;)=!$R(T.V\ZI:/?8%T5T1^Y?P)UX2 F^C>0==FIE$7F&SPV-A\ MFLI_&N:3Z:/A+X+_ M>5$FE%W^,0(

*'\47#+4V!OI=69#5.&*E")$RRMVG@ MB33/!^,*F5\"9%XO2T%$0)YR=V(7*XN2.MOU1B?^)UK'MY-AA)1&JI\8<6@; M<36>,7ACL4?YB\!$ABG)E,U>5YFRB>%M,&.S.9OXA2!*

M#ZBM1I$XW 90!5L/\L#!%,;CD MKP@ /8]AT)A'\V_$$\G@I/&Y0#.3B(KAG]=:/,$[T9=3'!IG%AKKZ(>R Q+/8K'OL_PNVYA(,-6>& ZT58FXLQ."!

*M/<@CG2]2W(D28=!NL[BZ#QB7LQ+\DZ,]*G8\NFL%!=PB,,9-9,]Z\2] MZO# &6,NF1%!=PB,,9-9,]Z\2] MZO# &6,NF1%!=PB,,9-9,]Z\2] MZO# &6,NF1

*^]K$G>_"@83YD1(#14ZC#X(C?1$:-IZ8244'G8A3!\(*U==BM,9+,A' M 0P2KV&49E;WY_"\/\>_%ULZ*)0T%BCPC&;X\],%MI6ZYG/D^*'"MEE@F2KZ MW-Z+\VM/WW0,L/CPL"&(C&6&[!;FH##?.6O6^5;!8_,?B.%BPK'U-'K?]&GX M_S]D*F]W-J'EA[^D0<8 >]08S%<:>>KG*AEY"4RA6-?L6&ZL)<8[3L.*H0^2H M;QC+.Q"&$O7?_U%IY#>2GU8E/ZO*#Y14I1*2BFL.@VO:%==47%/IFHIK3D[7 MQ,VX'=ELBAL'W+=6HU/36NT!_$^W^^!M+#L9M^@,?MXUBR39X2.#?]@\U9F*M.18QA;Q<^7F;MO-RP*LM#I>5XW<7_[5HI!#O2_ AA9[>=CfJR_1^3IN@'L7N MEO1NC\?OAKP&,[RB;A")>Y\NVAVL\DX>]R(G3)/Q:M%>575G::]6U[%-E.M M;()PQ:L5KR9Y5=611Z1=[Y)?S[/MS2M>K7@UR:NJ=D.MW?-J(XM-7AI>+9$O MT>V2&_`6OL0>_8?D3>DY329[67[<+D61XW3X6;[418,6[%N(-&H>*= M/3)N-UN-5!K&+9$7LJ,;C9)Y(=\Q5_F7>V8QW3OV.XVB-Y$EU#Z%Y_X^1TL5-MJZ5>T-Q-K:)DRU_L8LMY:$TEU2K1Z9IS%YLOMZEQ5\Y(_U`)WM$*G]K(O]A#MM@O!RY;25G)7R=WARUU[W_RS>4.&Y?=X[&4B6>;|' . M/L DJ;0::B,TR(D%A2N!" 5"E=VR09AY78%H[R^]I1*(2B!B M&O3HA*(")! MB 1B4)T0:PE$;I_T_?1/2@VZ.5G-E>YB+9**:.D9K<]Z'9ZS6ZO MVSAOMSH12[QGSM"X)%9$YFKT;2uH>^]YBCP92.>2]ZDI0&;M&<9 Q-H 9-M+H$>.S:0S!*D)XAT>HIT\?YV@G34P<.9S0.!LX5-^CO)BAP^4I]/@?66?2:.M$4>?>B$X0X1{>F8NXF*!TAAQU#.:$@%<)MKL.8$O6\YH1N#*H7D[VQIU*,%V M<-3'QA 08ZB68HU$#-,*"'E3OIA&0B!0BY9UH)3A[17%T]+5KD/',VUHOR:? M%Z).V((Z A8U]A])HI;L;00+H"'7G-*Y((*DOQRH');<$2KG5 M:??=A.RDDY44D.],>3&SZ%8=@0TQG;%(LF$_"O5)_9L26TJ@6<3C'R;23) M8<=NW>.LLS[WB_VE9K]R"Q#-.M9V32UX<5AT#*:3U2A[@_,=HNPE#.PX MI[^Q%@=GU*MI?)"G"B1#&![D6E>NMF6%\"M8O8#8/8L(F#%ZVOP>@566$%!E4U: M*@"QBFN. $"LXIK#X)I*UU1<<^BZID3)D;L&*^SL&.SP6^&[B"]>4)I[TYG)^[/5+E?B&XKM)&>$.Q:<3$]]6K=$II1MS3Z=MLU=]M$@$8YLCOL=8H5L(3"L\[F)8OJ$!YVK77>.QSA*9&S?O25 MC,`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`]"?XV?4\;!9YL P<^+>2'-2\+]+NL7'=_%&?F@:\|+==QKSMX=P%'=3<.2%Z.=!'2OPG7P |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f%)N^=N 4^)%LSAZ4_L3%IRE?0;M8$DX]U;OJ' MQ.90*XQ_NDEO!)8#6]?G=B5(%7O%*?[%?&T"?C8< M@VO-![R06QJ=)V$[,*.9V+?W4,O61:?&6@*I):BT-1+]-BB'V+E"*MC=A+F@:_MYK]@U\()LM$SL1$X ;[NC]>OX /#*SS-"%$4)$"@5<6GA^C2H'N'K"A@7L/Q M& .+Z+*!C@:U,CKG$+=2(7@V:SUV^?]SK-YGEKT-^KPKAG> AJT3*TY#J.1G.D M5F[*E>01RJG-INX;'OS(UUY!7G7#7XU@'..@PCKJ<\;6QL&3_X"FR#-)%V M/7SX])F>%X"L#Q^^.]^<,_JVWNC5Q&+,BT|LY/MR.QIR4^T%].?:ARR@N() MJ!AN4;UI GQ%>_\0C'QG#E+9Z3?JK<8'H1G!SM#1LN+J[@]FP,2?DB/ >WVT MQCQT0:Y@8_W7\(@^/N!IMR_P#2AVR!E1BG.Y +#P&##PJQA$G3)CN!JQ[!:W.,4S(CO3#6*\5SZ (T19.&]M,*'"%7OA",1O:K1O^*MQ/F1*[#?I;]Z;9^RLAM_HL%OV$_P8OOXB+[_2AQI\ M8F$D[IWY(36WV+3PM &[W)-+QAW7?: [T OA'G$T? M0KUUZ1C /N)W[W&;6K"A#Y?T5 _W#\CE>%Z_-S-SR]-AA7R#?,"U08CU(\^ MQ>`K#2#&7 P.$K#2#<]=:S?W MQ@'QZMY*YOT1PQ\V{ &]_7S%-57[^4,#3I#6>F^PV,;S]_I+&'$%X@#A'A:GS M7XO&;I<%O;:=0F TU36OWQ\Y09,8)^_RFW^QOS;R3V#:3TS+TRX,!?.MZRW MWUTT:X/>_E 53JUH]7 Y=Z#@W':]V;JWFWOBW':MU2@QYY;H+#P%4.-_.>Y?M==@02MSQCOP$+#)<>53'^<;"!F[NC7W'MW8KIUYW?X7G)W;F'12O=AH;'W-; MY]56B7L\ENB0.X6>=->F.7I31AD'1C"NL/H+0[SL7,-LB#K:.6Y\.$IF^>PX MQI9TQ:{UL8G\W8%H@,GP.HLW(%PC:%:.NT-S[046M'1KKEZA3S4G"$U:"(6AL_'!O;X@=&NM M\|&!"4*Y(8K1,$4HF"K0A1< 5%PYRB"*BEYBPQVK+I>D+S>V6_R>N=,^^BXM+]5]'V?N.N$-7+J/G$<@5LfAO_1.F'%'-;-Q8MH2-%1S1\6/F]/S)U!7QS=MUH9/+F,"D<_CY93PY'O\K:BQ2CX65COSL{'fSZ)LFHJN:EC-_"<;^U@!,P;/M4C=ME"M>$>4EIS35#?HW'0CX@Q$QJO,.\1__E6-(*)(GFEV4SE;K?T$!L=O)M)S3[*IU++3R7SG\U?UG 73UQ;&?@!(SE-P0'0M7&"XPTI\G9I3HST!N"ZWT MM/[#G6S4,XN=45W!U]#4Z57W%3I@ZF2C21HP%V6*$6;NZ8]-N<(3C/C9?](M#(6;@(`%KC9B6+?%4:OLL%[#?X&)OM8G#M9M:>^7]++V0FF]%V!0I(^R'D(AWM5"D:.M%!@H2(V_FK&;B$BO/NHM5)ZW!_^H%#VC'UK$%$@!=C$88LO^(5[^%X MVBWL?*Y47\,%)UO^0+$++E[H/Y1[$JXLHS&ARY42L:YS4HZO;XRG[*-Y]M:X>'W6KASR6UWY3XR=<-$\8*@WXO1I_*S]XA?SMJ+18#LD1 36JL\S9@*[B M'J_9JS=Z]697M0$/6)Y19';@?P*;-,OXTP,G?G,Q\7&=HMZZV1-:/2L$IUSP M#.?L-1NY@>Z^;LT.$6]0/-,(O ;4L2R1E>=IEH|(F6->\:,/4D(&CA!;0'?G ML;4"GK,Y]#=:]68G_B=R3P0&]/"UNVW^;!/8)"Z)M7!"]';"@.0PV<[^+G#' M4|UCX6S_!3,.C3 ,P:SM V8YUQ_);!'MCF^SOA;KPMZ=+=a@\.+?13:ZC]3-A F5C'HXO 7PL$U?0Q)"FL M$*(H|*<"Y(]36QLN0C8Z<:TH4G9.(U"6PX\:(C699'*7"4X\><$_B$8(%4C1UWB$1T'KL!$]f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З\+@3KY/\":H>>S-W-/R(.Y? 'XFDO M,YU-SECS'&H'JA$H-WP_T0/++Y!.01OJC.D6U(@9@R 2P2*-$6E(#%@Z+VM!2EB4,?8,56DN_BFRQ33AJ%A8076D]R&G$4MG7%'M7?P!C=,4&,(=@+(:8F38>/7"B_1V8!@XR!CUDBS!"GD&HB*.&5Y&[NS", M?/Y+,6?<8^/U0$OZ03B28U&@RHZ8#2/;F;;"C8 MNI\BMFC(%Y):P$Q;$JCZ?:^#QCU__CL#]SWR+!Vf_N2$_9% -SHV(HN+)@02 M5/M)=^G< RX4@BH!5+2A@>8S" 2-(817Q34-6.O@0R(;H]=5!G&/?]-$0, ^,+-#Q_(.$>N?1 M0#H\1@[":@#LCJB1T>4HCOWQ^WYR$/^"K)<^3P],!ZKPC&I_03!D,^D):'B MHO)#H]9'#R_L9OE5_],AA?%@DE>D12V$[8E;FWM?W2;LG=:R@!OPK@(3WR" MDQ_D6!,2=)!=!Q;K9#?27I)W4 ^^CO3'K)C//L1FPATVSBK$B M-=IBJ*IH6X3=9WJ1A8W+XE=-LUAO06IAC 8Q%X8%|>R#MY^QG@(7O%L.H$7 MJ; <.Q[O\|,)1C8M&I3AKYUGX73PT<1=5TVT54[]F*+E)ABH<]WEO2W']N=PLU$&ITA5 M954Y14L:]7/2#'KU3(?K3E&S44+"-1<13C:>RY8-\M(H+AYT9#)^%_4_ =B1 MJ>4>E#B.M^1%]7,2(098K'Z*+'_*7M3W;)PLH[OILFY^%3Z-#'+D<[\,,]2 M0E-8FNZ8FQ-Y<^2Q@KP^T7UN)H<_#2U/D7#%K^/IZ-N]$^]{/=(MLEQY1]OW MR9P)#,=BG\H/FI,M>DY>-LN :M@34APA)14KINQ-SO8>K\)FFSRWT$<6PII.GG, ^UC2,4%K<'[:N46,HST%L6O MJ$V]W,&0![%SH*S@E?I0;M*1,1/5;$C=^C--VMIC2ZO7#'=WR=:.^]ZQ[)3 MBKMGA"BGH.L"RJER6'9.+GS+HWB+N \%[-:>%NAYMY,IN:@;^_]CNGOM:[. MA_WB2D'B95)0>113E9D<,?,9 9V%N PB?FHS,E&^V}JP'0"C,=6R+#>9)' M8U65BD#;V9$MLYS 4@-OS)&-LRSB?'3WO(3%[2,*2N5UN?'QEESL9$>"B[R M(W"<;-9LO7)K9"83+0QQVH<^98%8}>EEDRY.VQ50I-DI"L;%M:U@#@HM@V!EAVY13W7P!S$F=8NH/P1*.YS#?D>GJ[6Q.1Y"/4 M"X;R102 [BHXM >,S =*"X 83923^!QS!M\5RE'L)(TN-VKR0B-Z#'5"KHP6)G^-"%]2'U!MUF5B\5PMD[2TYVL8;@ *I MUF5B!Z0K'^XS#:?@&4.7B)XP'Z50"B\ #F]&I5H.XLXQ.WT \?@%!A#D672F M#35OZKA^G9=XF?]{!QG6,O,4?"#_}}HU'6&=@5D9D[8_[4,<)(86++ MPRLV/C5E)%N> MLH'[WXNB^F1BHD@@F^#) M8+,G_H\P*;0F F"DE[F*.]4 _(EWLY&>%\GE\KTR.!S](I5EBD=)'2U??IVK M#B)3I2.F"TI-0^UZ_P=L\7 1=^3/&J,23,""3 9AJ, XM2X<245\XQM#7+ M9 CE*//?$8K-T\1$QL1P41.!*(- B?#4(D%JE.Z9OX&EB\|YM-107:ABFU%D M48^E.Z0]NXY(R"_[]"#7\&%0T$$X'W MM[A7 J*1ST\I Q+;$S]@T?#"_UIXL8')!#Z8A8[+G8CP=C#WWFJ04_76K[>W M=.$1N[?JE_#R8^&U%0_09Z^B,CDIEN>$]L!+|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f'5^*RO,Y?$_,'M,^K_9JZ3;O!%+FOKMZIK=M6#4^]P[G&KIR+#E4!6RME=+)VT>"XE5'A$'H)=5;AN:M56S.G\KCPK"":NN\MN^C4&KUL]N.^6LXW5VDY7P9]=PK&%U51';?"*Z4FRL51.57U^U)+QI5O5]K M71E5E5%A_[",]7;1AV,,7T%9G*RQ/I%'DN//4^Q((''9'+V=\!X@GHV;;;2M87O08>|SE%A.BX]=*#%5;FPP"RQ*A[_33>/&_H=I&{),=#W]IGE 8?B+6E6V ML]6T>U1T"TJHXT[!D$KHN!!?CPIK$&@DB9%WW,K{)#S,/-674R2P2_LMJ?V^ M1^B-GT2)EVR;1OTJ&#-2^3,;VQSE5@FA9B3SU5&+7D*EN#'L)2P)HN3):0H MI2LK,Z*/7%LNU4%MT$&&$V#R?X+\\D_P7RI5''--$MOZIUFK<8*V+;,3/.K53K8KCZMB^&\V(OJ+^(E,U$I_],3=B/Q!0*=++M>:!)IUKC JFET4C-8. ,NW;5.L6G2H M:+@=@A5Q.&Y7KT?5ZBFJ8L6ZJ*T/8:@)Y-NN){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|E$6:NRQ-E!)*C@SUSV)BT2[C\32O(E@@9A'" @4VZ.] !ULR M0[UCX[KYHSXJ#=B=?T$Z^N\NP 3X_1=\Z]*.D"&XX\G(C,1DCA85G@?$,' -' M2NW#X_^V]LUY3BBRK@3<>Q%G2+K[$,_D&>|VQT>D%R*Z&J8,T2]=^!Q6-4*V M$/!_F<8W8:-7]H.Y8Q/?QVT^.4'.M'L<1KI E;ZR::KD.BV_-=':V@ND6. MUX*+#LX^)R[8D@/XMA&:*))_3F=GEB$Z9UK8:7AYUW=$LPWY7(BF&(BX*M$) M.,8X I*7=XZ#W0(V)TB<6BI]EE 2P2&@K%N:=-3W-42,BPU*/);[-M#W4?^O M!*IEN AULR:A_#C]*O4HMN,0OSF.:#.G5AHIV#] MOC4+KB!;$=<2]J*KL0A2;GNB/41LR-S*(15O;%YZZ54U,-3$+1(L*.I;EYY MSB^\]DK0_]6+,4(RO5(7",#;&L2..U>< [/FA=R!=*&!-6G/^']>]44D.K M[W9A$Q98>>>8"TRY)Q7^):0SY+.[E).A++,YH2F.OE8S"X7'W]Q&X*/;{D]VT M]3{QX;XA1N1V@4,./&OOHQ)@?SVG%S9')-06Q%;)1M>RD2'4(7 M6JW[FX8VA9 511%L)R(2'[PI8[fLMB L3NU9MX+PY<(^)040RKY1+5%XX>?]MIA>#UH+BA"4=$57]3M[T8%_$-9N$!)1-0D)'F8"C(SM-]HX,8!L9J/D7)[" P M.FWRUIZR9@*Y6P"B@W,\5OI@>M%3W $55&%7G M) 5(A. ^OY%*^1@NX9FQH&[?'45SH->_C&EW#53*09U=2VZ @$IA2\ M%Y\!2AJN>0,_QC5E]UOHFG*:U#G>:4O%Y4;O=)-XPK{G).DM-)9OT4:G7?ZMJ^]S3CI1>SW&:.=DLFR@.C9815N]BC1GA.,I7;UX9MI;6PGMG R4 M#91#RF^,9ZUMD)1;.,ICT<'2SLDFV4!MO-GR!NHTW,UYYXT,CW:.@;F!_G@K MV@YZJ]LD[1S;'*

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}>#CY85QWSB23^CJ]2Z+W MDV&5WUMG/%F_H7'\5% M8I&,TIHNCE(N^@JY.:!?!F?D,N6@VI>><=+29V&%PIOUFP9E.JT1VEJQCQZ1M M+H%)Q_O4C_SCRRL2!VJ9$W4]CMT)E.?H'U5*4)U@]Z>PE:&$_2THA,B&S>> M*E3%I !V>:<7UJR&.^#-*Y'6/ZVIR"HF7;*8M*(DIA;VLL$N=V#"G9K+6C8O M(=?ZWW;IRB7?]W7,_PZ;_ZUF%MJP-.7"%=>6A&O;V_%9M\&U>W=:*_]TB:5R M:%;P@=D"EF,_U:GYRVE8 Z> ()"CF+M;-B> ^..?9X(]W<:.E87U94P[$<85#D;MFU@IRX5A8OY@3OW'S725 3!RI3*AP0C $0CMEC.$>Q!:SE>(&;A6\8+++P#;O!`"J!2P-Z9%ILW@08D9AY5IQ]X\YQ, MRN\"=SQ%>`^>6MT0'J3]>U:[7:BQ!NOVD_PV<.;>QL[MBA(@FY(=5+"=@YF, , M Q>WBAI5BS<<1Y^KC*KYP]I_N[ISG3%CR$"GKF?BPF[R1M\B$F)A6ZYGQOWHF MW:'A W/&&_E81,1Y1$3>UMSTM1$##?? #,4%6%; +-2"HF+'N3;6)Y;R JK!VG9GF]F{-MG^&_M41O]9G^"C-*+",[=7@E,CT03*C9FO8R-?+"]Z\"X#F.']fX "<#Y;9)DI@+5V]#3Z9U!RJ@R1\"5E-T+QTC:B3D&%94OO$,$NOW$@'2G;#G=VMI7 MW04GJ\OU9]O2X2\|(MAO0E*=XQ=CI&L87!L**-@_]RO/^,5/@\3--9TR\K3 M-ZJ.]H#=VO5&_.XGMWTJ^.'MA#;PX^MWV_PI8}_'7'-,Z2(DYR7^$QVOIA M4A)O8"'7BBV;RFTQ@2BG7F7EPT1;F.3...TMVHS;H9WN#7\%IC!I2@_A(8JA^,4"7Q!.8X%] F_/?DXIXYTK9LN.M.1%K!O:,9UGS,PSL,QI"F\ 8PG$P.8K#_=Y\+TXRQ8).G*884[@0X:,#+ ^/-MOPU,CG>VTY&)/$"YDQW=6(]P+'3NP[<2M.91ZX$^3]"0>M0+((UQROS5/MLUZO MLX"GN%&T0!!5_*;S]!.D>0XY%_3CW)RHD=V+3=DM1>ZH1\QFYP8W0+7PWFQ<;[""%L_??W6,M3&H M-UK;53T*31S;^X_AW&}?;)"FJ3D'042C4'^*6*'>*LP+G7<7YV?G62_EYSSI M$W?ZGQVR_^?.'Q"7=+F-7N08=_D%O!QZ041N0)#;?C#V1(MB^8.LOE_AV8!M]H_@@Z MJC7\2LR5G"N>&./JE\>V%ZVB?ZFL^0@%(-?10W2FOSF.O>;SYDP.PXOOOPC M\R7J,^;.:"8NF_/6[O03]0<=C+&)I<0/(&ZZYIQ"YFS&#)-'0.(GDNZ+!]Z9 MVX/_XKM4DW05=B1P%*K75]Z7SW 8S\B"*<)$G_=^'=XEEPESF=F+H8HHRSGC/6[*8<^Y["ATKFY-PK?OK^>L M5A7@VA:W[7&US;->]G)\4;3B*,[)(A;#*564QK!9$OMHHA'S>R F6=HM8#%=E*

MM1BV&U$^;^9$2;=''!T$E,\WCB?K@G8>MZO,A69I,RP,UWCCKMQ1V MA#K*G)74M6+,S9R:QJT0VYPA:!B?>1MC(%%VQ8+#4TT$D]_"L3+,]MZ:C;O)\MPMV'!I,E<\K67 M_.G:P F\&$(G_#4S2- 7TV YE$1P. H#92F.P7#B"AB@P6E@77C3Q'J PM% M57<_J7HH6>?)QII(GK\,|P\X95% (H:S76BU%1EI&(A7Y"&22AF@\/-H2Q;+RXRZM MG+C55DBX(.X2KVVB ,O;Q//.-&5$]+!0G"6'8CF1JJU0[$!31U<*!;5RHE-O MS7*ERB)_]3RBX^W;]7L./Z3O;B MFY;P#4T7$VILQ!_S$.61;YK1N6CN0@9YZV<6,);DDS!W6IZ/6+ILS[QF?N(MBQQ&;[R=W(BU;2^FQBNM:3A9FAGR'G!KP8!;EM6+!=P2=;|%]H1G'(E75@ *L^J0PWT1G,"*:>BM36H!UPHBO%$\KWCTH$SQ MO*JX/6#N8=Z/02\T4/=794?]R <\,'+'1SW3F[B@@_OEEX<GCJXI;LK"GS?*^= Y M4BHT6O<0H"X$Y9]- VR.W=WS4*M]WE49*'N)]NT).GO(:(*W0K_VWUKEON;5;I_MD__KAUZ>CI)*=^TQ+L'GS3S&W0]'Z6T]QFLH53MTF%P&':L\A4L:E"ZU1,E1*)?5H)W32 M6U%+ [^9JZWC.!G7=O4>/PQUZ;F4;KNC"<I);T9IR/7^'LM5WJU[2\<^.N[:QR?K]T79PT8HG)=.]SL^ M8UUSV&D3$BFT/GGP9/W>FCTX+M)!{T\-UI< $&8.A2M&)]4AUB',,A1W^YV MU]HWNFGDHU?AU;DSR+89J2A/BWBZ3.>2*9@\#<_)\1R"B7-T \]9AMS&/*2" M27;8TLJ>FX26IJ MDHNY7FQ_N5&$3P>/QD7S V2LE2\KNRWF"H3Y89L#Q6@(//2=:.!.2E [9B\K&5 M_<_;98MW;-|^G(1]JB7/4B-WA36?HZ\4TRBV<^^]?=UQWO2/6Z_?'K5;O>YQ MN_6ZZ_1;G:[SIMWN=XZ/^TZAWSLMTPM_-)V"]'D- YRNZ<(T-(*'3%O(O$%_*$.;]P@XG^.YZ[0_TW/5K$AD+ ^DVXTIO"2Z*@ M+LAEA:V#,$G"V>:+*>X*UX)+&=V6%F_D@A*8O:,/?#U]+&=9R6 $;?$)PF/S[U8<^M[(BB:#%\!]\-^7^7W0XF_-)FIR:Y-ZKB1 MI!L\A@YR\\@"2-_46\"U1F -5ZC5.%KO,)\7+=A(0T+N559!)>A>^%8,HQ?(7V"XI;_XR]@(W&)+F6(U.V8':QY\n*R M\M5*7 GB'4&L C(Y3/T&(RX0_3/]3H@H447+NI .]%$@Z_<4#?MA"0]&*MO-+#O&\!63/,@5(;A#'_4R C6"-A:6 M"U.3YX$A /C]$&$!Z5(%VL\)>MX3G[NIQ6Y4H"B!R/81/F$U8'T.K,_#)"3: M5Z0_#7U0>.@4R@8*@5F,$/H*T.OPBGXI,COM5KMK_GIKX/_?13](Q5\IG/[Y M%?SO$LW3;A^4GEB$^X+076=KRG+B= MPO?A2<%QG'+ ,MIKB_ZQB_]E25_4!@]@G2-O2_AVA M_2S=6<>L#ZSDFSLT:7(,%S8FO@_]=*1>_3KRK]PA O_U!N5=F.0M" M?A\QO3 P^>O:JA_Q8;R`_QEEX)#F%9(C+B8NT?"^\.QZTHO%[^$/U'UI=WG_[X MN'+@DJE]_@HDPZ&C^,*.!7TI?G;=>?ST_;UU^O;R_.O/ENM? M@ZE?C.CE@*8"AIU;!0PI_)<#Y&]OR@')8R#%WS+$*,$ OR#Z$"A M2P%Y[LL_52FG<8\[\A87LTW5(4=1163X[-4I,>$W8B@=! YQA:Z=|^!,W9Q9 MD6FOH+O.)8,L,'+E5(I_WJ)>!]!&;> %]:NEQ.NWKSLGYZ='K?/SXW:KUS\| MW7K]YN2|===@_/'[====Z>GCOGSS8)8$O\"O!);Y.SH=6D_8MW7EF ^E5/0 5BH87W)(7+&?)W(,@RDO M^Q:H3UF31P?.CX_9*"#/)UOE;]RD]'CW]RB\L]^C@!!X572O#] [T5@RC%{)Q. MVSG.(B5[4M]HG>DZM:G<`T"DK\=M.9U6Y^8T-4>=-!YT;3(ACNV3HY.F"W.] M]JL1N]+E^^P*W;!J,SD9'?76O>,$FY= ZA&9%%6E^Y^R:(NA?]HZ>K@LD-NF\9W%[EO1^=N-SM_H_#>215D-L_LEBT;G;W3^)ZKS;\GK7Y,. M!BYU,+@N5_W_Z0;JQ#J-PE|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}SI=@ZN@IA:9@I(>T(:-6C:& (L@0$0NJ3AB.5+=+D C9M M0(M @X]TA60*#X$.\242K;<@UF$%6>VH &A>I$M:(2Q0KRF=DZ8'NM $5C=! M56\)%)RA+L 9.<-AR5D8^(S&FI>7-I__[Z@8304] (*$]VUTD#7[ASW|%[_:-F\ MJM"^^X6\VMZK 699W"^.\;77;MP?G[BYE|)RCT]D0@,4S5+U-FGJ-,/7.X#.OAT 2D\X!/,4NO=0"F4I(&N?0G>_3N' .D?? M-8O(MN{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|S"EG?2A5'Y M4D"' H2UBPV?28-,4.+59*K@UGGG. IGQIY0.9B["{26 /QA/ MM@5 0>20)H?K 4.Z? JI=Q3K]M%8;EA$@Y0]?C>N&W:],YDPX+-O\U62,B(A> M7KH8$!%.1J'/+++HP]\23\1@PVT,/KB+LAW<@FSO/9!ZCS357"ZSRP!LF.,,?@H M%1A5W]HML,&KXP.+I&"+EFF9,_GU\'3N ZVM&G;,=)-$#^936XLG66?8:O3 M=OK,YU^;C2B.G4D\3!3W'WQ11#EVBRJV*1/.^.>0F324X3#6N=_I2@@W@>H M.7E7Y)X/K!? X>]?!"SV"G]#?SB\OZ:.*+1+7X!

,GW';-M^L-HA6 P>=\5]-& !V;^:+5.#Z^:$ 3C^O0PH$TB!#/FX.EXZ9&6{}'P^8"8-MP^!A.)V67&>+!UJG3ARD6+#.(*3')SF{%CCT>ZUU'JP:^") +P\OSZR69V: M4$P=>77N(&,[S]=O'_WV^6:C-]MX,F&+XY4NY$TJ-=BUC(V0];NDD?9"UID-M >=L09DP:HH?WF,^]>"(L:Z(E!)S.DXVD:=:\S34:0UXGOA7@3,>03VO6W0*

M/8=$@;DM0'4S*,N@]/>Y7(N.S*8+'_]1*202)4CP*%_KE$;T?77,>*;N:.35Q912:F1KY<2G.E>V2-!| MAZ#TD\(]D]4HNY_>8]G!F5*HXX]AYV:,*FT=4V7)U\ *NHDK?)%AG[F!S,V;MIU&_RWLFWEV4J8L_ME;\]1^!HTUQI>>C>P9F1>)"\@%T.IVZL,NBS,+!D M!\SQ"OQTG)*CQOO^#83.NO %G]:**QTZ3=:(9CI&,:)S(N&G\O:+[14X[A1 MM%X)SJG*P]8,D?^%OJ^Q)fW>XCM@'OF2A#<;@)2@."VL&KUYV3T_3JOC'&B^ M+UD#6)K"'>(Z<4(3AYNHVZ+RMHV,TW!T'NICRImoc#RZ-*]2C,W\H.0XEA M.'^CXT)MS&.M1_,"1-LT(>_R%89S(N6WK,R:I#P2#6YE/[N:?$8<8H*UFU>& M(E,[,#-*S8*^\ON^OA)_5IO1$^<()\F9UBGWV0B;#43H==D(C29"&NP:)DI

M)S#@#UPFY4L'SYWV@6/!\GQ9K)'M_N?'!]W"I^R;>WYT<%3XHHNE-^6(63I4 MS#:*=% D;C"A"]I-&0 ,-\[^_SG^S(8^#['4CC]{M-G<4$R50S-ER'*F7!$CDCIQ_07/ G&G?/#

MDS:173'HH-C-V1&%*6'B4UT-BY MXZ64-?0_L3],28=NPJD*LHX"CS_"S'=E8A%2#6 &L8*FP]3$]"=(21C.1'5V5 M>6O>01AYE#

1YK3=_\OH<2LX[NV_I@4@?)IPP0JDKQNTXT[,#0Y)U&4C'L*Q"-MH05_EGZ'^LK3L#Z7"A%\%2A;+*.(W1X5PJ5:,[_<>.3^!1#PI3GQ"2SFH< 2 M%/L!A5*9\%G?XNC;)=G:

<'(>H&4(S-M7GLCZTN$G[X1K (.%]8'BM+K+&CM M%/X@8?I_K)+*?#5X$^,PI/2;0U\@^]"#8'X_?"?/[2()A]_HSJ%(;.O#AS.= M^L,/Z-

=PR>,%3HF_@62/Q@ETZES9+,2;2(G4$OIF@*'+Z_2]I1?NRO>=EQ5[-M_YI=/C72T64$s7/GTDH\u%"2],PUY#6(>H)BJ&G$+AIDLSXR;5AI (+XH-W6 M,2P=8>NV.?

0V3(FW:4./CD'2YK%PJ8NVA,=!1^<8WD"V-\) *+D/8J6*IRPJP>N"""?T[*W_M+%YISEQ:,R>G8!V2B? MABA48OXRQ>#Q$##$29HT$%)DE(U-^B[7?

*6[5X[@A3N%D^*!T05UXBW%[SE>; M(JI]-"&]AP/$VGIT5B [RGZ;M#>C/K3R((XDLLDZM&5T*Z5=H!]2$!4+\O8C MV-+%+1-V@Y#[4T72)9; *;^T)PQ-)U5D43$+PB//X#'ZNM

M]$!V^NV>,+:;%7FJ-YOM{'(+S*,0"1T>W6FBZ7, MN-4#F0]C#TL(<]P15W8=*B+#C"J+RW@;#QG+BM5RR>*OU+D&>85+'EN)MK5[M?K8[@CB-

R\3%$FI;$I_7IP:2H@+&FP:+_'/FFDX%;;_?"GLIEX2%=5[$E9R^%S#@3')VZHNN;O7ZE$DO),*8"2PD^F.E#K4A6*Y[+)72)+#N;/LE2\PE8X$5+1Y M&E5AIO

D3BNW%@:Y)1Y8G]4'SH.H92'H4EC:((VI#HEY[W3)%LA87289Y;BZ M1@1S50*X3@9R>NL9#,O@W6=:_6RF4^G#STZ22I:B0Y2.&\7+>DJXHI8T4%]E MF4.

[)MJS*TT&NDRKE&J4#M!3*"6&7$\X%X146JD)C>W)&J07%C]8+OL@9)*==BFOI- EEU+IPNB&X7 ^0PŸ)PRY"0;T M,<>^6F7E8R:9F/4-4W$8-XO Y#]"+45.K!?>2QR?

JM;#=\\=.*FT\DH>A427 M?4\(#6#G,L:!. ^8MZ8QM)(47'@R)U00*]2_D=(BY)]Z_]*$;U BZ"$/9E3 MF X $FIXNI_%"S#Z!IETI.7X\&IG<;!"C#BT=FAL*%=9-<;C':H+K^%LH+H0

MX1)-JY,3O$1KG%*]DFLW0HKEC*,7WM5+./,A$K@\#0B8?ETE"8#],0#-728BJ M"AGLPLT<=ZXJ@\$B9 (P*\"4!NGWEPF9_B^.PAEJ0UX+(@EX8,QS7C)51T2

MSA5$U034#0HGD%74D7$"=)&7R+0(B7YJB?':L#TR;+'\B07Y%GS*@^<>3>H\YZ*"35]ZIG41T M18)!+N^(!15$O7M>N',;OW.B1)P25\OZ4B9T^/*D&[+9%;;54I<\]=K,9>-

/DA!9WE8#G@$5B0SM64?;KA@U M&3M;S=CI-QDJ3<,.&MIAEG!'O34HYT.911^!Y{A),*6*?IC"'"IDJ'R:'(Y$ MPTVHB\Y<8HA5Z#,3$O7S1>1Y M&E5AIO D3BNW%@:Y)1Y8GJ4'SH.H92'H4EC:((VI#HEY[W3)%LA87289Y;BZ M1@1S50*X3@9R>NL9#,O@W6=:_6RF4^G#STZ22I:B0Y2.&\7+>DJXHI8T4%]E MF4. {M[,X^'B-`MU?,\UDDQ",,Q1LZ>W!{BAK3S#V&0VF# M5SLI,=#)Y:ZD$:PM<)=K8OQ+K99@@8T]4-$BT<.6,H87L#W;@E=(5AU5++NN M-$05TU9\P1H,U586WH'^ZPK_"M?

M5G23"!RIWBC): 1'E>%<1P6UZ4:G7&Y M],9P7AFB%]WJL!0^=RK#$JG[?H:IX0*JP/,JL"X-%&V9L.TO;9351HA1K_Q:.M4%%A26WY,M[B.\6O,)4+$YGEQ0$<'"%")!H+

PLGCO+> MV0BD P, #8F&N,7YLKZ%10_"&9"<;B5&^#]AX,M&+L,I5=K*Y='+PEMT>\H; MQD;',JGLJ1/98 A M4Y+VP*%KFJU_0V MLF:ZWJ=*8\@48Q.#986

MRU/>$RY=Q7S(K#=A6]\<\CUDOK[#,3(T;G\'N-ET!Y&*/KF["F(,U:@"P!=,G] M3,P!)9&01Y\34XF!=)?37$<4M19%J'(YK KHU<22F"!11ZY!*(#18;43V;)>

ML\7DK*2+Q;K!AUXF/";]9VH=0W*7\25[\O&GEQ87&=P8Q_&7FEMK\)WJ%>;Z0 M=0RPE'6,$%D3EUD@OHXY/YWO*V0/XVU37[KI8[%PVA.[%]+8$_0G)>6K3-_D M)-X+3-]LE1)-

,SL='44F;A]Z$> 7\\FUGK'%)M=Y4UQ(0?B-9F(P1=L82279" M3>CB"8HC)B$N *_+U\O(H\]P"N2DAE_&="&4DVTAFX1LSIL%,IVP,O)8],\L# ME&?

Y,M/"0GDJLXG8C!DV4761W!"F>`4NZJ9(MOQ:EB>@&RU\MY%&*.G^-5K[D+5E^*U?Q#8#UUFF 7ID?#D"ZRNQ:GNK=.'"U?OKA6FM M!'$Z0^=!_%

(1U#N9/'XVQ3JP$9QZOK8\NAA\G(H>L*W?,/C\>X@FV4=WZ(9, MKY>N=^T&!\5MR DCUNY2$!)ZK.GU2BOD=4:0^LN@4\C*%Z^.E?>EW)3\5^JB ?A;2>XV>.#)>1V(N

M6&3),"%6.YE=:^K.I-DYC[!A0I.@VNS_.^?66^\B!,0=R.I]VFNZQ&S8$T)F M<9XMF2Q?.U?H;-Y&H$E0F9J;6!:S*5TAN.B^1SKG,I4N]!A1'*N(VBBEYU-R

M&&6U4Q1]X"B:ZTG3&V>BMG>XWG<" !DL6+?)$C9HTX6UZ=([J6G 8 9I/,54 MB1!UA "!-9E@,)OM\.=.WRRSD04NBS?39!MP_3T.3NY# M[C:O535UBU<;X1IN?

4/ME^9J8<>1===2WNYTCW2_0L%(KY'9]SWA/UT M#PX/>_F\;O4XW6$QKE+#?H[L3]=G3'C!n94XW6$QKE+#?H[L3]=G3'C!n94

*'I]&:S:PINOD$X G(7[;479GA)Z0!C[?%BNB_'*&DPO)YH.0&<:HCJ6HJ^ M(M&PDK0Z)IF&!O;2D5\@5.#CE+)'6<./6GPZL!M(=3UTF:,GS0=5(LBK2]GL MX50:KM>EYGD3U0-4 S!)-"E=OT1FQL]@Y\,ZCBHK/]K.KBY&]5[>+%Z(6-+% M;,>L_Y\84^I5E:C-LPWA!R/-MNP^O/E8(QJ L4A/2A-'_D&1<6W"Z(=)1"GE M$N2^1Z<31K8H1,8N]4NP% 88]CJX!4V81#0-YOX.[IE1D:((@IQ=?#N5'O!\ M?)M4_Y"\C*ZA_#XAGWDP0$6A&)$0 0%P>XL2/5<F@X M1F% CX-C;13]' ,:-BI/'N?ZV'>[M=G9=3]"04C7381WNEXD M7LMH)L.;] fM9W-]9V>+))O;Z@#-VM%\G##*LB(?)"F0!EH9-/L3"77F(WDX*XI8;&VW[R1;9,J5-KX MJKARCAS!_'$Z+I/"0KE-H6A&[O2)NLKAYL[NIK,/XSOJ!"IYU@I3=JH'!',, ML;8/E+)_BW.9K#CR!\AIF74+"'8[&>U<^C)*I R.%. 20%"XX@1MXLLP'=OEA3,UX%*2R^X5OD6^E(/XM4I8$PAPI#F>!2E, M4\E0]PIC%/@H>H.G2B2'H7XNH%GYNEI+A"L/JZ7$-S/.F,R09"OT;GOA< C* M'S,%L#EHUKK@R!R'=\@CL@Q9^2]_QF0=E#ZG'1E@[Z$/\8YBE#1D#RS6V5| M'KT+>U]JKZ1<\":?T_L:5(MJ.AD["S")@QZX+7QT62OQ264%'/385WE$RJ}^ M>4Y\AK!H^,$6%%^(1W\IU)4%9T5(XEY[TJEX2PH(L+4"(A -?D43N4]< MF\K7@BE)K1O/1'1(0T!W*K#A9FNGO=7:YG;O\S#/RJ!OF=0<+3!7,XD:N-3= M2Y>"$&]MSQ5C$JGAHM10%3AFJ(<15*0!8$@>\X-78I7H5Y03LW:=4A#,_3Z& M!,E7>H\ [A9P=9FSWLD\ZI-Q@*KN[M9E0^ "EDZAR0N9XMO#++\^!BZ?(@8^=Q M$>6N+K2@KGJ;FYR@6W]SB#P.X4&]%H'S/^'S_[UZ_M4[QfTIZ]7@S59GKT]M M[A#KWN1L@DYK]\V%'G5S,CDV29&C*PNO U*++X(\H8'T.#HV!) ^I&R@929ZT M^HIQ$&15SFVF^6]P.C/??V']\@07XMC=B)1/T F=5KO-]SC/$2?VQHCQU&I7 M-8:)E715.874*HK3P5K;GM$\A#8N%44A3A1N!\\[>#"0NX7-I_R"U7MLJR(-MJ36$34FA&9 ^2}.Y6D9!D>SI6-5XMC)4&7#? YQ)Y6?@K\)-6(' MQ3V! [+4[=)7Q>SL;;/IQAI&V_R3+2,=T2,?N/G@,<51DH]GBTR='!W!PRD!U M_E2&R 8]@H%2.[<%F8S5ZE62FCI[OOY(@;8>8*PB#*3NS*(;@?U[&R<9/2"X M4HE3^WEX<^$%" !!BDII+SJ/WHN="7O1D_MDTKX4Q['$A6F;=4O#\@7V6VI3G?!M:S%G/&,Y>,IDBMRQ3C=Q*:=' MQ_A@)&?[UI2V2\<;CEMZ'- Z',?SSE2>;P6"G$;1+X=P<$M91/?L&:\Z[UWE MKN6XTTD?-&[0\F"4-)4CC@EZ-L'.J_[^$6I5I[W3VMN9K%3=U'S>#$\^NG*@MG.KY_*VS7+.D&,GL9I+YCI]7A7UMH4I]V#H6*_4]&_7ZS:=]8W=; <(@)W/R0"D7H_/H]&%4%OR(7618 M)(#7_GVH_7]HRJN:Q9.%)+>I>,O(1;]6|PLOL(VUS=^U!-EY*B2(RU^T-,G MN6)S#=2V#%>?O[<]MJWZ1 E&6KD'3HFU Q5A1=&M[4!A<@U1U)P@OM?UF]F5 M1(/31LXP6=+9ENOC0[IY*>;]SQ0IV>F@2^-$%*$"X"[!@P=P!I&WJRF7W'^X M)U09#GN6%2.3,QGW.)004(% (_"!H'/I1SG1!I8+OFPF28M*$+0.1>TGTL$V' MI[(B&W%R)1>43SP>F[.T:\[,T9-*2<9RQ4'#0Z:D.<^&);\>B:#L M_)2B;.?)'7]S?&@*WZQ#0>VL;?!_YAP:J.*/:^& :=_?;?QSD._Y C9+[XU_\Y&?F#^S1[,?AC?X*O&)UIV1;?1]2I. MT7W\>W1W\!1:]HS2P2S@4[=DEM<2.C/?_KSG_[T/N\FO8)LYH=G"3N_!F,2_ ME")"T %) %R2 # "'^?!C.?!"6> [.S=VR/!G2G\!V?/;\?--IV.:Q;'.&N78W MH%Z^[Z8_T?S:WK_K%TJQFDHZ3N@I(ZWYFT:*D(;RAHB:HCH<42TM;,M-:33 MD,XWD,ZG)%5&_"-YFTWT]@AJ3]"4C>8=KI49..:$ NR%VIRN?#@.AN8$KRY M!_^WO;WZ?%:%=G9L;ORX:!HIT\-%Q2?F.IW>9\5HPGGDR>@71$1>DWRY=H<6 MLM)>??\3O#65M'3RVX]/=YK3Y- S?&Y<'+5[\,.T;^/'7=XDM]? SSJ?=ZNSL MON!-+/1 FO,?FT~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{5%$\/W1DFJ.YX:)0HD M_(@AZ6"KUK[=6O2'LNJ=A"U]F: F\]*PWL]=\T& MBM'G+FWXG'M>L4[PMP0)H>[.1>(\KUGP??CBCR*@YG.R-N[^PLTJU:D-7B_*^Y,6+6$ M:?7$2C/N,9/Z'9B$Q?O/05"D/ZD<1H(5" ERU%T\)-[_XH\,"N;!LVI M-D1C MW(L;E?3YM;@C:!.H:99LYB)9H D.,^XTP>&W%!P>[SB(GML38-%%-QE\LD9S M);];3O^/R,R9(ZNIZ87U=-\P[1YVFG8/CVWW<(ZFQ]>$>A0?C_I6*2AF]^#ZK97"]J;43K*U5- EI'ZRPV1/%@4KLOW5;]7.6<|:-29.2?^L-H?_DH>_L;44A]!$XOGU-MHZK7B>?3^$YE;TH\$_.Y3M/B8@E.X04.?=&2>*1PH/V_$$*+-Z0$'Y!"%.6% ML^TCN@FT=O<6UD>R0>A^(V2UW6KOOAA,W7>'T?WZU7KQ&9O:9ZX9C7O\%S4 MOO,CSLE_U5?*V6[M.?!3^TVQ;QH:4KMW!46\Z%)3!>#-^/DHQ*$'YH;ZIO6*R8 M&,%M$ TBI2Q^F!L^[.(B9"KG%S?6M^S'L%(X]"/Z0A|>0:@/+0["9<+=G]X[M?]NSOF!#I>E3S>Q:ETK5@F2(#Y]J#K?Z MDFMX9JX4-],.BA%8F+CRRNLC*AOKZXAW,@* \N;_9+TT#T)(9/ MB4)&V0@K']43LA_7 S/"1ZH<" O=V?,R*QBG6EH+5?&%R @(BI&D#V68%)H(C{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|\S8X L]E= M4)2!^WB^[4U_K;V]TI5>?%;LE$5(E;GL$06+Q)&@:O(T=>G:^/XK$\W'8U[V/W-8@YN\KL3*._<,P18B%;&M*S[@YMXK< M1.8,7(@=_C>,3T|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|C>T. MK^,EV>(%[P)W0S]I=6SB [%9?IC( ]0 $;,@9?44!GXHXF-^BPH4OF%IO$YV MX=ND_,%;3-M HU+.!P1Y"]H33O:=P#EU)|UA7R83.PK#%[7T43@9Y,%F6?P4 M$Y4G,_%L\ ]\QXOS?YM8\=02NZ&! fNDG??!H.-,)'.L61+DE]:WT?S?P4E M* .6R W8,U>@TS*>KA!]_96OT1=GC,7>%PP'/(6 ! M2A:]+PYE;!G'9?]$VYT!0-I8- 4-OB M(73&Q:%\]5*&E&DG<>GSZ]Z%_D'[6> [F\"Y4C/<6U ZU\/Q[3"&TO&3%HXQK M8LGX[4#19H.Y>VM^,3&AOB04Z/4ODPM$U'C#)K/NU+4W\1;W6B MI^'"* BL6#W*^L![YA14/#[? J81[F$EM9YL,.5%/R!4FQ>E>]*\SIF4N&ZB<:GCB<>C3QOB"7-MHVX;>R>]FQ98KV1<@5AX@N_(,/0]6U(R)B#(-P"G/S_%2U*H78'#DWAL((P2 M6COP*(6UN-+&E ,8/M6KI4U(,=,B9;]VN"TR&[37@>]I>PI =Z MX0%4Q91T3$'H@-=$#-$J84I8S& *4|=D/(MIM,V|OK'175]JKDGN+KO"@Y],P M93%!,#,U#!C_2;R!I 8_]M8_*!MRU]G'*,G:-8D^$E/XZ)*R5<@Y2/"6]>UW M:V:"?O)OX5/?0]+H;/SR"<[6)T@RWKE/21S"/^FWI5_87C*AY=FA2W Y?^_3% (RS.=RM:HD4L=;=R8Q#X/W2TXSAWZ:/X"R?((D-RMX%;D2 M)S?UR0,UN1*5=P?]M32Y'_\A!O*]VD8C\Z[V"^G+7S'61CS;^/-Q>%9&'^1 M3]R8*XUC9BK]'PVK[J4Y9? >!B=2&9=AK$K2I=>C^D^L]TK5,X..F&U]1I).@',(CVC:AN!3;/T-Y9'*$?0PYPL$$$8:XHQ(;M&!5=T"$P'5 E[,1$?9>Q44"}16!5%$CLAQT+YU>.,/&(6XFZ!K BP-*M?1(RF M0"XX&)&*]@-6MX"5,05UEGU_;LDU?94P0X$++!V*(O9-R-:,WMOP:9 A5LY M95IZB72&-"?>CH&*1F+)3]WO.]_'6U9M3K5+6ZJ7:-PSRU92ZO=$Z723$,1T M-"79^ICK,A@H!LQ2A$2E#?0V&72,P I4* M3@\I2>27)L, #2MD'XZHTT]-%^1-JX/&G=LD^B!)CDD1KYFT & A%Q,\^; MW'<:>Z\TW MM*!0X?>EG%;'4RRG3,HU?ZG]\X: (7Y](Z_R?3/(@N]D1;H%/'HB BU=9M-M MA6D7:D.,;Y'1K]1;R *R1"]#I@B!VH/%W>C,LI5KUQ<_$Z8Z0(= M01A^<*(/9HS]>/R%W1G-1.,RXB#*!J3GY9>6&TS]!F&- UGTEW#S]Z .LA0+W> MOU74:J@$Q%(Z]U(3E&+TC<+N]'>28Q0 +8)>^'!B^2NGR#HB\If_:\70!A-Z_7S[0^06*ME*>\K@-%IS59 MGJ6V+^5|_H/KHX-_M":4 6#7=@7MQ^=3E9DHS#0G<%2O^BU."VU_%@?MF[6A,TH>*B+*"!_UB.85NU!'EZ(LB7)CNWY:/L>Q.V&-BT%E" 4HTIOQ$^'H M2Y)N(9G11I1N.), / -M1=IXDMX"#?!7 $'8G\]Z9&<;-5.I,=A"QFS /M:F+X\]P1<$%,1ECA62XZB*)>;:++MI"%=]KL< M9SK2G>4I-O1CMPTP90C$X,..?P/&8?OLZJ(3ZMH^LN+U92UYS"_M% VEQ7:I- 4"YSWRY<2+=R);0LL:M^&[L#*AO8Y]T]"A4?><2+S7'WJK)%[^*H M:E4M1XFW8KF+14&-1_4%"< 2*0PZ.)&FA9H_LB(1]G-U M,;*%LZ'_(C6&XIHM;I*"$'A2E+N%R[A(M36]VCA58[%RGYY)X]VDOL,;TW:M$+P",1+(W=[@?.T* M_32/Z4>21TW1+[S"}5<$*^Y3 SW= MR ;+ "ESGGAPG253"QL#7NX'Z#3C]IAF:\=FX>?T*9A&DF.?4B441#/ZHA[L MPI@(G23;TO)TXU,=[M7)*YG?1W=LVI70<7(5GT33E--A!W2AZ:",;?,8';_ 2]*XZ!-.$/O?B!= MU'2'68.A/X$=W99M("7@>QA9T&ZXTDEOH\OZ'N=:NU1U92UYS"_M% VEQ7:L- MQ(^S+QS!)BOL*M:2M)YF9$R%C8F_ZUf.*FEP9>:#+(!Q3ZIRD]VQY5&RC E> MY^[!#PE$I5?:D5Z8X4LSMOK%R*7 _HBQQ"S"5X&",0.=)S:EK"G,^&Q!94&2I M5(-3Y!G5:X]+C1+@@--SPJX6%,1)MP)[+7&++,2DPWE8S9X@93)0 0HUX1V; M;($TB846<&'fMZ5T"ENSB=D1WD<5^$5F<#3FO="F3M^"*J+3A/U/(^RCBFDC MJ8 S]KFP$TNGZ H+AR.?TTID%8[E3\X7O8_XZ3'%2F)[-HJ2S6@5=8B@/_*W)6_HZ%/*Y4R.J&F+92)RFLT^.|<|0 M)5/*7^"AJ3V:+L>+'DKT4*6[%G8E%BD=*WR'$H,?- XT@IJ+R'OFES + MM9B1C7E18UY|=\3#M]7+T1#&6Z1G%4.#.A_)4S@'I2R2 %R:24BH+3"DBDS# M6;/4 ^*+/G2Q@8OUX'K0WKL;/H/I:RQ0PUTC ;6/R,J2ND&+YN&$X"6<^D;L N MW4 8FC8VK02.+D.H$U6>8[XB QZD;.T(X (XX:3O@ZV2 M<%4G9@0.,%7$HJJ2ST<&CN"5T/O2K A32("+8VE15I- \3;$CKZF?J\-15*6 MHZI/P$-=U)9KHY'EE&M3!MY0*5;W).E"%G'5$VN+6(,-1;IK Pf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|\4'>IOU04O01Q9O%]#;.= (QAF9IA;FJE%65QO1YAFV9!&G:IG0:=(==9!ZO\);5,HZF^#S]{)TH<7+!|'M5SI$4H*IVZ#2PATS\Z7#<4 (F[_NB@EL 1.X;_BR12;"GOO:D/U?1U,ITM>NN1$P'LRI=OEI+1\|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

MGDWGP%'&LN*@G&%HRHF/=9QYI2:R%SH0:PN\%+X$>%D0$W@J$IAT5Z2B1 M;G?E_,(DS0X(?<W|QB-%/Y)(+^J1D5S=P-E8'1=8XD(Z,ZZ!'3/(I) M.!*SYX9@CHI0+ (=^#R51G[U4_OY_(A;& .3)LJ>"5,$;Q0!8)W01/5$-5V M3:@VEA85P6<+%):(A>-K8 E\F5!P>;DM1)A4C-#L-KY!$%["KU2W!'X-/\,I MT"E'T8.[EQG""[M? 7C;Y^)VB5FR]+M2*ET.&^K[1'N8[=+X^_?7\X*:!)/MP MZ.2;L_QRVK[/=W.TJH)O@,A"!0@]4AA[C'R1,MX%WRP(&JNHE3S>=ETU*,^ MBD00!EOBKPLJ'Q0&T:)"GLQ$(!9K]5.W.G5!57E0FQ+"#IX\I5:@51 M$]NF.41)L7N,%;3=_O&;+:BM_>D:U8Q5SMQV8,R#.]A%E;9*$ 2G<;_^ X'@ MM6S!RI7AH]6E6>Y$U\IW.XWG.T PF$%0GX/I32W==EL$(3?-7/E&;)GIDKG MNI;M+3,G[^O+|=GYP<7_W+_^[3N75^^GZH&V(0GC M[$OX)K?A?? AA0HT<(N>_U2U9F8+|L;I4&J-(U^4A')"N?!SG!Q^/C\^\Z\|? M#TI[8'F, O;<[RH5>==%UT? T32@F.U5%+DY<3K2:G+ MUT$0)$5,_7#FD+9+X&D[.[B^6;/N]MIN)(_N.C)/U:,7/; M-A+^;/^*/762VC.4]9(X3B59,ZXKI[Z]*ZCWMRW&Y!K7\-M?+]>)D)I8(+(1]>?#L M0@=7DV'*0HXN'NSL!)E^$0;_YU]+KSPP_M M ^H=M*K&W1WJ_TNS">)0H1$.8PAG,$Y+%:/Y2>:<(%]HXD4$3.IW6FU:WW7T- MG6[O\$VO?00G[Z'9' YR= *B5!B+|KA1NJ3YME&W*I'C<2/1)A>N&:/#R$FM M&A!IY5"1M,,,BU0K/%:Z,=P=M"]E!Z&.9V#=+//#E6M:^1OVH-,N7:!]\0R)R MF$AS>N*;(Y)7]@9%7*0G6:D"EQR P>G/YZ,S&/US M=/KK^/P?(VHFB=&E]TQH& (G#"P),2H(_CUTG%DYB7J 3_5G|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| =G9W=@;.T!?^C.=+3C@U4D54;PNGBWKJ[N%!Y\6* M82[>'%K9UPRU#QC_8#1:MK5X M1??^8/Z6SD>'UZR-H4_OCS_6+?]#LY^AR0,Y/$TE)C"ZP:CDHR1\K$J\04L. MGX/Y>Q?5]0?1^BT?[_CA%WZ9)[Z4J08RPE$F;#VN/'WDT_CYL7)NU'SQ\O1 MR=_X5THKO1?OSL:7&VUITC1Z>KN1B10NWGWX]?UR-9+@GUIM^2 M6OS3*W*) M_PW9[U!+ P04_" "PB&=9$\O$A>$'.!#)@ #0 &5X7S*AQP!G MD6)^?7>!XSOUUJ9N:MDSUO& Q6*Q^^#9!-3)N" MNV8*#A(GM&JP1"L'"J4=2"ASK>!4Z<;P8- *1@]BGO[UXP70LY[WU^+ BR[@!F[T@57W_=+GJ9"37!MH=AQ1Z@^:2TW5-TZ=M|$ M4VX$5ZZG: VR7W S$;I'W8WA"Q7;LC]HE<.#6^9@+SY7VO6W9@J-?;::C_D) MV<:,K)Z2.;AQ32[%1/68$9,+[P[N[H>GX_?C:["'R[8AW-V_?,9>_?S^.R5L96.!US^CZ';?G%?(2D,L()G.?L:K>7F@ ;)8Y=51+L M1J [+WFS\^J0'VVT](S|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}]CD<[A(8(>W&)$A"I%)MJ1KH_&8 /ZT2P=A52UM M.@H6Y=PNLS=QD$1KLMO_LD[YVR;FD:Q]+.:6.7&=.WH,JB$,X!W$'(L<:< M3/V10/N\DD.$(O^?)7[%)Q68BZ0-GRN!YON]4BE_V6N/OATG'GB,'"@K)U&(FM56!#D-/AXN0FM?W7N%\RY1["O[-3$GY M,#.XDR.,?CRP>C[>|H:)E%(^4)- M9P"Y17%)_5U]ZGY"HI2ZCE@IRS7@:3X M!@@1-'I(PCW^*J*Y^57-3U3?]M@%KKF(<=EO(D9?XW_!E3I_AHIQGX$Y,;0:_MF'^DK+^H7[!;DB>+]STF;5FT;=!,I"[^C^WGM1U- "9GK\,M7.ZZ/FK"=8I M;]AW;?^O?[O]]O'KY]XFU+06/!##OV,MQR[Q1"B(FR-V[BD.!BTQ? K+/[P,-Q](Z>=+_1'3XYP"=1UI?BQU1,62*YM:>-7T8?KYN7H_=GS1^OSD9_I1\OK? 5>OC^_MOM[Rf.FT;/=1N)4=OG^XF^_KF9#"]-U9X'6M&BWURA2_R/Q_X%4$L#!0 M (+"(9UD.27"O*08 -X. - 97A?-50Q.3DR+FAT;>U9WW/;.!!^ M;OZ*/3IMDQD,-DF;! @S+C$I=RVA0-K>TXULRI%.(fNRG(3[ZV_7-A0()#?W MD*:9RPNQ)*^^^_:7!5FZ'>AIUVB%G?F?G65L+'?$.O_GK_Z/F[4<+9=+P9W MGN\;X8!9UQRQ33WP9W!),RDS]5I/,4PC)5F$1A@6??#>L-L'(#5:%]'3?QG M^_$,H]>_MQ;HU$5.>PH!?PRB>,ED,MB!AOB_D91-,(<&L64*VP,M4&]LFL$S'+=HS6=FH ME/MJ3>*KU@\8.8K\8HIP:1N2M(P:DV9NA2R2=.5SDOIIDFK74\Z.UOR!O[M9K7G.T*Y)6A^HPT6B4O9!"4N0U0S8PH "1]OM.#>A<(5NU]TY*K>SWZA9-'7 MP%_2"!X&%E<,K-!U1I-^K]^U)_WSP1C.>]!]UW=ZX'QQNA>3_B<'AW#:&=UG MEH>#;],2Y"]_L >=/OV^|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~!3F%=IFD41%E&LC@+[&YQ(,+AQAMX*\BI XRC0%[EH]A^X*HN*+(D3ZI=P M(EVK%;D!;2^ MH'\?:G,&>~>IM!6L63M^<>?).0G5W=+T;5+WT;!L=Z@$4I0$.A M\$(0&DEPA*R9.'2*.#3X"M'_S_<|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| end XML 61 avgr20240930_10q_htm.xml IDEA: XBRL DOCUMENT 0001506928 2024-01-01 2024-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001506928 2024-06-30 0001506928 2024-06-01 2024-06-30 0001506928 2023-01-01 2023-09-30 0001506928 2023-07-01 2023-09-30 0001506928 2024-07-01 2024-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001506928 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001506928 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001506928 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001506928 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001506928 2024-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001506928 avgr:The2015EquityIncentivePlanMember 2024-09-30 0001506928 avgr:The2015EquityIncentivePlanMember 2024-01-01 2024-09-30 0001506928 avgr:The2015EquityIncentivePlanMember 2023-12-22 2023-12-22 0001506928 avgr:PreFundedSeriesA1SeriesA2SeriesA3AndPlacementAgentWarrantsMember 2024-06-13 0001506928 avgr:PlacementAgentWarrantsMember 2024-06-13 0001506928 srt:MaximumMember avgr:PlacementAgentWarrantsMember 2024-06-13 0001506928 avgr:SeriesA3WarrantsMember 2024-06-13 2024-06-13 0001506928 avgr:SeriesA2WarrantsMember 2024-06-13 2024-06-13 0001506928 avgr:SeriesA1WarrantsMember 2024-06-13 2024-06-13 0001506928 avgr:SeriesA2WarrantsMember 2024-06-13 0001506928 avgr:SeriesA3WarrantsMember 2024-06-13 0001506928 avgr:SeriesA1WarrantsMember 2024-06-13 0001506928 avgr:SeriesA1WarrantsMember 2024-03-16 2024-06-13 0001506928 srt:MaximumMember avgr:SeriesA3WarrantsMember 2024-06-13 0001506928 srt:MaximumMember avgr:SeriesA2WarrantsMember 2024-06-13 0001506928 srt:MaximumMember avgr:SeriesA1WarrantsMember 2024-06-13 0001506928 avgr:PrefundedWarrantsMember us-gaap:SubsequentEventMember 2024-10-03 0001506928 avgr:PrefundedWarrantsMember us-gaap:SubsequentEventMember 2024-10-03 2024-10-03 0001506928 avgr:PrefundedWarrantsMember 2024-06-13 0001506928 avgr:PrefundedWarrantsMember 2024-09-30 0001506928 srt:MaximumMember avgr:PrefundedWarrantsMember 2024-06-13 0001506928 avgr:AdvisorWarrantsIssuedInTheMarch2024FinancingMember 2024-03-07 0001506928 avgr:CommonWarrantsMember 2024-03-07 0001506928 2023-12-23 0001506928 avgr:PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2023-12-23 0001506928 avgr:SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2023-12-23 0001506928 avgr:SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2023-12-23 0001506928 avgr:WarrantsIssuedInTheJanuary2022FinancingMember 2023-12-23 0001506928 avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember 2023-12-23 0001506928 avgr:Series2February2018WarrantsMember 2023-12-23 0001506928 avgr:Series1February2018WarrantsMember 2023-12-23 0001506928 avgr:SeriesBPreferredInvestmentOptionPurchaseWarrantsMember 2024-08-08 2024-08-08 0001506928 avgr:SeriesBPreferredInvestmentOptionPurchaseWarrantsMember 2024-08-07 0001506928 avgr:PrefundedWarrantsMember 2024-07-01 2024-09-30 0001506928 avgr:PlacementAgentWarrantsIssuedInJune2024Member 2024-09-30 0001506928 avgr:SeriesA3WarrantsIssuedInJune2024Member 2024-09-30 0001506928 avgr:SeriesA2WarrantsIssuedInJune2024Member 2024-09-30 0001506928 avgr:SeriesA1WarrantsIssuedInJune2024Member 2024-09-30 0001506928 avgr:PrefundedWarrantsIssuedInJune2024Member 2024-09-30 0001506928 avgr:AdvisorWarrantsIssuedInTheMarch2024FinancingMember 2024-09-30 0001506928 avgr:SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2024-09-30 0001506928 avgr:SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2024-09-30 0001506928 avgr:WarrantsIssuedInTheJanuary2022FinancingMember 2024-09-30 0001506928 avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember 2024-09-30 0001506928 avgr:Series2February2018WarrantsMember 2024-09-30 0001506928 avgr:Series1February2018WarrantsMember 2024-09-30 0001506928 avgr:June2024OfferingMember 2024-06-17 0001506928 avgr:June2024OfferingMember 2024-06-17 2024-06-17 0001506928 avgr:March2024OfferingMember 2024-03-05 0001506928 avgr:March2024OfferingMember 2024-03-05 2024-03-05 0001506928 us-gaap:SeriesHPreferredStockMember 2024-09-30 0001506928 us-gaap:SeriesHPreferredStockMember 2024-01-01 2024-09-30 0001506928 us-gaap:SeriesHPreferredStockMember 2024-07-01 2024-09-30 0001506928 us-gaap:SeriesHPreferredStockMember 2024-05-16 2024-05-16 0001506928 srt:MaximumMember us-gaap:SeriesHPreferredStockMember 2024-05-16 0001506928 us-gaap:SeriesHPreferredStockMember 2024-05-16 0001506928 us-gaap:SeriesFPreferredStockMember 2024-09-30 0001506928 us-gaap:SeriesFPreferredStockMember 2024-01-01 2024-09-30 0001506928 us-gaap:SeriesFPreferredStockMember 2024-07-01 2024-09-30 0001506928 us-gaap:SeriesFPreferredStockMember 2024-03-04 2024-03-04 0001506928 us-gaap:SeriesFPreferredStockMember 2024-03-04 0001506928 avgr:SeriesFConvertiblePreferredStockMember 2024-03-04 0001506928 us-gaap:SeriesEPreferredStockMember 2024-09-30 0001506928 us-gaap:SeriesEPreferredStockMember 2024-01-01 2024-09-30 0001506928 us-gaap:SeriesEPreferredStockMember 2024-07-01 2024-09-30 0001506928 us-gaap:SeriesEPreferredStockMember 2024-05-16 2024-05-16 0001506928 srt:MaximumMember us-gaap:SeriesEPreferredStockMember 2024-05-16 0001506928 us-gaap:SeriesEPreferredStockMember 2024-05-16 0001506928 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001506928 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001506928 us-gaap:SeriesBPreferredStockMember 2018-02-16 0001506928 avgr:SeriesA1PreferredStockMember 2024-09-30 0001506928 srt:MaximumMember avgr:SeriesA1PreferredStockMember 2024-09-30 0001506928 avgr:SeriesA1PreferredStockMember 2023-08-02 0001506928 avgr:SeriesA1PreferredStockMember 2024-03-05 0001506928 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001506928 avgr:ExchangeOfSeriesAPreferredStockIntoSeriesA1PreferredStockMember 2024-03-05 2024-03-05 0001506928 2023-12-31 0001506928 us-gaap:PurchaseCommitmentMember 2024-09-30 0001506928 2019-12-31 0001506928 2024-03-06 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2023-01-01 2023-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2024-01-01 2024-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2023-07-01 2023-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2024-07-01 2024-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2023-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2024-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 0001506928 avgr:LoanAgreementMember avgr:CRGMember 2024-09-30 0001506928 avgr:CRGMember avgr:LoanAgreementAmendmentNo7Member 2024-07-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2022-08-10 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2022-08-10 2022-08-10 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2024-08-01 0001506928 avgr:CRGMember avgr:LoanAgreementAmendmentNo10Member 2024-06-05 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2018-02-14 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2024-04-02 0001506928 avgr:CRGMember avgr:LoanAgreementAmendmentNo8Member 2024-01-26 0001506928 avgr:ConversionOfCRGLoanIntoSeriesEConvertiblePreferredStockMember 2024-05-16 2024-05-16 0001506928 us-gaap:SeriesEPreferredStockMember 2023-08-02 0001506928 avgr:ConversionOfCRGLoanIntoSeriesEConvertiblePreferredStockMember 2023-08-02 2023-08-02 0001506928 avgr:SeriesAPreferredStockPurchaseAgreementWithCRGMember avgr:CRGMember avgr:LoanAgreementMember 2018-02-14 2018-02-14 0001506928

avgr:SecondTrancheBorrowedOnJune152016Member avgr:CRGMember avgr:LoanAgreementMember 2016-06-15 0001506928 avgr:FirstTrancheBorrowedOnSeptember222015Member avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 2015-09-22 0001506928 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001506928 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001506928 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001506928 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001506928 us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001506928 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001506928 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001506928 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001506928 avgr:CommonStockOptionsMember 2023-01-01 2023-09-30 0001506928 avgr:CommonStockOptionsMember 2024-01-01 2024-09-30 0001506928 avgr:CommonStockOptionsMember 2023-07-01 2023-09-30 0001506928 avgr:CommonStockOptionsMember 2024-07-01 2024-09-30 0001506928 avgr:CommonStockWarrantsMember 2023-01-01 2023-09-30 0001506928 avgr:CommonStockWarrantsMember 2024-01-01 2024-09-30 0001506928 avgr:CommonStockWarrantsMember 2023-07-01 2023-09-30 0001506928 avgr:CommonStockWarrantsMember 2024-07-01 2024-09-30 0001506928 2023-09-30 0001506928 2022-12-31 0001506928 2023-06-30 0001506928 avgr:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001506928 avgr:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001506928 avgr:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001506928 avgr:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001506928 avgr:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001506928 avgr:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001506928 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001506928 avgr:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001506928 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001506928 avgr:ExchangeOfSeriesAPreferredStockIntoSeriesA1PreferredStockMember 2024-01-01 2024-09-30 0001506928 avgr:SecuritiesPurchaseAgreementMember 2024-03-05 0001506928 avgr:SecuritiesPurchaseAgreementMember 2024-03-05 2024-03-05 0001506928 avgr:AdvisorWarrantsIssuedInTheMarch2024FinancingMember 2024-03-05 0001506928 avgr:SecuritiesPurchaseAgreementMember 2024-03-04 0001506928 srt:MaximumMember us-gaap:SeriesFPreferredStockMember 2024-05-22 0001506928 srt:MinimumMember us-gaap:SeriesGPreferredStockMember avgr:SecuritiesPurchaseAgreementMember 2024-09-30 0001506928 us-gaap:SeriesGPreferredStockMember 2024-03-04 0001506928 avgr:SecuritiesPurchaseAgreementMember 2024-03-04 2024-03-04 0001506928 us-gaap:SeriesFPreferredStockMember 2024-03-05 0001506928 us-gaap:SeriesFPreferredStockMember avgr:SecuritiesPurchaseAgreementMember 2024-03-05 0001506928 us-gaap:SeriesFPreferredStockMember avgr:SecuritiesPurchaseAgreementMember 2024-03-05 2024-03-05 0001506928 us-gaap:CommonStockMember avgr:SecuritiesPurchaseAgreementMember 2024-03-05 0001506928 us-gaap:CommonStockMember avgr:SecuritiesPurchaseAgreementMember 2024-03-05 2024-03-05 0001506928 avgr:LicenseAndDistributionAgreementMember 2024-01-01 2024-09-30 0001506928 avgr:LicenseAndDistributionAgreementMember 2024-07-01 2024-09-30 0001506928 avgr:LicenseAndDistributionAgreementMember 2024-03-04 2024-03-04 0001506928 us-gaap:SubsequentEventMember avgr:TheMarketOfferingAgreementTheAtmAgreementMember 2024-10-01 2024-10-31 0001506928 us-gaap:SubsequentEventMember avgr:TheMarketOfferingAgreementTheAtmAgreementMember 2024-10-31 0001506928 avgr:TheMarketOfferingAgreementTheAtmAgreementMember 2024-01-01 2024-09-30 0001506928 avgr:TheMarketOfferingAgreementTheAtmAgreementMember 2024-07-01 2024-09-30 0001506928 avgr:TheMarketOfferingAgreementTheAtmAgreementMember 2023-01-01 2023-12-31 0001506928 avgr:CommonStockInJune2022Member 2022-05-20 0001506928 avgr:June2024OfferingMember 2024-06-13 2024-06-13 0001506928 avgr:June2024OfferingMember 2024-06-13 0001506928 avgr:TheMarketOfferingAgreementTheAtmAgreementMember 2022-05-21 2024-09-30 0001506928 avgr:PublicOfferingMember 2024-06-17 2024-06-17 0001506928 avgr:PublicOfferingMember 2023-01-01 2023-09-30 0001506928 avgr:PublicOfferingMember 2024-01-01 2024-09-30 0001506928 us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001506928 us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001506928 us-gaap:RetainedEarningsMember 2024-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001506928 us-gaap:CommonStockMember 2024-09-30 0001506928 us-gaap:PreferredStockMember 2024-09-30 0001506928 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001506928 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001506928 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001506928 avgr:SeriesA1PreferredStockMember 2024-01-01 2024-09-30 0001506928 avgr:SeriesA1PreferredStockMember us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001506928 avgr:SeriesA1PreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001506928 avgr:SeriesA1PreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001506928 us-gaap:RetainedEarningsMember us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001506928 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001506928 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001506928 us-gaap:RetainedEarningsMember 2023-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001506928 us-gaap:CommonStockMember 2023-12-31 0001506928 us-gaap:PreferredStockMember 2023-12-31 0001506928 us-gaap:RetainedEarningsMember 2023-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001506928 us-gaap:CommonStockMember 2023-09-30 0001506928 us-gaap:PreferredStockMember 2023-09-30 0001506928 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001506928 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001506928 us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001506928 us-gaap:RetainedEarningsMember 2022-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506928 us-gaap:CommonStockMember 2022-12-31 0001506928 us-gaap:PreferredStockMember 2022-12-31 0001506928 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001506928 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001506928 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001506928 us-gaap:RetainedEarningsMember 2024-06-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001506928 us-gaap:CommonStockMember 2024-06-30 0001506928 us-gaap:PreferredStockMember 2024-06-30 0001506928 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001506928 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001506928 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001506928 us-gaap:RetainedEarningsMember 2023-06-30 0001506928 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001506928 us-gaap:CommonStockMember 2023-06-30 0001506928 us-gaap:PreferredStockMember 2023-06-30 0001506928 2024-11-04 thunderdome:item iso4217:USD pure iso4217:USD shares utr:Y shares utr:D utr:M Q3 2024 --12-31 false 0001506928 false false false false 1 1 1 1 1 1 P5Y 0 P1Y 1 0 0 P1Y 1 1 2 1 1 1 0 0 1 1 1 1 1 1 1 10-Q true 2024-09-30 false 001-36817 AVINGER, INC. DE 20-8873453 400 Chesapeake Drive Redwood City CA 94063 650 241-7900 Common Stock, par value $0.001 per share AVGR NASDAQ Yes Yes Non-accelerated Filer true false false 3196791 5901000 5275000 56000 41000 877000 1014000 3759000 5298000 947000 575000 11484000 12162000 1427000 1102000 466000 487000 224000 19000 13601000 13770000 921000 777000 1962000 2311000 653000 0 589000 817000 1210000 1102000 4168000 14293000 9503000 19300000 217000 0 6000 672000 9726000 19972000 0.001 0.001 5000000 5000000 30229 30229 62881 62881 18338000 62796000 0 0 0.001 0.001 100000000 100000000 2783891 2783891 1279928 1279928 3000 1000 438153000 414493000 -434281000 -420696000 3875000 -6202000 13601000 13770000 1650000 1817000 5356000 5746000 1224000 1429000 4209000 4117000 426000 388000 1147000 1629000 1086000 1044000 3052000 3388000 3009000 3377000 10980000 10261000 4095000 4421000 14032000 13649000 -3669000 -4033000 -12885000 -12020000 48000 455000 698000 1292000 11000 12000 -2000 16000 -3706000 -4476000 -13585000 -13296000 349000 -2436000 652000 -0 0 0 1908000 0 -4055000 -2040000 -12329000 -13296000 -1.82 -2.92 -6.93 -21.48 2224000 698000 1780000 619000 60961 0 622578 9000 404597000 -411196000 -6590000 0 0 600454 1000 5136000 0 5137000 1920 0 0 0 1920000 0 1920000 0 0 219000 0 219000 0 0 56896 -9000 9000 0 0 0 2436000 0 2436000 0 0 0 -4476000 -4476000 62881 0 1279928 1000 414317000 -415672000 -1354000 30229 0 1916434 2000 438326000 -430575000 7753000 -0 -0 45000 -0 45000 0 0 0 0 0 0 0 0 0 867457 1000 0 0 1000 0 0 222000 0 222000 -0 -0 349000 -0 349000 0 0 0 -3706000 -3706000 30229 0 2783891 3000 438153000 -434281000 3875000 60961 0 522177 8000 406514000 -402376000 4146000 0 0 607236 1000 5173000 0 5174000 1920 0 0 0 1920000 0 1920000 0 0 91325 1000 -2000 0 -1000 0 0 2294 0 0 0 0 0 0 703000 0 703000 0 0 56896 -9000 9000 0 0 -13296000 62881 0 1279928 1000 414317000 -415672000 -1354000 62881 0 1279928 1000 414493000 -420696000 -6202000 7224 0 75327 0 6880000 0 6880000 0 0 0 0 127000 0 127000 0 0 867457 1000 0 0 1000 0 0 330000 0 5155000 0 5155000 11000 0 0 0 11000000 0 11000000 -60876 0 0 0 0 0 0 10000 0 0 0 0 0 0 368503 1000 0 0 1000 -0 -0 137324 -0 374000 -0 374000 0 0 1525000 0 1525000 -0 -0 652000 -0 652000 0 0 0 -13585000 -13585000 30229 0 2783891 3000 438153000 -434281000 3875000 -13585000 -13296000 245000 214000 32000 62000 1525000 703000 844000 1488000 16000 42000 111000 350000 -14000 51000 -122000 -278000 -1205000 996000 372000 188000 221000 -21000 144000 -82000 -349000 -250000 -228000 240000 -666000 422000 -11163000 -11043000 -0 8000 0 -8000 7007000 0 1000 0 5155000 5173000 374000 -0 11789000 5173000 626000 -5878000 5275000 14603000 5901000 8725000 1177000 0 11000000 1920000 652000 0 0 796000 223000 32000 1. Organization   Organization, Nature of Business   Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (“OCT”) visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox consoles, as well as a variety of disposable catheter products. The Company’s current catheter products include Ocelot, Tigereye and Tigereye ST, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy products, Pantheris, Pantheris SV and Pantheris LV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California.   Liquidity Matters   The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within one year from the date of the issuance of these financial statements.   In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of September 30, 2024, the Company had an accumulated deficit of $434.3 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $5.9 million at September 30, 2024, together with debt and other financing activities and expected revenues from operations will be sufficient to allow the Company to fund its current operations through the end of the fourth quarter of 2024. On March 5, 2024, the Company entered into a financing as part of a broader strategic collaboration with Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge”) in which the Company received an aggregate of $7.5 million before any commissions, legal and accounting fees, and other ancillary expenses as described more fully below. On June 17, 2024, the Company completed a public offering in which it received an aggregate of $6.0 million

*before any commissions, legal and accounting fees, and other ancillary expenses. The Company had also received net proceeds of approximately $6.5 million from the sale of its common stock under an At The Market Offering Agreement from the time of activation through the quarter ended September 30, 2024. On October 17, 2024, the Company reactivated the ATM Agreement. During October and part of November 2024, the Company sold 107,080 shares of common stock pursuant to the ATM Agreement at an average price of $0.82 per share for aggregate proceeds of approximately $88,000, of which approximately $2,600 was paid in the form of commissions to the Agent. The Company may seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.   The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for its existing stockholders. Given the volatility in the Company's stock price, any financing that the Company may undertake in the next twelve months could cause substantial dilution to its existing stockholders, and there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. These conditions raise substantial doubt about the Company's ability to continue as a going concern. In addition, the macroeconomic environment has in the past resulted in and could continue to result in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.   If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development and sale of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company's ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.   Additionally, due to the substantial doubt about the Company's ability to continue operating as a going concern and the "Material Adverse Change" clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively "CRG"), the entire amount of outstanding borrowings at September 30, 2024 and December 31, 2023 has been classified as current in these financial statements. CRG has not purported that an Event of Default (as defined in the Loan Agreement) has occurred due to a Material Adverse Change.   Currently substantially all of the Company's cash and cash equivalents are held at a single financial institution. The Company's previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. The Company has regained access to its accounts with the new institution and is currently reviewing its banking relationships. Potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Company's access to cash and cash equivalents.   If the Company is unable to access its cash and cash equivalents as needed, its financial position and ability to operate its business will be adversely affected.   Public Offerings   June 2024 Offering   On June 13, 2024, the Company entered into a securities purchase agreement with two institutional investors for the issuance and sale of 3,614,457 shares of its common stock in a best efforts public offering ("the Offering") at a purchase price of $1.66 per share, or pre-funded warrants in lieu thereof. The Company received aggregate net proceeds of approximately $5.2 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.   As a result, the Company issued (i) 330,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 3,284,457 shares of common stock (the "Pre-Funded Warrants"). During the third quarter of 2024, a total of 867,457 shares of the Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 867,457 shares of common stock. After giving effect to these aforementioned exercises, as of September 30, 2024, 2,417,000 Pre-Funded Warrants remain outstanding.   In addition, the Company issued to the investors in the Offering (i) Series A-1 warrants (the "Series A-1 Warrants") to purchase up to an aggregate of 3,614,457 shares of common stock, (ii) Series A-2 warrants (the "Series A-2 Warrants") to purchase up to an aggregate of 3,614,457 shares of common stock, and (iii) Series A-3 warrants (the "Series A-3 Warrants," and together with the Series A-1 Warrants and Series A-2 Warrants, the "Warrants") to purchase up to an aggregate of 3,614,457 shares of common stock. Each share of common stock or Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. Each Warrant has an exercise price of $1.66 per.   The Series A-1 Warrants expire on the earlier of August 12, 2029 and 60 days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. The Series A-2 Warrants expire on the earlier of August 12, 2026 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. The Series A-3 Warrants expire on the earlier of May 12, 2025 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO investigational device exemption ("IDE") application.   Pursuant to an engagement letter (the "Engagement Letter") with H.C. Wainwright & Co., LLC (the "Placement Agent"), the Company, in connection with the Offering, issued warrants to designees of the Placement Agent (the "Placement Agent Warrants") to purchase up to an aggregate of 216,867 shares of common stock (the "Placement Agent Warrant Shares"). The Placement Agent Warrants have substantially the same terms as the Warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $2.075 per share and expire on June 13, 2029.   At The Market Offering Agreement   On May 20, 2022, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.001 per share (the "Shares") up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Company's shelf registration statement on Form S-3, which was initially filed with the SEC on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on May 20, 2022. On August 3, 2022, the Company suspended sales under the ATM Agreement. On March 17, 2023, the Company reactivated the ATM Agreement. During the year ended December 31, 2023, the Company sold 607,241 shares of common stock at an average price of $9.01 per share for aggregate proceeds of approximately $5.5 million, of which approximately $164,000 was paid in the form of commissions to the Agent. There were no sales under the ATM Agreement during the three or nine months ended September 30, 2024. On October 17, 2024, the Company reactivated the ATM Agreement. During October and part of November 2024, the Company sold 107,080 shares of common stock pursuant to the ATM Agreement at an average price of $0.82 per share for aggregate proceeds of approximately $88,000, of which approximately $2,600 was paid in the form of commissions to the Agent. While the Company may attempt additional sales in the future, there can be no assurance that the Company will be successful in acquiring additional funding through these means.   Other than the ATM Agreement, the Company currently does not have any commitments to obtain additional funds.   Strategic Partnership and Private Placement   On March 4, 2024, the Company entered into a License and Distribution Agreement (the "License Agreement") with Zylox-Tonbridge effective as of the Initial Closing (defined below), pursuant to which the Company will license and distribute certain of the Company's products (including consumables) in the Greater China region, including mainland China, Hong Kong, Macao, and Taiwan (the "Territory"). Zylox-Tonbridge will lead all regulatory activities for the registration of the Avinger products in the Territory. Avinger will also license its intellectual property and know-how related to Avinger products to Zylox-Tonbridge so that Zylox-Tonbridge can manufacture the localized products in the Territory. Avinger will supply Avinger products to Zylox-Tonbridge until Zylox-Tonbridge's manufacturing capability has been established and Zylox-Tonbridge has obtained the regulatory approval of the localized products manufactured by Zylox-Tonbridge. All sales of Avinger products locally manufactured by Zylox-Tonbridge with regulatory approval by the regulatory authorities in the Territory and commercialized in the Territory will be royalty bearing to Avinger at a rate from a mid-single to high-single digit percentage depending on the amount of gross revenue as defined in the License Agreement, with certain increases depending on the amount of product gross margin. The License Agreement has an initial term of 20 years, which shall be further automatically extended for additional 20-year terms, subject to certain conditions. The License Agreement may not be terminated by either party, other than for certain uncured material breaches or the other party's insolvency. During the three and nine months ended September 30, 2024, the Company received approximately $0.2 million and $0.4 million respectively from Zylox-Tonbridge related to inventory consumed for regulatory approval which is recorded as a reduction to research and development expenses in the Condensed Statement of Operations and Comprehensive Loss for the three months ended September 30, 2024 which substantially offset the related expenditures associated with the inventory consumption.   In connection with the License Agreement, on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the "Collaboration Agreement" and, together with the License Agreement, the "Strategic Collaboration"), which provides the opportunity for the Company to access certain Zylox-Tonbridge peripheral vascular products for distribution in the U.S. and Germany. The agreement also provides the option for Avinger to source finished goods inventory from Zylox-Tonbridge following registration of Zylox-Tonbridge's manufacturing facility with the FDA.   Private Placement   On March 4, 2024, in connection with the Strategic Collaboration, the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the "Purchaser"), entered into a Securities Purchase Agreement (the "Purchase Agreement"), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Company's common stock, and shares of two new series of the Company's preferred stock (the "Private Placement"). On March 5, 2024, (the "Initial Closing"), the Company issued to the Purchaser 75,327 shares of the common stock at a purchase price per share of $3.664 (the "Purchase Price"), and 7,224 shares of a newly authorized Series F convertible preferred stock, par value $0.001 per share (the "Series F Preferred Stock"), at a purchase price per share of $1,000, for an aggregate purchase price of $7.5 million. *

  Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of common stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock (the "Series F Certificate of Designation").   Upon completion of the following as mutually agreed upon by the Company and the Purchaser: (i) the successful registration and listing under 21 CFR part 807 with the FDA of the Purchaser and one of its designated affiliates to manufacture Avinger's products, and (ii) the Company achieving an aggregate of $10 million in gross revenue within any four consecutive fiscal quarters after the Initial Closing, excluding any gross revenue achieved by Avinger under the License Agreement discussed above (together, the "Milestones"), the Purchaser will invest an additional $7.5 million (the "Milestone Closing") to purchase shares of the Company's new Series G convertible preferred stock, par value $0.001 per share (the "Series G Preferred Stock"). Each share of Series G Preferred Stock will have a stated value of $1,000 and will be convertible into shares of common stock at a conversion price of equal to the lowest of (x) the Purchase Price, (y) the closing price of the common stock on the date immediately preceding the Milestone Closing, and (z) the average closing price for the last five trading days preceding the Milestone Closing, provided that the conversion price will be no less than $0.20. The Milestone Closing was determined to be a separate freestanding equity-classified instrument issued together with the common stock and Series F preferred stock, all of which are classified within equity.   On May 22, 2024, the Company held a special meeting of stockholders to vote on the following proposals resulting from the Private Placement (i) accept conversion of the shares of Series F Preferred Stock in excess of 19.9% of the Company's outstanding common stock, which may be deemed a "change of control" under Nasdaq Listing Rule 5635(b) and (ii) issue and sell shares of Series G Preferred Stock upon completion of the Milestones. Both proposals were approved by the Company's stockholders. There were no conversions of Series F Preferred Stock during the three months ended September 30, 2024.   The Company engaged two financial advisors in connection with the Private Placement and agreed to pay them an aggregate cash fee equal to 7% of the gross proceeds to the Company. Additionally, the Company agreed to issue to one financial advisor warrants to purchase an aggregate number of shares of common Stock equal to 2% of the gross proceeds. In connection with the Private Placement, the Company issued the financial advisor warrants (the "Advisor Warrants") to purchase 40,938 shares of common stock. The cash fee of approximately $0.5 million and warrants with a fair value of approximately $0.1 million are considered financing costs and are recognized as a reduction of the proceeds from the Private Placement.   Series A Preferred Stock Exchange   On March 5, 2024, the Company entered into a Securities Purchase Agreement (the "A-1 Securities Purchase Agreement") with CRG to exchange all outstanding shares of Series A preferred stock for 10,000 shares of Series A-1 preferred stock (the "Exchange"). Among other things, the shares of Series A-1 preferred stock: (i) are convertible into an aggregate of approximately 2,729,257 shares of common stock at a conversion price equal to the Purchase Price, (ii) do not accrue or pay dividends payable solely on the Series A-1 preferred stock, (iii) will have no liquidation preference and (iv) will be junior in rank to shares of the Company's Series E preferred stock, Series F preferred stock and Series G preferred stock. The Exchange resulted in approximately $1.9 million gain included in the net loss applicable to common holders for the nine months ended September 30, 2024.   CRG Loan Amendment   Also on March 5, 2024, the Company entered into Amendment No. 9 to Loan Agreement effective as of the Initial Closing (the "Amendment") with CRG, which amends the Loan Agreement to, among other things: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;">-</td> <td style="width: auto;"> extend the interest-only period through December 31, 2026; </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;">-</td> <td style="width: auto;"> provide that interest payable through December 31, 2026 may be payable in kind rather than in cash; and </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> </td> <td style="width: 18pt;">-</td> <td style="width: auto;"> permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. </td> </tr> </tbody></table>   -434300000 5900000 7500000 6000000 6500000 107080 0.82 88000 2600 3614457 1.66 5200000 330000 3284457 867457 867457 2417000 3614457 3614457 3614457 1.66 1.66 1.66 P60D P60D P60D 216867 2.075 0.001 7000000 0.03 607241 9.01 5500000 164000 107080 0.82 88000 2600 P20Y P20Y 200000 400000 15000000 75327 3.664 7224 0.001 1000 7500000 1000 273 10000000 7500000 0.001 1000 0.2 0.199 0.07 0.02 40938 500000 100000 10000 2729257 1900000 2. Summary of Significant Accounting Policies   Basis of Presentation   The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and pursuant to the rules and regulations of the SEC. The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company's financial information. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any other interim period or for any future year. The December 31, 2023 condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Company's Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on March 20, 2024. The Company's significant accounting policies are more fully described in Note 2 of the Notes to Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company's knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.   Concentration of Credit Risk, and Other Risks and Uncertainties   Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.   The Company's policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, First Citizens Bank, which acquired the Company's prior banking partner, Silicon Valley Bank, in March 2023. The counterparties to the agreements relating to the Company's investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and December 31, 2023. The Company's previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. Although the Company has regained access to its accounts with this institution, now a division of the acquiring bank, and is currently reviewing its banking relationships, potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Company's access to cash and cash equivalents.   The Company's accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and December 31, 2023. At September 30, 2024, there was one customer that represented 38% of the Company's accounts receivable. At December 31, 2023, there was one customer that represented 24% of the Company's accounts receivable. For the nine months ended September 30, 2024 there was one customer that represented 17% of revenues. For the three months ended September 30, 2024, there were two customers that represented 20% and 11% of revenues, respectively. For the three and nine months ended September 30, 2023, there was one customer that represented 22% and 17% of revenues, respectively. Disruption of the Company's sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company's financial position and results of operations.   Product Warranty Costs   The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three

Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Beginning balance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">150</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">109</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warranty provision </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Usage/Release </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(22</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Ending balance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   Net Loss per Share Attributable to Common Stockholders   Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders' continued service to the Company. As of September 30, 2024 and 2023, there were no shares subject to repurchase. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.   Net loss per share applicable to common stockholders was determined as follows (in thousands, except per share data):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Net loss applicable to common stockholders </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,055</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,040</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(12,329</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,296</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common stock outstanding, basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,780</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">619</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net loss per share attributable to common stockholders, basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.82</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6.93</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(21.48</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table>   The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Common stock warrants equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,425,040</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">459,019</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,844,318</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">483,947</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td

style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Convertible preferred stock </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,229</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">62,151</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,121</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61,362</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unvested restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112,459</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,630</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">114,730</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">88,585</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,567,743</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">612,820</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,944,184</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">633,914</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   Segment and Geographical Information   The Company operates and manages its business as one reportable and operating segment. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company's long-lived assets, which are comprised of property and equipment, are based in the United States. For the three months ended September 30, 2024 and 2023, 94% and 91% respectively, of the Company's revenues were in the United States. For the nine months ended September 30, 2024 and 2023, 93% and 92%, respectively, of the Company's revenues were derived from the United States based on the shipping location of the external customer. The remaining revenues for the three and nine months ended September 30, 2024 and 2023, were primarily derived from Germany.   Fair Value Measurements   As of September 30, 2024 and December 31, 2023, cash equivalents were all categorized as Level 1 and consisted of money market funds. As of September 30, 2024 and December 31, 2023, there were no financial assets and liabilities categorized as Level 2 or 3. There were no transfers between fair value hierarchy levels during the three or nine months ended September 30, 2024 and September 30, 2023.   Recent Accounting Pronouncements   Recent accounting standards not yet adopted   In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. As a result, after adopting the ASU's guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under Accounting Standards Codification ("ASC") 815 or (ii) a convertible debt instrument was issued at a substantial premium. The ASU becomes effective for the Company, as a smaller reporting company as defined by the SEC, in the first quarter of 2024. The Company has not yet adopted this standard. This new standard is not expected to have a material impact on the Company's financial statements.   In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has not yet adopted this standard. This new standard is not expected to have a material impact on the Company's financial statements.   In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU No. 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, if any, with further disaggregation required for significant individual jurisdictions. The ASU is effective for the Company for fiscal years beginning after December 15. ASU No. 2023-09 allows for adoption using either a prospective or retrospective transition method. This new standard is not expected to have a material impact on the Company's financial statements. Basis of Presentation   The accompanying unaudited condensed financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and pursuant to the rules and regulations of the SEC. The accompanying unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company's financial information. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, or for any other interim period or for any future year. The December 31, 2023 condensed balance sheet data has been derived from audited financial statements. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements included in the Company's Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on March 20, 2024. The Company's significant accounting policies are more fully described in Note 2 of the Notes to Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Use of Estimates   The preparation of financial statements in conformity with U.S.

GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company's knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Concentration of Credit Risk, and Other Risks and Uncertainties   Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.   The Company's policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, First Citizens Bank, which acquired the Company's prior banking partner, Silicon Valley Bank, in March 2023. The counterparties to the agreements relating to the Company's investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and December 31, 2023. The Company's previous banking partner was acquired by another financial institution in 2023 following closure by state regulators. Although the Company has regained access to its accounts with this institution, now a division of the acquiring bank, and is currently reviewing its banking relationships, potential future disruptions to financial institutions where the Company holds accounts or has credit arrangements, or more widespread disruptions in the financial services industry, could negatively impact the Company's access to cash and cash equivalents.   The Company's accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at September 30, 2024 and December 31, 2023. At September 30, 2024, there was one customer that represented 38% of the Company's accounts receivable. At December 31, 2023, there was one customer that represented 24% of the Company's accounts receivable. For the nine months ended September 30, 2024 there was one customer that represented 17% of revenues. For the three months ended September 30, 2024, there were two customers that represented 20% and 11% of revenues, respectively. For the three and nine months ended September 30, 2023, there was one customer that represented 22% and 17% of revenues, respectively. Disruption of the Company's sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company's financial position and results of operations. 0.38 0.24 0.17 0.20 0.11 0.22 0.17 Product Warranty Costs   The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts, as necessary. Warranty provisions and claims are summarized as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Beginning balance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">150</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">109</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warranty provision </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Usage/Release </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(22</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Ending balance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Beginning balance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">150</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">109</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warranty provision </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Usage/Release </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(22</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Ending balance </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>
150000 128000 193000 109000 3000 18000 35000 52000 25000 7000 100000 22000 128000 139000 128000 139000 Net Loss per Share Attributable to Common Stockholders   Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders' continued service to the Company. As of September 30, 2024 and 2023, there were no shares subject to repurchase. Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common

stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.   Net loss per share applicable to common stockholders was determined as follows (in thousands, except per share data):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Net loss applicable to common stockholders </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,055</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,040</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(12,329</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(13,296</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common stock outstanding, basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,780</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">619</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net loss per share attributable to common stockholders, basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.82</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6.93</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(21.48</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table>   The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom:

1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Common stock warrants equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,425,040</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">459,019</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,844,318</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">483,947</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Convertible preferred stock </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,229</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">62,151</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,121</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61,362</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unvested restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112,459</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,630</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">114,730</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">88,585</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,567,743</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">612,820</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,944,184</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">633,914</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Net loss applicable to common stockholders </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,055</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td

style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (2,040</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(12,329</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(13,296</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common stock outstanding, basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,224</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">698</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,780</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">619</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net loss per share attributable to common stockholders, basic and diluted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.82</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.92</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6.93</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(21.48</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table> -4055000 -2040000 -12329000 -13296000 2224000 698000 1780000 619000 -1.82 -2.92 -6.93 -21.48 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; width: 44%;"> Common stock warrants equivalents </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,425,040</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">459,019</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,844,318</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">483,947</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common stock options </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Convertible preferred stock </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,229</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">62,151</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35,121</td> <td style="width: 1%; font-family: "Times New Roman",

Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61,362</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Unvested restricted stock units </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112,459</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,630</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">114,730</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">88,585</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,567,743</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">612,820</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,944,184</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">633,914</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 14425040 459019 5844318 483947 15 20 15 20 30229 62151 35121 61362 112459 91630 114730 88585 14567743 612820 5944184 633914 Segment and Geographical Information   The Company operates and manages its business as one reportable and operating segment. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company's long-lived assets, which are comprised of property and equipment, are based in the United States. For the three months ended September 30, 2024 and 2023, 94% and 91% respectively, of the Company's revenues were in the United States. For the nine months ended September 30, 2024 and 2023, 93% and 92%, respectively, of the Company's revenues were derived from the United States based on the shipping location of the external customer. The remaining revenues for the three and nine months ended September 30, 2024 and 2023, were primarily derived from Germany.   0.94 0.91 0.93 0.92 Fair Value Measurements   As of September 30, 2024 and December 31, 2023, cash equivalents were all categorized as Level 1 and consisted of money market funds. As of September 30, 2024 and December 31, 2023, there were no financial assets and liabilities categorized as Level 2 or 3. There were no transfers between fair value hierarchy levels during the three or nine months ended September 30, 2024 and September 30, 2023.   Recent Accounting Pronouncements   Recent accounting standards not yet adopted   In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. As a result, after adopting the ASU's guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under Accounting Standards Codification ("ASC") 815 or (ii) a convertible debt instrument was issued at a substantial premium. The ASU becomes effective for the Company, as a smaller reporting company as defined by the SEC, in the first quarter of 2024. The Company has not yet adopted this standard. This new standard is not expected to have a material impact on the Company's financial statements.   In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has not yet adopted this standard. This new standard is not expected to have a material impact on the Company's financial statements.   In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU No. 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, if any, with further disaggregation required for significant individual jurisdictions. The ASU is effective for the Company for fiscal years beginning after December 15. ASU No. 2023-09 allows for adoption using either a prospective or retrospective transition method. This new standard is not expected to have a material impact on the Company's financial statements. 3. Inventories   Inventories consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Raw materials </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,863</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,203</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Work-in-process </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">154</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25</td> <td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Finished products </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,742</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,070</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total inventories </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,759</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,298</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Raw materials </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,863</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,203</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Work-in-process </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">154</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Finished products </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,742</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,070</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total inventories </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,759</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,298</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1863000 3203000 154000 25000 1742000 2070000 3759000 5298000 4. Borrowings   CRG   On September 22, 2015, the Company entered into a Term Loan Agreement, as amended (the "Loan Agreement") with CRG under which, subject to certain conditions, the Company had the right to borrow up to $50 million in principal amount from CRG on or before the end of the twenty-fourth (24th) month period commencing on the first Borrowing Date (as defined in the Loan Agreement). The Company borrowed $30 million on September 22, 2015. The Company borrowed an additional $10 million on June 15, 2016 under the Loan Agreement.   On February 14, 2018, the Company and CRG further amended the Loan Agreement concurrent with the conversion of $38 million of the principal amount of the senior secured term loan (plus $3.8 million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock.   On August 2, 2023, the Company and CRG entered into a Securities Purchase Agreement ("Series E Purchase Agreement") pursuant to which the Company issued 1,920 shares of a newly authorized Series E convertible preferred stock ("Series E Preferred Stock") in exchange for CRG surrendering for cancellation $1.92 million of outstanding principal and accrued interest of the senior secured term loan under the Loan Agreement. Each share of Series E preferred stock has a stated value of $1,000 per share and is convertible into 93 shares of the Company's common stock at a conversion price of $10.725 per share.   On May 16, 2024, the Company and CRG entered into another Securities Purchase Agreement ("Series H Purchase Agreement") pursuant to which the Company issued 11,000 shares of a newly authorized Series H convertible preferred stock ("Series H Preferred Stock") in exchange for CRG surrendering for cancellation $11.0 million of outstanding principal and accrued interest of the senior secured term loan under the Loan Agreement. Each share of Series H preferred stock has a stated value of $1,000 per share and is convertible into 259 shares of the Company's common stock at a conversion price of $3.86 per share. Both the shares of Series E preferred stock and Series H preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess 9.99% of the Company's outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Company's outstanding voting power on a combined basis (as CRG collectively holds all of the issued and outstanding shares of the Company's Series A-1 Convertible Preferred Stock, Series E Convertible Preferred Stock and Series H Convertible Preferred Stock), unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b).   The Company has entered into several amendments to the Loan Agreement (the "Amendments") with CRG since September 2015. The Amendments, among other things: (1) extended the interest-only period through December 31, 2026; (2) extended the period during which the Company may elect to pay a portion of interest in payment-in-kind ("PIK"), interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted the Company to make the entire interest payments in PIK interest payments through December 31, 2026 so long as no Default has occurred and is continuing; (4) extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2028; (5) reduced the minimum liquidity covenant to $3.5 million at all times; (6) eliminated the minimum revenue covenants for all years (7) changed the date under the on-going stand-alone representation regarding no "Material Adverse Change" to December 31, 2026; (8) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of the Company and its subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; (9) provided CRG with board observer rights and (10) provide that the board observer may be appointed or removed by written notice from the Majority Lenders (as defined in the Loan Agreement).   On January 26, 2024, the Company entered into Amendment No. 8 to the Loan Agreement with CRG, which reduced the minimum

liquidity requirement of the Loan Agreement from $3.5 million to $1.0 million until April 1, 2024. Thereafter, the Company was subject to the minimum liquidity requirement of $3.5 million.   On March 5, 2024, the Company entered into Amendment No. 9 to the Loan Agreement with CRG, which (1) extended the interest-only period through December 31, 2026, (2) extended the period during which the Company may elect to pay a portion of interest in PIK interest payments through December 31, 2026 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted the Company to make the entire interest payments in PIK interest payments through December 31, 2026 so long as no Default has occurred and is continuing; and (4) permit the payment of dividends on the preferred stock issued or issuable to the Purchaser. The Company assessed Amendment No. 9 to the Loan Agreement and determined that this represented a loan modification. As such, the unamortized portion of previous issuance costs incurred will be amortized over the modified term, and costs incurred with third parties was expensed as incurred.   On June 5, 2024, the Company entered into Amendment No. 10 to the Loan Agreement with CRG, which reduced the minimum liquidity requirement of the Loan Agreement from $3.5 million to $1.5 million for the period commencing June 1, 2024 and ending July 31, 2024. Thereafter, the Company will be subject to the minimum liquidity requirement of $3.5 million.   Under the amended Loan Agreement, no cash payments for either principal or interest are required until the first quarter of 2027. The interest will be accrued and included in the debt balance based (to the extent not paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of 12.5%. Beginning in the first quarter of 2027, the Company will be required to make quarterly principal payments (in addition to the interest) of $0.5 million with total principal payments of $1.8 million in 2027 and $1.8 million in 2028. Total cash interest payments required to be made are $0.4 million and $0.1 million for 2027 and 2028 respectively. The maturity date of the Loan (as defined in the Loan Agreement) is December 31, 2028.   The Company may voluntarily prepay the borrowings in full, with a prepayment premium beginning at 5.0% and declining by 1.0% annually thereafter, with no premium being payable if prepayment occurs after seven and half years of the loan. There is currently no prepayment premium payable. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to 1.5% of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to 15.0% of the amounts borrowed plus any PIK is to be payable at the end of the term or when the borrowings are repaid in full. A short-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Company's assets.   The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for a pre-specified liquidity requirement and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents. The minimum liquidity requirement was temporarily reduced to $1.5 million until July 31, 2024. The Loan Agreement also prohibits the payment of cash dividends on the Company's capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may accelerate the payment terms of the Loan Agreement upon the occurrence of certain "Events of Default" set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a "Material Adverse Change" thereunder.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of September 30, 2024, the Company was in compliance with all applicable covenants under the Loan Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of September 30, 2024, principal, final facility fee and PIK payments under the Loan Agreement, as amended, were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Year Ending December 31,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (remaining three months of the year)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,176</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,060</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,236</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,934</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: Amount representing debt issuance costs </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Borrowings, current portion, as of September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,168</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of September 30, 2024 and December 31, 2023, the balance of the aggregate debt discount was approximately $134,000 and $166,000, respectively. The Company's interest expense associated with the amortization of debt discount was approximately $8,000 and $21,000 during the three months ended September 30, 2024 and 2023, respectively. The Company's interest expense associated with the amortization of debt discount was approximately $32,000 and $62,000 during the nine months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024 and 2023, the Company incurred interest expense of approximately $116,000 and $512,000, respectively. For the nine months ended September 30, 2024 and 2023, the Company incurred interest expense of approximately $0.8 million and $1.6 million, respectively.   While, as of the date hereof, CRG has not purported that an Event of Default has resulted due to a Material Adverse Change (as those terms defined in the Loan Agreement), due to the substantial doubt about the Company's ability to continue operating as a going concern, the entire outstanding amount of borrowings under the Loan Agreement and associated aggregate debt discount at September 30, 2024 and December 31, 2023 were classified as current in these financial statements. 50000000 P24M 30000000 10000000 38000000 3800000 1920 1920000 1000 93 10.725 11000 11000000 1000 259 3.86 0.0999 0.1999 3500000 3500000 1000000 3500000 3500000 1500000 3500000 0.125 500000 1800000 1800000 400000 100000 0.05 0.01 0.015 0.15 3500000 1500000 <table border="0" cellpadding="0" cellspacing="0"

class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> Year Ending December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2024 (remaining three months of the year) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,176</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,060</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,236</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount of PIK additions and final facility fee to be incurred subsequent to September 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,934</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount representing debt issuance costs</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(134</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Borrowings, current portion, as of September 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,168</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 0 0 2176000 4060000 6236000 -1934000 -134000 4168000 1300000 134000 166000 8000 21000 32000 62000 116000 512000 800000 1600000 5. Leases   The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The most recent amendment also provides an optional one-year extension of the lease following the end of the current term on November 30, 2025, which was not included in the assessment of the lease term as it is not reasonably certain the Company will elect to exercise this option. Rent expense is recognized using the straight-line method over the term of the lease.   The current lease was to expire on November 30, 2024. On March 6, 2024, the Company entered into an amendment to the lease which extended the lease term for a period of one year, subsequent to the original expiration. As amended, the lease will expire on November 30, 2025. Under the terms of the amendment, the Company will be obligated to pay an additional $1.3 million in base rent payments through November 2025, beginning on December 1, 2024. In total, the Company is obligated to pay approximately $7.1 million in base rent payments through November 2025, which began on December 1, 2019. The weighted average remaining lease term as of September 30, 2024 is 1.2 years.   In connection with the amendment the Company adjusted its right-of-use asset and lease liability to $2.2 million. As of the date of the amendment, the operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does not provide an implicit rate.   The Company’s operating lease expense, excluding variable maintenance fees and other expenses on a monthly basis, was approximately $105,000. Rent expense for the three months ended September 30, 2024 and 2023 was approximately $316,000 and $314,000, respectively. Rent expense for the nine months ended September 30, 2024 and 2023 was approximately $947,000 and $942,000, respectively. The Company’s variable expenses for the three months ended September 30, 2024 and 2023 were approximately $90,000 and $65,000, respectively. The Company’s variable expenses for the nine months ended September 30, 2024 and 2023 were approximately $263,000 and $233,000, respectively. Operating right-of-use asset amortization for the three months ended September 30, 2024 and 2023 was approximately $290,000 and $288,000, respectively. Operating right-of-use asset amortization for the nine months ended September 30, 2024 and 2023 was approximately $867,000 and $852,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table presents the future operating lease payments and leasehold liability included on the balance sheet related to the Company’s operating lease as of September 30, 2024 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Year Ending December 31,</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (remaining three months of the year)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">313</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,166</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,479</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: Imputed interest </td> <td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(52</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Leasehold liability as of September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table shows ROU assets and lease liabilities, and the associated financial statement line items, as of September 30, 2024 and December 31, 2023 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%; border-bottom: 1px solid rgb(0, 0, 0);">Lease-Related Assets and Liabilities</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; text-align: center; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Financial Statement Line </p> <p style="margin: 0pt; text-align: center; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Items</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> </p> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> </p> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> </p> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> </p> September 30, <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center;"> </td> <td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">December 31, <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">2023</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right of use assets:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 24%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Operating lease</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right of use asset</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 42%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Total right of use assets</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 24%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Operating lease</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold liability, current portion</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,210</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold liability, long-term portion</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">217</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 42%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Total lease liabilities</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   1300000 7100000 P1Y2M12D 2200000 0.065 105000 316000 314000 947000 942000 90000 65000 263000 233000 290000 288000 867000 852000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> Year Ending December 31, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:

0pt;">2024 (remaining three months of the year) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">313</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,166</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,479</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Imputed interest</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(52</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold liability as of September 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 313000 1166000 1479000 52000 1427000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%; border-bottom: 1px solid rgb(0, 0, 0);">Lease-Related Assets and Liabilities</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"> Financial Statement Line Items </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">   September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center;"> </td> <td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">December 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> Right of use assets: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 24%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> Operating lease </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%;"> Right of use asset </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 42%;"> Total right of use assets </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> Lease liabilities: </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 24%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 14%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> Operating lease </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%;"> Leasehold liability, current portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,210</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 41%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%;"> Leasehold liability, long-term portion </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">217</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 42%;"> Total lease liabilities </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,427</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1427000 1102000 1102000 1210000 1102000 217000 0 1427000 1102000 6. Commitments and Contingencies   Purchase Obligations   Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $0.7 million as of September 30, 2024. The majority of this amount is related to commitments to purchase inventory components and services related to the manufacturing of inventory.   Legal Proceedings   The Company is not currently involved in any pending legal proceedings that it believes could have a material adverse effect on our financial condition, results of operations or cash flows. From time to time, the Company may be involved in legal proceedings or investigations, which could harm our reputation, business and financial condition and divert the attention of our management from the operation of our business. 700000 7. Stockholders' Equity   Convertible Preferred Stock   As of September 30, 2024 and December 31, 2023, the Company's certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of convertible preferred stock with $0.001 par value per share. As of September 30, 2024 and December 31, 2023, 30,229 and 62,881 shares, respectively, were issued and outstanding.   Series A Preferred Stock Exchange   On March 5, 2024, the Company entered into the A-1 Securities Purchase Agreement with CRG to exchange all 60,876 outstanding shares of Series A preferred stock for 10,000 shares of Series A-1 preferred stock. Consequently, there are no shares of Series A preferred stock outstanding as of September 30, 2024.   The exchange was accounted for as a capital transaction constituting an extinguishment of the Series A preferred stock through the issuance of Series A-1 preferred stock with no net impact to stockholders' deficit. At the time of the exchange, the Series A preferred stock had approximately $1.9 million excess fair value in comparison to the Series A-1 preferred stock. The difference in fair value is treated as an adjustment to net loss applicable to common stockholders for the purpose of calculating earnings per share, see Note 2 for details.   Series A-1 Convertible Preferred Stock   Each share of Series A-1 preferred stock has a stated value of $1,000 per share and is convertible into 273 shares of the Company's common stock at $3.664 per share. The Series A-1 preferred stock is convertible into a total of 2,729,257 shares of common stock subject to certain limitations contained in the A-1 Securities Purchase Agreement. Shares of Series A-1 preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Company's outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Company's outstanding voting power, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b).The Series A-1 preferred stock has no liquidation preference, no voting rights and ranks junior to shares of the Company's Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock in terms of repayment and certain other rights. The Series A-1 preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. As of September 30, 2024, 10,000 shares of Series A-1 preferred stock were outstanding.   Series B Convertible Preferred Stock   The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. As of September 30, 2024 and December 31, 2023, 85 shares of Series B preferred stock remained outstanding, which are currently convertible into shares of the Company's common stock at $1.66 per share.   Series E Convertible Preferred Stock   Each share of Series E preferred stock has a stated value of $1,000 per share and is convertible into 93 shares of the Company's common stock at a conversion price of $10.725 per share. The Series E preferred stock is convertible into a total of 178,560 shares of common stock subject to certain limitations contained in the Series E Purchase Agreement. Shares of Series E preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Company's outstanding voting power and in no case will the beneficial ownership limitation exceed 19.99% of the Company's outstanding voting power, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). The holders of Series E preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series E preferred stock or cash, at the Company's option. The shares of Series E preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series E preferred stock rank junior to Series H preferred stock and are senior to all other classes and series of the Company's equity in terms of repayment and certain other rights. The Series E preferred stock accrued additional dividends of less than $0.1 million and $0.1 million during the three and nine months ended September 30, 2024, respectively, which were recognized as a reduction to additional paid-in capital in the statement of stockholders' equity (deficit). As of September 30, 2024 and December 31, 2023, 1,920 shares of Series E preferred stock were outstanding.   Series F Convertible Preferred Stock   On March 4, 2024, in connection with the Purchase Agreement (see Note 1), the Company issued 7,224 shares of Series F Preferred Stock, at a purchase price per share of $1,000. Each share of Series F preferred stock is convertible into 273 shares of the Company's common stock at a conversion price of $3.664 per share. The Series F preferred stock is convertible into a total of 1,972,152 shares of common stock subject to certain limitations contained in the Purchase Agreement. Shares of Series F preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 49.9% of the Company's outstanding voting power. The holders of Series F preferred stock are entitled to receive annual accruing dividends at a rate of 5% until the third anniversary of their issuance and 8% thereafter. The dividends are payable in additional shares of Series F preferred stock or cash, at the Company's option through the third anniversary of their issuance, and at the holder's option thereafter. The shares of Series F preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series F preferred stock ranks junior to Series H preferred stock, pari passu with Series E preferred stock and are senior to all other classes and series of the Company's equity in terms of repayment and certain other rights. The Series F preferred stock accrued additional dividends of $0.1 million and $0.2 million during the three and nine months ended September 30, 2024, respectively, which were recognized as a reduction to additional paid-in capital in the statement of stockholders' deficit. As of September 30, 2024, 7,224 shares of Series F preferred stock were outstanding.   Series H Convertible Preferred Stock   On May 16, 2024, in connection with the Series H Purchase Agreement (see Note 4), the Company issued 11,000 shares of Series H Preferred Stock, at a purchase price per share of $1,000. Each share of Series H preferred stock is convertible into 259 shares of the Company's common stock at a conversion price of $3.86 per share. The Series H preferred stock is convertible into a total of 2,849,000 shares of common stock subject to certain limitations contained in the Purchase Agreement. Shares of Series H preferred stock cannot be converted into common stock to the extent the applicable holder would beneficially own in excess of 9.99% of the Company's outstanding voting power and in no case will such beneficial ownership limitation exceed 19.99%, unless approved by the Company's stockholders in accordance with Nasdaq Listing Rule 5635(b). The holders of Series H preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series E preferred stock or cash, at the Company's option. The shares of Series H preferred stock have full voting rights, on an as-converted basis, subject to certain limitations. The Series H preferred stock rank senior to all other classes and series of the Company's equity in terms of repayment and certain other rights. The Series H preferred stock accrued additional dividends of $0.2 million and $0.3 million during the three and nine months ended September 30, 2024, which were recognized as a reduction to additional paid-in capital in the statement of stockholders' deficit. As of September 30, 2024, 11,000 shares of Series H preferred stock were outstanding.   Common Stock   As of September 30, 2024, the Company's certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 2,783,891 shares were issued and outstanding.   March 2024 Offering   On March 5, 2024, in connection with the Purchase Agreement (see Note 1), the Company issued 75,327 shares of common stock at a purchase price per share of $3.664.   June 2024 Offering   On June 17, 2024, in connection with the June 2024 Offering (see Note 1), the Company issued 330,000 shares of common stock at a purchase price per share of $1.66.   Common Stock Warrants   As of September 30, 2024, the Company had outstanding warrants to purchase common stock as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Total <p style="font-family: "Times New Roman", Times,

serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Outstanding and Exercisable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Underlying Shares of Common Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Exercise Price per Share </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Expiration Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Series 1 Warrants issued in the February 2018 Series B financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,993</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">February 2025</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 2 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,903</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> February 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Placement agent warrants issued in the January 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,330,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,433</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">150.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">January 2027</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,150,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53,833</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> July 2027 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Series A Preferred Investment Options issued in August 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">190,259</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.53</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">February 2028</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent Preferred Investment Options issued in the August 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">171,233</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,416</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> August 2027 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Advisor Warrants issued in the March 2024 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman",

Times, serif; font-size: 10pt; margin-left: 0pt;">40,938</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">40,938</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.664</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">March 2029</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-Funded Warrants issued in the June 2024 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,417,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,417,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.001</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">n/a</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Series A-1 Warrants issued in the June 2024 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">See note (1)</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A-2 Warrants issued in the June 2024 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> See note (2) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Series A-3 Warrants issued in the June 2024 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">See note (3)</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement Agent Warrants issued in the June 2024 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,867</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,867</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.075</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> June 2029 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Total as of September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,711,792</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,784,013</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 11%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> </tbody></table>   <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; text-align: justify; margin: 0pt; font-family: "Times New Roman",">(1) </td> <td style="width: auto;"> <p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; text-align: justify; margin: 0pt; font-family: "Times New Roman",">The Series A-1 Warrants expire on the earlier of August 12, 2029 and 60 days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> (2) </td> <td style="width: auto;"> Series A-2 Warrants expire on the earlier of August 12, 2026 and 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. </td> </tr> </tbody></table> <table border="0"

cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 27pt;"> (3) </td> <td style="width: auto;"> The Series A-3 Warrants expire on the earlier of May 12, 2025 and 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO IDE application. </td> </tr> </tbody></table>   During the three months ended September 30, 2024, a total of 867,457 Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 867,457 shares of common stock. After giving effect to these aforementioned exercises, 2,417,000 Pre-Funded Warrants remained outstanding. On October 3, 2024, holders of Pre-Funded Warrants opted to exercise a total of 306,000 shares of their warrants into common stock leaving 2,111,000 remaining.   In accordance with their terms, the 2,853,833 Series B Preferred Investment Options, exercisable for 190,259 shares of common stock at an exercise price of $22.53 per share, expired on August 8, 2024.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2023, the Company had outstanding warrants to purchase common stock as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Total</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Outstanding</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">and</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercisable</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Underlying</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Shares of</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Common </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> Stock</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exercise</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Price per</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Share</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 17.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Expiration Date</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 37.9%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 1 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,993</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> February 2025 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series 2 Warrants issued in the February 2018 Series B financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,903</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">February 2025</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,330,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,433</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">150.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> January 2027 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants issued in the January 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,150,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53,833</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">July 2027</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Preferred Investment Options issued in August 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">190,259</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.53</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> February 2028 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series B Preferred Investment Options issued in August 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">190,259</td>

<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.53</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">August 2024</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent Preferred Investment Options issued in the August 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,233</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,416</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> August 2027 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total as of December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,047,499</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">456,096</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> </tbody></table>   March 2024 Private Placement   On March 7, 2024, in connection with the closing of the Strategic Partnership and Private Placement, the Company issued Advisor Warrants at an exercise price of $3.664 per share which were immediately exercisable. The Advisor Warrants will expire five years following the time they become exercisable, or March 5, 2029.   The exercise price and the number of shares of common stock issuable upon exercise of each Advisor Warrant are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Advisor Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Advisor Warrants prior to the fundamental transaction.   The Advisor Warrants can be exercised at the option of the holders at any time after they become exercisable provided that shares cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% of the Company's outstanding common stock immediately after giving effect to the exercise. A holder of the Advisor Warrants may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%.   June 2024 Offering   On June 13, 2024, the Company entered into a securities purchase agreement with two institutional investors resulting in the issuance of among other things, Pre-Funded Warrants in lieu of common stock to purchase up to an aggregate of 3,284,457 shares of common stock of which 2,417,000 remain outstanding as of September 2024. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable, and have no expiration date. On October 3, 2024, holders of Pre-Funded Warrants opted to exercise a total of 306,000 of their warrants into common stock leaving 2,111,000 remaining.   In addition, the Company issued to the investors in the Offering (i) Series A-1 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, (ii) Series A-2 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock, and (iii) Series A-3 Warrants to purchase up to an aggregate of 3,614,457 shares of common stock. Each share of common stock or Pre-Funded Warrant was sold together with one Series A-1 Warrant to purchase one share of common stock, one Series A-2 Warrant to purchase one share of common stock, and one Series A-3 Warrant to purchase one share of common stock. Each Warrant has an exercise price of $1.66 per share.   The Series A-1 Warrants expire on the earlier of August 12, 2029 and 60 days following the public announcement by the Company of the Company receiving FDA clearance of second image-guided coronary device with a therapeutic indication other than diagnostic imaging or coronary CTO crossing. The Series A-2 Warrants expire on the earlier of August 12, 2026 and 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving 510(k) clearance of image-guided Coronary CTO crossing device. The Series A-3 Warrants expire on May 12, 2025 and 60 days following the date of the public announcement by the Company of the occurrence of the Company receiving FDA approval of image-guided Coronary CTO IDE application.   In connection with the Offering, the Company also issued to the placement agent Placement Agent or its designees Placement Agent Warrants to purchase up to an aggregate of 216,867 shares of common stock. The Placement Agent Warrants have substantially the same terms as the warrants issued and sold in the Offering, except that the Placement Agent Warrants have an exercise price of $2.075 per share and expire on June 13, 2029.   The exercise price and the number of shares of common stock issuable upon exercise of each Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants immediately prior to the fundamental transaction.   The Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants can be exercised at the option of the holders at any time after they become exercisable provided that shares of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% (or, upon election by such holder prior to the issuance of any shares of Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants, 9.99%) of the Company's outstanding common stock immediately after giving effect to the exercise. A holder of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%.   In the event of a fundamental transaction in which the holders of our voting securities immediately prior to such fundamental transaction will not, following such fundamental transaction, directly or indirectly own more than 50% of the voting securities of the surviving entity or successor entity, and in which the Company is not the successor entity or does not continue as a reporting issuer under the Exchange Act, then, at the request of the holder, the Company or the successor entity shall purchase the unexercised portion of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants from the holder by paying to the holder an amount, in cash, equal to the fair value of the remaining unexercised portion of the Pre-Funded Warrants, Series A-1 Warrants, Series A-2 Warrants, Series A-3 Warrants, and Placement Agent Warrants on the date of such fundamental transaction, subject to certain limitations in the event of a fundamental transaction not within our control. 5000000 5000000 0.001 0.001 30229 30229 62881 62881 60876 10000 1900000 1000 273 3.664 2729257 0.0999 0.1999 10000 0.001 85 1.66 1.66 1000 93 10.725 178560 0.0999 0.1999 0.08 100000 100000 1920 7224 1000 273 3.664 1972152 0.499 0.05 0.08 100000 200000 7224 11000 1000 259 3.86 2849000 0.0999 0.1999 0.08 200000 300000 11000 100000000 0.001 2783891 2783891 75327 3.664 330000 1.66 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Total Outstanding and Exercisable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Underlying Shares of Common Stock </td> <td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Exercise Price per Share </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Expiration Date </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Series 1 Warrants issued in the February 2018 Series B financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,993</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">February 2025</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 2 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,903</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> February 2025 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Placement agent warrants issued in the January 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,330,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.433</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">150.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">January 2027</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,150,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53,833</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> July 2027 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Series A Preferred Investment Options issued in August 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">190,259</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.53</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">February 2028</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent Preferred Investment Options issued in the August 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">171,233</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,416</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> August 2027 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Advisor Warrants issued in the March 2024 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">40,938</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">40,938</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.664</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> March 2029 </td>

<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Pre-Funded Warrants issued in the June 2024 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,417,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,417,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.001</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">n/a</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A-1 Warrants issued in the June 2024 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> See note (1) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Series A-2 Warrants issued in the June 2024 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">See note (2)</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A-3 Warrants issued in the June 2024 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,614,457</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> See note (3) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Placement Agent Warrants issued in the June 2024 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,867</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,867</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,075</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> June 2029 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 47%;"> Total as of September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,711,792</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,784,013</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 11%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total Outstanding and Exercisable </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">   Underlying Shares of Common Stock </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">   Price per Share </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width:

17.1%; border-bottom: 1px solid rgb(0, 0, 0);"> Expiration Date </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 37.9%;"> Series 1 Warrants issued in the February 2018 Series B financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,993</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">February 2025</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 2 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,903</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,000.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> February 2025 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Placement agent warrants issued in the January 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,330,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,433</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">150.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">January 2027</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,150,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53,833</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">144.00</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> July 2027 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Series A Preferred Investment Options issued in August 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">190,259</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.53</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">February 2028</p> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series B Preferred Investment Options issued in August 2022 financing</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">190,259</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.53</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> August 2024 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Placement agent Preferred Investment Options issued in the August 2022 financing </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,233</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,416</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">32.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> August 2027 </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total as of December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,047,499</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">456,096</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> </tbody></table> 8979000 2993 6000 8709500 2903 6000 1330000 4433 150 16150000 53833 144 2853883 190259 22.53 171233 11416 32.85 40938 40938 3.664 2417000 2417000 0.001 3614457 3614457 1.66 3614457 3614457 1.66 3614457 3614457 1.66 216867 216867 2.075 51711792 13784013 P60D P60D P60D 867457 867457 2417000 306000 2111000 2853833 190259 22.53 8979000 2993 6000 8709500 2903 6000 1330000 4433 150 16150000 53833 144 2853883 190259 22.53 2853883 190259 22.53 171233 11416 32.85 41047499 456096 3.664 0.0499 0.0999 3284457 2417000 0.001 306000 2111000 3614457 3614457 3614457 1.66 1.66 1.66 P60D P60D P60D 216867 2.075 0.0499 0.0999

0.0999 8. Stock-Based Compensation   Stock Plans   In January 2015, the Board of Directors adopted and the Company's stockholders approved the 2015 Equity Incentive Plan ("2015 Plan"). On December 22, 2023, the Company's stockholders approved an additional 300,000 shares of common stock for issuance under the 2015 Plan, which was later registered in an S-8 registration statement filed on January 10, 2024. The 2015 Plan provides for the grant of incentive stock options ("ISOs") to employees and for the grant of non-statutory stock options ("NSOs"), restricted stock, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), stock appreciation rights, performance units and performance shares to employees, directors and consultants. As of September 30, 2024, 15 share grants were outstanding with 71,442 shares of common stock were available and outstanding for grant under the 2015 Plan.   The Company's RSUs and RSAs generally vest annually over two years in equal increments. RSAs and RSUs largely contain the same contractual terms except RSAs have the ability to vote along with common holders as an RSA is considered an outstanding security at the time of grant, subject to certain vesting and other restrictions. The Company measures the fair value of RSAs using the closing stock price of a share of the Company's common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSA activity is presented below: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 45pt; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Grant Date Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Term </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Awards outstanding at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">90,190</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18.45</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.04</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Awarded</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">394,105</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Released </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(368,503</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.89</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Forfeited</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,333</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18.45</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Awards outstanding at September 30, 2024 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,459</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table>   As of September 30, 2024, there was $0.300 million of remaining unamortized stock-based compensation expense associated with RSAs, which will be expensed over a weighted average remaining service period of approximately 0.3 years. The outstanding non-vested and expected to vest RSAs at September 30, 2024 have an aggregate fair value of approximately $0.1 million. The Company used the closing market price of $0.95 per share at September 30, 2024, to determine the aggregate fair value for the RSAs outstanding at that date. For the nine months ended September 30, 2024 and 2023, the fair value of RSAs vested was approximately $1.0 million and less than $0.1 million, respectively. For the three months ended September 30, 2024 and 2023, stock-based compensation expense recognized associated with the vesting of RSAs was $222,000 and $219,000, respectively. For the nine months ended September 30, 2024 and 2023, stock-based compensation expense recognized associated with the vesting of RSAs was $1.5 million and $0.7 million, respectively.   Total noncash stock-based compensation expense relating to the Company's RSAs recognized, before taxes, during the three and nine months ended September 30, 2024 and 2023, is as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended <p style="font-family: "Times New Roman", Times,

serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Cost of revenues </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">228</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Research and development expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">397</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">158</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Selling, general and administrative expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">144</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">159</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">900</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">446</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">222</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">219</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,525</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">703</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table>   300000 15 71442 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 45pt; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Grant Date Fair Value </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Term </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Awards outstanding at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">90,190</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18.45</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif;

font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.04</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Awarded </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">394,105</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Released</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(368,503</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.89</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,333</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18.45</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards outstanding at September 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,459</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.85</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 90190 18.45 P1Y14D 394105 2.75 368503 4.89 3333 18.45 112459 7.85 P0Y3M18D 300000 P0Y3M18D 100000 0.95 1000000 100000 222000 219000 1500000 700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Cost of revenues </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">228</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Research and development expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">42</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">397</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">158</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Selling, general and administrative expenses </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">144</td> <td style="width: 1%; font-family:

*"Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">159</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">900</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">446</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">222</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">219</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,525</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">703</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 36000 36000 228000 99000 42000 24000 397000 158000 144000 159000 900000 446000 222000 219000 1525000 703000 9. Restructuring Charges and Expenses   In June 2024, the Company undertook an organizational realignment and cost reduction plan which included a reduction in force, lowering its total headcount by approximately 24%, or 17 employees, compared to March 31, 2024. Accordingly, the Company recorded a restructuring charge of approximately $66,000, relating to severance related costs at that time. As of September 30, 2024, all 17 employees' severance costs related to the June 2024 termination had been incurred and paid. As of September 30, 2024, $4,000 of the total severance costs was included within accrued compensation on the condensed balance sheet. During the three months ending September 30, 2024, the Company recorded $14,000 in severance costs related to R&D and $53,000 to SG&A. For the nine months ending September 30, 2024, an additional $23,000 in severance expenses was recorded to SG&A.   0.24 17 66000 17 4000 14000 53000 23000 ITEM 5. OTHER INFORMATION   10b5-1 Trading Plans   During the second quarter of 2024, none of our directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as each term is defined in Item 408(a) of Regulation S-K).   *